

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

6 IN RE: NATIONAL : HON. DAN A.
PRESCRIPTION OPIATE : POLSTER
LITIGATION :
7 :
APPLIES TO ALL CASES : NO.
8 : 1:17-MD-2804
:

- HIGHLY CONFIDENTIAL -

SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

July 19, 2018

Videotaped deposition of
MICHAEL ORIENTE, taken pursuant to
notice, was held at the law offices of
Weitz & Luxenberg, 700 Broadway, New York
New York, beginning at 9:01 a.m., on the
above date, before Michelle L. Gray, a
Registered Professional Reporter,
Certified Shorthand Reporter, Certified
Realtime Reporter, and Notary Public.

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

<p style="text-align: right;">Page 2</p> <p>1 APPEARANCES:</p> <p>2 LEVIN PAPANTONIO THOMAS 3 MITCHELL RAFFERTY PROCTOR, P.A. 4 BY: MIKE PAPANTONIO, ESQUIRE 5 ARCHIE C. LAMB, JR., ESQUIRE 6 316 South Baylen Street 7 Pensacola, Florida 32502 8 (850) 435-7000 9 mpapantonio@levinlaw.com 10 alamb@levinlaw.com</p> <p>11 - and -</p> <p>12 WEISMAN KENNEDY & BERRIS CO LPA 13 BY: ERIC KENNEDY, ESQUIRE 14 BRIAN ASQUITH, ESQUIRE 15 1600 Midland Building 16 101 W. Prospect Avenue 17 Cleveland, Ohio 44115 18 (216) 781-1111 19 ekennedy@weismanlaw.com 20 basquith@weismanlaw.com</p> <p>21 - and -</p> <p>22 NAPOLI SHKOLNIK, PLLC 23 BY: SHAYNA E. SACKS, ESQUIRE 24 360 Lexington Avenue, 11th Floor New York, New York 10017 (212) 397-1000 Sacks@napolilaw.com</p> <p>25 - and -</p> <p>26 GRAY & WHITE LAW 27 BY: MARK K. GRAY, ESQUIRE 28 713 East Market Street Louisville, Kentucky 40202 29 (502) 805-1800 30 Mgray@grayandwhitelaw.com 31 Representing the Plaintiffs</p>	<p style="text-align: right;">Page 4</p> <p>1 APPEARANCES: (Cont'd.)</p> <p>2 JONES DAY 3 BY: LAURA JANE DURFEE, ESQUIRE 2727 North Harwood Street Dallas, Texas 75201 (214) 220-3939 Ldurfee@jonesday.com Representing the Defendant, Walmart</p> <p>4 MORGAN LEWIS & BOCKIUS, LLP 5 BY: CAROLYN A. SILANE, ESQUIRE 101 Park Avenue New York, New York 10178 (212) 309-6734 Csilane@morganlewis.com Representing the Defendant, Rite Aid of Maryland</p> <p>6 PELINI CAMPBELL & WILLIAMS, LLC 7 BY: ERIC J. WILLIAMS, ESQ. 8 8040 Cleveland Avenue NW Suite 400 North Canton, Ohio 44720 (330) 305-6400 ejwilliams@pelini-law.com Representing the Defendant, Prescription Supply, Inc.</p> <p>8 DECHERT, LLP 9 BY: DEBRA D. O'GORMAN, ESQUIRE 10 1095 Avenue of the Americas New York, New York 10036 (212) 698-3500 Debra.ogorman@dechert.com Representing the Defendant, Purdue Pharmaceuticals</p>
<p style="text-align: right;">Page 3</p> <p>1 APPEARANCES: (Cont'd.)</p> <p>2 COVINGTON & BURLING, LLP 3 BY: EMILY JOHNSON HENN, ESQUIRE 4 333 Twin Dolphin Drive, Suite 766 Redwood Shores, California 94065 (650) 632-4715 Ehenn@cov.com</p> <p>5 - and -</p> <p>6 COVINGTON & BURLING, LLP 7 BY: EMILY KVESELIS, ESQUIRE 8 850 Tenth Street, NW Suite 586N Washington, D.C. 20001 Ekveselis&cov.com 10 (202) 662-5110 Representing the Defendant, McKesson Corporation</p> <p>11 MARCUS & SHAPIRA, LLP 12 BY: JAMES F. ROSENBERG, ESQUIRE One Oxford Centre, 35th Floor Pittsburgh, Pennsylvania 15219 (412) 338-4683 Rosenberg@marcus-shapira.com Representing the Defendant, HBC Service Company</p> <p>13 REED SMITH, LLP 14 BY: NEIL A. HLAWATSCHE, ESQUIRE 1717 Arch Street, Suite 3100 Philadelphia, Pennsylvania 19103 (215) 851-8245 nhlawatsch@reedsmith.com Representing the Defendant, Amerisource Bergen Drug Corporation</p>	<p style="text-align: right;">Page 5</p> <p>1 APPEARANCES: (Cont'd.)</p> <p>2 ZUCKERMAN SPAEDER LLP 3 BY: CONOR B. O'CROININ, ESQUIRE 4 100 East Pratt Street, Suite 2440 Baltimore, Maryland 21202 (410) 949-1160 Cocroinin@zuckerman.com Representing the Defendant, CVS</p> <p>5 ARNOLD & PORTER KAYE SCHOLER, LLP 6 BY: ANGELA R. VICARI, ESQUIRE 7 250 West 55th Street New York, New York 10019 (212) 836-8214 Angela.vicari@apks.com Representing the Defendants, Endo Health Solutions; Endo Pharmaceuticals, Inc.; Barr Pharmaceutical, Inc.; and Barr Pharmaceutical Company, Inc.</p>

<p style="text-align: right;">Page 6</p> <p>1 TELEPHONIC APPEARANCES:</p> <p>2 SEEGER WEISS, LLP</p> <p>3 BY: DAVID R. BUCHANAN, ESQUIRE</p> <p>4 77 Water Street</p> <p>5 New York, New York 10005</p> <p>6 (212) 584-0700</p> <p>7 Dbuchanan@seegerweiss.com</p> <p>8 - and -</p> <p>9 SPANGENBERG SHIBLEY & LIBER, LLP</p> <p>10 BY: DUSTIN B. HERMAN, ESQUIRE</p> <p>11 1001 Lakeside Avenue East</p> <p>12 Suite 1700</p> <p>13 Cleveland, Ohio 44114</p> <p>14 (216) 696-3232</p> <p>15 Dherman@spanglaw.com</p> <p>16 - and -</p> <p>17 WEISMAN KENNEDY & BERRIS CO LPA</p> <p>18 BY: DANIEL P. GOETZ, ESQUIRE</p> <p>19 1600 Midland Building</p> <p>20 101 W. Prospect Avenue</p> <p>21 Cleveland, Ohio 44115</p> <p>22 (216) 781-1111</p> <p>23 Dgoetz@weismanlaw.com</p> <p>24 - and -</p> <p>25 NAPOLI SHKOLNIK, PLLC</p> <p>26 BY: JOSEPH L. CIACCIO, ESQUIRE</p> <p>27 360 Lexington Avenue, 11th Floor</p> <p>28 New York, New York 10017</p> <p>29 (212) 397-1000</p> <p>30 jciaccio@napolilaw.com</p> <p>31 - and -</p> <p>32 TAFT STETTINIUS & HOLLISTER, LLP</p> <p>33 BY: CHOU-IL LEE, ESQUIRE</p> <p>34 One Indiana Square</p> <p>35 Indianapolis, Indiana 46204</p> <p>36 (317) 713-3519</p> <p>37 Clee@taftlaw.com</p>	<p style="text-align: right;">Page 8</p> <p>1 APPEARANCES: (Cont'd.)</p> <p>2 ROPES & GRAY, LLP</p> <p>3 BY: JOSH GOLDSTEIN, ESQUIRE</p> <p>4 800 Boylston Street</p> <p>5 Boston, Massachusetts 02199</p> <p>6 (617) 951-7234</p> <p>7 Josh.goldstein@ropesgray.com</p> <p>8 Representing the Defendant,</p> <p>9 Mallinckrodt</p> <p>10 WILLIAMS & CONNOLLY, LLP</p> <p>11 BY: MATTHEW C. MONAHAN, ESQUIRE</p> <p>12 725 12th Street, NW</p> <p>13 Washington, D.C. 20005</p> <p>14 (202) 434-5148</p> <p>15 Mmonahan@wc.com</p> <p>16 Representing the Defendant, Cardinal</p> <p>17 Health</p> <p>18 KIRKLAND & ELLIS, LLP</p> <p>19 BY: KAITLYN COVERSTONE, ESQUIRE</p> <p>20 300 North LaSalle Street</p> <p>21 Chicago, Illinois 60654</p> <p>22 (312) 862-7184</p> <p>23 Kaitlyn.coverstone@kirkland.com</p> <p>24 Representing the Defendant, Allergan</p> <p>25 MORGAN LEWIS BOCKIUS LLP</p> <p>26 BY: ZACHARY R. LAZAR, ESQUIRE</p> <p>27 77 West Wacker Drive</p> <p>28 Chicago, Illinois 60601</p> <p>29 (312) 324-1492</p> <p>30 Zachary.lazar@morganlewis.com</p> <p>31 Representing the Defendants, Teva</p> <p>32 Pharmaceuticals, Inc. Cephalon Inc,</p> <p>33 Watson Laboratories, Actavis LLC,</p> <p>34 Actavis Pharma, Inc.</p>
<p style="text-align: right;">Page 7</p> <p>1 TELEPHONIC APPEARANCES: (Cont'd.)</p> <p>2 - and -</p> <p>3 GREENE KETCHUM, LLP</p> <p>4 PAUL T. FARRELL, JR., ESQUIRE</p> <p>5 419 11th Street</p> <p>6 Huntington, West Virginia 25701</p> <p>7 (304) 521-4778</p> <p>8 Paul@greeneketchum.com</p> <p>9 - and -</p> <p>10 GARSON JOHNSON, LLC</p> <p>11 BY: JAMES A. DEROCHE, ESQUIRE</p> <p>12 101 West Prospect Avenue, Suite 1600</p> <p>13 Midland Building</p> <p>14 Cleveland, Ohio 44115</p> <p>15 (216) 696-7009</p> <p>16 - and -</p> <p>17 LAW OFFICE OF LUKE D. MAHONEY</p> <p>18 BY: LUKE DANIEL MAHONEY, ESQUIRE</p> <p>19 1200 Ontario St</p> <p>20 Cleveland, Ohio 44113</p> <p>21 (216) 443-7800</p> <p>22 Representing the Plaintiffs</p>	<p style="text-align: right;">Page 9</p> <p>1 APPEARANCES: (Cont'd.)</p> <p>2 JACKSON KELLY, PLLC</p> <p>3 BY: DOUGLAS J. CROUSE, ESQUIRE</p> <p>4 500 Lee Street East, Suite 1600</p> <p>5 Charleston, West Virginia 25301</p> <p>6 (304) 340-1347</p> <p>7 Dcrouse@jacksonkelly.com</p> <p>8 Representing the Defendant,</p> <p>9 Miami-Luken</p> <p>10 ALSO PRESENT:</p> <p>11 VIDEOTAPE TECHNICIAN:</p> <p>12 Henry Marte</p> <p>13 LITIGATION TECHNICIAN:</p> <p>14 Evan Wolfe</p> <p>15 ALSO PRESENT:</p> <p>16 Carol Moore</p> <p>17 Sarah Merced</p> <p>18 Sara Papantonio</p> <p>19 Olivia Bergert</p> <p>20 (Levin Papantonio)</p> <p>21 Donna Rozman</p> <p>22 (Weisman Kennedy)</p> <p>23 - - -</p>

			Page 10				Page 12
1	I N D E X			1	E X H I B I T S (Cont'd.)		
2	- - -			2	- - -		
3	Testimony of: MICHAEL ORIENTE			3			
4				4			
5				5	NO.	DESCRIPTION	PAGE
6	By Mr. Papantonio 25, 583			6	MCK-Oriente-529 Threshold Change Form		
7	By Mr. Kennedy 321, 603			7	12/30/09 P1.1243		
8	By Ms. Henn 575			8	MCKMDL00385989-95		
9	By Mr. O'Croinin 598			9			
10				10	MCK-Oriente 535 CVS to Pay		
11				11	Penalty in Methamphetamine Case		
12	- - -			12	P1.5005.1		
13	E X H I B I T S			13	MCK-Oriente-062 McKesson Operations Manual		
14	- - -			14	P1.345 MCKMDL000002509-539		
15	NO.	DESCRIPTION	PAGE	15	MCK-Oriente-020 E-mail Thread		
16	MCK-Oriente-515 GAO State Monitoring Programs			16	8/18/11 Subject, McKesson Marketing Opportunities		
17	Provide Useful Tool to Reduce Diversion			17	Actavis Oxymorphone ER P1.113		
18	P1.1076			18	ACTAVIS0623837-40		
19	MCK-Oriente-518 Memo for ASA Hutchinson			19	MCK-Oriente-322 DOJ, Biopharmaceutical Company, Cephalon to		
20	Subject, Review Of the DEA Report No. I-2002-010			20	Pay 425 Million P1.1381		
21	P1.1086			21			
22				22			
23				23			
24				24			
			Page 11				Page 13
1	E X H I B I T S (Cont'd.)			1	E X H I B I T S (Cont'd.)		
2	- - -			2	- - -		
3				3			
4				4			
5	NO.	DESCRIPTION	PAGE	5	NO.	DESCRIPTION	PAGE
6	MCK-Oriente-519 Follow-Up Review Of the DEA Efforts			6	MCK-Oriente-279 McKesson Manufacturer		
7	To Control the Diversion of Controlled Pharmaceuticals			7	Marketing Contract P1.1317		
8	July 2006			8	MCKMDL00353368-69		
9	P1.1088			9	MCK-Oriente-144 McKesson Manufacturer		
10	MCK-Oriente-525 Threshold Change Form			10	Marketing Product Promotional Agreement		
11	12/30/09			11	P1.1154 MCKMDL00353305-06		
12	P1.1228			12	MCK-Oriente-060 Death Map P1.324		
13	MCKMDL00368716-22			13	584		
14	MCK-Oriente-526 Threshold Change Form			14	MCK-Oriente-383 In the Matter Of McKesson Corporation		
15	12/30/09			15	P1.1428		
16	P1.1236			16	MCKMDL00409050-112		
17	MCKMDL00381960-66			17	MCK-Oriente-503 US DOJ CVS Pharmacy Inc.		
18	MCK-Oriente-527 Threshold Change Form			18	Pays 5 Million to Settle		
19	12/30/09			19	P1.296		
20	P1.1239			20	MCK-Oriente-504 US DOJ US Reaches 8 Million Settlement		
21	MCKMDL00382971-77			21	P1.297		
22	MCK-Oriente-528 Threshold Change Form			22	MCK-Oriente-506 US DOJ CVS to Pay 3.5 Million		
23	12/30/09			23	P1.300		
24	P1.1240			24			

			Page 14				Page 16
			EXHIBITS (Cont'd.)				EXHIBITS (Cont'd.)
1	NO.	DESCRIPTION	PAGE	1	NO.	DESCRIPTION	PAGE
2	MCK-Oriente-507	US DOJ Drug Diversion Claims Against CVS P1.301	566	2	MCK-Oriente-548	Threshold Change Forms 11/26/08 P1.5018.1	459
3	MCK-Oriente-511	US DOJ CVS to Pay 11 Million P1 .305	560	3	MCK-Oriente-559	CSMP Observation Level 1 Documentation Forms P1.5030.1	510
4	MCK-Oriente-534	5 Things News Letter DEA Moves Against Two Florida Pharmacies P1.5004.1	554	4	MCK-Oriente-562	Memo, 4/1/10 Subject, FY11 Compensation Plan P1.5035.1	518
5	MCK-Oriente-537	CVS DEA Settlements Total Paid 130.6 Million P1.5007	570	5	MCK-Oriente-563	Settlement & Release Agreement P1.5036.1	506
6	MCK-Oriente-544	Giant Eagle Threshold Change Form P1.5014.1	410	6	MCK-Oriente-567	E-mail Thread 9/26/12 Subject, Good Day #1 P1.5040.1	536
7	MCK-Oriente-545	PowerPoint Lifestyle Drugs & Internet Pharmacies P1.5015.1	327	7	MCK-Oriente-564	E-mail Thread 5/31/11 Subject, High Percentage To Threshold Customers P1.5037	490
8		MCKMDL00364141-44		8		MCKMDL00409289-99	
9		MCK-Oriente-546		9		MCKMDL00409355-57	
10		Threshold Change Form 11/28/08 P1.5016		10			
11		MCKMDL00000524		11			
12		MCK-Oriente-539	Establishing Opioid Threshold P1.5009	12			
13		MCK-Oriente-541	CSMP P1.5011.1	13			
14		MCKMDL00144473-86		14			
15		MCK-Oriente-542	ISMC CSMP Outbound Calls SF Pilot Program P1.5012.1	15			
16		MCKMDL00317004-10		16			
17		MCK-Oriente-543	RNA Threshold Change/Level 1 Form P1.5013.1	17			
18		MCKMDL00000497-512		18			
19		MCK-Oriente-547	E-mail Thread 12/16/08 Subject, Could you Do Me a Favor P1.5017.1	19			
20		MCKMDL00000515-18		20			
21				21			
22				22			
23				23			
24				24			
			Page 15				Page 17
			EXHIBITS (Cont'd.)				EXHIBITS (Cont'd.)
1	NO.	DESCRIPTION	PAGE	1	NO.	DESCRIPTION	PAGE
2	MCK-Oriente-546	Threshold Change Form 11/28/08 P1.5016	401	2	MCK-Oriente-564	E-mail Thread 5/31/11 Subject, High Percentage To Threshold Customers P1.5037	490
3	MCK-Oriente-539	Establishing Opioid Threshold P1.5009	509	3	MCK-Oriente-566	E-mail, 2/28/12 Subject, CSMP Omit v Report P1.5039	530
4	MCK-Oriente-541	CSMP P1.5011.1	378	4	MCK-Oriente-569	E-mail Thread 8/19/10 Subject, Sales Ride Along P1.5042.1	532
5	MCKMDL00144473-86			5	MCK-Oriente-570	US DOJ Letter 8/13/14 P1.5043.1	498
6	MCK-Oriente-542	ISMC CSMP Outbound Calls SF Pilot Program P1.5012.1	389	6	MCKMDL00409224-246		
7	MCKMDL00317004-10			7	MCK-Oriente-571	CSMP Observation Level 1 Documentation Forms P1.5044.1	526
8	MCK-Oriente-543	RNA Threshold Change/Level 1 Form P1.5013.1	467	8			
9	MCKMDL00000497-512			9			
10	MCK-Oriente-547	E-mail Thread 12/16/08 Subject, Could you Do Me a Favor P1.5017.1	445	10			
11	MCKMDL00000515-18			11			
12				12			
13				13			
14				14			
15				15			
16				16			
17				17			
18				18			
19				19			
20				20			
21				21			
22				22			
23				23			
24				24			

EXHIBITS (Cont'd.)			Page 18	Page 20
NO.	DESCRIPTION	PAGE		
5 MCK-Oriente-572	Handwritten Demonstrative When Made Increase In Threshold	365		THE VIDEOGRAPHER: We are now on the record. My name is Henry Marte. I am a videographer for Golkow Litigation Services.
6 MCK-Oriente-573	Handwritten Demonstrative McKesson Took Our Responsibilities Very Seriously	341		Today's date is July 19, 2018. And the time is 9:01 a.m.
7 MCK-Oriente-574	Handwritten Demonstrative CVS Performs Its Own Due Diligence	548		This videotaped deposition is being held at 700 Broadway, New York, New York in the matter of In Re: National Prescription Opiate Litigation.
8 MCK-Oriente-V-1	Video 1	266		The deponent today is Mr. Michael Oriente.
9 MCK-Oriente-V-7	Video 7	182		All appearances please introduce themselves for the record.
10 MCK-Oriente-V-8	Video 8	456		MR. PAPANTONIO: Mike Papantonio for the plaintiff.
11	-			You know what, let's just get everybody in the room so there's no --
12	-			MS. MOORE: Okay. Carol Moore for the plaintiff.
13	-			MS. MERCED: Sarah Merced
14	-			
15	-			
16	-			
17	-			
18	-			
19	-			
20	-			
21	-			
22	-			
23	-			
24	-			
DEPOSITION SUPPORT INDEX			Page 19	Page 21
1	-			for the plaintiff.
2	-			MR. WOLFE: Evan Wolfe for plaintiff.
3	-			MR. KENNEDY: Eric Kennedy, plaintiffs.
4	-			MS. ROZMAN: Donna Rozman for plaintiff.
5	-			MR. ASQUITH: Brian Asquith for plaintiff.
6	-			MR. GRAY: Mark Gray, plaintiffs.
7	-			MR. LAMB: Archie Lamb for the plaintiff.
8	-			MR. O'CROININ: Conor O'Croinin for defendant, CVS.
9	-			MR. HLAWATSCH: Neil Hlawatsch, defendant Amerisource Bergen Corporation -- Amerisource Bergen Drug Corporation and Amerisource Bergen Corporation.
10	-			MR. WILLIAMS: Eric Williams for defendant Prescription Supply, Inc.
11	-			MR. ROSENBERG: James
12	-			
13	-			
14	-			
15	-			
16	-			
17	-			
18	-			
19	-			
20	-			
21	-			
22	-			
23	-			
24	-			

Page 22	Page 24
1 Rosenberg, HBC Services Company. 2 MS. DURFEE: Laura Jane 3 Durfee, Walmart. 4 MS. KVESELIS: Emily 5 Kveselis, McKesson. 6 MS. HENN: Emily Henn on 7 behalf of McKesson and the 8 witness. 9 MR. ORIENTE: Michael 10 Oriente, McKesson. 11 MR. PAPANTONIO: We get 12 everybody? 13 Go ahead. 14 MS. VICARI: Angela Vicari 15 of Arnold and Porter, here for 16 Endo Health Solutions; Endo 17 Pharmaceuticals, Inc.; Barr 18 Pharmaceutical, Inc.; and Barr 19 Pharmaceutical Company, Inc. 20 MR. SALTZ: Adam Saltz for 21 the plaintiff. 22 MR. GOLDSTEIN: Josh 23 Goldstein, Ropes & Gray for 24 Mallinckrodt.	1 Purdue. 2 MR. PAPANTONIO: Purdue. 3 And what is your name? 4 MS. O'GORMAN: Debra 5 O'Gorman. 6 MR. PAPANTONIO: Debra. All 7 right. So we got everybody in 8 here right now. 9 Okay. On the telephone, who 10 do we have on the phone? 11 Nobody? Okay. 12 MR. CROUSE: Doug Crouse for 13 Miami-Luken. 14 MR. PAPANTONIO: Okay. Who 15 else? 16 MR. LAZAR: Good morning. 17 This is Zach Lazar from Morgan 18 Lewis, on behalf of the Teva 19 defendants. 20 MR. PAPANTONIO: Okay. 21 Anybody else? 22 MS. COVERSTONE: Kaitlyn 23 Coverstone from Kirkland & Ellis, 24 on behalf of Allergan.
Page 23	Page 25
1 MR. PAPANTONIO: We have 2 people on the telephone. If 3 you're on the phone, would you 4 identify yourself, please? 5 MS. SACKS: Shayna Sacks -- 6 MR. PAPANTONIO: Oh, I'm 7 sorry. Hang on. 8 MS. SACKS: -- for the 9 plaintiff. Sorry. 10 MR. PAPANTONIO: Shayna? 11 Okay. My apologies. 12 MS. SILANE: Caroline Silane 13 for defendant, Rite Aid of 14 Maryland, Inc. 15 MR. MONAHAN: Matthew 16 Monahan on behalf of defendant 17 Cardinal Health, Inc. 18 MS. PAPANTONIO: Sara 19 Papantonio, plaintiff. 20 MS. BERGERT: Olivia 21 Bergert, plaintiff. 22 MR. PAPANTONIO: We've got 23 people coming in. 24 MS. O'GORMAN: I represent	1 MR. PAPANTONIO: All right. 2 Anybody else? 3 MR. FARRELL: Paul Farrell 4 on behalf of plaintiffs. 5 MR. PAPANTONIO: All right. 6 Anybody else? 7 All right. With that, it 8 sounds we are about ready. Just 9 swear the witness and we'll get 10 started. 11 - - - 12 ... MICHAEL ORIENTE, having 13 been first duly sworn, was 14 examined and testified as follows: 15 - - - 16 EXAMINATION 17 - - - 18 BY MR. PAPANTONIO: 19 Q. Sir, state your name, 20 please? 21 A. My name is Michael Oriente. 22 Q. Mr. Oriente, you were one of 23 the directors of regulatory affairs for 24 McKesson; is that correct?

<p>1 A. Yes.</p> <p>2 Q. How many years did you do</p> <p>3 that?</p> <p>4 A. I have been doing it since</p> <p>5 late 2007 and continue to still do it</p> <p>6 today.</p> <p>7 Q. And with that, sir, you were</p> <p>8 expected to understand all of the</p> <p>9 regulatory -- all of the regulatory</p> <p>10 requirements that McKesson was supposed</p> <p>11 to follow in the sale of opioids; is that</p> <p>12 correct?</p> <p>13 A. I would monitor the</p> <p>14 purchases for the sales of controlled</p> <p>15 substances to our customers.</p> <p>16 Q. Let me ask the question</p> <p>17 again. You were expected to understand</p> <p>18 all of the regulatory requirements that</p> <p>19 McKesson was supposed to follow as it</p> <p>20 sold narcotic drugs, opioids?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 THE WITNESS: Yes.</p> <p>24 BY MR. PAPANTONIO:</p>	<p>Page 26</p> <p>1 Mr. Oriente.</p> <p>2 I asked you if McKesson</p> <p>3 management hid information about how they</p> <p>4 were going about distributing narcotic</p> <p>5 drugs, that would affect your ability to</p> <p>6 do your job as a regulator. Is that yes</p> <p>7 or no?</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 THE WITNESS: It could if I</p> <p>11 didn't have all the information,</p> <p>12 yes.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. It could if you didn't have</p> <p>15 all the information. Why would it affect</p> <p>16 you if you didn't have all the</p> <p>17 information?</p> <p>18 MS. HENN: Objection to</p> <p>19 form.</p> <p>20 THE WITNESS: I would -- I</p> <p>21 would need to understand the full</p> <p>22 amount that a customer was</p> <p>23 purchasing.</p> <p>24 BY MR. PAPANTONIO:</p>
<p>1 Q. Is that a correct statement?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. Mr. Oriente, I</p> <p>4 understand that you sometimes have a</p> <p>5 problem hearing. If you can't hear what</p> <p>6 I'm saying, please interrupt me. Say, "I</p> <p>7 just didn't hear you. Repeat the</p> <p>8 question." Okay? And we'll do that as</p> <p>9 we proceed here today.</p> <p>10 A. Okay.</p> <p>11 Q. All right. So if management</p> <p>12 at McKesson hid information from you</p> <p>13 about how they were going about</p> <p>14 distributing their drugs, that would</p> <p>15 affect your ability as a regulator to do</p> <p>16 your job, wouldn't it?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: I did -- I did</p> <p>20 not know of any hidden</p> <p>21 information.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. I didn't say that. Listen</p> <p>24 very carefully to the questions,</p>	<p>Page 27</p> <p>1 Q. Okay. Fair enough. So the</p> <p>2 more information you had about how</p> <p>3 McKesson was going about distributing</p> <p>4 narcotic drugs, the better you can</p> <p>5 determine how to adjust your job in</p> <p>6 regulatory; is that a correct statement?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: Could you</p> <p>10 repeat the question?</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Yeah. The more information</p> <p>13 you had about how McKesson was</p> <p>14 distributing their drugs, their narcotic</p> <p>15 drugs, the better you could do as a</p> <p>16 regulator in performing your job?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: Yes. The more</p> <p>20 information I had, the better</p> <p>21 decision I could make.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. And, Mr. Oriente, if the</p> <p>24 information about distribution of those</p>

Page 30	Page 31	Page 32
<p>1 narcotics is hidden from you as a 2 regulator, you're not able to adjust to 3 what you need to do as a regulator. If 4 they're hiding information, you can't do 5 your job as a regulator. Would you agree 6 with that?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: I would say 10 that I had all the information 11 that I needed to perform my job. 12 I was unaware of any information 13 not being shared with myself.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. All right. Let's talk about 16 some of that information right now.</p> <p>17 MR. PAPANTONIO: Please put 18 up Document 1428, Evan. Mr. -- 19 huh?</p> <p>20 MS. MOORE: That's McKesson 21 Oriente 383.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Okay. As we're proceeding 24 here, Emily, what's going to happen is</p>		<p>1 reason not to start with McKesson 2 Oriente-1?</p> <p>3 MR. PAPANTONIO: Yeah, there 4 is. There is. And we'll explain 5 that as we go. But this is easily 6 identified when you go back and 7 look at the record. That's all 8 I'm saying.</p> <p>9 MS. HENN: Just for the 10 record, our preference would be to 11 do it in order to make it simpler. 12 You handed me two copies. Which 13 one is for the witness?</p> <p>14 MR. PAPANTONIO: One is for 15 the witness, and one for you, and 16 one is for Emily next to you if 17 you'd like.</p> <p>18 MS. HENN: Do you have one 19 for -- additional copies?</p> <p>20 MR. PAPANTONIO: I don't 21 think we have that many. You may 22 have to -- you may have to share.</p> <p>23 MS. HENN: I think the 24 protocol requires four copies --</p>
	Page 31	Page 33
	<p>1 she's going to read a number for 2 identification of the document into the 3 record because we're marking each one of 4 these as we go.</p> <p>5 MR. PAPANTONIO: Okay. So, 6 Carol, if you would do that as you 7 proceed.</p> <p>8 Did you hear what that 9 number was? Okay.</p> <p>10 MS. HENN: So, Counsel, is 11 the document premarked? Is that 12 what you're saying?</p> <p>13 MR. PAPANTONIO: Yes, it's 14 premarked, because that way we 15 can -- we're doing it by Oriente exhibit as a deposition. We're going to be doing that as we go forward. I'm sure you are going to be covering a lot of these depos.</p> <p>21 The idea is we're going to 22 be marking a document with an 23 exhibit for that deposition.</p> <p>24 MS. HENN: Is there any</p>	<p>1 MR. PAPANTONIO: I'm sure we 2 do have four copies.</p> <p>3 MS. HENN: -- so defendants 4 can have copies.</p> <p>5 (Document marked for 6 identification as Exhibit 7 MCK-Oriente-383.)</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. All right. Let -- sir,</p> <p>10 Mr. Oriente, as we're proceeding today 11 what I'm going to be doing is I'm going 12 to be putting documents up on the screen. 13 The screen will both be in front of you, 14 you'll be able to see the big screen up 15 here.</p> <p>16 Either -- feel free to use 17 either one.</p> <p>18 A. All right. Thank you.</p> <p>19 Q. Now, this document is titled 20 "In the Matter of McKesson Corporation." 21 Take a look at that. Let's go -- let's 22 take a look at this document.</p> <p>23 Have you seen this document?</p> <p>24 A. I have not.</p>

<p style="text-align: right;">Page 34</p> <p>1 Q. Okay. When did you first 2 get information -- when were you first 3 told by your company that you were going 4 to be appearing here in a deposition? 5 A. I don't recall the exact 6 date. It would have been a few weeks 7 back. 8 Q. Would you say three weeks, 9 four weeks? What would you say? 10 MS. HENN: Objection to 11 form. 12 THE WITNESS: I would take 13 an estimate of about four weeks. 14 BY MR. PAPANTONIO: 15 Q. Okay. In that time that you 16 knew that you were going to be coming 17 here for a deposition, did you have the 18 opportunity to review any documents? 19 A. No. I did not go back and 20 look at anything. 21 Q. All right. But this 22 document that we're looking at right now 23 called, "In the Matter of McKesson 24 Corporation," it says at the bottom, "DEA</p>	<p style="text-align: right;">Page 36</p> <p>1 numbers as we go. Okay. 2 MS. HENN: Okay. I would 3 just like to note that this 4 document is marked confidential, 5 and that pursuant to the protocol 6 entered by the court, the court 7 reporter shall clearly mark this 8 transcript prior to the expiration 9 of the 30-day period as highly 10 confidential subject to further 11 confidentiality review. Thank 12 you. 13 BY MR. PAPANTONIO: 14 Q. Well, Mr. Oriente, this was 15 so confidential that they didn't tell you 16 about it, did they? 17 MS. HENN: Objection to 18 form. 19 BY MR. PAPANTONIO: 20 Q. I mean, this is -- you heard 21 this is a confidential document. And you 22 had been with the company -- how many -- 23 how many years you've been with the 24 company?</p>
<p style="text-align: right;">Page 35</p> <p>1 Diversion Group, Washington Division." 2 You've never seen this 3 document; is that a correct statement? 4 A. That is correct. 5 Q. All right. Would you turn 6 to the next page of that document. I 7 want to review this document with you. 8 And I want to ask you questions about 9 this document as far as your 10 understanding of your regulatory 11 responsibilities for this company. Okay? 12 MS. HENN: Counsel, just one 13 statement I'd like to make on the 14 record. 15 First of all, did we get the 16 Bates number of the document into 17 the record? 18 MR. PAPANTONIO: No. We're 19 going to -- here's what we're 20 going to do. We're not going to 21 take the time to read Bates 22 numbers here, because we only have 23 so much time. At the end of it we 24 will sit there and read the Bates</p>	<p style="text-align: right;">Page 37</p> <p>1 A. With McKesson total, 2 14 years. 3 Q. And this is so confidential 4 that they didn't tell you about it and 5 you're one of the directors of regulatory 6 for McKesson; is that a correct 7 statement? 8 MS. HENN: Objection to 9 form. 10 THE WITNESS: I am one of 11 the directors of regulatory, yes. 12 BY MR. PAPANTONIO: 13 Q. And do you see where it 14 says -- the very first line, "This is an 15 investigation of the actions and 16 practices of McKesson Corporation." 17 Did you know that this 18 investigation was going on by the DEA? 19 A. I knew that Landover was 20 being involved in an investigation. But 21 I have not seen the document. 22 Q. Well, sir, you -- Landover 23 was an area that you regulated, isn't it? 24 MS. HENN: Objection to</p>

<p>1 form.</p> <p>2 THE WITNESS: I was 3 responsible for the Landover 4 distribution center, yes.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Tell the jury what the 7 Landover distribution center is.</p> <p>8 A. Landover distribution center 9 was located in Landover, Maryland, and it 10 distributed controlled substances, Rx 11 product and OTC to McKesson customers in 12 that geographic area.</p> <p>13 Q. Tell me what the 14 geographic -- how many states did that 15 geographic area cover?</p> <p>16 A. The Landover distribution 17 center had customers in, of course, 18 Maryland, West Virginia, Delaware, 19 Washington D.C. I believe that was the 20 general area that they serviced.</p> <p>21 Q. How many years were you the 22 director of regulatory there at Landover?</p> <p>23 MS. HENN: Objection to 24 form.</p>	<p>Page 38</p> <p>1 A. That's what the document 2 says, yes.</p> <p>3 Q. And during that entire time, 4 you were there at Landover, weren't you?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: Yes.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. During the time 2008 through 10 2012, you were there and you were the 11 director -- you were the director of 12 regulatory; is that a correct statement?</p> <p>13 A. Yes.</p> <p>14 Q. And then it actually -- it 15 mentions right down underneath the next 16 line, it says, "Landover" -- do you see 17 where it says "Landover distribution 18 center"? It gives DEA, and then it gives 19 a number. That number, what is that 20 number, sir?</p> <p>21 A. I do not know what that 22 number stands for.</p> <p>23 Q. Okay. And then it says, 24 "Landover is no longer in operation."</p>
<p>1 THE WITNESS: I'm not 2 exactly sure when the Landover 3 distribution center stopped 4 operating. But I was there from 5 late 2007 to when it closed.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And it closed in 2012, 8 didn't it?</p> <p>9 A. I am unaware of the exact 10 date that it closed.</p> <p>11 Q. All right. We'll get to 12 that.</p> <p>13 It says, "This is an 14 investigation of the actions and 15 practices of McKesson Corporation." 16 That's what the first line reads, right?</p> <p>17 And you knew about the 18 investigation going on, correct?</p> <p>19 A. Yes.</p> <p>20 Q. And then it says, from 21 May 2008 through May -- through 22 March 2012. That was the area of time 23 that the investigation was taking place 24 on Landover, correct?</p>	<p>Page 39</p> <p>1 Do you see that?</p> <p>2 A. Yes.</p> <p>3 Q. Go to the next page please.</p> <p>4 MS. HENN: And I'll just 5 remind the witness he can take 6 whatever time he'd like to review 7 the document.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Do you see the next page 10 there? It says, "Civil liability." 11 Do you see that?</p> <p>12 A. Yes. It's at the top of the 13 page.</p> <p>14 Q. In this confidential 15 document that you've never seen prior to 16 me putting it in front of you today, the 17 first thing it says is it talks about 18 what McKesson liability is.</p> <p>19 Do you see, "McKesson 20 liability emanates from 21 U.S.C. 21 842(a)5."</p> <p>22 Do you see that?</p> <p>23 A. Yes, I see it here.</p> <p>24 Q. You know what that is, don't</p>

<p>1 you, Mr. Oriente?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. You've seen that number</p> <p>6 before, haven't you?</p> <p>7 A. I have not seen that number</p> <p>8 before, no.</p> <p>9 Q. Before you went to -- before</p> <p>10 you went to regulatory, nobody told you</p> <p>11 about 21 U.S.C. 842. Is that your</p> <p>12 testimony here today?</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 THE WITNESS: I am not</p> <p>16 familiar with that specific</p> <p>17 listing.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Well, let's do -- let's look</p> <p>20 at the next listing, 21 U.S.C. 823. Had</p> <p>21 anybody shown you that prior to the time</p> <p>22 that you took over regulatory -- director</p> <p>23 of regulatory at Landover? Had anybody</p> <p>24 showed you that?</p>	<p>Page 42</p> <p>1 MS. HENN: Objection to</p> <p>2 form.</p> <p>3 THE WITNESS: I believe they</p> <p>4 would have the ability to. It's</p> <p>5 not necessarily that they would.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, not to comply with 21</p> <p>8 U.S.C. 823 would be unlawful. Can we</p> <p>9 agree on that?</p> <p>10 A. We need to follow the</p> <p>11 regulation. That is correct.</p> <p>12 Q. And not to do it would be</p> <p>13 considered unlawful, yes or no?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: We would need</p> <p>17 to follow that, and I believe that</p> <p>18 we would be out of compliance if</p> <p>19 we did not.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Well, you see it says,</p> <p>22 "Failure to provide effective controls</p> <p>23 against theft, diversion of controlled</p> <p>24 substance in violation of 21 C.F.R.," and</p>
<p>1 A. No one showed me that. But</p> <p>2 I am familiar that, you know, we had a</p> <p>3 system in place to watch for diversion as</p> <p>4 far as sales for size, frequency, and</p> <p>5 pattern of orders.</p> <p>6 Q. Right. And if you didn't do</p> <p>7 that, you would be breaking the law,</p> <p>8 wouldn't you?</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 THE WITNESS: I can't say</p> <p>12 that we'd be breaking the law.</p> <p>13 That is the requirement to meet</p> <p>14 that requirement.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Well, if you didn't do that,</p> <p>17 sir, the DEA would fine you, wouldn't</p> <p>18 they?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. If you didn't do what 21</p> <p>23 U.S.C. 823 told you to do, the DEA would</p> <p>24 fine you, yes or no?</p>	<p>Page 43</p> <p>1 then it gives you a section, right?</p> <p>2 Are you familiar with 21</p> <p>3 C.F.R. 1301?</p> <p>4 A. I don't know the exact</p> <p>5 listing of 21 C.F.R. and that section.</p> <p>6 But I do understand that we needed to</p> <p>7 have a controlled substance in place, and</p> <p>8 that is, you know, how we monitored the</p> <p>9 sales of the controlled substances.</p> <p>10 Q. Well, you know one thing 21</p> <p>11 U.S.C. 823 told you to do is that you</p> <p>12 were supposed to provide suspicious order</p> <p>13 reports to the DEA, weren't you?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: Yes, we would</p> <p>17 report suspicious orders when we</p> <p>18 deemed them suspicious.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. And if you deemed them</p> <p>21 suspicious and you failed to report them,</p> <p>22 that would be unlawful, wouldn't it?</p> <p>23 MS. HENN: Objection to</p> <p>24 form.</p>

<p style="text-align: right;">Page 46</p> <p>1 THE WITNESS: We would 2 report those that were deemed 3 suspicious, yes. 4 BY MR. PAPANTONIO: 5 Q. And if you failed to do 6 that, that would be unlawful, correct? 7 Yes or no sir? 8 MS. HENN: Objection. 9 Objection to form. 10 THE WITNESS: If we did not 11 report a suspicious order that we 12 deemed suspicious, yes. 13 BY MR. PAPANTONIO: 14 Q. All right. And then it says 15 right -- the next one is C.F.R. 1301. 16 You've seen that before, haven't you? In 17 your role as regulatory for Landover, you 18 were familiar with 21 C.F.R. 1301, 19 correct? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: I, again, do 23 not know the specific regulation 24 from -- from memory. I know that</p>	<p style="text-align: right;">Page 48</p> <p>1 correct. 2 BY MR. PAPANTONIO: 3 Q. And not to do that would be 4 breaking the law, wouldn't it? 5 MS. HENN: Same objection. 6 BY MR. PAPANTONIO: 7 Q. Correct? It would be 8 breaking the law, wouldn't it, 9 Mr. Oriente? 10 A. Not to report the suspicious 11 orders would not be following the 12 regulation. 13 Q. Isn't -- but let's be clear. 14 Because we're going to be talking. It 15 would be breaking the law that you're 16 supposed to follow under 21 U.S.C., yes 17 or no? 18 MS. HENN: Objection to 19 form. 20 THE WITNESS: We have a 21 requirement to follow that 22 requirement, and so we need to 23 follow the law. 24 BY MR. PAPANTONIO:</p>
<p style="text-align: right;">Page 47</p> <p>1 we followed the 21 C.F.R. But I 2 don't -- I cannot tell you what 21 3 C.F.R. Section 1301.71 4 specifically states. 5 BY MR. PAPANTONIO: 6 Q. You did -- how many years 7 were you regulatory? 8 MS. HENN: Objection to 9 form. 10 THE WITNESS: Since late 11 2007 through today. 12 BY MR. PAPANTONIO: 13 Q. You're still in regulatory 14 today, correct? 15 A. That is correct. 16 Q. And you understand, being in 17 regulatory, that you had a responsibility 18 to design and operate a system that would 19 disclose suspicious orders to the DEA 20 when you found them to be suspicious; is 21 that correct? 22 MS. HENN: Objection to 23 form. 24 THE WITNESS: That is</p>	<p style="text-align: right;">Page 49</p> <p>1 Q. And if you don't, that's 2 called breaking the law, isn't it? Can 3 we agree on that? 4 MS. HENN: Objection to 5 form. 6 BY MR. PAPANTONIO: 7 Q. Because if there's something 8 in between, Mr. Oriente, this is your 9 time to tell everybody in this room, if 10 there's something that's different from 11 what I'm saying, break the law. Is there 12 another term that you want to use as we 13 proceed here today? 14 MS. HENN: Objection to 15 form. 16 THE WITNESS: I would not 17 say that -- a different term. It 18 would -- it would not be following 19 the law. 20 BY MR. PAPANTONIO: 21 Q. Okay. Okay. I'm good with 22 that, Mr. Oriente. We'll move on. 23 Let's go to the next page. 24 MS. HENN: I'd also like to</p>

Page 50	Page 52
<p>1 ask the approximately three people 2 that joined the phone call since 3 we began to please identify 4 themselves for the record.</p> <p>5 Anybody on the phone who's 6 not yet identified yourself, could 7 you please just identify yourself 8 for the record?</p> <p>9 MR. GOETZ: Dan Goetz from 10 Weisman Kennedy.</p> <p>11 MS. COOK: Renee Cook.</p> <p>12 MR. HERMAN: Dustin Herman 13 from Spangenberg, for the 14 plaintiffs.</p> <p>15 MS. HENN: Anybody else?</p> <p>16 MR. DeROCHE: James DeRoche 17 from Weisman Kennedy.</p> <p>18 MS. HENN: Anybody else? Thank you.</p> <p>19 MR. PAPANTONIO: Thank you, 20 Emily, for catching that. I 21 didn't hear the little beeps.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. All right. Mr. Oriente,</p>	<p>1 very things that you're supposed to be 2 doing as a regulator?</p> <p>3 MS. HENN: Objection to 4 form.</p> <p>5 THE WITNESS: I personally 6 did not attend the seminar.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. But you were a director. Is 9 there any -- at Landover, correct? You 10 were a director of regulatory?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: Landover was 14 one of my distribution centers 15 that I oversaw, yes.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. We're going to talk about 18 other distribution centers. But right 19 now, we can establish that you were the 20 director at Landover; is that a correct 21 statement?</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: For</p>
Page 51	Page 53
<p>1 let's go ahead to the next page. Now, as 2 your lawyer told you, I don't want to 3 jump into this page without you taking a 4 look at it. Take a minute and look at 5 it, because this is the first time you've 6 seen this confidential document. I think 7 it was characterized as highly 8 confidential, right?</p> <p>9 MS. HENN: Objection to 10 form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. It says, "McKesson is 13 subject" -- let's just look at Paragraph 14 2. 21 U.S.C. 842.</p> <p>15 Do you see that?</p> <p>16 Have you ever seen 21 U.S.C. 17 842?</p> <p>18 A. I have not.</p> <p>19 Q. Sir, let me preface 20 something. Did you not attend -- did you 21 not attend seminars that the DEA actually 22 put on for directors of regulatory for 23 McKesson? Do you ever remember attending 24 a seminar that talked to you about these</p>	<p>1 regulatory, yes.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. All right. And you never 4 attended any of the DEA seminars that 5 they put on for directors of regulatory 6 telling them what the laws were and what 7 your responsibilities were; is that a 8 correct statement?</p> <p>9 A. I did not attend.</p> <p>10 Q. All right. So let's --</p> <p>11 let's read this. It says, "21 U.S.C. 12 provides that it's unlawful" -- they're 13 using that word too, unlawful -- 14 "unlawful to refuse or negligently fail 15 to make, keep, furnish any record, 16 report, notification, declaration, order, 17 order form, statement, invoice, 18 information required under this section."</p> <p>19 Do you see that?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: I see that 23 listed here.</p> <p>24 BY MR. PAPANTONIO:</p>

Page 54	Page 56
<p>1 Q. And the truth is, where it 2 says -- where it says it's unlawful to 3 refuse to fail to make this information 4 available to the DEA, that's exactly what 5 McKesson did, is they refused to give 6 information to the DEA about their 7 narcotic drugs that they were selling to 8 pharmacies, even when McKesson understood 9 that suspicious orders were taking place?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 THE WITNESS: I'm not -- 13 not -- I am not aware of any 14 refusal to give information to DEA 15 when they requested it.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Sir, is there anybody else 18 that was -- was it just you directing -- 19 was it just you who was the director at 20 Landover of regulatory?</p> <p>21 A. I was the director of 22 regulatory at Landover. Any type of 23 information that the DEA requested would 24 go through our legal department.</p>	<p>1 or other action through our legal 2 department in San Francisco, they 3 would then furnish the information 4 to DEA.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. So the lawyers decided what 7 was supposed to go on to the DEA. Is 8 that your testimony?</p> <p>9 A. My testimony is the legal 10 department would send it in. I don't 11 know exactly who in the legal department 12 would furnish the information that DEA 13 was requesting.</p> <p>14 Q. But nobody -- we know this 15 much. The legal department never gave 16 you this document, this highly 17 confidential document that we're looking 18 at right now. Nobody in legal gave you 19 that, did they?</p> <p>20 MS. HENN: Counsel, you're 21 referring to the DEA document, 22 Exhibit --</p> <p>23 (Brief interruption.)</p> <p>24 BY MR. PAPANTONIO:</p>
<p>1 I was not responsible to 2 send that information to DEA.</p> <p>3 Q. Okay. So lawyers -- what 4 you're telling us is lawyers had the last 5 decision on what was supposed to be sent 6 to the DEA. Is that your testimony?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: I don't know 10 if it was lawyers. It was our 11 legal department that we would 12 submit all requests to.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. And they certainly -- it's 15 important that you know what they're 16 submitting to the DEA and what they're 17 not submitting to the DEA. As a 18 regulator, that's important to you, isn't 19 it, Mr. Oriente?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: Once we would 23 send in the request that we would 24 receive either through a subpoena</p>	<p>1 Q. Okay. Listen to the 2 question again. All right? You never 3 received this document that is -- that 4 we've decided is a confidential document. 5 Legal never gave you that when you were 6 trying to do your job as a regulator; is 7 that correct statement?</p> <p>8 A. It's a correct statement 9 that I've not seen this document, yes.</p> <p>10 Q. Okay. And legal never gave 11 it to you as far as you can remember; is 12 that correct statement?</p> <p>13 A. I thought I just answered 14 that, but.</p> <p>15 Q. Well, if you did, are you --</p> <p>16 A. Yeah.</p> <p>17 Q. -- satisfied with your 18 answer?</p> <p>19 A. I have not seen this 20 document before today.</p> <p>21 Q. Mr. Oriente, I'm not trying 22 to accuse you of anything you haven't 23 done here or -- there's no accusation 24 here. I'm simply trying to find out what</p>
Page 55	Page 57

<p style="text-align: right;">Page 58</p> <p>1 information was shared with you so you 2 could do your job as a regulator at 3 Landover. Do you understand that? 4 A. Yes. 5 Q. Okay. So let's go -- let's 6 go to the next page. The next page is 7 Page 3; is that right? No. Excuse me, 8 page -- next page over, 5. It says 9 statute and regs --</p> <p>10 MS. HENN: Counsel, is there 11 a page number you're referring to?</p> <p>12 MR. PAPANTONIO: Yeah, if 13 you look at -- on the Bates stamp, 14 that five down there would be your 15 page number.</p> <p>16 THE WITNESS: The next one.</p> <p>17 MR. PAPANTONIO: The very 18 next page.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. At the top of it, it says, 21 "Statute and regs." 22 Do you see that? 23 A. Yes. 24 Q. It says, "The registrant</p>	<p style="text-align: right;">Page 60</p> <p>1 that says, "Oh, we don't -- McKesson 2 doesn't have to report suspicious orders. 3 We have the right to report suspicious 4 customers"? 5 Do you see anything in that 6 wording there?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: The statement 10 here says suspicious orders.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Correct. It doesn't say 13 suspicious customers, does it? 14 A. Suspicious customers is not 15 listed here, no. 16 Q. And that would -- so let's 17 go to the next page. 18 Statute and regulations. It 19 says, "The registrant" -- that would be 20 McKesson, right? You'd be a registrant 21 with the DEA? 22 A. Yes. 23 Q. All right. Landover would 24 be a registrant with the DEA; is that</p>
<p style="text-align: right;">Page 59</p> <p>1 shall design and operate a system to 2 disclose the registrant's suspicious 3 orders of controlled substances." 4 Do you see the term 5 "suspicious orders"? 6 A. Yes. 7 Q. Do you ever -- do you see 8 any mention about there being a 9 responsibility to report suspicious 10 customers? 11 MS. HENN: Objection to 12 form.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Is there anything -- is 15 there anything in that statute right 16 there that says you have the right not to 17 report suspicious orders, but to report 18 suspicious customers? 19 MS. HENN: Counsel, you're 20 referring to the quote from the 21 regulation there on Page 5? 22 MR. PAPANTONIO: Right. 23 BY MR. PAPANTONIO: 24 Q. Do you see anything in there</p>	<p style="text-align: right;">Page 61</p> <p>1 correct? 2 A. Yes. 3 Q. "The registrant shall inform 4 the field division of the DEA in this 5 area of suspicious orders when discovered 6 by the registrant." 7 Do you see that? 8 MS. HENN: Objection to 9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. The registrant shall inform 12 the field division office of the DEA in 13 this area of suspicious orders when 14 discovered by the registrant." 15 Do you see that? 16 A. Yes. I see that. 17 Q. Now, this says "when 18 discovered." Do you see those two words, 19 "when discovered"? 20 A. Yes. 21 Q. This doesn't say you can do 22 it three months after you find it. It 23 doesn't say you can -- you can report the 24 suspicious order four months after you</p>

<p style="text-align: right;">Page 62</p> <p>1 find it. This says when it's discovered, 2 you have responsibility to tell the DEA 3 about the fact that you're finding a 4 suspicious order; is that correct?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: It's 8 underlined in this document, "when 9 discovered."</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. All right. And it goes on 12 to even tell you -- it even tells you 13 what a suspicious order is supposed to 14 look like. It says -- it says, 15 "Suspicious orders include orders of 16 unusual size."</p> <p>17 Do you see that? Unusual 18 size. You would agree with that. That'd 19 be suspicious if it's an unusual size, 20 right?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 THE WITNESS: Yes.</p> <p>24 BY MR. PAPANTONIO:</p>	<p style="text-align: right;">Page 64</p> <p>1 Civil liability at the top of it. 2 Do you see that? 3 It says, "Civil liability." 4 It says, "A registrant who violates 842 5 is" -- "842(a)5 is subject to a civil 6 penalty of \$10,000 per occurrence." 7 Did you know that every time 8 you violated one of these statutes that 9 were you subject to a civic penalty of up 10 to \$10,000 every time you did it?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: I was aware 14 that there was a penalty for each 15 occurrence, yes.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Did you know it was \$10,000? 18 A. I wasn't exactly sure of the 19 monetary fine.</p> <p>20 Q. It says, "In other words, 21 McKesson is subject to a civil penalty up 22 to \$10,000 for each suspicious order or 23 activity that went unreported."</p> <p>24 Do you follow that? Each</p>
<p style="text-align: right;">Page 63</p> <p>1 Q. And you'd agree it would be 2 suspicious if it's -- if it's not a -- if 3 it's not a normal pattern. You'd agree 4 with that, right?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: It says 8 "deviating substantially from a 9 normal pattern."</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Right. You would agree that 12 would be suspicious, correct?</p> <p>13 A. Deviating substantially, 14 yes.</p> <p>15 Q. And you would agree that 16 unusual frequency of an order would be 17 suspicious, correct?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 THE WITNESS: Yes. Orders 21 of unusual frequency, size and 22 pattern. Those are the three.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Let's go to the next page.</p>	<p style="text-align: right;">Page 65</p> <p>1 activity that went unreported, or was not 2 reported when discovered.</p> <p>3 Do you see that?</p> <p>4 A. Yes, I see that.</p> <p>5 Q. And when -- do you see this, 6 sir, the word, sir, "when discovered"?</p> <p>7 Do you see those words in that statement, 8 "when discovered"? Do you see anything 9 in there that tells you that you're able 10 to report a suspicious order four months 11 after you get the suspicious order? Is 12 there anything in that statute that says 13 that?</p> <p>14 A. The statute says "when 15 discovered."</p> <p>16 Q. So you'd agree that if you 17 break this law, this is not -- this is a 18 serious violation, isn't it? \$10,000 19 fine is a pretty serious violation, isn't 20 it?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 THE WITNESS: I really can't 24 say if that's a serious --</p>

<p style="text-align: right;">Page 66</p> <p>1 BY MR. PAPANTONIO: 2 Q. Well, I mean, for most 3 people on the jury watching this, 4 \$10,000, if they have to pay \$10,000, 5 that's pretty serious, isn't it? 6 MS. HENN: Objection to 7 form. 8 THE WITNESS: It's a high 9 dollar amount, absolutely.</p> <p>10 BY MR. PAPANTONIO: 11 Q. Well, yeah. Is it an -- is 12 it an amount of money that got your 13 attention, as far as not being willing to 14 violate this statute? Does \$10,000 per 15 violation get your attention?</p> <p>16 MS. HENN: Objection to 17 form. 18 THE WITNESS: That would not 19 make my determination on, you 20 know, getting my attention. 21 Any fine would get my 22 attention.</p> <p>23 BY MR. PAPANTONIO: 24 Q. Okay. Certainly a \$10,000</p>	<p style="text-align: right;">Page 68</p> <p>1 BY MR. PAPANTONIO: 2 Q. Did you know that prior to 3 coming here today? 4 MS. HENN: Objection to 5 form. 6 THE WITNESS: I knew in 2008 7 that McKesson paid a settlement 8 fine, yes.</p> <p>9 BY MR. PAPANTONIO: 10 Q. And did you know that they 11 agreed that they had broken the law? 12 MS. HENN: Objection to 13 form.</p> <p>14 BY MR. PAPANTONIO: 15 Q. That your company admitted 16 that they knowingly broke the law dealing 17 with narcotic drugs?</p> <p>18 MS. HENN: Objection.</p> <p>19 BY MR. PAPANTONIO: 20 Q. Did you know that prior to 21 coming here today? 22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: I did not know</p>
<p>1 fine would get your attention, wouldn't 2 it? 3 A. It would. 4 Q. And we've also -- and we've 5 also established that, again, in defense 6 of you, you haven't seen this document 7 prior to today, correct? 8 A. That is correct. 9 Q. All right. The next page, 10 it says, "2008 settlement terms." 11 Do you see that? 12 A. Yes. 13 Q. Now, it says, "In 2008 14 McKesson entered into a settlement 15 agreement resolving claims under 21 16 U.S.C. 842(a)5 and C." 17 Now, did you -- did you know 18 prior to coming here today to testify 19 that before this document -- well, did 20 you know that in 2008 the DEA and the DOJ 21 caught you engaged in break -- caught 22 McKesson engaged in breaking the law? 23 MS. HENN: Objection to 24 form.</p>	<p style="text-align: right;">Page 69</p> <p>1 that. I know they paid the fine. 2 But I didn't know about the 3 agreement that they broke the law.</p> <p>4 BY MR. PAPANTONIO: 5 Q. Well, you were with them in 6 2008, weren't you? 7 A. Yes. 8 Q. And so nobody gave you the 9 details of them admitting that they broke 10 the law --</p> <p>11 MS. HENN: Objection.</p> <p>12 BY MR. PAPANTONIO: 13 Q. -- in dealing with 14 narcotics?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 THE WITNESS: I understood 18 that a fine was paid. And that 19 was my understanding.</p> <p>20 BY MR. PAPANTONIO: 21 Q. All right. Did anybody talk 22 to you about the things they had done 23 wrong prior to 2008? Did anybody tell 24 you, we did this wrong, we did that</p>

<p style="text-align: right;">Page 70</p> <p>1 wrong? Did anybody give you a list of 2 all the things that McKesson had done to 3 break the law and be fined in this 2008 4 settlement?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: I understood 8 that it was for not reporting what 9 was deemed suspicious orders by 10 DEA.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Well, did you take the time 13 to take a look at what they had done to 14 where the DEA said, "You broke the law, 15 McKesson," and then McKesson admits, 16 "Yeah, we broke the law"? Did you take a 17 look to see what they did to break the 18 law?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: Again, I was 22 not aware that we had broken the 23 law. I know that there was an 24 agreement to settle and that the</p>	<p style="text-align: right;">Page 72</p> <p>1 Q. Okay. Nobody told you that 2 McKesson admitted that they broke the 3 law? Prior to you coming here today, 4 that's the first time you've heard that; 5 is that correct?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 THE WITNESS: I understood 9 that we paid a settlement. That 10 is -- and I thought there was an 11 agreement that the settlement --</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Well, you just --</p> <p>14 MS. HENN: Counsel, could 15 you please --</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Go ahead go ahead.</p> <p>18 MS. HENN: -- let him finish 19 his answers. Thank you.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Go ahead.</p> <p>22 A. The settlement would be paid 23 and that McKesson would make changes but 24 not that there was, you know, guilt and</p>
<p style="text-align: right;">Page 71</p> <p>1 fine was paid.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Well, you paid a \$13 million 4 fine for that one thing in 2008, didn't 5 you?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Did you know that?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. \$13 million.</p> <p>14 MS. HENN: Same objection.</p> <p>15 THE WITNESS: I knew that 16 the fine was paid. And I knew 17 there was settlement and an 18 agreement. But I did not know 19 that there was, you know, the 20 amount -- the amount that was 21 paid, it was a settlement. I did 22 not know that there was wrongdoing 23 admitted.</p> <p>24 BY MR. PAPANTONIO:</p>	<p style="text-align: right;">Page 73</p> <p>1 admittance of not reporting the errors --</p> <p>2 Q. So --</p> <p>3 A. -- the way I understood it.</p> <p>4 Q. So you understood that 5 McKesson, just out of -- just paid 6 \$13 million? For what, you don't know 7 what it is, correct?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: No.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Is that right?</p> <p>13 A. No, that is not correct.</p> <p>14 What I understood was that 15 McKesson paid a settlement fine for not 16 reporting what the DEA deemed as 17 suspicious orders.</p> <p>18 Q. Well, it was more than that, 19 wasn't it, sir? You know that it 20 involved more than just suspicious 21 orders, don't you?</p> <p>22 A. I do not know that.</p> <p>23 Q. Is that the first time 24 you've heard it?</p>

<p style="text-align: right;">Page 74</p> <p>1 MS. HENN: Objection to 2 form. 3 THE WITNESS: You're saying 4 that it involved more? 5 BY MR. PAPANTONIO: 6 Q. Yes. 7 A. I don't know what more 8 you're referring to. 9 Q. Because you never took the 10 time to look at the settlement, did you? 11 MS. HENN: Objection to 12 form. 13 THE WITNESS: It was not my 14 responsibility to look at the 15 settlement. 16 BY MR. PAPANTONIO: 17 Q. Sir, it was your 18 responsibility to be a regulator for 19 McKesson that was selling narcotics to 20 the American public. That was your job, 21 wasn't it? 22 MS. HENN: Objection to 23 form. 24 THE WITNESS: My job was to</p>	<p style="text-align: right;">Page 76</p> <p>1 MS. HENN: Objection to 2 form. 3 THE WITNESS: What we should 4 be doing is reviewing purchases, 5 as it was stated in the 6 requirement, for size, pattern and 7 frequency, and then making a 8 determination if we deemed any of 9 those suspicious. 10 BY MR. PAPANTONIO: 11 Q. And if you don't do that, it 12 is unlawful, correct? 13 MS. HENN: Objection to 14 form. 15 BY MR. PAPANTONIO: 16 Q. It's breaking the law. If 17 you don't do what you just described, you 18 are breaking the law of the United 19 States, correct? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: In order to 23 meet the requirement, you need to 24 do that.</p>
<p style="text-align: right;">Page 75</p> <p>1 review purchases that were made by 2 customers on a daily basis and to 3 look at what customers are 4 purchasing, the amount they are 5 purchasing, the quantity that they 6 are purchasing. That was my 7 responsibility as the regulatory 8 director over Landover 9 distribution center. 10 BY MR. PAPANTONIO: 11 Q. And in that responsibility, 12 we've already, within the last half hour, 13 established that nobody has even shown 14 you this document that we're looking at 15 called "In the Matter of McKesson 16 Corporation," nobody showed that to you, 17 right? 18 A. I have not seen this 19 document. 20 Q. And nobody showed you the 21 2008 settlement that McKesson had with 22 the DEA and the Department of Justice to 23 instruct you about what you should or 24 should not be doing as a regulator?</p>	<p style="text-align: right;">Page 77</p> <p>1 BY MR. PAPANTONIO: 2 Q. All right. And then so you 3 said -- I think you just mentioned that 4 in 2008 it's your understanding that 5 McKesson settled with the Department of 6 Justice and agreed to do what? Do you 7 know what they agreed to do? 8 A. From the way I understood 9 it, McKesson would report suspicious 10 orders on a more ongoing basis to 11 determine if customers were purchasing in 12 the correct amount for their size 13 business. 14 Q. Sir, you see the second 15 paragraph, okay. Look, you can read 16 this. It says, "McKesson agreed to 17 implement a program designed to detect 18 and prevent diversion of controlled 19 substances." 20 Do you see where it says 21 that? 22 MS. HENN: Objection to 23 form. 24 And, Counsel, I'd appreciate</p>

	Page 78	Page 80
1 it if you would treat the witness 2 a little more respectfully. 3 BY MR. PAPANTONIO: 4 Q. Do you see that, sir? 5 A. Yes, the second bullet says 6 that. 7 MR. PAPANTONIO: I'm trying 8 to speak up. 9 BY MR. PAPANTONIO: 10 Q. All right. And can you hear 11 me okay, Mr. Oriente? 12 A. Yes, I can. Thanks. 13 Q. So McKesson agreed to 14 implement a program designed to detect 15 and prevent diversion of controlled 16 substances. 17 Now, if I got it right, you 18 were supposed to already be doing that 19 prior to 2008, weren't you? Weren't 20 you -- 21 MS. HENN: Objection to 22 form. 23 MR. PAPANTONIO: Emily, 24 would you let me finish?	1 to detect and prevent diversion of 2 controlled substances long before 2008, 3 right? You know that? 4 A. We had a program prior to 5 2008. 6 Q. This says, "McKesson agreed 7 to implement a program designed to detect 8 and prevent diversion of controlled 9 substance." 10 That's what you agreed to in 11 2008, correct? 12 MS. HENN: Objection to 13 form. 14 THE WITNESS: It is in this 15 document. When you say "you 16 agreed to," it is not me, because 17 prior to this we had a manual 18 system, and we would look at 19 purchases, so we were always 20 looking at purchases. It was a 21 manual system. And I'm just 22 telling you. 23 And so it would be people 24 looking at reports to determine	
	Page 79	Page 81
1 MS. HENN: I refer to you as 2 counsel -- 3 MR. PAPANTONIO: Oh, 4 counsel. 5 MS. HENN: -- and I would 6 prefer that you refer to me -- 7 MR. PAPANTONIO: Okay. 8 However you want me to -- 9 MS. HENN: -- with respect, 10 not by my first name. 11 MR. PAPANTONIO: I'm sorry. 12 Tell me your last name. 13 MS. HENN: My last name is 14 Henn. But counsel will be -- 15 MR. PAPANTONIO: Henn. So 16 I'll call you Ms. Henn. Is that 17 okay? 18 MS. HENN: Yes. 19 MR. PAPANTONIO: All right, 20 Ms. Henn. 21 BY MR. PAPANTONIO: 22 Q. So let me be clear about 23 something. You know that you were 24 supposed to implement a program designed	1 amounts that customers were 2 buying. 3 Since 2008 there was an 4 automated system put in place that 5 would assist in that process. But 6 there was always a system in place 7 to detect and look at what was 8 being purchased. It wasn't like 9 it started in 2008. 10 BY MR. PAPANTONIO: 11 Q. Okay. So you're saying in 12 2008 you had a new and improved program 13 that was going to keep track of 14 suspicious orders. Is that your 15 testimony? It was new improved? 16 MS. HENN: Objection to 17 form. 18 THE WITNESS: I would say 19 it's not new. It was enhanced to 20 be a system-generated, allowed 21 things to be more efficiently 22 identified, allow us to review 23 more quickly. 24 BY MR. PAPANTONIO:	

1 Q. And your prior system was so 2 bad that the DEA and the Department of 3 Justice actually fined you \$13 million 4 because you were not reporting suspicious 5 orders, correct? 6 MS. HENN: Objection to 7 form. 8 THE WITNESS: I would not 9 say that it was a bad system. We 10 were fined for not reporting what 11 DEA deemed as suspicious orders. 12 BY MR. PAPANTONIO: 13 Q. Well, I mean, you weren't 14 doing your job? 15 MS. HENN: Counsel. 16 BY MR. PAPANTONIO: 17 Q. You were breaking the law, 18 correct? 19 MS. HENN: Mr. Oriente, did 20 you finish your last answer? 21 THE WITNESS: I was going to 22 add more, that the determination 23 of a suspicious order is when the 24 wholesaler has an order, they look	Page 82 1 Q. Right. Let's go to the next 2 page. You see the next page, Page 8. It 3 says, "Failure to report timeline." 4 Now, do you see -- turn that 5 next page, Mr. Oriente. 6 MS. HENN: Are you referring 7 to Page 9, Counsel? 8 MR. PAPANTONIO: Page 9. It 9 says Page 9, yeah. 10 BY MR. PAPANTONIO: 11 Q. Okay. It says, "Failure to 12 report timeline." 13 Do you see that? 14 A. Yes. 15 Q. Now, had anybody prior to 16 you coming here today told you that the 17 DEA did an investigation on Landover, and 18 they made records and they made 19 presentations right in this document that 20 show how many times McKesson violated the 21 agreement of 2008 by not reporting 22 suspicious orders? Had anybody shared 23 any time talking to you about that? 24 MS. HENN: Objection to
1 at pattern of ordering, size, 2 frequency, quantity. And then a 3 determination, is that order 4 suspicious or not. 5 BY MR. PAPANTONIO: 6 Q. Okay. 7 A. If we don't report that 8 order as suspicious because we felt that 9 that particular customer has followed 10 that pattern of ordering previously, then 11 that may be why that order was not 12 reported. 13 Q. Well, we know this much. 14 Prior to 2008, that system that you just 15 described, it wasn't working, was it? 16 Because the DEA and the DOJ hit you for a 17 \$13 million fine for not reporting 18 suspicious orders. We know that much, 19 correct? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: That did occur 23 in 2008. 24 BY MR. PAPANTONIO:	Page 83 1 form. 2 THE WITNESS: Could you 3 repeat the question? 4 BY MR. PAPANTONIO: 5 Q. Yeah, I'll be glad to. 6 Prior to coming here today -- you had -- 7 three weeks ago, you knew you were coming 8 here today, right? 9 A. Yes. 10 Q. Did anybody from McKesson -- 11 I'm not interested in what you said to 12 your lawyers. I'm interested in what 13 McKesson -- did anyone at McKesson sit 14 down with you and go over the list of 15 things that they did to violate the 2008 16 agreement where you were found -- your 17 company was found to have engaged in 18 unlawful contact -- conduct and fined 19 \$13 million? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: Since the 23 three weeks back or ever? 24 BY MR. PAPANTONIO:

Page 86	Page 88
<p>1 Q. How about -- let's go with 2 ever, Mr. Oriente. Let's go with ever. 3 Did McKesson -- anybody from 4 McKesson sit down with you and say, 5 "Listen, we have an agreement. We paid 6 our \$13 million, and as of 2008 we now 7 have an agreement. And the agreement 8 says that we're supposed to do A, B, and 9 C."</p> <p>10 Has anybody shared that 11 agreement with you?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 THE WITNESS: The -- what 15 was shared with me, was that we 16 would be sharing suspicious orders 17 on a more frequent basis.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. All right. So in other 20 words, okay, if you didn't do that, if 21 you didn't follow that agreement, where 22 you were fined \$13 million, you would be 23 engaged in unlawful conduct, yes or no?</p> <p>24 MS. HENN: Objection to</p>	<p>1 law, Mr. Oriente, yes or no? 2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: As the way 5 it's written, yes.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Okay. Let's go to the next 8 page. It's Page 10. It says, "Failure 9 to report timeline."</p> <p>10 Do you see that?</p> <p>11 And then the first thing it 12 has there, it says, "May 2nd, 2008, 13 settlement."</p> <p>14 Do you see that? That's 15 what we've been talking about, 16 Mr. Oriente. Do you see that?</p> <p>17 A. Yes, yes.</p> <p>18 Q. And then it says, "On 19 July 15, 2011, the DEA requested a list 20 of McKesson's top 20 purchase" -- 21 "purchasers of oxycodone, oxymorphone, 22 hydrocodone, and alprazolam."</p> <p>23 Do you see that?</p> <p>24 A. Yes, that's here.</p>
Page 87	Page 89
<p>1 form.</p> <p>2 THE WITNESS: Since the 2008 3 agreement, McKesson agreed to 4 report suspicious orders on a more 5 regular basis.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And if you didn't do that, 8 you would be engaged in unlawful conduct, 9 correct?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 THE WITNESS: That would be 13 correct.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. You would be breaking the 16 law, just breaking the law; is that 17 correct?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Yes?</p> <p>22 A. We would be out of 23 compliance.</p> <p>24 Q. You would be breaking the</p>	<p>1 Q. And then it says, "CSMP 2 files" -- they requested files for 3 Accokeek Drug Healthcare and Family Meds. 4 Do you see that?</p> <p>5 A. Yes.</p> <p>6 Q. And it says, "Purchase 7 history for Accokeek," right?</p> <p>8 A. Yes.</p> <p>9 Q. And tell me which one of 10 those -- those pharmacies you're familiar 11 with?</p> <p>12 A. Both Accokeek and Family 13 Meds.</p> <p>14 Q. How are you familiar with 15 them personally?</p> <p>16 A. I made site visits to 17 Accokeek pharmacy and met with the 18 pharmacists. Part of our program for 19 controlled substance monitoring was to 20 make pharmacy visits, and so I had been 21 to Accokeek pharmacy.</p> <p>22 Q. So you had -- you had direct 23 contract -- contact with Accokeek, right?</p> <p>24 A. I did.</p>

<p style="text-align: right;">Page 90</p> <p>1 Q. And who else did you have 2 direct contact with? 3 A. Family Meds, I believe, is 4 the same owner as Accokeek, if I recall. 5 Q. Okay. All right. And it 6 says that the -- it says as of July 15, 7 2011, they requested a list of the top 20 8 purchases.</p> <p>9 And, sir, you would agree 10 that the reason that you report this kind 11 of information to the DEA of suspicious 12 orders is because they have -- you have 13 to be part of the policing in the -- in 14 the sale of narcotics. That's what a 15 distributor is. You have to be part of 16 the policing to keep narcotics running -- 17 you know, running in a way they are 18 supposed to run, correct?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: We are 22 responsible as a distributor to 23 have a program in place that would 24 monitor controlled substance</p>	<p style="text-align: right;">Page 92</p> <p>1 use of drugs, correct? 2 MS. HENN: Objection to 3 form. 4 THE WITNESS: In what case 5 are you referring to? In the case 6 of Accokeek?</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. No, no particular case. As 9 a broad statement, the reasons that you 10 were supposed to report suspicious orders 11 is because one thing you wanted to try to 12 prevent was the criminal use of drugs, 13 correct?</p> <p>14 A. If -- if we deemed an order 15 suspicious and -- and we would report it 16 to prevent diversion.</p> <p>17 Q. And that is criminal use of 18 drugs, correct? That's one diversion is 19 criminal use of drugs?</p> <p>20 A. For nonmedical purpose, yes.</p> <p>21 Q. And you clearly knew in 2011 22 that there was already, as you said, you 23 already understood there was an opioid 24 drug crisis in America, correct?</p>
<p style="text-align: right;">Page 91</p> <p>1 sales.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. In fact, you were actually 4 part of the policing of the drug sales, 5 correct? Your organization, McKesson, or 6 any distributor is part of that policing 7 process, aren't you?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: Part of our 11 requirement as a distributor and 12 registrant is to have a monitoring 13 program in place, yes.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. And certainly, on July 15th, 16 2011, you were aware that there was also 17 a drug crisis that was taking place, an 18 opioid drug crisis taking place in 19 America. You knew that, didn't you?</p> <p>20 A. I knew that there was high 21 opioid problem, yes.</p> <p>22 Q. And you were supposed to 23 report this information because you 24 wanted to make sure there was no criminal</p>	<p style="text-align: right;">Page 93</p> <p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. You knew that?</p> <p>5 A. Yes.</p> <p>6 Q. And you knew that there was 7 actually -- that there was occurrences 8 that were even characterized as the oxy 9 express. Have you ever heard of the oxy 10 express?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: I have heard 14 of the oxy express. I believe 15 that was a problem in Florida 16 coming up the east coast.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Well, as a matter of fact, 19 it came up right into the area that you 20 were part of a distributor, right in your 21 part of the country. The oxy express 22 came right up to where you were a 23 distributor. So where -- excuse me, 24 where you were a regulator for the</p>

<p style="text-align: right;">Page 94</p> <p>1 distribution of McKesson narcotics. You 2 knew that, right? 3 MS. HENN: Objection to 4 form. 5 BY MR. PAPANTONIO: 6 Q. I'm going to -- let me 7 repeat the question, because I want to be 8 clear about this. 9 You knew in 2011 that the 10 oxy express ran right through the very 11 territory where you were working as a 12 regulator for the sale in regard to the 13 sale of narcotic drugs for McKesson. You 14 knew that, didn't you? 15 MS. HENN: Objection to 16 form. 17 THE WITNESS: I didn't know 18 that it was specifically at any 19 one pharmacy. I knew that it was 20 along the east coast. 21 BY MR. PAPANTONIO: 22 Q. You didn't know where it 23 ended? 24 MS. HENN: Objection to</p>	<p style="text-align: right;">Page 96</p> <p>1 unless there was a glut of opioids out in 2 the market? 3 A. I have not heard that 4 before, no. 5 Q. All right. Let's go to the 6 next page here. It says, "Failure to 7 report timeline. Between May 2008 and 8 July 15, 2011, McKesson did not submit a 9 single suspicious order." 10 Do you see that? 11 MR. PAPANTONIO: Could you 12 underline this for me, Evan? If 13 you don't mind, I want you to 14 underline between May 2008 and 15 July 15, 2011, McKesson did not 16 submit a single suspicious order. 17 BY MR. PAPANTONIO: 18 Q. Do you see that? 19 A. I see that. 20 Q. And you, sir, were working 21 as a regulator between 2008 and 22 July 2011. That was your job as a 23 regulator, right? 24 MS. HENN: Objection to</p>
<p style="text-align: right;">Page 95</p> <p>1 form. 2 THE WITNESS: From my 3 understanding it went all the way 4 up to Boston. 5 BY MR. PAPANTONIO: 6 Q. And you -- so it covered the 7 very territory -- some of the very 8 territory you worked, the oxy express? 9 MS. HENN: Objection to 10 form. 11 BY MR. PAPANTONIO: 12 Q. Right? 13 A. The oxycodone problem was 14 along the entire east coast. 15 Q. And the only way the oxy 16 express could work is there was a glut of 17 opioids out there -- for the oxy express 18 to work, there had to be extra drugs out 19 on the market, correct? 20 MS. HENN: Objection to 21 form. 22 BY MR. PAPANTONIO: 23 Q. Have you ever heard that, 24 that the oxy express could not operate</p>	<p style="text-align: right;">Page 97</p> <p>1 form. 2 THE WITNESS: Yes, that was 3 part of my job. 4 BY MR. PAPANTONIO: 5 Q. And you, sir -- so if we 6 read this right, you never were involved 7 in submitting one single suspicious order 8 to the DEA even after you had already 9 been fined -- McKesson had already been 10 fined \$13 million the first time, right? 11 A. In this time period from 12 2008 to 2011 -- 13 Q. We're talking almost four 14 years. 15 MS. HENN: Counsel. 16 BY MR. PAPANTONIO: 17 Q. I'm sorry. Go ahead. 18 A. In this time period between 19 2008 and 2011, I know that I had 20 customers that we stopped doing business 21 with. As far as the suspicious order 22 reporting, I don't recall the exact 23 number. Here it's saying that it did not 24 submit a single one.</p>

Page 98	Page 100
<p>1 Q. The exact number --</p> <p>2 MS. HENN: Counsel.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. I'm sorry. Go ahead.</p> <p>5 A. But I do not recall the</p> <p>6 exact number that that would have been.</p> <p>7 I know that we had customers that we</p> <p>8 would stop doing business with. But as</p> <p>9 far as a single suspicious order, I'm not</p> <p>10 familiar with that.</p> <p>11 Q. Well, the number here, sir,</p> <p>12 there are no numbers.</p> <p>13 A. Right.</p> <p>14 Q. They're saying zero.</p> <p>15 A. Mm-hmm.</p> <p>16 Q. Your company was fined</p> <p>17 \$13 million for breaking the law in 2008,</p> <p>18 right? And then your company, McKesson,</p> <p>19 agreed to say, oh, we're going to do</p> <p>20 better. Isn't that what you told me a</p> <p>21 few minutes ago? We're going to do</p> <p>22 better?</p> <p>23 MS. HENN: Objection to</p> <p>24 form.</p>	<p>1 Q. McKesson, not you, but</p> <p>2 McKesson is breaking the law?</p> <p>3 A. If there were --</p> <p>4 MS. HENN: Objection to form</p> <p>5 go ahead.</p> <p>6 THE WITNESS: If there were</p> <p>7 suspicious orders during that</p> <p>8 period and we did not report them,</p> <p>9 then yes.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. You're breaking the law.</p> <p>12 A. And the second thing is, if</p> <p>13 there were no suspicious orders at that</p> <p>14 time, you are absolutely violating your</p> <p>15 2008 agreement with the Department of</p> <p>16 Justice where you said you were going to</p> <p>17 build an enhanced program, right?</p> <p>18 MS. HENN: Objection to</p> <p>19 form.</p> <p>20 THE WITNESS: We did build</p> <p>21 that enhanced program.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. I'm looking at the enhanced</p> <p>24 program. The enhanced program says that</p>
<p>1 THE WITNESS: What I -- what</p> <p>2 I said was we had enhanced the</p> <p>3 program to identify suspicious</p> <p>4 orders, yes.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. So let me get this right.</p> <p>7 This is your enhanced program. Between</p> <p>8 2008 and 2011, your enhanced program</p> <p>9 reported zero suspicious orders. That's</p> <p>10 the enhanced program that you're talking</p> <p>11 about?</p> <p>12 A. The -- I can't say exactly</p> <p>13 what would have been suspicious between</p> <p>14 that time period because I don't -- I</p> <p>15 don't have that information. What --</p> <p>16 Q. This -- go ahead.</p> <p>17 A. But what I was going to say</p> <p>18 is that, according to this document,</p> <p>19 yeah, zero orders were reported.</p> <p>20 Q. Okay. And if zero orders</p> <p>21 are reported, A, you were breaking the</p> <p>22 law, correct?</p> <p>23 MS. HENN: Objection.</p> <p>24 BY MR. PAPANTONIO:</p>	<p>1 between 2008 and 2011, the enhanced</p> <p>2 program didn't report one suspicious</p> <p>3 order. Do you understand what I'm saying</p> <p>4 here, Mr. Oriente?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 THE WITNESS: No orders were</p> <p>8 reported during that time period.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Gotcha.</p> <p>11 A. We were still monitoring and</p> <p>12 watching what purchases were being made.</p> <p>13 Q. Okay. Where is it -- you</p> <p>14 tell me anywhere, in everything that</p> <p>15 we've just reviewed so far, that it says</p> <p>16 that you can monitor and not report a</p> <p>17 suspicious order?</p> <p>18 MS. HENN: Objection.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. You tell me where I'm</p> <p>21 supposed to find that law. I'll go to it</p> <p>22 right now. We'll talk about it. Where</p> <p>23 is the law that says all you have to do</p> <p>24 is monitor and not report suspicious</p>

Page 102	Page 104
<p>1 orders?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: We have to --</p> <p>5 we have to report suspicious</p> <p>6 orders if identified as</p> <p>7 suspicious.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Right. Right. And you</p> <p>10 identified no suspicious orders between</p> <p>11 2008 and 2011 under your new, improved,</p> <p>12 enhanced program, correct? That's what</p> <p>13 this says, isn't it?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: That's what</p> <p>17 this says.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Okay. And it says -- as a</p> <p>20 matter of fact, it says, in fact,</p> <p>21 McKesson did not submit a suspicious</p> <p>22 order until November of 2011.</p> <p>23 Do you see that?</p> <p>24 A. Yes, I see that.</p>	<p>1 THE WITNESS: No, it wasn't</p> <p>2 me. There was a phone beeping.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. And then the next paragraph</p> <p>5 is -- is -- it says, "McKesson did not</p> <p>6 submit a suspicious order until November</p> <p>7 of 2011, but that was four months after</p> <p>8 the DEA requested the information,</p> <p>9 customer lists, and the files for</p> <p>10 Accokeek and Family Meds Incorporated,"</p> <p>11 right?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. That's what it says, right?</p> <p>16 A. That's what -- yeah, that's</p> <p>17 what --</p> <p>18 Q. All right.</p> <p>19 A. -- this bullet is saying,</p> <p>20 that they requested the 20 top customers</p> <p>21 and files for Accokeek and Family Meds.</p> <p>22 Q. All right, sir. As we go</p> <p>23 forward, I want to be very clear about</p> <p>24 something. It was not your -- what you</p>
<p>1 Q. And then underneath it says,</p> <p>2 "Four months after DEA requested the top</p> <p>3 customer list and CSMP files for Accokeek</p> <p>4 and Family Meds."</p> <p>5 Do you see that? Take a</p> <p>6 minute and read -- take a minute and read</p> <p>7 that. I want you to get that in your</p> <p>8 head before I ask you questions about it.</p> <p>9 "Four months after DEA requested the top</p> <p>10 20 customer list and the CSMP files for</p> <p>11 Accokeek and Family Meds is the first</p> <p>12 time that McKesson submitted a suspicious</p> <p>13 order."</p> <p>14 Do you see that?</p> <p>15 A. Yes, I see that.</p> <p>16 Q. All right. So if I'm</p> <p>17 reading this right, four years -- I mean,</p> <p>18 between 2008 and 2011, there's no</p> <p>19 suspicious orders reported by McKesson,</p> <p>20 if we take that first paragraph, right?</p> <p>21 And then -- sir, did you</p> <p>22 want to say something?</p> <p>23 MS. HENN: That was the</p> <p>24 phone.</p>	<p>1 told me at the beginning of this</p> <p>2 deposition, that it was the lawyers for</p> <p>3 McKesson who was supposed to be reporting</p> <p>4 the suspicious orders. Is that what you</p> <p>5 told me?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: No. What I</p> <p>9 said was when requests came in for</p> <p>10 customer files like for Accokeek</p> <p>11 and Family Meds, that request</p> <p>12 would go from me to our legal</p> <p>13 department for them to pull the</p> <p>14 reports to send to Accokeek and</p> <p>15 Family Meds.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. So did you personally do any</p> <p>18 reporting of suspicious orders between</p> <p>19 2008 and 2011? Did you?</p> <p>20 A. I don't recall the exact</p> <p>21 amount that I would have done. I</p> <p>22 don't -- I don't remember how many</p> <p>23 customers I would have sent in to DEA,</p> <p>24 nor if I reported any orders. It's seven</p>
Page 103	Page 105

Page 106	Page 108
<p>1 to 10 years ago.</p> <p>2 Q. Well, I understand that.</p> <p>3 But, so we have to go -- the only</p> <p>4 document we have is the DEA investigation</p> <p>5 that says that between May 2008 and</p> <p>6 July 2011, McKesson did zero reports,</p> <p>7 correct?</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. That's all we have to go by.</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: That's what is</p> <p>15 listed here, yes.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Yeah. And let's go to</p> <p>18 the -- let me ask you something. If this</p> <p>19 is true, if it's true that between 2008</p> <p>20 and 2011 that there were suspicious</p> <p>21 orders that were reported to McKesson,</p> <p>22 but McKesson did not report them to the</p> <p>23 DEA, that would be breaking the law,</p> <p>24 correct?</p>	<p>1 suspicious order, we report a</p> <p>2 suspicious order.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. So according --</p> <p>5 A. If you don't identify a</p> <p>6 suspicious order, you don't report it.</p> <p>7 Q. Okay. Right. So according</p> <p>8 to Mr. Oriente, there were no suspicious</p> <p>9 orders that were identified between May</p> <p>10 2008 and July of 2011. According to</p> <p>11 Mr. Oriente, there were no suspicious</p> <p>12 orders identified by McKesson during that</p> <p>13 period of time; is that right?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: What -- what I</p> <p>17 said was if we identified a</p> <p>18 suspicious order, we would report</p> <p>19 it. I can't say that one was</p> <p>20 identified and not reported</p> <p>21 because I do not know that.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Well, if we go by this</p> <p>24 document, which is an investigation that</p>
<p>1 MS. HENN: Objection to</p> <p>2 form.</p> <p>3 THE WITNESS: They would not</p> <p>4 have been reported to McKesson.</p> <p>5 McKesson would have identified</p> <p>6 them as suspicious.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Okay. Fine. If McKesson</p> <p>9 identified -- identified suspicious</p> <p>10 orders --</p> <p>11 A. Right.</p> <p>12 Q. -- and failed to report them</p> <p>13 to the DEA, that would be breaking the</p> <p>14 law, wouldn't it?</p> <p>15 A. If McKesson identified a</p> <p>16 suspicious order, McKesson would have</p> <p>17 reported a suspicious order.</p> <p>18 Q. You believe they would have</p> <p>19 reported. But this says they did not.</p> <p>20 MS. HENN: Objection to</p> <p>21 form.</p> <p>22 THE WITNESS: This says they</p> <p>23 didn't report any. So what I'm</p> <p>24 saying is, if we identified a</p>	<p>1 was done by the U.S. government,</p> <p>2 Department -- the DEA and the Department</p> <p>3 of Justice, if we go by this document, it</p> <p>4 says that under this enhanced program,</p> <p>5 that McKesson had in place, there were</p> <p>6 zero suspicious orders reported during</p> <p>7 that time between 2008 and 2011, right?</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. If we go by this document.</p> <p>12 A. That's what -- yes.</p> <p>13 Q. Do you have any reason to</p> <p>14 believe --</p> <p>15 MS. HENN: Can you let the</p> <p>16 witness finish his answers?</p> <p>17 MR. PAPANTONIO: Yeah. I'm</p> <p>18 sorry.</p> <p>19 THE WITNESS: I was going to</p> <p>20 say, that's what the document has</p> <p>21 listed here, that there were none</p> <p>22 reported between May of 2008 and</p> <p>23 July 15th of 2011.</p> <p>24 BY MR. PAPANTONIO:</p>
	Page 109

Page 110	Page 112
<p>1 Q. Do you have any independent 2 knowledge, sir, about the DEA taking it 3 on themselves to phony -- phony up 4 information and lie about what we're 5 reporting right here?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 THE WITNESS: No, I would 9 not believe that.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. I wouldn't believe -- no, 12 that's what I'm -- I want to make sure 13 you're not taking the position that what 14 the DEA is representing here, that there 15 were zero suspicious orders between 2008 16 and 2011. You're not taking the position 17 that the DEA in any way lied about that, 18 right?</p> <p>19 A. No, absolutely not.</p> <p>20 Q. All right. That's good.</p> <p>21 MS. HENN: Counsel, there 22 have been additional beeps. 23 You've heard them. Can we ask 24 anyone on the phone who's not yet</p>	<p>1 October 25th, 2011, the DEA requested the 2 CSMP files for ten additional McKesson 3 customers, including Drug City, Judy's 4 Drug Store, and Herndon Pharmacy.</p> <p>5 Now, first of all, tell the 6 jury what is -- at this point, they've 7 probably heard this already, but tell 8 them what a CSMP is?</p> <p>9 A. CSMP is an acronym for 10 controlled substance monitoring program.</p> <p>11 Q. And that was your 12 responsibility to run a controlled 13 substance monitoring program at McKesson, 14 right?</p> <p>15 A. I used the controlled 16 substance monitoring program, yes. It 17 was a corporatewide program that was used 18 by myself to review customers of their 19 controlled purchases.</p> <p>20 Q. Is that the same controlled 21 substance program that failed to report a 22 single suspicious order between 2008 and 23 2011? Is that the same suspicious -- is 24 that the same CSMP we're talking about</p>
<p>1 noted their appearance and is 2 listening in to please do so now.</p> <p>3 Is there anyone on the phone 4 who has not yet noted their 5 appearance?</p> <p>6 MR. PAPANTONIO: All right.</p> <p>7 THE WITNESS: Must not be.</p> <p>8 MR. PAPANTONIO: I guess 9 not.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Let's go to the next page, 12 Page 12. Just turn one page over there 13 if you would, Mr. Oriente.</p> <p>14 It continues. The headline 15 on this DEA report, Department of Justice 16 report, is, "Failure to Report Timeline." 17 And we're talking about McKesson; is that 18 correct? Right. The cover on this is -- 19 is "In the Matter of McKesson 20 Corporation," right?</p> <p>21 A. Yes.</p> <p>22 Q. And this says, "Failure to 23 report timeline." And the first -- the 24 very first thing we see there is on</p>	<p>1 here?</p> <p>2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: There was one 5 CSMP. There was one program.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. All right. So the CSMP is 8 the same one that we're talking about 9 that failed to report even one suspicious 10 order for three and a half years, right?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: That would be 14 the same program.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Then it goes on to say -- 17 now, I want to ask you. Which one of 18 these -- Drug City, Judy's Drug, and 19 Herndon Pharmacy, which one of those did 20 you have personal involvement with?</p> <p>21 A. I was responsible for all 22 three customers. I made site visits to 23 Drug City. And I also made site visits 24 to Herndon Pharmacy. Herndon Pharmacy</p>

Page 114	Page 116
<p>1 was actually one of the customers that I 2 turned off and reported to DEA. 3 Q. Right. We're going to talk 4 about that in just a minute. So you 5 actually -- you actually were hands-on 6 with these drug stores, right, these 7 pharmacies?</p> <p>8 A. The Drug City and Herndon I 9 made actual physical site visits to. I 10 don't recall visiting Judy's, no.</p> <p>11 Q. Okay. And the next line 12 is -- it says, "On November 8, 2011, 13 McKesson ceased shipping controlled 14 substances to Herndon Pharmacy."</p> <p>15 Do you see that?</p> <p>16 A. Yes, sir.</p> <p>17 Q. Now, that's 2011. And 18 that's less than one month after the DEA 19 requested the CSMP file. Do you 20 remember? They requested the file. And 21 then right after they requested the file, 22 you say that you cut-off Herndon after -- 23 after that request; is that right?</p> <p>24 MS. HENN: Objection to</p>	<p>1 filling prescriptions for. 2 I remember this one very 3 intimately because the doctor was 4 Dr. Salerian in Washington D.C., 5 And he was a psychiatrist, and he 6 was writing prescriptions for 7 oxycodone.</p> <p>8 And when I visited Herndon 9 Pharmacy, Herndon Pharmacy 10 would -- we would get pharmacy 11 information from the pharmacy to 12 see how many doctors they were 13 filling for and a percent of a 14 certain doctor. And that one 15 doctor was greater than 80 percent 16 of his oxycodone business.</p> <p>17 And the distance from the 18 doctor's office all the way out to 19 Herndon Pharmacy in Herndon, 20 Virginia was, I think, greater 21 than 25 miles. And between the 22 distance and the fact that one 23 doctor was greater than 80 percent 24 of the oxycodone, I made a</p>
<p>1 form.</p> <p>2 THE WITNESS: I turned off 3 Herndon Pharmacy as I was doing my 4 due diligence and research on that 5 particular customer.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And so is it just a 8 coincidence that one month after the DEA 9 requested the CSMP files on Herndon 10 Drugs, you made the determination, less 11 than one month after that, that you were 12 going to terminate them? Is that 13 coincidence?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 THE WITNESS: My decision 17 had nothing to do with the DEA 18 request for top customers. What I 19 would have been looking at is how 20 much Herndon Pharmacy had 21 purchased, their percentage of 22 controls to RX, what type of 23 controls were they purchasing, 24 what doctors the pharmacy was</p>	<p>1 decision that -- to cease selling 2 controlled substances to Herndon.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Right.</p> <p>5 A. Herndon Pharmacy then 6 brought a lawsuit against McKesson 7 because I did terminate selling controls 8 to him.</p> <p>9 Q. And you terminated them one 10 month --</p> <p>11 A. That --</p> <p>12 Q. Wait a second.</p> <p>13 You terminated them less 14 than one month after the DEA in 2011 15 said, "We want the records on Herndon." 16 That's a correct statement, isn't it?</p> <p>17 A. I would not have known that 18 Herndon was one that was sent in to DEA.</p> <p>19 Q. Well, so it's purely 20 coincidental? Is that what we're saying 21 here?</p> <p>22 A. Herndon was one of my top 23 customers that I was looking at. The 24 fact that they were also on the list to</p>

<p style="text-align: right;">Page 118</p> <p>1 DEA was not my -- you know, did not make 2 my decision based off of what I found in 3 doing my due diligence of the doctor, the 4 distance, the type of controls that he 5 was purchasing for me to make the 6 decision to recommend turning him off.</p> <p>7 Q. Okay. But between 2008 and 8 2011, that's the first time that you ever 9 did that, isn't it?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. It's the first time that you 14 closed a pharmacy down between 2008 and 15 2011, right?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: It may have 19 been in Landover.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Yeah.</p> <p>22 A. But I'm not aware. I would 23 have to go and see what other customers I 24 had between '8 and '11 at other</p>	<p style="text-align: right;">Page 120</p> <p>1 words, you -- there were things that 2 Herndon was doing that was suspicious to 3 you; is that correct? Long before they 4 were closed down; is that your testimony?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: We look at all 8 customers. And I would have been 9 looking at Herndon as one of my 10 customers. And then once I made 11 the determination that it was 12 suspicious, we turned them off.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. How many years were you 15 doing business with Herndon before you 16 simply turn them off after the DEA asked 17 for their files? How many years have you 18 been doing business?</p> <p>19 A. I do not know when Herndon 20 Pharmacy exactly started with McKesson. 21 I don't know --</p> <p>22 Q. Were they -- go ahead.</p> <p>23 A. It could have been a newer 24 pharmacy. It may have been a year. I do</p>
<p style="text-align: right;">Page 119</p> <p>1 distribution centers that may have been 2 turned off.</p> <p>3 Q. So between 2008 and 2011, 4 Mr. Oriente, that's you, reports no 5 suspicious orders, closes no pharmacies 6 down. And then, after the DEA in 7 October 2011 says, "Hey, we want the 8 files on Herndon drugs," that's when you 9 close them down, one month later?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Is that -- is that right?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 THE WITNESS: It would have 17 been more than one month that I 18 was looking at Herndon Pharmacy. 19 So I would have been looking at 20 Herndon Pharmacy prior to the DEA 21 requesting their top -- or 22 McKesson's top customers. So...</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. So you had -- so in other</p>	<p style="text-align: right;">Page 121</p> <p>1 not know that, when Herndon started with 2 McKesson.</p> <p>3 Q. You don't -- you don't know 4 that Herndon Pharmacy was there with 5 Landover the entire time that Landover 6 was in operation. That's what your 7 testimony is?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: I don't know 11 when Herndon Pharmacy opened with 12 McKesson as a customer. Yeah, I 13 don't have that date in my head.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. All right. So just to be 16 clear, prior to the time that the DEA 17 says, "Give us the files on Herndon 18 Pharmacy," you had, first of all, never 19 reported a suspicious order on Herndon; 20 B, you determined that you would close 21 them down one month after the DEA 22 requested their files; is that correct?</p> <p>23 MS. HENN: Objection to 24 form.</p>

Page 122	Page 124
<p>1 THE WITNESS: As I said, my 2 investigation of Herndon Pharmacy 3 would not have been done in four 4 weeks. It would have been ongoing 5 before the DEA asked for the list 6 of top 20 customers.</p> <p>7 So during my research of 8 Herndon which included site 9 visits, going past where the 10 doctor was located, seeing the 11 distance from the doctor to the 12 pharmacy, looking at their percent 13 of controlled substances that they 14 were purchasing -- excuse me -- 15 purchasing, that would have taken 16 time.</p> <p>17 And then when I received the 18 information that I had, made my 19 report, I requested and submitted 20 saying that we should terminate 21 Herndon Pharmacy as a customer.</p> <p>22 Now the fact that they were 23 happening simultaneously, that 24 again did not weigh in on my</p>	<p>1 customer of interest because of 2 their volume. They were a 3 customer of interest because of 4 their volume. So they were one of 5 the customers that I was 6 researching.</p> <p>7 We have thousands of 8 customers. And so I was 9 researching Herndon, doing my due 10 diligence to determine if they 11 were a suspicious customer. And 12 as my research determined, I felt 13 they were, and, therefore, we 14 terminated business.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. So you had been doing 17 business with them for, you don't know 18 how many years before you terminated 19 them?</p> <p>20 A. That is correct. I know 21 they were a newer pharmacy and had opened 22 recently, I don't know the exact time 23 that they did business with McKesson.</p> <p>24 Q. And you were -- you're</p>
Page 123	Page 125
<p>1 decision to review Herndon.</p> <p>2 I looked at our top 3 customers. So if our top 4 customers and DEA asked for that 5 top customer list, basically 6 equated to the same list of 7 customers, that makes sense 8 because we're looking at the same 9 top purchasing customers. Once it 10 was determined that Herndon was a 11 risk, I terminated them.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Well, the truth is, you were 14 suspicious of Herndon -- what you're 15 telling me is that you were suspicious of 16 Herndon prior to the time that the DEA 17 sent you a letter saying send us the 18 files? You were suspicious of them 19 already, right?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: I wouldn't say 23 that I was suspicious. They were 24 one that was identified as a</p>	<p>1 saying that you were running some kind of 2 private investigation? I mean you were 3 investigating them on your own?</p> <p>4 A. Yeah. I wouldn't say it was 5 a private investigation.</p> <p>6 I mean, part of the 7 controlled substance monitoring program 8 that McKesson had was to know our 9 customer and do a site visit, talk with 10 the pharmacy, understand their business, 11 look for any signs such as, you know, 12 lines that may be outside the pharmacy, 13 look for any activity at a pharmacy that 14 doesn't look quite right.</p> <p>15 Also go by a doctor's 16 office, see if there's a line of people 17 standing outside the doctor's office. 18 Are the license plate of cars driving up, 19 are they from within the state, or are 20 they from out of state. Those are the 21 type of things we looked for.</p> <p>22 Q. Right. As a matter of fact, 23 sir, you actually had salespeople on the 24 ground working in different areas of the</p>

Page 126	Page 128
<p>1 country that lived right in the very city 2 where there were pill mills, right? You 3 had McKesson employees -- if a city had a 4 pill mill, they lived right in that city, 5 didn't they?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 THE WITNESS: I'm unaware of 9 where McKesson employees live. 10 I -- you know, we have people that 11 live all over the country.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Right.</p> <p>14 A. So specifically to where 15 they live, I do not know.</p> <p>16 Q. So but if you had an 17 employee that lived next to a pill mill 18 and they saw people lined up around the 19 pill mill at 8 o'clock in the morning, 20 that's something that you would want to 21 know as a regulatory guy, right?</p> <p>22 A. Yes, I would -- I would want 23 to know that information. And 24 salespeople would call me from time to</p>	<p>1 ten-minute break. 2 MR. PAPANTONIO: Sure. 3 MS. HENN: Thank you. 4 THE VIDEOGRAPHER: Off the 5 record, right? All right. Stand 6 by, please. The time is 7 10:20 a.m. Going off the record. 8 (Short break.) 9 THE VIDEOGRAPHER: We are 10 back on the record. The time is 11 10:32 a.m.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. All right. Sir, to continue 14 where we are, go to the page that's 15 marked -- go to the page that's marked 16 13. I want to ask you, as you're looking 17 at that. Now, I -- so one thing I'm not 18 clear about that you said prior to this 19 break was that you did an investigation 20 and you shut down Herndon; is that right?</p> <p>21 A. Yeah.</p> <p>22 Q. You did that, right?</p> <p>23 A. Yeah. It was my 24 recommendation.</p>
Page 127	Page 129
<p>1 time and tell me that, you know, they 2 were either at a -- at a pharmacy. So 3 there was some correspondence between 4 salespeople and myself if they saw 5 something and wanted to alert me to.</p> <p>6 Q. And how many -- tell me how 7 many pharmacies you closed down besides 8 Herndon?</p> <p>9 MS. HENN: Objection to 10 form.</p> <p>11 THE WITNESS: I don't know 12 off the top of my head. I would 13 have to go back to records.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. More than three?</p> <p>16 A. Oh, yes.</p> <p>17 Q. Okay. You have records that 18 show that, right?</p> <p>19 A. Yes.</p> <p>20 MS. HENN: Counsel, we've 21 been going over an hour. I've 22 been waiting for a break. But I 23 haven't really come to a natural 24 one. I'd like to take a</p>	<p>1 Q. When you did that, did you 2 report suspicious orders to the DEA? 3 A. We reported the closing of 4 Herndon Pharmacy to DEA. 5 Q. Did you report suspicious 6 orders to the DEA when you shut Herndon 7 down, yes or no?</p> <p>8 A. We -- I would say that that 9 was the same thing. We reported 10 suspicious activity and that we closed 11 Herndon Pharmacy.</p> <p>12 Q. No, sir. It's not the same 13 thing.</p> <p>14 You -- for the record, I 15 want to be very clear. When you decided 16 to shut down Herndon, you did not even 17 report suspicious orders to the DEA when 18 you did that, did you?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Right?</p> <p>23 A. I'm not familiar with 24 reporting suspicious orders versus we're</p>

Page 130	Page 132
<p>1 closing a customer because of activity 2 that we don't feel -- 3 Q. Sir, you understand -- 4 MS. HENN: Sir, please let 5 him finish his answer.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Were you finished? 8 A. I wasn't. 9 Q. Go ahead. Finish your 10 answer.</p> <p>11 MS. HENN: Thank you, sir.</p> <p>12 THE WITNESS: We closed the 13 pharmacy because -- I don't 14 remember the exact letter that was 15 sent to DEA. I know there was a 16 letter sent to DEA -- in the local 17 DEA, that oversaw the Landover DC, 18 saying that we were closing 19 Herndon Pharmacy.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. So you closed them 22 down. You saw clearly there were 23 suspicious orders before you closed them 24 down, correct? Right?</p>	<p>1 "Pharmacy," and sent a follow-up letter to 2 DEA saying we're closing them. 3 Q. Did you report the 4 suspicious orders in the letter that you 5 sent, yes or no? 6 A. The specific orders? 7 Q. Yes. Suspicious orders, did 8 you report them when you closed down 9 Herndon? 10 A. We reported the customer. 11 We reported the customer as being 12 suspicious. 13 Q. Where is it that you get the 14 right to report a customer? Where does 15 that come from? There's nothing in the 16 statute that says all you have to do is 17 report a customer. If it's there, please 18 show it to me.</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Please show me in the U.S. 23 21 statute anywhere where it says, "Hey, 24 all you have to do is report a suspicious</p>
<p>1 A. Suspicious activity with the 2 doctors and the distance.</p> <p>3 Q. And you did not report that 4 to the DEA, yes or no, Mr. Oriente? Very 5 simple? When you saw suspicious 6 orders -- you want to call it suspicious 7 activity -- you did not report that to 8 the DEA?</p> <p>9 A. We --</p> <p>10 MS. HENN: Objection.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. You just said we shut them 13 down?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 THE WITNESS: We reported 17 when we closed them.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Oh. You -- after you closed 20 them is when you reported them to the 21 DEA? Is that what you're telling us?</p> <p>22 A. At the same time. We closed 23 them and sent the letter. We called the 24 DEA and said, "We're a closing Herndon</p>	<p>1 customer. You don't have to report 2 suspicious orders." How about showing 3 that to me, so we can proceed with that. 4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: I don't see it 7 in the document anywhere.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. It's not there?</p> <p>10 A. So it's not there.</p> <p>11 Q. Yeah, it's not there. You 12 just made that up just now, didn't you?</p> <p>13 A. No, I didn't make it up. We 14 reported a suspicious customer to DEA.</p> <p>15 Q. But you did not report 16 suspicious orders to the DEA; is that 17 correct?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Right? You did not?</p> <p>22 A. Not specific orders.</p> <p>23 Q. And you understand that the 24 DEA was not -- the DEA was investigating</p>
Page 131	Page 133

Page 134	Page 136
<p>1 you, McKesson, not, Herndon. You 2 understand that, right? This thing that 3 we're covering right now is where the DEA 4 was trying to determine whether or not 5 your company engaged in unlawful conduct 6 by selling narcotics in the United 7 States. Yes or no, do you know that?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: When the DEA 11 asked for the list of top 20 12 customers and asked for specific 13 records on certain pharmacies, I 14 was not aware that we were being 15 investigated, no.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Okay. So, but you 18 understand, sir, that if your company -- 19 let's take Herndon out of it. This is 20 not about the Herndon Pharmacy, sir. 21 This investigation is about your company, 22 your CEO, you, Michael Oriente. This is 23 about you. It's not about Herndon, 24 right?</p>	<p>1 controlled substances that that 2 one doctor was writing at that 3 pharmacy, my interview with the 4 pharmacist, then owner, that 5 activity was suspicious.</p> <p>6 Any one order may not have 7 been deemed suspicious, but the 8 total activity at the pharmacy, 9 when taking all those variables 10 into account, that's what made it 11 a suspicious activity pharmacy.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Let's explore that a little 14 further.</p> <p>15 Where's my -- where's my 16 video here?</p> <p>17 Let's go to the next page.</p> <p>18 13 -- it's Page 13. And we'll -- I want 19 to explore what you just said.</p> <p>20 Because you just said that 21 all you had a responsibility to do was to 22 report suspicious activity, didn't you?</p> <p>23 MS. HENN: Objection to 24 form.</p>
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Correct?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: Yes.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. And the information that you 10 didn't give to the -- to the DEA, we know 11 that you didn't give them suspicious 12 orders for sales that you had been 13 performing with Herndon for how many 14 years?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 THE WITNESS: Again, I said 18 I don't know how long Herndon was 19 a customer of McKesson. But if 20 the orders going into Herndon were 21 not deemed suspicious, but the 22 activity of the distance of the 23 doctor, the type of practice the 24 doctor was, the percentage of</p>	<p>1 THE WITNESS: No, I didn't 2 say that. I didn't say that. 3 What I said was the variable 4 elements that made up my due 5 diligence of distance from the 6 pharmacy to the -- doctor to the 7 pharmacy, the amount that that one 8 doctor was writing, the fact that 9 when I talked to the PIC owner, 10 PIC being pharmacist in charge and 11 owner, that when he requested an 12 increase, a threshold increase, he 13 did not mention Dr. Salerian at 14 all, which was the top prescribing 15 doctor that he was filling for. 16 So he mentioned two or three other 17 doctors in the area that were not, 18 you know, high amount of 19 prescriptions.</p> <p>20 The leading doctor that he 21 was filling for, he never 22 mentioned to me. So his activity 23 is what made me deem him 24 suspicious, not necessarily one</p>
Page 135	Page 137

Page 138	Page 140
<p>1 order that he placed.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. But you'd agree that he did</p> <p>4 place suspicious orders?</p> <p>5 A. No, I wouldn't agree with</p> <p>6 that.</p> <p>7 Q. All right. Well, let's go</p> <p>8 to -- let's see. There's more in this</p> <p>9 document that tells us about Herndon.</p> <p>10 A. Yeah. Yeah.</p> <p>11 Q. Let's take a look at it.</p> <p>12 A. All right.</p> <p>13 Q. Okay. Go to the next page.</p> <p>14 A. Is that 13?</p> <p>15 Q. Yep. Do you see where it</p> <p>16 says, "Failure to report timeline"?</p> <p>17 A. Yes.</p> <p>18 Q. And the failure to report is</p> <p>19 McKesson company, isn't it? We're</p> <p>20 talking about McKesson failure to report?</p> <p>21 A. Yes, yes.</p> <p>22 Q. We're not talking about</p> <p>23 Herndon's failure to report, right?</p> <p>24 A. No.</p>	<p>1 sudden, between 2008 and 2011 there is</p> <p>2 absolutely zero reporting about</p> <p>3 suspicious orders or suspicious customers</p> <p>4 or suspicious anything, right?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Right?</p> <p>9 A. That is what this document</p> <p>10 has. And what I was thinking, where you</p> <p>11 had here that we did not submit a single</p> <p>12 suspicious order from '8 to '11.</p> <p>13 Q. Right.</p> <p>14 A. Was that to DEA headquarters</p> <p>15 or to the field offices?</p> <p>16 Q. Well, you have to tell me,</p> <p>17 sir. You're the one in charge of</p> <p>18 regulatory. This is an -- this is an</p> <p>19 investigation done by the DEA, and they</p> <p>20 said between those years, there's no</p> <p>21 record that you -- that you reported any</p> <p>22 suspicious orders.</p> <p>23 A. Because when we were out in</p> <p>24 the -- in the field, we had</p>
<p>1 Q. This is about a criminal --</p> <p>2 this is -- excuse me. This is about a</p> <p>3 DOJ investigation into McKesson, right?</p> <p>4 A. That is what this document</p> <p>5 would appear, yes.</p> <p>6 Q. And it says, "On January 13,</p> <p>7 2012, McKesson discontinued Accokeek."</p> <p>8 All right. Do you see that?</p> <p>9 A. Yeah, Accokeek.</p> <p>10 Q. Accokeek. "On that same</p> <p>11 date, McKesson discontinued Family Meds."</p> <p>12 Do you see that?</p> <p>13 A. Right. As I stated, I</p> <p>14 believe they were the same owner.</p> <p>15 Q. And then it says, "On</p> <p>16 January 19, 2012, McKesson submitted SORs</p> <p>17 for these two pharmacies a week before</p> <p>18 scheduling a meeting at DEA."</p> <p>19 Do you see that?</p> <p>20 MS. HENN: Objection to</p> <p>21 form.</p> <p>22 THE WITNESS: Mm-hmm.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. All right. So all of the</p>	<p>1 correspondence with DEA offices that are</p> <p>2 out overseeing our distribution centers.</p> <p>3 So I'm trying to understand,</p> <p>4 in that statement where nothing was sent</p> <p>5 into DEA, does that include the field</p> <p>6 offices and the headquarters or just</p> <p>7 headquarters?</p> <p>8 Q. Sir, this document speaks</p> <p>9 for itself. This document says that your</p> <p>10 company failed to do any suspicious order</p> <p>11 reporting for four years. That speaks</p> <p>12 for itself. Okay.</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Let's go to the next page.</p> <p>17 The next page is -- it is --</p> <p>18 we are on 13. It says on January 13th --</p> <p>19 on January 13 --</p> <p>20 MS. HENN: Counsel can we</p> <p>21 pause for a second until the</p> <p>22 disruption is over.</p> <p>23 (Brief interruption.)</p> <p>24 BY MR. PAPANTONIO:</p>

<p style="text-align: right;">Page 142</p> <p>1 Q. "On January 13, 2012, 2 McKesson discontinued sales to Accokeek." 3 Do you see that? 4 A. Yes. 5 Q. And it before then had -- 6 had done no reporting about suspicious 7 orders to the DEA, right? 8 MS. HENN: Objection to 9 form.</p> <p>10 BY MR. PAPANTONIO: 11 Q. Right? 12 MS. HENN: Objection to 13 form. 14 THE WITNESS: I would say 15 that based off of the document, 16 that is correct.</p> <p>17 BY MR. PAPANTONIO: 18 Q. And then it says on the same 19 date, McKesson discontinued sales to the 20 Family Meds, right? 21 A. That is what it states, yes. 22 Q. And up to that point, there 23 was no reporting by McKesson about any 24 suspicious orders before you discontinued</p>	<p style="text-align: right;">Page 144</p> <p>1 Q. After you got the letter 2 from the DEA requesting files, that they 3 wanted to investigate for ten additional 4 McKesson customers including Drug City, 5 including Judy's Drug, including Herndon 6 and Accokeek, until you got that letter, 7 you were doing business with these folks, 8 weren't you? 9 MS. HENN: Objection to 10 form. 11 THE WITNESS: As I stated, 12 simultaneously, my review of these 13 customers would have been ongoing. 14 So the fact that I'm reviewing the 15 same customers that the DEA has 16 asked who our top ten are, shows 17 that I was reviewing our top 18 customers.</p> <p>19 BY MR. PAPANTONIO: 20 Q. And it's just a coincidence 21 that you dropped them after the DEA 22 started their investigation? Is that 23 coincidence? 24 MS. HENN: Objection to</p>
<p style="text-align: right;">Page 143</p> <p>1 selling to these two pharmacies, correct? 2 MS. HENN: Objection to 3 form.</p> <p>4 BY MR. PAPANTONIO: 5 Q. Yes? 6 A. Since this listed the 7 July 15, 2011, and we closed them on 8 January 13, 2012, I don't know what 9 occurred between July 15, 2011, and 10 January 13, 2012. 11 Q. But after you got the letter 12 from the DEA saying that we want the 13 records on ten pharmacies, that is when 14 you discontinued selling to Accokeek. 15 That is when you discontinued selling to 16 Family Meds, correct? After you got the 17 letter -- 18 A. I can't -- 19 MS. HENN: Objection.</p> <p>20 BY MR. PAPANTONIO: 21 Q. After you got the letter 22 from the -- let me ask the question 23 again. After you got the letter -- 24 A. Go ahead.</p>	<p style="text-align: right;">Page 145</p> <p>1 form. 2 THE WITNESS: I was not 3 aware that they had started the 4 investigation.</p> <p>5 BY MR. PAPANTONIO: 6 Q. Your legal department -- you 7 say you sent this information, all -- 8 your legal department made decisions 9 about contact between McKesson and the 10 DEA in regard to suspicious orders? 11 MS. HENN: Objection to 12 form. 13 THE WITNESS: The legal 14 department would have sent in to 15 DEA any request for information on 16 customers.</p> <p>17 BY MR. PAPANTONIO: 18 Q. Okay. So we have this 19 timewise, the investigation starts by the 20 DEA. You say you did not know about an 21 investigation. And immediately, within 22 one month after the investigation starts, 23 you start discontinuing business to 24 customers, right?</p>

Page 146	Page 148
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 THE WITNESS: These 4 customers, Accokeek, Family Meds, 5 Herndon, would have been customers 6 that I would have been reviewing 7 for weeks and months.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Okay. And tell me how 10 many -- while you were reviewing them for 11 weeks and months, tell me how many times 12 you reported to the DEA that there were 13 suspicious orders taking place. Since 14 you have such a great memory of this, you 15 tell me how many times you reported 16 suspicious orders between -- with 17 these -- with these particular -- with 18 these particular pharmacies?</p> <p>19 A. I never said --</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: I never said 23 that I had a great memory. So 24 what I'm going to tell you is I</p>	<p>1 BY MR. PAPANTONIO: 2 Q. Right. 3 A. So, yeah, we would have been 4 reviewing the same customers. 5 Q. Yeah. And you start 6 dropping them, and you start closing down 7 your business with them after you get a 8 letter from the DEA saying, "Let me see 9 their files." That's when that starts 10 happening, right?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: DEA would have 14 had the ARCOS records to see all 15 along --</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Right. 18 A. -- that they were high 19 purchasers.</p> <p>20 Q. And you did too?</p> <p>21 A. Right. And that's why I was 22 reviewing them.</p> <p>23 Q. Right. And when they asked 24 for your files to find out whether you</p>
<p>1 don't recall how many orders, 2 suspicious orders, were reported. 3 And I don't recall exactly 4 how many customers were turned 5 off. I know I ceased business 6 with several customers because of 7 suspicious activity that we deemed 8 this customer was doing. And so 9 we did not want to continue 10 selling controls to.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. All right. So at this 13 point, it's either that you just happened 14 to be investigating them at the same time 15 the DEA was, and that's just a 16 coincidence. Is that -- is that your -- 17 is that your testimony here today? 18 That's a coincidence?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: My -- my 22 statement is that we are looking 23 at the same customers. We're 24 looking at the top purchases.</p>	<p>1 had actually done any reporting of 2 suspicious orders, they found that you 3 did no reporting, right?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: I wouldn't 7 know what they found.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Yeah. Well, let's talk 10 about what they found. Let's go to the 11 next page.</p> <p>12 MS. HENN: Counsel, just one 13 thing.</p> <p>14 For those on the phone, 15 we're getting a fair amount of 16 noise. And we would appreciate it 17 if you could all make sure that 18 you're on mute. Thank you.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. "On February 24, 2012, 21 McKesson produced" --</p> <p>22 A. Wait, wait. What page?</p> <p>23 Q. I'm on Page 14. Actually, 24 it's 15. If you look down in the bottom</p>
Page 147	Page 149

Page 150	Page 152
<p>1 corner, 15.</p> <p>2 A. Right, right. That's why I</p> <p>3 asked.</p> <p>4 Q. "On February 24th, McKesson</p> <p>5 produced a summary of the SOR that were</p> <p>6 ostensibly submitted to the DEA. Five of</p> <p>7 the pharmacies included in the summary</p> <p>8 were customers of McKesson Landover."</p> <p>9 Do you see that?</p> <p>10 A. Yes.</p> <p>11 Q. And that's where you did</p> <p>12 business. That's the plan that you ran.</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Right?</p> <p>17 A. I didn't -- I didn't --</p> <p>18 Q. Not ran, but --</p> <p>19 A. Right. I oversaw their --</p> <p>20 Q. Regulatory.</p> <p>21 A. -- controlled substance.</p> <p>22 MS. HENN: And I'm just</p> <p>23 going to note, there's a lot of</p> <p>24 talking over each other, which</p>	<p>1 that.</p> <p>2 Do you see that?</p> <p>3 MS. HENN: Objection to</p> <p>4 form.</p> <p>5 THE WITNESS: That is what's</p> <p>6 here in the report. I don't know</p> <p>7 when they were discovered versus</p> <p>8 when they were reported. It</p> <p>9 doesn't have dates.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Well, it says they weren't</p> <p>12 reported when they were discovered. Do</p> <p>13 you have any reason to believe that the</p> <p>14 DEA is lying about that --</p> <p>15 MS. HENN: Objection.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. -- as you look at this -- as</p> <p>18 you look at this thing?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: I cannot tell</p> <p>22 from what's written here. But no,</p> <p>23 I don't believe they're lying.</p> <p>24 But it doesn't say that they were</p>
<p>1 makes the court reporter's job</p> <p>2 really difficult.</p> <p>3 So I'm going to ask that you</p> <p>4 allow counsel to finish his</p> <p>5 answer, he allows you to finish</p> <p>6 your answer, and just try not to</p> <p>7 talk over each other.</p> <p>8 THE WITNESS: Okay.</p> <p>9 MS. HENN: Thank you.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. It says, "Of these five</p> <p>12 pharmacies the DEA could only find SORs</p> <p>13 for three of them; that is, Accokeek,</p> <p>14 Family Meds and Herndon."</p> <p>15 Do you see that?</p> <p>16 A. Yes, I see that.</p> <p>17 Q. And then it goes on, "But</p> <p>18 none were timely. They weren't reported</p> <p>19 when they were discovered."</p> <p>20 Do you see -- that's the DEA</p> <p>21 saying that you reported these, they</p> <p>22 weren't timely, and they were reported,</p> <p>23 they were not -- were reported when they</p> <p>24 were discovered. That's the DEA saying</p>	<p>1 reported on what date and they</p> <p>2 were discovered on what date.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. It just says, we looked at</p> <p>5 the record. It says they weren't</p> <p>6 reported when they were discovered. Do I</p> <p>7 need to be any clearer than that? That's</p> <p>8 what it says.</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. They weren't -- wait, let me</p> <p>13 break it down.</p> <p>14 "The suspicious orders were</p> <p>15 not reported when they were discovered."</p> <p>16 Yes, that's what it says, correct?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: That is what</p> <p>20 it says.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. And that break -- that is</p> <p>23 breaking the law when a suspicious order</p> <p>24 is not reported when they're discovered,</p>

Page 154	Page 156
<p>1 that break -- that's unlawful, correct?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: The</p> <p>5 requirement is you report it when</p> <p>6 discovered.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Not three months later? Not</p> <p>9 four months later, correct?</p> <p>10 A. Not later, yes.</p> <p>11 Q. And when the DEA took a look</p> <p>12 at the records that you gave them, and</p> <p>13 reviewed them, for the very place,</p> <p>14 Landover, where you were the number one</p> <p>15 guy in regulatory, they said, "You know</p> <p>16 what? They weren't reported when they</p> <p>17 were supposed to be reported."</p> <p>18 That's what that says,</p> <p>19 doesn't it?</p> <p>20 A. It's saying that they</p> <p>21 weren't reported when they were</p> <p>22 discovered. It doesn't give dates</p> <p>23 exactly when.</p> <p>24 Q. And that's a violation that</p>	<p>1 Q. And you knew that if the DEA</p> <p>2 found out that you had a pharmacy that</p> <p>3 was engaged in suspicious orders, that</p> <p>4 the DEA could close them down. You</p> <p>5 actually had that happen to you, didn't</p> <p>6 you, the DEA closing down pharmacies that</p> <p>7 you were in charge of?</p> <p>8 A. I believe that has happened.</p> <p>9 I can't recall exactly which ones they</p> <p>10 closed before we stopped shipment.</p> <p>11 Q. Well, sir, you -- let me do</p> <p>12 this -- let me get this right.</p> <p>13 A. Yeah.</p> <p>14 Q. You're telling us right now</p> <p>15 you don't have any memory of the DEA</p> <p>16 closing pharmacies that you, Mr. Oriente,</p> <p>17 was involved with. Is that your</p> <p>18 testimony here today?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: No. That is</p> <p>22 not what I'm saying. What I'm</p> <p>23 saying is I don't recall in</p> <p>24 Landover. I know of ones out of</p>
Page 155	Page 157
<p>1 is -- that is -- actually is a violation</p> <p>2 that's unlawful where it comes to selling</p> <p>3 the kind of narcotics that you were</p> <p>4 distributing here in the United States,</p> <p>5 correct?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. It's unlawful?</p> <p>10 A. Yes.</p> <p>11 Q. And you know it's unlawful</p> <p>12 as we sit here today, correct?</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 THE WITNESS: Yes.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. And you knew it was unlawful</p> <p>18 when you were working as director of</p> <p>19 regulatory. You knew it was unlawful not</p> <p>20 to report when a suspicious order is</p> <p>21 discovered, you knew it was unlawful not</p> <p>22 to report it, right?</p> <p>23 A. When it's discovered as</p> <p>24 suspicious, yes.</p>	<p>1 Pennsylvania where pharmacy was</p> <p>2 closed. But that was one where I</p> <p>3 actually reported to DEA activity,</p> <p>4 and then they did their</p> <p>5 investigation and closed the</p> <p>6 pharmacy.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Sir, you're aware of -- if</p> <p>9 you take a customer off of line, a</p> <p>10 customer that's selling McKesson product,</p> <p>11 and you close that pharmacy, McKesson</p> <p>12 loses business, right?</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 THE WITNESS: Yeah.</p> <p>16 McKesson would stop doing business</p> <p>17 with that customer.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. And if you lose business,</p> <p>20 you lose money, don't you?</p> <p>21 A. That was never my</p> <p>22 determining factor.</p> <p>23 Q. That's not my question.</p> <p>24 If you close a pharmacy,</p>

Page 158	Page 160
<p>1 McKesson loses money, don't they?</p> <p>2 A. McKesson would lose money,</p> <p>3 yes.</p> <p>4 Q. Yeah. And as a matter of</p> <p>5 fact, one reason that the DEA would close</p> <p>6 a pharmacy down is because of suspicious</p> <p>7 orders, right?</p> <p>8 A. That would be right.</p> <p>9 Q. And so between 2008 and 2011</p> <p>10 when you reported zero suspicious orders,</p> <p>11 the DEA had no reason to close down a</p> <p>12 pharmacy, did they?</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 THE WITNESS: I wouldn't</p> <p>16 know what -- why DEA would or</p> <p>17 wouldn't act on a pharmacy.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Well, you know why -- you</p> <p>20 know that one of the major reasons the</p> <p>21 DEA will close down a pharmacy is because</p> <p>22 of suspicious orders, right?</p> <p>23 MS. HENN: Objection to</p> <p>24 form.</p>	<p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Well, for four years we know</p> <p>3 that you didn't do that, and you know</p> <p>4 that during your four years your company</p> <p>5 was selling narcotics -- McKesson selling</p> <p>6 narcotics to pharmacies all over the</p> <p>7 country, right?</p> <p>8 A. Yes --</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 THE WITNESS: -- we had</p> <p>12 customers throughout all 50</p> <p>13 states.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. And if you reported</p> <p>16 suspicious orders, that would put the DEA</p> <p>17 on notice that there might be a problem</p> <p>18 with one of your customers, right?</p> <p>19 A. That is a correct statement.</p> <p>20 Q. Okay. Let's go to this</p> <p>21 page -- next page is 16. It says,</p> <p>22 "Failure to report timeline.</p> <p>23 "Specifically DEA found just</p> <p>24 three suspicious orders for the Herndon</p>
<p>1 THE WITNESS: If they deemed</p> <p>2 there was diversion going on, they</p> <p>3 would, yes.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. And if you don't report</p> <p>6 suspicious orders, the DEA doesn't know</p> <p>7 about it, and they don't know to close</p> <p>8 down the pharmacy, right?</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 THE WITNESS: Well --</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. True?</p> <p>14 A. If we don't report a</p> <p>15 suspicious order, because we haven't</p> <p>16 identified it as a suspicious order.</p> <p>17 Q. Right. And if you don't</p> <p>18 report a suspicious order, DEA has no</p> <p>19 reason to go close down a pharmacy,</p> <p>20 right?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 THE WITNESS: No, I can't</p> <p>24 speak for DEA.</p>	<p>1 Pharmacy."</p> <p>2 Do you see that?</p> <p>3 A. Yes.</p> <p>4 Q. And that's the one you said</p> <p>5 closed down? They found three suspicious</p> <p>6 orders that were reported after they</p> <p>7 started their investigation, right?</p> <p>8 A. In November, yes.</p> <p>9 Q. Let me be very clear about</p> <p>10 what we're talking about here. Okay.</p> <p>11 In November, 2011, is the</p> <p>12 first time that these suspicious orders</p> <p>13 were submitted by you to the DEA; is that</p> <p>14 right?</p> <p>15 MS. HENN: Objection to</p> <p>16 form.</p> <p>17 THE WITNESS: That's what it</p> <p>18 says here, that they were</p> <p>19 submitted on November 15th.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Mm-hmm. And tell me when --</p> <p>22 and if I remember, the first time that</p> <p>23 they started asking about an</p> <p>24 investigation of Herndon, was in January,</p>

Page 162	Page 164
<p>1 correct? Excuse me, January 12th --</p> <p>2 January 2012.</p> <p>3 A. It's October 25, 2011, DEA</p> <p>4 requested the files.</p> <p>5 Q. Right. And then let's look</p> <p>6 at the next line. It says, "And 226" --</p> <p>7 "226 suspicious orders for Accokeek and</p> <p>8 Family Meds were not reported until</p> <p>9 January 2012." Right? That's what that</p> <p>10 says, doesn't it?</p> <p>11 A. Yes. That's what the</p> <p>12 document says.</p> <p>13 Q. So for each one of the 226</p> <p>14 suspicious orders that weren't reported,</p> <p>15 there is a fine of, what, \$10,000 per</p> <p>16 suspicious order? Is that how that</p> <p>17 works?</p> <p>18 A. That's what the requirement</p> <p>19 said, yes.</p> <p>20 Q. And then it goes on, let's</p> <p>21 go to the next page. By the way, before</p> <p>22 we get there, let's go back to that page.</p> <p>23 It says -- you understand that the -- the</p> <p>24 226 suspicious orders for Accokeek, they</p>	<p>1 have handled that.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. They didn't tell you what</p> <p>4 happened, did they?</p> <p>5 A. They did not make --</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: They did not</p> <p>9 make me aware, no.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. They didn't even tell you</p> <p>12 what happened at the end of this</p> <p>13 investigation, did they?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: They did not.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. They didn't tell you the</p> <p>19 fines. They didn't tell you what the DEA</p> <p>20 found. They didn't tell you anything,</p> <p>21 did they?</p> <p>22 A. I knew of the fine, but I --</p> <p>23 and I knew of the findings, but I did not</p> <p>24 know of the, you know, the guilty verdict</p>
<p>1 were reported a week before the DEA</p> <p>2 demanded a meeting with your company.</p> <p>3 Did you know that?</p> <p>4 MS. HENN: Objection to</p> <p>5 form.</p> <p>6 THE WITNESS: I did not know</p> <p>7 that.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Nobody had told you that</p> <p>10 before, that these 226 -- 226 suspicious</p> <p>11 orders that just happened to be reported</p> <p>12 about Accokeek and Family Meds were</p> <p>13 reported a week before the DEA had</p> <p>14 demanded a meeting with McKesson. Nobody</p> <p>15 told you that prior to today, correct?</p> <p>16 MS. HENN: Objection to</p> <p>17 form.</p> <p>18 THE WITNESS: I was unaware</p> <p>19 that that took place. Once --</p> <p>20 once the DEA got involved, our</p> <p>21 corporate offices handled those.</p> <p>22 They would -- they would have the</p> <p>23 interaction. It would have been</p> <p>24 my boss, Don Walker, who would</p>	<p>1 that you mentioned earlier.</p> <p>2 Q. Okay. The -- let's go to</p> <p>3 Page 17. It says, "On February 28, 2012,</p> <p>4 McKesson discontinued sales to Family</p> <p>5 Pharmacy."</p> <p>6 Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. And then right underneath</p> <p>9 it, it says, "22" -- "22 suspicious</p> <p>10 orders were submitted in March after</p> <p>11 McKesson discontinued sales. That's what</p> <p>12 that says, doesn't it?</p> <p>13 A. It's what the document is</p> <p>14 showing.</p> <p>15 Q. Do you have --</p> <p>16 A. I am not familiar as to why</p> <p>17 the SORs would have been submitted after</p> <p>18 we closed them.</p> <p>19 Q. Well, if you did that,</p> <p>20 that's absolutely a violation of the law,</p> <p>21 22 times, right?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 THE WITNESS: Again, having</p>

Page 166	Page 168
<p>1 not seen this document prior to 2 today, I see it's written here. 3 I'm not sure who would have sent 4 in the 22 suspicious orders. 5 Again, I did not. So I'm 6 not familiar with who or when this 7 was submitted.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Mr. Oriente --</p> <p>10 A. I would have written -- I 11 would have written a letter and sent to 12 DEA saying that we were closing family -- 13 it would have been a form letter, and I 14 fill in the information, the DEA number, 15 the customer, and I would have e-mailed 16 that to DEA saying that we were closing 17 Family Pharmacy and Accokeek.</p> <p>18 But I'm not, you know, 19 familiar as to then what suspicious 20 orders would have been sent in after the 21 fact that we closed them.</p> <p>22 Q. But you can agree that if 23 you held suspicious orders and did not 24 report the suspicious orders as they were</p>	<p>1 that told the DEA that you had 22 2 suspicious orders after you had already 3 discontinued doing business with this 4 pharmacy?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Is there somebody who you 9 could give me a name about, that did 10 that, that maybe misled the DEA?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: No. I don't 14 have anyone. I'm just trying to 15 determine, you know, what -- what 16 determination was made in March of 17 2012 that those 22 were deemed 18 suspicious. That's all I'm 19 asking.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. And the next thing that 22 maybe you're asking is -- because I'm 23 asking it -- is, do you believe that the 24 DEA is lying about what they're saying in</p>
<p>1 discovered, that is a violation -- a 2 violation of the law, 22 times here, 3 right?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: In seeing 7 this, I'm wondering who determined 8 that they were suspicious.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. You answer my questions. 11 Don't ask me questions. I'm asking 12 you --</p> <p>13 A. No, that wasn't -- I didn't 14 ask a question. I said -- I said --</p> <p>15 Q. Well --</p> <p>16 MS. HENN: Counsel --</p> <p>17 THE WITNESS: I said I'm 18 wondering who. It's not a 19 question. It's a statement. I 20 wonder who deemed them suspicious.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Well, do you think there's 23 somebody working for McKesson who maybe 24 doesn't know what a suspicious order is,</p>	<p>1 this investigation report?</p> <p>2 A. No, I do not believe that 3 the DEA is lying.</p> <p>4 Q. Okay. All right. The next 5 thing it says, did -- "McKesson 6 discontinued sales to Drug City Pharmacy 7 on March 19, 2012."</p> <p>8 Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. And then 65 suspicious 11 orders were submitted on March 21, 2012, 12 right?</p> <p>13 A. Yeah. Two days afterwards.</p> <p>14 Q. Yeah, so McKesson 15 discontinues sales to Drug City, and then 16 after they discontinue the sales, they 17 send in 65 suspicious orders to the DEA, 18 correct?</p> <p>19 A. That's what this is saying, 20 yes.</p> <p>21 Q. All right. And then let's 22 go to the next page. That's Page 18.</p> <p>23 Sir, when you have questions about who 24 did what and why they did it, you're</p>
Page 167	Page 169

Page 170	Page 172
<p>1 going to have to ask your lawyer, because 2 right now this is DEA report. This is 3 their investigation. 4 A. Understood. 5 Q. This is not my 6 investigation.</p> <p>7 MS. HENN: And, Counsel, I 8 would ask you not to instruct my 9 witness how to respond to your 10 questions.</p> <p>11 MR. PAPANTONIO: Well, he 12 obviously --</p> <p>13 MS. HENN: He will 14 respond --</p> <p>15 MR. PAPANTONIO: He needs to 16 ask questions --</p> <p>17 MS. HENN: -- as best he 18 can.</p> <p>19 MR. PAPANTONIO: -- to 20 somebody other than me.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Okay. So let's go to this 23 one. This is Page 18. And it says 24 failure -- again, "Failure to report."</p>	<p>1 form. 2 THE WITNESS: Yes. 3 BY MR. PAPANTONIO: 4 Q. The next one is 5 January 19th. It's Accokeek, 226 6 suspicious orders. 7 Do you see that? 8 A. Yes. 9 Q. The next one is Family Meds. 10 Do you see that? McKesson, two 11 suspicious orders, right? 12 A. What I'm -- what I'm seeing 13 here, it says that we reported them. And 14 then at the top it says, "Failure to 15 report." So -- 16 Q. Yeah, well, we're -- you're 17 going to see why they said that in just a 18 minute. 19 A. Okay. 20 Q. So the next one says 65 21 suspicious orders on March 12th -- 22 March 2012, failed to report. Right? 23 A. Mm-hmm. 24 Q. Go to the next page. Page</p>
<p>1 And this is about McKesson's failure to 2 report. 3 Do you see that? 4 A. That's what it's titled. 5 Q. It even gives us a summary 6 of the things that McKesson failed to 7 report, right? That's what it does, it 8 gives a summary? 9 A. Yes. 10 Q. And it says on November 15, 11 2011, McKesson failed to report -- 12 McKesson reported three suspicious order 13 transactions at Herndon Pharmacy in 14 medical -- medical D -- medical supply. 15 Do you see that? 16 A. Yes. 17 Q. It goes on. And this is 18 saying "Failure to report," at the top of 19 this, right? 20 MS. HENN: Objection. 21 BY MR. PAPANTONIO: 22 Q. Do you see where it says 23 failure to report in big bold letters? 24 MS. HENN: Objection to</p>	<p>19. It says failure to report. That's 2 not my words. That is the DEA saying 3 failure to report. 4 It says, "Even after 5 entering into the settlement 6 agreement" -- we're talking about the 7 2008 settlement agreement, right? 8 A. Right. 9 Q. Do you know of any other 10 settlement agreement that they entered 11 into besides 2008? 12 A. I believe there was one in 13 2013. 14 Q. Okay. So they entered into 15 a settlement agreement in 2013. They 16 entered into a settlement agreement in 17 2008. And they entered into settlement 18 agreements because they were breaking the 19 law, correct? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: I don't know 23 exactly why they settled. That 24 was -- I was not involved with the</p>

Page 174	Page 176
<p>1 settlement.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. But you know they were</p> <p>4 breaking the law, don't you?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 THE WITNESS: You mentioned</p> <p>8 that earlier today in the 2008</p> <p>9 case.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Yeah.</p> <p>12 A. As I stated earlier, I</p> <p>13 thought they had a settlement and simply</p> <p>14 paid a civil fine.</p> <p>15 Q. Okay. So we had -- so far</p> <p>16 we have 2008, 2013, where they enter into</p> <p>17 a settlement with the DEA. And what they</p> <p>18 say in the settlement, we're going to get</p> <p>19 it right this time, right? We're going</p> <p>20 to do right. That's what they say,</p> <p>21 right?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 THE WITNESS: We're going to</p>	<p>1 Q. Okay. Because nobody ever</p> <p>2 showed this to you. And you were the</p> <p>3 director of regulatory at Landover, one</p> <p>4 of the biggest distribution sites</p> <p>5 McKesson owned, right?</p> <p>6 A. I don't know how Landover</p> <p>7 compared to the other 20 something</p> <p>8 distribution centers that we have.</p> <p>9 Q. So let's see what the DEA</p> <p>10 says on this page. And again, this is</p> <p>11 your opportunity to tell me that you</p> <p>12 believe the DEA was lying. If you want</p> <p>13 to say that on the record, I'll be glad</p> <p>14 to take it. But let's look at what it</p> <p>15 says.</p> <p>16 A. I've said more than twice</p> <p>17 that I don't believe the DEA is lying.</p> <p>18 Q. All right. If they're not</p> <p>19 lying, here is what it says. "Even after</p> <p>20 entering into the settlement agreement,</p> <p>21 McKesson by its own admissions failed to</p> <p>22 report at least 318 suspicious orders at</p> <p>23 the time that they were or should have</p> <p>24 been discovered."</p>
Page 175	Page 177
<p>1 make changes, yes.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Okay. How many narcotics do</p> <p>4 you think McKesson sold between 2008 and</p> <p>5 2013? Do you have a swag number of how</p> <p>6 many millions of narcotic pills that</p> <p>7 McKesson put on the street in America</p> <p>8 between 2008 and 2013?</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 THE WITNESS: I don't have</p> <p>12 that total number, no.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Do you have any idea how</p> <p>15 many narcotic pills McKesson was selling</p> <p>16 every year?</p> <p>17 A. I do not have that total</p> <p>18 number, no.</p> <p>19 Q. We're going to look at it in</p> <p>20 a minute. I just want to know -- it's</p> <p>21 right here in this report. I want to</p> <p>22 know if you have any memory.</p> <p>23 A. No, I never seen that</p> <p>24 number.</p>	<p>1 Do you see that?</p> <p>2 A. Yes. That's the first</p> <p>3 bullet.</p> <p>4 Q. You understand that's not my</p> <p>5 words. That's the Department of Justice,</p> <p>6 the DEA, the U.S. government.</p> <p>7 A. Mm-hmm.</p> <p>8 Q. And they gave you the right</p> <p>9 to sell these -- the U.S. government</p> <p>10 gives the distributor, McKesson, the</p> <p>11 right to do this if they follow the law,</p> <p>12 correct?</p> <p>13 A. That is correct. That's</p> <p>14 stipulation of being a registrant.</p> <p>15 Q. And right now, in America,</p> <p>16 McKesson, Amerisource, and Cardinal are</p> <p>17 the three biggest narcotic distributors</p> <p>18 in the country, correct?</p> <p>19 A. Yes, that is correct.</p> <p>20 Q. And so those three people</p> <p>21 were given a special right to sell</p> <p>22 narcotics to the American public, and all</p> <p>23 the government asked you to do was report</p> <p>24 when you see suspicious orders, right?</p>

<p style="text-align: right;">Page 178</p> <p>1 Correct?</p> <p>2 A. That's part of the</p> <p>3 stipulation, yes.</p> <p>4 Q. And the DEA determined that</p> <p>5 there were -- at least right here, that</p> <p>6 there were 318 suspicious orders that, by</p> <p>7 McKesson's own admission, they failed to</p> <p>8 report and should have been reported,</p> <p>9 right?</p> <p>10 A. That's what it says here,</p> <p>11 yes, that McKesson by its own admission.</p> <p>12 Again, this is the first time I'm seeing</p> <p>13 this. So I was unaware of that.</p> <p>14 Q. Do you feel -- sir, would</p> <p>15 you like to have seen this before you</p> <p>16 came in here to testify about what you</p> <p>17 know about diversion and the sale of</p> <p>18 narcotic drugs by McKesson throughout the</p> <p>19 United States? Is this something that</p> <p>20 would have helped up testify here today?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 THE WITNESS: I don't</p> <p>24 believe it would have helped me</p>	<p style="text-align: right;">Page 180</p> <p>1 Q. Well, answer this. Do you</p> <p>2 see where it says, "This is only the tip</p> <p>3 of the iceberg"?</p> <p>4 A. That is the next bullet down</p> <p>5 on this report, yes.</p> <p>6 Q. That is the DEA saying that</p> <p>7 McKesson failed to report 318 suspicious</p> <p>8 orders at the time that they should have</p> <p>9 been reported and that, you know what,</p> <p>10 that's only the tip of the iceberg,</p> <p>11 that's the first time you saw those</p> <p>12 words, "tip of the iceberg," right?</p> <p>13 A. That is correct.</p> <p>14 Q. Do you know what the rest of</p> <p>15 the iceberg looks like underneath the</p> <p>16 tip? How much more failure to report</p> <p>17 took place at McKesson?</p> <p>18 MS. HENN: Objection to</p> <p>19 form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Do you know of any other</p> <p>22 reporting -- let me scratch that. Let me</p> <p>23 totally scratch that and ask you:</p> <p>24 This is telling me 318</p>
<p style="text-align: right;">Page 179</p> <p>1 testify here today, no.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Okay. Because you knew all</p> <p>4 this before you came here, didn't you?</p> <p>5 A. No, sir. That's not a true</p> <p>6 statement.</p> <p>7 Q. So you knew before you even</p> <p>8 walked in this room that McKesson had</p> <p>9 failed to report 318 suspicious orders</p> <p>10 when they should have reported it. You</p> <p>11 knew that prior to coming here today,</p> <p>12 didn't you?</p> <p>13 MS. HENN: Objection to</p> <p>14 form.</p> <p>15 THE WITNESS: No, I did not</p> <p>16 know that.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Nobody with McKesson shared</p> <p>19 that with you, did they?</p> <p>20 A. They did not.</p> <p>21 Q. And this is the first time</p> <p>22 you've heard it?</p> <p>23 A. The first time I'm seeing it</p> <p>24 and hearing it, yes.</p>	<p style="text-align: right;">Page 181</p> <p>1 suspicious orders that McKesson failed to</p> <p>2 report on narcotic drugs that they were</p> <p>3 selling to people in this country. 318.</p> <p>4 Now, are there more that I</p> <p>5 need to know about that you know about as</p> <p>6 we sit here and talk today?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: I am unaware</p> <p>10 of any others that were not</p> <p>11 reported.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. You weren't even aware that</p> <p>14 these weren't reported, right?</p> <p>15 A. That's what I said, yeah. I</p> <p>16 am unaware. I've never seen this report.</p> <p>17 I did not have these numbers. And you</p> <p>18 know, this report was handled between DEA</p> <p>19 and McKesson corporate offices.</p> <p>20 Q. Well, who is corporate -- is</p> <p>21 Mr. -- what's -- Hambergren, is he</p> <p>22 corporate office?</p> <p>23 A. My boss would have been Don</p> <p>24 Walker.</p>

Page 182	Page 184
<p>1 Q. Well, is Mr. Hammergren, is 2 he -- do you consider him corporate? 3 MR. PAPANTONIO: Give me the 4 video. Are you ready for a video 5 on this something? Give me 6 Video 7. 7 (Document marked for 8 identification as Exhibit 9 MCK-Oriente-Video-7.)</p> <p>10 BY MR. PAPANTONIO: 11 Q. Do you know Mr. Hammergren 12 is? 13 A. Yes. 14 Q. Have you ever walked up and 15 shaken his hand? 16 A. I met him one time. 17 Q. Did you watch him when he 18 swore before the -- when he raised his 19 right hand and swore to the congressional 20 hearing and testified? Did you watch him 21 testify? 22 A. I saw it on television. 23 MR. PAPANTONIO: Okay. 24 Could you -- are you able to show</p>	<p>1 role to play, Congressman, 2 certainly. And in your example 3 one of the most important roles we 4 play is to make sure we find 5 suspicious customers and 6 suspicious orders and cut off the 7 supply to those customers. 8 (End of video playback.)</p> <p>9 BY MR. PAPANTONIO: 10 Q. Did you hear that testimony? 11 A. I did hear it, yes. 12 Q. Okay. Will you tell 13 everybody -- tell the jury where it is 14 that Mr. Hammergren, the CEO of your 15 company, ever was told that it was okay 16 to report suspicious customers instead of 17 suspicious orders. 18 Please tell me, if you 19 can -- in your experience in regulatory, 20 would you please tell me any place that 21 you can identify that Mr. Hammergren 22 would be led to believe that it was okay 23 to report suspicious orders?</p> <p>24 MS. HENN: Objection to</p>
<p>1 that video. Let me give a copy 2 of -- give me -- the hard copies 3 to counsel.</p> <p>4 BY MR. PAPANTONIO: 5 Q. Let's watch this video. And 6 I want to ask you whether you saw this. 7 MS. HENN: You mentioned 8 hard copies. 9 MR. PAPANTONIO: Yeah, we 10 got -- we got hard copies of 11 transcripts. 12 MR. PAPANTONIO: So go ahead 13 and play this. 14 MS. HENN: Do you want the 15 witness to have a hard copy? 16 MR. PAPANTONIO: No, I 17 don't. I want him to watch this 18 video as a guy running his company 19 who testified in front of Congress 20 under the threat of perjury. 21 That's what I want. Show this 22 video, please. 23 (Video playback.) 24 MR. HAMMERGREN: We have a</p>	<p>1 form. 2 THE WITNESS: You just said 3 two different things you said 4 suspicious customers -- 5 BY MR. PAPANTONIO: 6 Q. Suspicious customers. 7 A. -- and suspicious orders. 8 Okay. So you want to -- 9 MS. HENN: Objection to 10 form. 11 MR. PAPANTONIO: Yeah, let's 12 play it again. I want to make 13 sure we get this. Play it again, 14 please. 15 (Video playback.) 16 MR. HAMMERGREN: We have a 17 role to play, Congressman, 18 certainly. And in your example 19 one of the most important roles we 20 play is to make sure we find 21 suspicious customers and 22 suspicious orders and cut off the 23 supply to those customers. 24 (End of video playback.)</p>

<p style="text-align: right;">Page 186</p> <p>¹ BY MR. PAPANTONIO:</p> <p>² Q. So he says that one of the ³ most important roles you play is to ⁴ report suspicious orders.</p> <p>⁵ That's what he just said, ⁶ right?</p> <p>⁷ A. Well, he said suspicious ⁸ customers and suspicious orders.</p> <p>⁹ Q. And you know there's nothing ¹⁰ in the -- there is -- at no time did the ¹¹ DEA tell you that it was okay to report ¹² suspicious customers?</p> <p>¹³ MS. HENN: Objection.</p> <p>¹⁴ BY MR. PAPANTONIO:</p> <p>¹⁵ Q. You know that that's ¹⁶ something that you made up?</p> <p>¹⁷ MS. HENN: Objection to ¹⁸ form.</p> <p>¹⁹ BY MR. PAPANTONIO:</p> <p>²⁰ Q. Suspicious customers?</p> <p>²¹ A. Suspicious customers is not ²² in the regulation.</p> <p>²³ Q. Right. And you know that ²⁴ Mr. Hammergren raised his right hand and</p>	<p style="text-align: right;">Page 188</p> <p>¹ our highest responsibility, to report ² suspicious orders." That's what he just ³ said, right?</p> <p>⁴ MS. HENN: Objection to form.</p> <p>⁶ THE WITNESS: He said that -- was it this year 2018? And this is referring to what 20-something.</p> <p>¹⁰ BY MR. PAPANTONIO:</p> <p>¹¹ Q. Is something different?</p> <p>¹² A. No. What I'm saying is, in his statement -- can we play it again?</p> <p>¹⁴ Q. Yes, sir. Before we play it, let me ask if you know this. Do you know that he raised his right hand --</p> <p>¹⁷ A. Okay.</p> <p>¹⁸ Q. -- and swore before Congress about what he was going to testify to?</p> <p>²⁰ Did you know that?</p> <p>²¹ A. Yeah, I watched it on television at home.</p> <p>²³ Q. You watched the whole thing?</p> <p>²⁴ A. Right. Yeah.</p>
<p style="text-align: right;">Page 187</p> <p>¹ testified in front of Congress, telling ² Congress that it was okay just to report ³ suspicious customers rather than ⁴ suspicious orders. That's what he just ⁵ said?</p> <p>⁶ MS. HENN: Objection to form.</p> <p>⁸ THE WITNESS: I believe he ⁹ said -- and I believe in his ¹⁰ statement he said suspicious ¹¹ customers and suspicious orders.</p> <p>¹² BY MR. PAPANTONIO:</p> <p>¹³ Q. Okay. So let's --</p> <p>¹⁴ A. Not or.</p> <p>¹⁵ Q. Let's talk about the ¹⁶ suspicious orders. We just saw a ¹⁷ document that 318 suspicious orders were ¹⁸ never reported to the DEA, right?</p> <p>¹⁹ A. That's what the document ²⁰ states. Yes.</p> <p>²¹ Q. And you just had the ²² president, the CEO of McKesson, the ²³ highest guy in the entire food chain, ²⁴ saying, "You know what? We think that's</p>	<p style="text-align: right;">Page 189</p> <p>¹ Q. Okay. Let's watch it again here.</p> <p>³ (Video playback.)</p> <p>⁴ MR. HAMMERGREN: We have a role to play, Congressman, certainly. And in your example one of the most important roles we play is to make sure we find suspicious customers and suspicious orders and cut off the supply to those customers.</p> <p>¹² (End of video playback.)</p> <p>¹³ BY MR. PAPANTONIO:</p> <p>¹⁴ Q. So the most important thing ¹⁵ is suspicious orders?</p> <p>¹⁶ A. And suspicious customers and ¹⁷ cut off the supply.</p> <p>¹⁸ Q. And you're not able to tell ¹⁹ me anywhere in the regulatory anywhere ²⁰ where it says, you know what, all we have ²¹ to do is report suspicious customers or ²² suspicious orders?</p> <p>²³ MS. HENN: Objection.</p> <p>²⁴ BY MR. PAPANTONIO:</p>

Page 190	Page 192
<p>1 Q. You're not aware of that 2 anywhere, right? 3 MS. HENN: Objection to 4 form. 5 THE WITNESS: It says we 6 need to report suspicious orders. 7 BY MR. PAPANTONIO: 8 Q. Orders. Not suspicious 9 customers, right? 10 A. That is correct. 11 Q. So he's making that up right 12 there, isn't he? 13 MS. HENN: Objection to 14 form. 15 THE WITNESS: I can't speak 16 for him. 17 BY MR. PAPANTONIO: 18 Q. Well, he's misleading 19 Congress, and he swore under oath to tell 20 the truth, right? 21 MS. HENN: Objection to 22 form. 23 BY MR. PAPANTONIO: 24 Q. Yes?</p>	<p>1 That's what that says right there, right? 2 MS. HENN: Objection to 3 form. 4 BY MR. PAPANTONIO: 5 Q. Am I right? 6 A. That's what it says here. 7 Q. Okay. 8 A. As I said, my review of 9 customers was continual. And again, if 10 I'm looking at the same customers that 11 the DEA was looking at, that would -- was 12 done because of the volume of these top 13 customers. 14 Q. Okay. And again, you have 15 no -- 16 MS. HENN: Counsel, please 17 let him finish his answer. 18 BY MR. PAPANTONIO: 19 Q. Are you finished? 20 A. What is DF customers? 21 Q. Sir, I'm not going to -- 22 this is me asking questions of you. 23 Okay? This isn't you asking questions of 24 me.</p>
<p style="text-align: center;">Page 191</p> <p>1 A. He was before Congress, yes. 2 But I can't speak for Mr. Hambergren. 3 MR. PAPANTONIO: Let's go 4 back to this document. We have 5 more videos we'll listen to. 6 BY MR. PAPANTONIO: 7 Q. In fact, in this -- this 8 document we're talking about, it says, 9 "In fact, McKesson did not report any of 10 these suspicious orders until it was 11 known" -- 12 MR. PAPANTONIO: Would you 13 please underline this. 14 BY MR. PAPANTONIO: 15 Q. "McKesson did not report any 16 of these suspicious orders until it was 17 known that the DEA was inquiring about 18 the ordering patterns of McKesson's top 19 Landover DF customers." 20 Do you see that? Isn't that 21 what we've been talking about, 22 Mr. Oriente, that none of these 23 suspicious orders were actually reported 24 until the DEA started this investigation.</p>	<p style="text-align: center;">Page 193</p> <p>1 A. Well, then I don't 2 understand what this says. 3 Q. Okay. Fine. 4 A. It says McKesson's top 5 Landover DF customers. 6 Q. So you don't -- let's go 7 with you don't understand what this says. 8 A. The DF piece. Let's be 9 specific. 10 Q. Okay. You don't 11 understand -- you don't understand what 12 DF means. Nobody had ever told you that 13 318 suspicious orders were never 14 reported, right? 15 A. That is correct. 16 Q. Let's go to -- and by the 17 way, you were the number one guy in 18 Landover for regulatory, right? 19 A. I was responsible to monitor 20 what was being purchased. The suspicious 21 order reporting was done from McKesson's 22 corporate office. 23 Q. And the corporate office, 24 was that a bunch -- were those lawyers</p>

Page 194	Page 196
<p>1 sitting around determining what ought to 2 go to the DEA or not go to the DEA? Were 3 those lawyers who made that 4 determination?</p> <p>5 A. I don't know that. I don't 6 know who made the determination.</p> <p>7 Q. Because I thought earlier in 8 this -- in this discussion you told me 9 that it was sent to the lawyers.</p> <p>10 A. When a request for DEA 11 information from a subpoena or top 12 customers, when a request came in for 13 information, that went to our law 14 department.</p> <p>15 If it was the suspicious 16 orders, I'm not sure if that was Don 17 Walker sending that in or -- or someone 18 in our law department.</p> <p>19 Q. So nobody -- at least we 20 know this much. Nobody in the law 21 department called you up and said, "Hey, 22 Mr. Oriente, you might want to know 23 before you go testify today that we 24 didn't report 318 suspicious orders."</p>	<p>1 department, right?</p> <p>2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: I said a DEA 5 request for information was sent 6 to our law department. All our 7 correspondence with DEA, we do not 8 decide what we submit. It goes to 9 our law department. They review 10 it. They pull the documents. 11 They would send the top ten 12 customers that the DEA requested. 13 I did not say suspicious orders 14 would go through the law 15 department.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. So let's go on. Okay. 18 Let's go to the next page.</p> <p>19 "Multiple analysis." Do you 20 see where it says multiple analysis?</p> <p>21 A. Yes.</p> <p>22 Q. Next page, please.</p> <p>23 "Multiple analysis. The DEA analyzed 24 data submitted by McKesson."</p>
Page 195	Page 197
<p>1 MS. HENN: Objection. I 2 think you're asking him what a 3 lawyer told him.</p> <p>4 MR. PAPANTONIO: Let me -- 5 I'm --</p> <p>6 MS. HENN: I'm going to 7 instruct -- can I finish?</p> <p>8 MR. PAPANTONIO: Yeah, go 9 ahead. Instruct him.</p> <p>10 MS. HENN: I'm going to 11 instruct the witness not to answer 12 questions about what lawyers did 13 or didn't say to him. That's not 14 a proper question.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. You told us that suspicious 17 information was sent to the lawyers in 18 San Francisco. Didn't you tell me that?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: I did not say 22 that.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. It was sent to the law</p>	<p>1 Do you see that?</p> <p>2 A. Yes.</p> <p>3 Q. In other words, the DEA 4 asked you, "Would you please give us all 5 the information about these ten 6 pharmacies?"</p> <p>7 Do you remember that?</p> <p>8 A. Yes.</p> <p>9 Q. Let's look -- let's look at 10 the pharmacies. So they analyze the 11 pharmacies, right? Right?</p> <p>12 A. That's what it says here, 13 yes.</p> <p>14 Q. And then they do this 15 report, correct?</p> <p>16 A. That's -- it says they 17 analyzed the data that McKesson submitted 18 to them.</p> <p>19 Q. And they say they analyzed 20 it monthly. Do you see where it says 21 monthly?</p> <p>22 A. Mm-hmm.</p> <p>23 Q. Let's see -- let's see what 24 they found. Okay. Go to the next page.</p>

<p style="text-align: right;">Page 198</p> <p>1 The DEA then determined the 2 average monthly orders of controlled 3 substances. Do you see where it says 4 that?</p> <p>5 A. Yes.</p> <p>6 Q. The DEA then determined the 7 average monthly orders of controlled 8 substances.</p> <p>9 Tell the jury why it's so 10 important to analyze the monthly orders 11 of controlled substances narcotics?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Tell the jury why that's so 16 important?</p> <p>17 MS. HENN: Same objection.</p> <p>18 THE WITNESS: We looked at 19 customers on a monthly threshold 20 basis. And by that, I mean that 21 they are allocated a quantity that 22 they can order per month. And 23 then orders are automatically 24 blocked if they try to exceed that</p>	<p style="text-align: right;">Page 200</p> <p>1 Another red flag would be 2 distance of patients to the pharmacy. So 3 there are several red flags to look at.</p> <p>4 Q. Let's talk about this red 5 flag. One red flag is when the average 6 monthly orders of controlled substances 7 look like they're higher than they should 8 be, right? That's a red flag, isn't it?</p> <p>9 A. Higher than they should be?</p> <p>10 Q. The average is. The average 11 is higher than the typical average. 12 That's a red flag, right?</p> <p>13 A. If a -- that could be one 14 red flag. Volume does not, you know, 15 constitute -- volume alone, depending on 16 the size of the pharmacy, does not 17 constitute a diversion. It would be one 18 red flag of many that would require 19 additional due diligence to research.</p> <p>20 Q. In other words, if a 21 pharmacy all of the sudden orders 40 22 times the average that they should be -- 23 of their monthly average, that's 24 certainly a red flag, isn't it?</p>
<p style="text-align: right;">Page 199</p> <p>1 monthly allocation.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. And so, that -- isn't there 4 something called a red flag? Have you 5 ever heard the term "red flag"?</p> <p>6 A. I have.</p> <p>7 Q. Tell the jury what a red 8 flag is.</p> <p>9 A. There are different red 10 flags. Red flags could be a customer is 11 omitting, and by that I mean that the 12 order is being blocked. They're trying 13 to order more than what they're 14 authorized to order.</p> <p>15 Another red flag that we 16 looked at were amount of cash sales that 17 a pharmacy might be doing.</p> <p>18 Another red flag would be if 19 one particular doctor was writing an 20 exorbitant of prescriptions at a 21 pharmacy.</p> <p>22 Another red flag is their 23 control percentage of total Rx within 24 pharmacy.</p>	<p style="text-align: right;">Page 201</p> <p>1 A. In that example it would be.</p> <p>2 Q. Yeah. How about 30 times?</p> <p>3 A. That example I would say it 4 would be.</p> <p>5 Q. Yeah. And so you're now 6 aware that the DEA has looked at all the 7 information that they gleaned from those 8 ten pharmacies, and they've done their 9 own analysis, according to this, right?</p> <p>10 According to this?</p> <p>11 A. According to this, yeah.</p> <p>12 Q. It says, "Finally, the DEA 13 identified the number of transactions 14 that represented multiples of the average 15 monthly orders of McKesson Landover."</p> <p>16 Sir, that's where you were 17 in charge. You were in charge of 18 regulatory at Landowner -- Landover, 19 right?</p> <p>20 A. Yes, I was responsible for 21 Landover.</p> <p>22 Q. That's your responsibility, 23 correct?</p> <p>24 A. Mm-hmm.</p>

Page 202	Page 204
<p>1 Q. Is there anybody there -- is 2 there anybody there in regulatory that 3 had a higher responsibility there at 4 Landover than you?</p> <p>5 A. No.</p> <p>6 Q. Okay. So we are talking to 7 the right guy where it becomes 8 responsibility about regulatory, aren't 9 we?</p> <p>10 A. For Landover, yes.</p> <p>11 Q. Yeah. Okay. So let's look 12 at what it says. Go to the next page. 13 "McKesson Landover, distributor 14 oxycodone, dosage units, sales to 15 pharmacies May 2008, month-to-date 16 totals."</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. "Month-to-date totals 20 compared with the monthly pharmacy 21 averages."</p> <p>22 Do you see that?</p> <p>23 A. Yes, I see that.</p> <p>24 Q. Now, you see the first --</p>	<p>1 oxycodone dosages that exceeded the 2 monthly average by two. 3 Do you see that?</p> <p>4 A. I see that. I'm trying to 5 understand what it is that they're -- 6 Q. We'll see if this helps you. 7 Let's go down to -- 8 MS. HENN: Counsel, he's 9 still talking.</p> <p>10 THE WITNESS: I'm trying to 11 see what it is -- the heading 12 says, "Number of sales 13 transactions" --</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Right.</p> <p>16 A. -- "with a month-to-date 17 total dosage units at least this multiple 18 of monthly pharmacy average."</p> <p>19 Q. Right.</p> <p>20 A. So they're saying that there 21 were certain pharmacies that are above 22 the average.</p> <p>23 Q. No, sir. They are talking 24 about Landover. They're saying --</p>
<p>1 you see the first column, it says the, 2 "Multiple of the monthly pharmacy 3 average."</p> <p>4 Go down to where -- you see 5 the -- you see the two. Do you see that 6 two?</p> <p>7 A. Mm-hmm.</p> <p>8 Q. It says that as far as times 9 that there were a month -- as far as 10 times that there were orders of two times 11 the monthly average, they say that 12 happened 122,288 times while they're at 13 Landover. That's what that says. Do you 14 see it?</p> <p>15 A. I see it. Can I have a 16 minute just to read this?</p> <p>17 Q. Yes, sir. You take all the 18 time you want. We're going to go through 19 the numbers because this is where you 20 were in charge.</p> <p>21 A. Okay.</p> <p>22 Q. All right. Now, you see 23 where it says one hundred -- forgive 24 me -- 122,280 times that there was</p>	<p>1 McKesson Landover as a distributor sold 2 oxycodone in dosage unit sales to 3 pharmacies between May 20 -- between May 4 2008 and 2012.</p> <p>5 Do you see that? Did I read 6 that right?</p> <p>7 A. Mm-hmm.</p> <p>8 Q. And then it shows you 9 exactly what the multiples are of how 10 many times the average McKesson sold. Do 11 you see where it says down here -- it 12 says, for example, three. Do you see the 13 three underneath the two?</p> <p>14 A. In the first column, yes.</p> <p>15 Q. Okay. So three -- we're 16 talking about three times the monthly 17 average. 71 thousand times that was sold 18 from Landover.</p> <p>19 A. Over four years.</p> <p>20 Q. Yes. Well, that's what it 21 says.</p> <p>22 A. Okay.</p> <p>23 Q. Okay. Now, they thought 24 that was important to the point -- if you</p>

Page 206	Page 208
<p>1 go to the right. They were going to 2 propose a fine -- if you go to the right. 3 They were going to propose a fine of 4 \$1,222,880,000. You see that? That's 5 the proposed fine for the violation of 6 selling 122,288 times a dosage of two as 7 a multiple?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Do you see that?</p> <p>12 A. I see what it's saying. I'm 13 not really understanding what this is 14 showing me.</p> <p>15 Q. Because nobody showed it to 16 you, right, before coming in here today. 17 Nobody showed this to you, did they?</p> <p>18 A. No, I never seen this 19 document.</p> <p>20 Q. You had -- you had no idea, 21 that as a matter of fact 10,000 times -- 22 if you go down to -- see where it says 23 ten right there? Do you see the ten?</p> <p>24 MS. HENN: Counsel, which</p>	<p>1 That's coming from the DEA. You 2 understand that, right?</p> <p>3 MS. HENN: Objection to 4 form. Let's let the witness 5 answer your question.</p> <p>6 THE WITNESS: The document 7 says that multiple of monthly 8 pharmacy average was ten times, 9 and that the number of sales 10 transactions month-to-date total 11 dosage units at least this 12 multiple of monthly pharmacy 13 average occurred 10,000 times over 14 a four-year period.</p> <p>15 MS. HENN: Now, are you -- 16 Mr. Oriente --</p> <p>17 THE WITNESS: Yeah, so we 18 had pharmacies that were above the 19 average.</p> <p>20 Now, since you're dealing 21 with an average, wouldn't you 22 expect to have pharmacies above 23 the average and others below the 24 average if you're looking at an</p>
Page 207	Page 209
<p>1 ten are you talking about?</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. The ten right on that page.</p> <p>4 It's about four from the bottom.</p> <p>5 MS. HENN: On the first 6 column?</p> <p>7 MR. PAPANTONIO: First 8 column.</p> <p>9 MS. HENN: Thank you.</p> <p>10 MR. PAPANTONIO: See where 11 that big ten is? Would you 12 highlight the ten, so everybody 13 can see the ten.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. See right there on that ten, 16 it says ten times -- excuse me. No, no. 17 It says 10,000 times. 10,609 times 18 McKesson Landover distributor allowed ten 19 times the averages -- monthly average to 20 be sold. That's what that says, right?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. I mean, that's not my words.</p>	<p>1 average?</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Sir, you are the guy in 4 charge of the -- you're in charge of --</p> <p>5 A. Well, I'm telling you that.</p> <p>6 If you take an average, you're going to 7 have --</p> <p>8 Q. Let's --</p> <p>9 MS. HENN: Let's --</p> <p>10 THE WITNESS: Let me finish, 11 please.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Finish your -- finish</p> <p>14 your -- because I'm -- because what I'm 15 trying to figure out --</p> <p>16 MS. HENN: Counsel --</p> <p>17 MR. PAPANTONIO: Hang on.</p> <p>18 MS. HENN: You've not 19 letting him finish.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. I want you to finish, 22 but here's what I want you to finish: 23 Why did they want to fine you 24 \$1,222,880,000 for that one entry?</p>

Page 210	Page 212
<p>1 MS. HENN: Counsel, he never 2 finished your prior question. 3 It's really not proper for you to 4 interrupt his answer and ask a 5 different question.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Go ahead and answer the best 8 you can.</p> <p>9 MS. HENN: So he was in the 10 middle of answering and if you 11 could just let him respond --</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. All right. I'll -- go ahead 14 and answer why --</p> <p>15 MS. HENN: -- it would be 16 helpful.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. -- answer how you allow ten 19 times --</p> <p>20 MS. HENN: You're doing it 21 again. You're asking a different 22 question.</p> <p>23 MR. PAPANTONIO: Yeah, well, 24 let me ask --</p>	<p>1 averages -- monthly average to be 2 sold. That's what it says, 3 right?"</p> <p>4 MR. PAPANTONIO: Okay. He 5 answered it.</p> <p>6 MS. HENN: And you went on 7 and said, "That's not my words. 8 That's coming from the DEA. You 9 understand that?"</p> <p>10 The witness was responding 11 to that when he was interrupted.</p> <p>12 MR. PAPANTONIO: Let him 13 respond to that question.</p> <p>14 MS. HENN: Thank you. Thank 15 you.</p> <p>16 THE WITNESS: So the 10,000 17 times over the four years would 18 equate to 2,500 times a year 19 divided by the 12 months in a 20 year. You are looking at 200 in 21 a -- in a month. And that's about 22 50 times in a week.</p> <p>23 And so that's ten orders a 24 day, where you have customers that</p>
Page 211	Page 213
<p>1 MS. HENN: If you can just 2 stop talking, so he can finish the 3 question --</p> <p>4 MR. PAPANTONIO: Well, would 5 you read the question I asked 6 where he started talking about 7 some -- Madam Court Reporter.</p> <p>8 THE COURT REPORTER: Sure.</p> <p>9 MR. PAPANTONIO: What is the 10 last question I asked before he 11 went off on what he wanted to talk 12 about? What was it?</p> <p>13 (The requested portion of 14 the testimony was read back by the 15 court reporter.)</p> <p>16 MS. HENN: And that's not 17 the question that he had been 18 responding to. The question that 19 he had been responding to was 20 about, "Right there on that ten, 21 it says ten times -- excuse me, 22 no, no. It says 10,000 times. 23 10,609 times McKesson Landover 24 distributor allowed ten times the</p>	<p>1 are above the average.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Yeah.</p> <p>4 A. So again, if you're dealing 5 with an average, you're going to have 6 certain customers that are above average, 7 and certain that are below.</p> <p>8 Q. Sir --</p> <p>9 MS. HENN: Counsel.</p> <p>10 THE WITNESS: You'll 11 always -- let me finish, please.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Go ahead.</p> <p>14 MS. HENN: Thank you.</p> <p>15 THE WITNESS: You'll always 16 have customers that are above an 17 average in any business.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. All right. Well, sir, 20 whatever it was, the DEA looked at it, 21 and they decided that along with you 22 filing to report 318 suspicious orders, 23 now they're taking a look at -- let's 24 take a look at averages of how much</p>

Page 214	Page 216
<p>1 McKesson -- how many narcotic drugs 2 McKesson was sending around this country 3 where a pharmacy was exceeding a monthly 4 average, right? That's what this is 5 doing, right? 6 MS. HENN: Objection to 7 form. 8 THE WITNESS: Right. 9 BY MR. PAPANTONIO: 10 Q. That's the second part. 11 Now, you know what, I said 12 one million a minute ago. They wanted to 13 fine you one billion. \$1,222,880,000 for 14 this thing that you just described as -- 15 shouldn't be a problem, right? 16 A. No, I didn't say that. 17 Q. Oh, it is a problem? 18 A. No, I didn't say that 19 either. I didn't say it was a problem. 20 I didn't say it wasn't a problem. 21 Q. Well, you -- 22 A. What I said was I broke it 23 out to what it equated to per day in the 24 amount of orders.</p>	<p>1 Do you see that? 2 MS. HENN: Page 24? 3 MR. PAPANTONIO: I'm on Page 4 24. 5 MS. HENN: Are you on 6 hydrocodone? 7 THE WITNESS: Hydrocodone. 8 BY MR. PAPANTONIO: 9 Q. I'm sorry. Hydrocodone. So 10 we start off with oxycodone was the 11 analysis. For example -- hey, I meant to 12 ask you, is oxycodone addictive? 13 A. I'm not a doctor. But from 14 what I've read, it is addictive. 15 Q. Yeah. And you know that the 16 people that you're buying from are 17 Purdue, right, Purdue Pharmacy? 18 A. Purdue is one of the 19 manufacturers that we sold, yes. 20 Q. And you know that while you 21 were selling this product, you were aware 22 that Purdue had been fined multi-million 23 dollars for lying about the addictive 24 nature of oxycodone. You know that,</p>
<p style="text-align: center;">Page 215</p> <p>1 Q. And after the DEA finally 2 got this information that you had been 3 not -- where information that you had not 4 been disclosing to them about ten 5 pharmacies, they do an analysis, right? 6 A. Mm-hmm. 7 Q. They do an analysis and they 8 find that 318 times you violated the law 9 by not reporting suspicious orders. 10 That's the first thing they find. 11 Do you remember that? 12 A. Mm-hmm. 13 Q. The second thing they find, 14 is they want to -- they want to propose a 15 fine of \$1,222,880,000 for your conduct. 16 Do you see that? 17 MS. HENN: Objection to 18 form. 19 BY MR. PAPANTONIO: 20 Q. Did I get that right? 21 A. That is the number on Line 22 2, yes. 23 Q. Okay. Let's go to the next 24 page. Now, this is oxycodone here?</p>	<p style="text-align: center;">Page 217</p> <p>1 right? 2 MS. O'GORMAN: Object to 3 form. 4 BY MR. PAPANTONIO: 5 Q. Did you not know that? 6 A. I knew that Purdue had 7 lawsuits against it regarding its 8 marketing practices. 9 Q. Right. 10 A. I don't follow that 11 particularly closely to see, you know, 12 whether they were found guilty and paid 13 fines. I'm busy with my McKesson 14 responsibilities. 15 Q. Sir, you're buying narcotic 16 drugs from Purdue, correct? We can agree 17 to that, as you just said. You know 18 that -- 19 A. McKesson does, yes. 20 Q. And yours -- 21 A. We deal with multiple 22 wholesale manufacturers. 23 Q. And second of all, you're 24 aware as you are buying those narcotic</p>

Page 218	Page 220
<p>1 drugs, that Purdue had been sued for -- 2 for lying about the addictive nature of 3 the drugs that you're distributing for 4 them, right.</p> <p>5 MS. O'GORMAN: Object to 6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. You know that?</p> <p>9 A. As I said, I was aware that 10 they were being sued, yes.</p> <p>11 Q. And you know that it had to 12 do with the fact that they were lying to 13 the American public about the addictive 14 nature of their drugs that they were 15 selling to you.</p> <p>16 MS. O'GORMAN: Objection.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Right?</p> <p>19 A. Again, I know there was 20 legal matters against Purdue. I didn't 21 really follow them to know whether or 22 not, you know, they were paid fines in 23 that case.</p> <p>24 Q. Sir, you knew when you were</p>	<p>1 MS. HENN: Objection to 2 form.</p> <p>3 THE WITNESS: Not the 4 full-time, no. I said I learned 5 of it.</p> <p>6 MS. HENN: Counsel, we've 7 been going another hour. So I 8 would suggest another ten-minute 9 break.</p> <p>10 MR. PAPANTONIO: That's 11 fine. If you'd like to, Ms. Henn, 12 we'll take a ten-minute break.</p> <p>13 THE VIDEOGRAPHER: The time 14 is 11:35 a.m. Going off the 15 record.</p> <p>16 (Short break.)</p> <p>17 THE VIDEOGRAPHER: We are 18 back on the record. The time is 19 11:46 a.m.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. You ready? Okay. Sir, 22 let's go -- let's go back to what we're 23 talking about here. I want to focus a 24 little bit on this \$1,222,880,000</p>
<p style="text-align: center;">Page 219</p> <p>1 distributing their drugs as their 2 distributor, you clearly understood that 3 they had been fined for lying about the 4 addictive nature of their drugs, 5 OxyContin and oxycodone. You knew that 6 didn't you?</p> <p>7 MS. O'GORMAN: Objection to 8 form.</p> <p>9 THE WITNESS: I would say 10 that I learned of it.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. All right. And is it -- 13 sir, as somebody that's involved with 14 actually regulatory matters, that's 15 pretty important to know that the people 16 that you're buying -- the people you're 17 buying narcotics from are out there 18 telling the American public, that, "Hey, 19 this stuff just ain't that addictive." 20 That's pretty information, isn't it?</p> <p>21 A. That's important, yes.</p> <p>22 Q. Yeah, and you knew that the 23 full time that you were a distributor 24 with this company, didn't you?</p>	<p style="text-align: center;">Page 221</p> <p>1 proposed fine for what McKesson had done. 2 The was this -- was this 3 built into the business plan as far as 4 you know? In other words, did McKesson 5 understand we can pay this kind of money 6 and still make a profit, we can pay these 7 fines and still make a profit?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Was that -- as far as you 12 know, was there any discussion about 13 well, you know, we can pay one billion, 14 we can pay \$700 million, all this list of 15 fines here? Was there a discussion that, 16 yeah, we're making so much money, we can 17 pay that kind of money and still make a 18 profit?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: In my area of 22 responsibility in regulatory, I 23 did not get involved with profit 24 and loss.</p>

Page 222	Page 224
<p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Okay. But this -- these are</p> <p>3 the proposed findings. You see them,</p> <p>4 right?</p> <p>5 A. Yes, I see them.</p> <p>6 Q. Okay. Would you please</p> <p>7 go -- let's go to Page 26. That's</p> <p>8 Accokeek. You're familiar with Accokeek.</p> <p>9 Am I saying --</p> <p>10 A. Accokeek.</p> <p>11 Q. Accokeek.</p> <p>12 A. Accokeek.</p> <p>13 Q. Okay. That's Page 26. And</p> <p>14 go to the next page right after that,</p> <p>15 Page 27.</p> <p>16 A. Okay.</p> <p>17 Q. It says up at the top,</p> <p>18 "Failure to report," and we're talking</p> <p>19 about suspicious orders, right?</p> <p>20 A. Mm-hmm.</p> <p>21 Q. It says November 29th they</p> <p>22 failed to report 40 suspicious orders.</p> <p>23 November they were -- failure to report.</p> <p>24 This is just on Accokeek, by -- Accokeek</p>	<p>1 MS. HENN: Objection to</p> <p>2 form.</p> <p>3 THE WITNESS: Yes. They're</p> <p>4 saying 40 times. Again, I don't</p> <p>5 know what the reference 40 refers</p> <p>6 to, whether that's an item, a line</p> <p>7 item on an order, or 40 orders in</p> <p>8 a day. That -- I'm not sure what</p> <p>9 the 40 references.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Okay. We'll clear that up</p> <p>12 as this goes on.</p> <p>13 But it says, it says then</p> <p>14 December failed to report 12.</p> <p>15 December 6th, failed to report 27</p> <p>16 suspicious orders. December 7th.</p> <p>17 This is just Accokeek.</p> <p>18 Do you see that?</p> <p>19 A. Yes.</p> <p>20 Q. Accokeek. And this Number</p> <p>21 7, failure to report 33. December 8th</p> <p>22 failed to report 38.</p> <p>23 And each time they failed to</p> <p>24 report that, you understand sir that that</p>
<p>1 by the way.</p> <p>2 40 times there was a failure</p> <p>3 to report suspicious orders on Accokeek.</p> <p>4 Do you see that?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Do you see that?</p> <p>9 A. I see the 40. I'm wondering</p> <p>10 what they're determining -- like 40</p> <p>11 orders on one day?</p> <p>12 Q. Sir, it just says the</p> <p>13 date --</p> <p>14 A. Yeah, it says 40. But I</p> <p>15 don't know what the 40 references.</p> <p>16 Q. Well, it says failure to</p> <p>17 report 40 times. And you understand 40</p> <p>18 times, if they failed to report 40 times,</p> <p>19 each time is -- they're actually</p> <p>20 violating the law?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. You understand that, right?</p>	<p>1 is actually a violation of the law. It's</p> <p>2 actually breaking the law.</p> <p>3 MS. HENN: Objection to</p> <p>4 form.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Correct?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: That's what</p> <p>10 this report is showing. Yes.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. And one reason that that law</p> <p>13 is so stringent is because we're selling</p> <p>14 narcotics to the American public,</p> <p>15 correct?</p> <p>16 A. We're selling them to</p> <p>17 Accokeek, yes.</p> <p>18 Q. Yeah, and Accokeek is</p> <p>19 selling them to the American public?</p> <p>20 A. Yes.</p> <p>21 Q. And you understand one</p> <p>22 reason you were given that McKesson was</p> <p>23 given the right to actually sell this</p> <p>24 drug is that you were supposed to police</p>
Page 223	Page 225

Page 226	Page 228
<p>1 these type of problems, McKesson was?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Right?</p> <p>6 A. We are responsible to have a</p> <p>7 controlled substance monitoring program</p> <p>8 in place, yes.</p> <p>9 Q. Would you go to page 29,</p> <p>10 please. And here's some more about</p> <p>11 Accokeek. Accokeek. And this was your</p> <p>12 account, true?</p> <p>13 A. Yes.</p> <p>14 Q. It says -- now, when did you</p> <p>15 start with them? When did you start</p> <p>16 there at Landover?</p> <p>17 A. It would have been late</p> <p>18 2007.</p> <p>19 Q. Okay. So in 2007 when you</p> <p>20 started, they were only selling 389,700</p> <p>21 oxycodone.</p> <p>22 Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. And then by 2011 when this</p>	<p>1 71 percent increase in population there</p> <p>2 in Maryland?</p> <p>3 A. I don't know what the</p> <p>4 population change was.</p> <p>5 Q. Was there something that</p> <p>6 where -- so you're not able to tell me</p> <p>7 anything that really happened in that</p> <p>8 area where Accokeek sold drugs that</p> <p>9 really should have caused it to go</p> <p>10 from -- to make a 71 percent increase in</p> <p>11 sales, right?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: The pharmacy</p> <p>15 would have had a business growth</p> <p>16 in their -- in their number of</p> <p>17 scripts and in their pharmacy</p> <p>18 sales. So they -- they had a</p> <p>19 business growth.</p> <p>20 It would have went through</p> <p>21 a -- what we call a threshold</p> <p>22 change request and a review to see</p> <p>23 whether or not the pharmacy should</p> <p>24 be granted an increase over what</p>
Page 227	Page 229
<p>1 investigation by the DEA started, they've</p> <p>2 increased that from -- they're increased</p> <p>3 that 71 percent in sales of just</p> <p>4 oxycodone alone, correct?</p> <p>5 MR. PAPANTONIO: Can you</p> <p>6 underline oxycodone for me, Evan.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. That's just oxycodone we're</p> <p>9 talking about?</p> <p>10 A. Yes, they increased over the</p> <p>11 five years.</p> <p>12 Q. And 71 percent increase.</p> <p>13 Now, are you familiar -- was</p> <p>14 there some -- was there some huge</p> <p>15 catastrophe that took place around where</p> <p>16 this Accokeek Drug Healthcare is? I</p> <p>17 mean, do you know where the town is?</p> <p>18 A. It's located in Maryland.</p> <p>19 Q. Was there some big</p> <p>20 catastrophe where people were injured or</p> <p>21 anything like that that happened between</p> <p>22 2007 and 2011?</p> <p>23 A. I don't believe there was.</p> <p>24 Q. Was there -- was there</p>	<p>1 their current threshold was</p> <p>2 established at. So there would</p> <p>3 have been a review by myself and a</p> <p>4 determination made whether or not</p> <p>5 their oxycodone should have been</p> <p>6 increased.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Increased 71 percent. If</p> <p>9 you look at hydrocodone, that was</p> <p>10 increased 185 percent between 2007 and</p> <p>11 2011. That's what that document says,</p> <p>12 right?</p> <p>13 A. Yeah. The 71 percent was</p> <p>14 over four years.</p> <p>15 Q. And this is 185 percent over</p> <p>16 four years, correct?</p> <p>17 A. Yes. In the hydrocodone, it</p> <p>18 went from 11 to 41 over four years.</p> <p>19 Q. And which of those two</p> <p>20 drugs, oxycodone or hydrocodone, have the</p> <p>21 biggest impact? Which one is the</p> <p>22 stronger narcotic?</p> <p>23 A. Oxycodone.</p> <p>24 Q. Oxycodone. Okay. And</p>

Page 230	Page 232
<p>1 you've got -- you've got oxymorphone that 2 had 132 percent increase, right? 3 A. Right. 4 Q. And this is while you were 5 there. They went from selling 400 -- 6 they went from selling 400 oxymorphone to 7 selling 24,400 oxymorphone, correct? 8 A. That is correct. They would 9 have been getting more scripts from 10 doctors prescribing it. 11 Q. Mm-hmm. Let's go to the 12 next page. That is Page 31. Oh, no is 13 it 30? 14 A. 30. 15 Q. So this says, "Accokeek Drug 16 Healthcare number of oxycodone sales 17 transactions with dosage units exceeding 18 the monthly average." 19 Do you see that? 20 So while they were growing 21 their business, as you described, they -- 22 you had 2,271 times that the transactions 23 they were involved with, exceeded three 24 times the monthly average, right?</p>	<p>1 A. It would not have been their 2 monthly average. It would have been the 3 average pharmacy. 4 Q. Yeah. That's what I'm 5 saying. Okay. The average pharmacy. 6 A. Yeah. 7 Q. In other words, a pharmacy 8 doing a regular business, day to day, 9 this -- the number of drugs, narcotic 10 drugs that they're selling is three times 11 that average, and that's 2,271 times they 12 exceeded three times. And then four 13 times they are selling their narcotics -- 14 these are your narcotics, right? 15 MS. HENN: Objection to 16 form. 17 BY MR. PAPANTONIO: 18 Q. These are McKesson 19 narcotics, right? 20 A. It's oxycodone sales. 21 Q. Yeah. 1,797 right, 22 transactions, where they exceeded the 23 average pharmacy by four times. That's 24 what it says, correct?</p>
<p>1 MS. HENN: Objection to 2 form. 3 BY MR. PAPANTONIO: 4 Q. That's what that says, 5 right? 6 MS. HENN: Objection to 7 form. 8 BY MR. PAPANTONIO: 9 Q. That's what that says, 10 right? 11 MS. HENN: Objection to 12 form. 13 THE WITNESS: That's what 14 the document shows, yes. 15 BY MR. PAPANTONIO: 16 Q. And that as they were 17 growing their business, as you described 18 there at Accokeek, four -- 1,797 times 19 they had transactions that exceeded their 20 monthly average by four times. 21 MS. HENN: Objection to 22 form. 23 BY MR. PAPANTONIO: 24 Q. Correct?</p>	<p>1 A. Yes. They were -- they were 2 a high volume larger pharmacy. Above the 3 average. 4 Q. All right. And so 5 ultimately they were closed down, right? 6 A. Ultimately McKesson -- a 7 decision was made by me that ceased 8 selling controls to them, yes. 9 Q. And how many years did it 10 take you to make that decision? 11 A. I don't know when they first 12 started. But whenever the date that I 13 closed them, I don't have that, I'm sure 14 it's in here when Accokeek was closed. 15 They would have been reviewed, since I 16 took the position in 2007, so it would 17 have been a couple years' review. 18 Q. And we all -- as we saw, 19 they increased their business -- we saw 20 clearly, oxy -- I mean, hydrocodone 21 alone, they increased their business 22 185 percent during the time that you were 23 there, correct? 24 MS. HENN: Objection to</p>
Page 231	Page 233

Page 234	Page 236
<p>1 form.</p> <p>2 THE WITNESS: Yeah, they</p> <p>3 would have been receiving</p> <p>4 prescriptions from doctors,</p> <p>5 writing for hydrocodone. That</p> <p>6 increased from seven -- 2007 to</p> <p>7 2011.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. During while they were doing</p> <p>10 all of that, if you were comparing what</p> <p>11 they were doing with the average pharmacy</p> <p>12 here in America, they committed 2,271</p> <p>13 transactions that exceeded the typical</p> <p>14 average pharmacy by three times, right?</p> <p>15 A. That's what the document is</p> <p>16 showing, yes. They were a large</p> <p>17 pharmacy, large volume pharmacy.</p> <p>18 Q. Okay. And they were a large</p> <p>19 pharmacy when you decided to stop doing</p> <p>20 business with them, right?</p> <p>21 A. They were, yes.</p> <p>22 Q. And oxycodone was a Purdue</p> <p>23 product; is that right?</p> <p>24 A. I don't believe so.</p>	<p>1 THE WITNESS: No, I didn't</p> <p>2 say that. I take my job very</p> <p>3 seriously. I take my</p> <p>4 responsibility very seriously.</p> <p>5 I said that I could not</p> <p>6 speak for what Purdue did or</p> <p>7 didn't do or said or didn't say.</p> <p>8 Obviously if any controlled</p> <p>9 substance has an addictive policy,</p> <p>10 DEA schedules them two through</p> <p>11 five, the lower the number the</p> <p>12 more addictive.</p> <p>13 So whether it's a Schedule</p> <p>14 II drug through a Schedule V drug,</p> <p>15 they all have benefits when used</p> <p>16 appropriately, and they all have,</p> <p>17 you know, problems where they can</p> <p>18 be abused.</p> <p>19 So I knew that a Schedule II</p> <p>20 drug obviously has a potential for</p> <p>21 more abuse than a Schedule V drug.</p> <p>22 So yes, I was aware of the</p> <p>23 potential, if not taken, you know,</p> <p>24 for medical purposes, that they</p>
Page 235	Page 237
<p>1 Oxycodone is the generic. Purdue product</p> <p>2 is OxyContin.</p> <p>3 Q. OxyContin, right. And</p> <p>4 that's -- OxyContin is the one that</p> <p>5 Purdue lied about as far as -- as far as</p> <p>6 its addictive nature, correct?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 MS. O'GORMAN: Same</p> <p>10 objection.</p> <p>11 THE WITNESS: I'm not --</p> <p>12 not -- I can't speak for what</p> <p>13 Purdue said or did.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Sir, you don't think you</p> <p>16 have a responsibility selling narcotics</p> <p>17 during a period of time where there is an</p> <p>18 opioid crisis going on in the United</p> <p>19 States, and you're buying from a company</p> <p>20 that has been hit for -- has been fined</p> <p>21 for lying about the qualities of their</p> <p>22 product. That's not important to you as</p> <p>23 a regulator?</p> <p>24 MS. O'GORMAN: Objection.</p>	<p>1 could be abused.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. In other words, you wouldn't</p> <p>4 go out and buy narcotics from Pablo</p> <p>5 Escobar without understanding Pablo</p> <p>6 Escobar and the cartel is selling you,</p> <p>7 right? You want to know what they are</p> <p>8 selling you, true?</p> <p>9 MS. HENN: Objection to</p> <p>10 form.</p> <p>11 THE WITNESS: Sir, I</p> <p>12 won't -- I won't speculate on</p> <p>13 that.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Yeah. Well, if you've got a</p> <p>16 company that's manufacturing a product</p> <p>17 and they're lying about how addictive the</p> <p>18 product is, that's a problem you want to</p> <p>19 know about, right?</p> <p>20 MS. HENN: Objection to</p> <p>21 form.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Because you're selling a lot</p> <p>24 of drugs.</p>

Page 238	Page 240
<p>1 MS. O'GORMAN: Same 2 objection. 3 THE WITNESS: I was 4 responsible for monitoring what 5 stores are purchasing. And that I 6 did. 7 As far as if the customer -- 8 the manufacturer and the 9 truthfulness of what they're 10 portraying, I did not get involved 11 with that, because the -- the 12 product has a medical purpose if 13 used correctly for medical 14 reasons.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. All right. Let's go to the 17 next -- let's go to the next slide. This 18 is the next page. This is 31. This is 19 Accokeek Drug Healthcare.</p> <p>20 Do you see that?</p> <p>21 A. Yes.</p> <p>22 Q. You see that? That line 23 goes straight up in the air.</p> <p>24 Do you see that? Or angle.</p>	<p>1 incentive -- you had an incentive program 2 that salespeople were actually making 3 more money if they sell more drugs, 4 right?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 THE WITNESS: When you said 8 "you," I am not on an incentive 9 program.</p> <p>10 The salespeople are 11 compensated on total sales of a 12 pharmacy, not just the controlled 13 substances.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. If they say more product, 16 they make more money, yes or no, 17 salespeople?</p> <p>18 A. Salespeople are on 19 commission, yes.</p> <p>20 Q. And if you were CEO, the 21 fellow we saw raise his right hand and 22 testify in front of Congress, if he has 23 the company selling more drugs, he's 24 making more money, right?</p>
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Do you see the angle on 5 that. That is -- that is dosage units 6 that are being sold out of one pharmacy 7 that you were selling drugs to, correct? 8 That's just for oxycodone?</p> <p>9 A. Yes. And this appears that 10 the dosage units cover a year's time; is 11 that correct?</p> <p>12 Q. Right. And as you're 13 selling that -- as you're selling that 14 product, your sales are going up, right? 15 As they are selling more drugs, your 16 sales are going up, correct?</p> <p>17 A. Sales would have increased. 18 But as I said, I don't get involved with 19 the dollars and cents. I'm looking at 20 their overall Rx business and then the 21 amount of controls to non-controls that 22 they are doing. I did not look at 23 dollars. I looked at dosages.</p> <p>24 Q. Okay. But you're on</p>	<p>1 A. It would -- it would appear 2 that total -- total sales of the company 3 would be, you know, included.</p> <p>4 Again the controlled 5 substances are a very small part of our 6 total sales.</p> <p>7 Q. And if you take -- if you 8 take one of your customers offline, you 9 take a pharmacy like Accokeek offline, 10 you're actually losing sales, aren't you?</p> <p>11 A. We would be losing sales.</p> <p>12 But as you saw, we did take them offline.</p> <p>13 Q. Yeah, after how many years?</p> <p>14 A. It looks like -- well, for 15 me, from '7 through, I guess, '11.</p> <p>16 Q. So from 2007 to 2011 during 17 a time where they had a 185 percent 18 increase in one of their sales of their 19 narcotic drugs, between that time you let 20 them continue selling drugs, right?</p> <p>21 A. I allowed them to continue 22 to purchase from McKesson, yes.</p> <p>23 Q. And then in 2011, when the 24 DEA comes and says, "Let me see the</p>

Page 242	Page 244
<p>1 records," that's when you took them 2 offline, correct? 3 MS. HENN: Objection to 4 form. 5 THE WITNESS: As I stated 6 earlier, my review of Accokeek was 7 not predicated upon the DEA's 8 request for information. 9 My job at Landover was to 10 review customers continuously, and 11 I did it on a daily basis. 12 Accokeek was one of several 13 of our top purchasers that I would 14 have been reviewing, going out to 15 make a site visit, looking at the 16 analysis of data of what they're 17 purchasing. 18 And then as I stated, in 19 2011, made a determination to 20 close the pharmacy.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Well, let's look on the Drug 23 Pharmacy. That's Page 34. That's 24 another one of your customers, right?</p>	<p>1 times. 2 Do you see that? 3 MS. HENN: Objection to 4 form. 5 THE WITNESS: I do. As I 6 stated earlier, I'm not sure if 7 that's orders or lines or what 8 that number references. It 9 doesn't say. 10 BY MR. PAPANTONIO: 11 Q. It was important enough, 12 though, that the DEA was ready to fine 13 you, fine McKesson for your conduct with 14 Drug City Pharmacy, right? 15 MS. HENN: Objection to 16 form. 17 THE WITNESS: Yes. I'm just 18 stating that it doesn't say orders 19 on here for me to agree or 20 disagree. 21 BY MR. PAPANTONIO: 22 Q. And so let look at this. 23 Let's see if we can find a pattern here. 24 They got -- go to Slide Number 37.</p>
<p>1 Drug Pharmacy. 2 A. Drug City, yes. 3 Q. Drug City. Yeah. You were 4 hands-on with them. You knew who was 5 running it. You showed up, shook their 6 hand, right? 7 MS. HENN: Objection to 8 form. 9 THE WITNESS: I visited the 10 pharmacy, yes. 11 BY MR. PAPANTONIO: 12 Q. Mm-hmm. Let's look at this 13 one. This is -- this is -- now we're 14 going to move from Accokeek and we're 15 going to move to another one. It's 16 called Drug City, Drug City Pharmacy. 17 And so it says on Drug City, 18 they begin by saying, "Let's look at the 19 failure to report" -- report suspicious 20 orders, right? Drug City Pharmacy. 21 And then it goes -- it tells 22 you the number of times that the Drug 23 City failed to report. It gives you a 24 whole list. 18 times, 13 times, 10</p>	<p>1 Now, here we have oxy -- 2 this is Drug City Pharmacy. One of 3 your -- one of the people that you dealt 4 with directly. Talking about oxycodone 5 and oxymorphone, right? In 2007 6 oxycodone, and you say that's -- excuse 7 me 2007, they were selling 1,281,700 8 doses there, right? 9 A. Yes. 10 Q. And then by 2011 they'd 11 increased 33 percent to 3,083,600. 12 Do you see that? 13 A. Yes. This is -- 14 Q. That -- 15 A. -- one of my larger accounts 16 that I monitored. 17 Q. Yeah. And let's talk 18 about -- let's go to the next page, after 19 looking at that increase. Let's see the 20 number of times that the sales 21 transaction with the dosage exceeded the 22 monthly pharmacy average. In other 23 words, let's compare them to other 24 pharmacies?</p>

Page 246	Page 248
<p>1 A. This customer, Drug City, 2 was the largest customer in that 3 distribution center.</p> <p>4 Q. Mm-hmm. I know. But let's 5 still talk about --</p> <p>6 A. It certainly would have been 7 above the average.</p> <p>8 Q. Let's talk about it.</p> <p>9 A. Okay.</p> <p>10 Q. Because you were -- McKesson 11 was making a lot of money on Drug City 12 Pharmacy, right?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 THE WITNESS: I -- again, I 16 don't look at the dollars at a 17 pharmacy. I'm not in sales.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Yeah, and --</p> <p>20 A. So I have no idea how much 21 they're spending with us. I just know 22 volumewise, dosages, they were the 23 largest customer I had out of Landover.</p> <p>24 Q. Okay. And as a matter of</p>	<p>1 A. Yeah, it's here.</p> <p>2 Q. And Drug City was closed 3 down also, wasn't it, after the DEA asked 4 you to provide information about their 5 files, give the DEA the information, they 6 were closed down after that too, weren't 7 they?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: Drug City 11 was -- had their threshold reduced 12 initially. And then eventually 13 they were closed from a McKesson 14 customer.</p> <p>15 It was not right after the 16 DEA inquiry.</p> <p>17 Again, I looked at the top 18 customers that I had.</p> <p>19 Every customer here that 20 we're talking about was one of my 21 top volume customers. So I would 22 have been looking at them even 23 without the DEA included.</p> <p>24 BY MR. PAPANTONIO:</p>
<p>1 fact they were so bad -- so big, if you 2 look at this document, Number 38, 30 3 times -- now, it's saying there were 914 4 transactions where the pharmacy was 5 exceeding the average pharmacy by 30 6 times the number of drugs -- number of 7 narcotics they were selling, right?</p> <p>8 A. That's what this is showing.</p> <p>9 Q. 30 times, right? Let's look 10 at the next page.</p> <p>11 A. And is that 30 times over 12 the four-year period?</p> <p>13 Q. Sir, I think the way it's 14 looking, it might be. Yeah, but how 15 about the top. You want to talk about a 16 four-year period.</p> <p>17 Thanks for interrupting me 18 there.</p> <p>19 Look at the times that they 20 exceeded four times the average --</p> <p>21 national average for pharmacies was 9,014 22 transactions where they exceeded the 23 averages by four times.</p> <p>24 Do you see that?</p>	<p>1 Q. Let's go to Page 40 there on 2 Drug City. Let's talk about how -- this 3 is their sales. Do you see those dosage 4 units, how it goes straight up. 2007, 5 2011, straight up, right?</p> <p>6 And as that straight up, 7 sales for McKesson went straight up too, 8 of selling narcotics there at that drug 9 store, right?</p> <p>10 A. Again, I don't deal with 11 sales. But yes, if you're selling more 12 and requesting, again, this means that 13 they would have been receiving more 14 prescriptions written by doctors for that 15 medication.</p> <p>16 Q. Now, I saved this last one. 17 Go to Page 40. I saved this last one for 18 right now because you wanted to talk 19 about Herndon and what you had done with 20 Herndon Pharmacy, how you were performing 21 your investigation. Do you remember we 22 were talking about that a while ago?</p> <p>23 A. Yeah. Herndon was one that 24 we spoke, yes.</p>

Page 250	Page 252
<p>1 Q. Yeah. Right. And that's 2 one that closed down, that you stopped 3 doing business with them, after the DEA 4 asked for information --</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. -- about their sales, true?</p> <p>9 MS. HENN: Objection to 10 form.</p> <p>11 THE WITNESS: They -- 12 Herndon Pharmacy is a pharmacy 13 that I closed based off of their 14 purchasing, yes.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. All right. And then if you 17 will go to Page 43 there. Let's see what 18 the DEA said -- had to say when they 19 looked at these files.</p> <p>20 Do you see where it says, 21 "Failure to report, Herndon Pharmacy"? 22 Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. It says, "Clearly, McKesson</p>	<p>1 Do you understand? Now they have all the 2 records. They've asked for them, and 3 they've been given over by McKesson. 4 Let's see what they find.</p> <p>5 A. They would have had the 6 records prior to that even in their ARCOS 7 reporting.</p> <p>8 Q. Well, they must not have had 9 all of them, because they asked you for 10 your files to see if what your company 11 was doing was consistent with what they 12 were reporting, right?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. In other words, your company 17 could be make -- phonying up records. 18 They don't know that.</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Your company could be 23 phonying up records left and right. 24 That's what they're trying to find out</p>
Page 251	Page 253
<p>1 identified suspicious orders on or before 2 August 19th" -- excuse me -- "August 19, 3 2011."</p> <p>4 Did I read that right?</p> <p>5 A. That's what it says there.</p> <p>6 Yes.</p> <p>7 Q. All right. And it says, "No 8 suspicious orders were submitted to the 9 DEA until November" -- "until 10 November 15, 1911 (sic)." So -- is that 11 right?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 THE WITNESS: That's what 15 it's saying here. I don't know 16 what they're basing the 17 identification of the suspicious 18 orders on or before August 19th 19 on.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Well, let's see. Let's see, 22 because now, by now, they have the 23 records. They finally can review the 24 records of these -- of Herndon Pharmacy.</p>	<p>1 here, right?</p> <p>2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: I don't know 5 what they are trying to find out. 6 But I know monthly it's a 7 requirement that we send into DEA 8 ARCOS reporting, so they would 9 have had Herndon Pharmacy's 10 purchases every month.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Unless McKesson is phonying 13 up the records and not telling them the 14 truth, right?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 THE WITNESS: I can't speak 18 on that, sir.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. All right. And it says, 21 "McKesson found Herndon's" -- "Herndon's 22 orders suspicious well before 23 August 19th."</p> <p>24 Do you see that?</p>

Page 254	Page 256
<p>1 A. Yeah, it's the third bullet. 2 Q. Yeah, it says as a matter of 3 fact, they found them suspicious -- it 4 says July 27, 2011, right? 5 MS. HENN: Objection to 6 form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. I want you to look at this 9 very carefully before we go to the next 10 page. You correct anything that you want 11 to correct on this page right now. Okay. 12 You understand that the DEA is saying 13 that you had clear information that there 14 were suspicious orders taking place 15 before August 19th, right? Didn't you 16 tell me that you did this investigation 17 yourself?</p> <p>18 A. Yeah, I visited the 19 pharmacy.</p> <p>20 Q. Okay. And apparently you 21 did not report the August 19th -- you did 22 not report suspicious orders till 23 July 27, 2011, right? That's what this 24 is saying.</p>	<p>1 investigation? 2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: I did not make 5 that comparison to the national 6 average.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Do you remember telling us 9 about Dr. Salerian?</p> <p>10 A. Yes.</p> <p>11 Q. Didn't you mention 12 Dr. Salerian?</p> <p>13 A. I did.</p> <p>14 Q. And as a matter of fact, you 15 knew that a search warrant had been 16 issued to Dr. Salerian before you ever 17 started your investigation, didn't you?</p> <p>18 A. I am not certain of that.</p> <p>19 Q. Well, let's look. Let's go 20 to Page 46. You talked about how you 21 did -- you looked at what Dr. Salerian 22 was doing. You looked at what other 23 pharmacies were doing around him. Do you 24 remember that big explanation you gave me</p>
<p>1 A. That's what it's saying. I 2 don't know if I had a suspicious order 3 prior to that.</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, okay. We either 8 believe the DEA or we don't. Do you 9 believe them, that you failed to report 10 suspicious orders?</p> <p>11 A. That is what they are 12 stating, yes.</p> <p>13 Q. Okay. That's all we can 14 accomplish. They -- as a matter of fact, 15 if you go to Page 45, it says Herndon 16 Pharmacy, number of oxycodone sales 17 transactions exceeding the monthly 18 pharmacy averages. It even gives us 19 that. Look what it says.</p> <p>20 Do you see those numbers? 21 We are talking about transactions, 124 22 transactions that exceeded the averages 23 by three times the national average. Do 24 you see that? Did you find that in your</p>	<p>1 about how your investigation was taking 2 place?</p> <p>3 MS. HENN: Objection to 4 form.</p> <p>5 THE WITNESS: Yeah, I gave 6 you the details of what I did in 7 my due diligence.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Well, you know, sir, don't 10 you, that a search warrant had already 11 been issued to Dr. Salerian before you 12 did the first thing? You know that.</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 THE WITNESS: How do I know 16 that, sir?</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Well, you get a report of 19 any search warrants that go out.</p> <p>20 A. From who?</p> <p>21 Q. From the DEA. If they're 22 doing a search warrant, you have a right 23 to get a report, correct?</p> <p>24 MS. HENN: Objection to</p>

Page 258	Page 260
<p>1 form.</p> <p>2 THE WITNESS: I have not</p> <p>3 seen that information prior to</p> <p>4 what I'd reviewed.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. All right. So why don't you</p> <p>7 take a look at Page 46 and tell me what</p> <p>8 you found about Dr. Salerian and when you</p> <p>9 reported any of this material that we are</p> <p>10 talking about here about Dr. Salerian.</p> <p>11 He ran a pill mill, didn't he?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: I don't know</p> <p>15 if he ran a pill mill.</p> <p>16 My suspicion was based off</p> <p>17 the fact that he was a</p> <p>18 psychiatrist writing for</p> <p>19 oxycodone, and the distance from</p> <p>20 his pharmacy -- excuse me, from</p> <p>21 his practice to the pharmacy.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. And he had people driving in</p> <p>24 from West Virginia that were going, a</p>	<p>1 form.</p> <p>2 THE WITNESS: Dr. Salerian</p> <p>3 wasn't buying any drugs. He was</p> <p>4 writing prescriptions.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Writing prescriptions.</p> <p>7 Okay. Well, let's --</p> <p>8 however you want -- let's say writing</p> <p>9 prescriptions.</p> <p>10 Tell us what red flags you</p> <p>11 saw about Dr. Salerian and when you saw</p> <p>12 them?</p> <p>13 A. Okay. The exact time that I</p> <p>14 saw them, I don't recall, but what I saw</p> <p>15 was the distance from the doctor's office</p> <p>16 to the pharmacy. He was in D.C. The</p> <p>17 pharmacy is in Herndon, Virginia. It was</p> <p>18 a distance.</p> <p>19 His practice, he was a</p> <p>20 psychiatrist writing for oxycodone. The</p> <p>21 amount of prescriptions that he -- both</p> <p>22 in quantity and the number of scripts</p> <p>23 percentage that he made up at Herndon</p> <p>24 Pharmacy, he was the top prescribing</p>
<p>1 part the oxy express, to buy narcotics</p> <p>2 that your company, McKesson, was selling</p> <p>3 to Dr. Salerian. Had people driving in</p> <p>4 from West Virginia to do that, right?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 THE WITNESS: We weren't</p> <p>8 selling to Dr. Salerian.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Who were you selling to?</p> <p>11 A. Herndon Pharmacy.</p> <p>12 Q. Okay. And how does Dr.</p> <p>13 Salerian fit into that?</p> <p>14 A. Dr. Salerian was the doctor</p> <p>15 writing the prescriptions that were</p> <p>16 getting filled at Herndon Pharmacy. But</p> <p>17 we were not selling to Dr. Salerian.</p> <p>18 Q. Okay. Got it. So you're</p> <p>19 saying I didn't sell to Dr. Salerian</p> <p>20 directly, but you know that Dr. Salerian</p> <p>21 was buying all of these -- all of these</p> <p>22 drugs that you were selling to Herndon.</p> <p>23 You knew that?</p> <p>24 MS. HENN: Objection to</p>	<p>1 doctor for the scripts that were getting</p> <p>2 filled at Herndon Pharmacy.</p> <p>3 Q. And how many years was he</p> <p>4 getting away with that? While this was</p> <p>5 your watch, how many years was</p> <p>6 Dr. Salerian getting away with what you</p> <p>7 just described?</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 THE WITNESS: I don't know</p> <p>11 the exact time that Herndon opened</p> <p>12 and I closed him. So I can't say.</p> <p>13 I don't have that information in</p> <p>14 front of me.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. We've already established</p> <p>17 that you closed them after the DEA asked</p> <p>18 for the records. That's when you closed</p> <p>19 them, right?</p> <p>20 A. I closed them when I</p> <p>21 concluded my review. I don't have the</p> <p>22 dates when I started and when I ended.</p> <p>23 My review may have been prior to the DEA</p> <p>24 asking for that list of top customers. I</p>

Page 262	Page 264
<p>1 don't have that information, nor do I 2 recollect the exact dates. 3 Q. We looked at the dates, and 4 we found that you actually stopped doing 5 business with Herndon after the DEA asked 6 you for the Herndon records. We saw 7 that. Do you remember that? Or do you 8 want to go back to it? 9 A. No. That would have been 10 when I resolved and saw that -- made a 11 determination, because I did visit this 12 pharmacy both with the sales team and 13 also our VP GM. I was there with -- I 14 was at Herndon several visits. I went 15 with upper management, who was 16 responsible for the distribution area, 17 the VP GM, vice president general 18 manager. And our determination was that 19 we would stop doing business with Herndon 20 Pharmacy.</p> <p>21 Q. And you knew that 22 Dr. Salerian had specialized in cash 23 customers. You knew that he was -- he 24 was a cash doctor. You knew that, right?</p>	<p>1 frequency, size and patterns. 2 And, you know, the fact that I did 3 turn this customer off shows that 4 I was doing my due diligence. 5 BY MR. PAPANTONIO: 6 Q. Yeah, you did your due 7 diligence after you sold him all of those 8 drugs for seven years, right? 9 MS. HENN: Objection to 10 form. 11 THE WITNESS: I don't know 12 the extent of Herndon, how long 13 they were open. I do not believe 14 that he was open seven years. 15 BY MR. PAPANTONIO: 16 Q. All right. How many years 17 they were open, you were make -- McKesson 18 was making a lot of money while 19 Dr. Salerian was dealing with Herndon 20 selling money -- selling dope for cash, 21 right? A lot of years that went on, 22 right? 23 A. Again, I said I don't know 24 if patients are paying cash at the</p>
<p>1 A. No, I did not. How -- no, I 2 would not have known that -- how patients 3 were paying Dr. Salerian. 4 Q. And you knew that most of 5 his customers were from West Virginia. 6 Did you know that? 7 A. I'm unaware. I'm not 8 certain of that to my recollection back 9 then. 10 Q. And -- but you had 11 responsibility under your responsibility 12 to protect the American public from a 13 drug crisis, you had a responsibility to 14 have in place a system that would 15 determine whether this type of thing was 16 going on, cash customers, people driving 17 in from out of town, you had a 18 responsibility to make sure you had a 19 system that prevented that, correct? 20 MS. HENN: Objection to 21 form. 22 THE WITNESS: We had 23 responsibility to have a system to 24 detect diversion based off of</p>	<p>1 doctor's office. It's protected. 2 Q. You had a marketing program. 3 McKesson had a marketing program, didn't 4 they, where they actually -- they 5 actually had marketing programs to 6 increase the sales of these drugs, all 7 over the country, correct? 8 MS. HENN: Objection to 9 form. 10 THE WITNESS: I am not 11 familiar with our marketing side 12 of the business. I don't get 13 involved with marketing. I was in 14 regulatory. So I'm not familiar 15 with what sales programs there 16 were out there. 17 BY MR. PAPANTONIO: 18 Q. So nobody ever told you, as 19 you were trying to do your job in 20 regulatory and control the flow of drugs, 21 nobody told you that, hey, we're out 22 there actually marketing drugs. We're 23 helping sell -- we're helping -- we're 24 helping push more pills. Nobody ever</p>

<p>1 told you that, did they?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: McKesson would</p> <p>5 be in the sales department they</p> <p>6 would be selling all products.</p> <p>7 Controlled substances, Rx, OTC.</p> <p>8 But as I said, I'm not aware</p> <p>9 of specific sales programs to</p> <p>10 increase sales of controlled</p> <p>11 substances.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Give me --</p> <p>14 MR. PAPANTONIO: What number</p> <p>15 is that? Video 1. Let's take a</p> <p>16 look at. No, wait I want -- yeah,</p> <p>17 Video Number 1. Video Number 1.</p> <p>18 Yeah, Video Number 1 if you could</p> <p>19 tee it up.</p> <p>20 (Document marked for</p> <p>21 identification as Exhibit</p> <p>22 MCK-Oriente-Video-1.)</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. You say you watched the</p>	<p>Page 266</p> <p>1 (End of video playback.)</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Wow, one of y'all are lying</p> <p>4 here. He just said that they don't</p> <p>5 market drugs. Isn't that what he just</p> <p>6 said? And you just said they do, which</p> <p>7 is it?</p> <p>8 MS. HENN: Objection to</p> <p>9 form, Counsel.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. I'm just curious. Is he</p> <p>12 lying about -- when he's testifying in</p> <p>13 front of Congress, swore to tell the</p> <p>14 truth, is he telling the truth when he</p> <p>15 tells the entire congressional meeting</p> <p>16 there that McKesson doesn't market drugs?</p> <p>17 Let's play it again I want</p> <p>18 to make sure we get this right.</p> <p>19 MR. PAPANTONIO: Play it</p> <p>20 again, please.</p> <p>21 (Video playback.)</p> <p>22 MR. HAMMERGREN: As a</p> <p>23 distributor, we don't manufacture</p> <p>24 prescription drugs. We don't</p>
<p>1 entire -- did you watch the entire</p> <p>2 congressional hearing with your boss</p> <p>3 testifying in front of the congressional</p> <p>4 hearing after he'd sworn to tell the</p> <p>5 truth?</p> <p>6 A. I was not at the TV the</p> <p>7 entire time, no.</p> <p>8 Q. All right. Let's see if you</p> <p>9 were at the TV during this time. Let's</p> <p>10 play this.</p> <p>11 MR. PAPANTONIO: You've got</p> <p>12 to turn it up. Start again and</p> <p>13 turn it up.</p> <p>14 (Video playback.)</p> <p>15 MR. HAMMERGREN: As a</p> <p>16 distributor, we don't manufacture</p> <p>17 prescription drugs. We don't</p> <p>18 market them to doctors or</p> <p>19 patients, nor do we market any</p> <p>20 particular category of drugs such</p> <p>21 as opioids to pharmacists.</p> <p>22 Distributors respond to</p> <p>23 pharmacy orders which are based on</p> <p>24 doctors' prescriptions.</p>	<p>Page 267</p> <p>1 market them to doctors or</p> <p>2 patients, nor do we market any</p> <p>3 particular category of drugs, such</p> <p>4 as opioids, to pharmacists.</p> <p>5 Distributors respond to</p> <p>6 pharmacy orders which are based on</p> <p>7 doctors' prescriptions.</p> <p>8 (End of video playback.)</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Did you know that he said</p> <p>11 that in front in front of Congress?</p> <p>12 A. No, I did not.</p> <p>13 Q. Okay. If he said that, he's</p> <p>14 not telling the truth. He's committing</p> <p>15 perjury, isn't he?</p> <p>16 MS. HENN: Objection to</p> <p>17 form.</p> <p>18 THE WITNESS: I'm not going</p> <p>19 to say if he is or isn't.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. If he's raising his</p> <p>22 right-hand and swearing to Congress that</p> <p>23 he's telling the truth, and he's lying,</p> <p>24 he's committing perjury, isn't he?</p>

Page 270	Page 272
<p>1 A. What he --</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: What I believe</p> <p>5 he's saying there is that we sell</p> <p>6 what pharmacies order.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. No, sir. No, sir. He</p> <p>9 says --</p> <p>10 MR. PAPANTONIO: Play it</p> <p>11 again. Play it again.</p> <p>12 (Video playback.)</p> <p>13 MR. HAMMERGREN: As a</p> <p>14 distributor, we don't manufacture</p> <p>15 prescription drugs. We don't</p> <p>16 market them to doctors or</p> <p>17 patients, nor do we market any</p> <p>18 particular category of drugs such</p> <p>19 as opioids to pharmacists.</p> <p>20 Distributors respond to</p> <p>21 pharmacy orders, which are based</p> <p>22 on doctors' prescriptions.</p> <p>23 (End of video playback.)</p> <p>24 BY MR. PAPANTONIO:</p>	<p>1 time is 12:24 p.m. Off the</p> <p>2 record.</p> <p>3 - - -</p> <p>4 (Lunch break.)</p> <p>5 - - -</p> <p>6 THE VIDEOGRAPHER: We are</p> <p>7 back on the record. The time is</p> <p>8 1:09 p.m.</p> <p>9 - - -</p> <p>10 EXAMINATION (Cont'd.)</p> <p>11 - - -</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Sir, when we took a lunch</p> <p>14 break, we were talking about the</p> <p>15 marketing that McKesson does. And in</p> <p>16 fact, marketing, by marketing, you</p> <p>17 increase sales, correct? Isn't that the</p> <p>18 idea of marketing?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: Well, I --</p> <p>22 marketing is not necessarily a</p> <p>23 correlation to increasing sales.</p> <p>24 I see it more of advertising.</p>
Page 271	Page 273
<p>1 Q. Wow. That's just not true,</p> <p>2 is it? What he just -- what he just said</p> <p>3 in front of Congress, the very highest</p> <p>4 man, very highest person in McKesson</p> <p>5 drugs just lied to Congress, didn't he?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: I can't say</p> <p>9 that he did. If you want me to --</p> <p>10 and know what he's saying, then</p> <p>11 he's saying that a doctor writes a</p> <p>12 prescription. A pharmacy orders</p> <p>13 product to fill that prescription.</p> <p>14 And then we fill -- we send an</p> <p>15 order to a pharmacy after they</p> <p>16 order it.</p> <p>17 MR. PAPANTONIO: All right.</p> <p>18 We'll -- we're going to explore</p> <p>19 this a little bit more after</p> <p>20 lunch. Okay. We'll take a lunch</p> <p>21 break, and we'll come back and</p> <p>22 pick up with this. Okay.</p> <p>23 THE VIDEOGRAPHER: All</p> <p>24 right. Stand by, please. The</p>	<p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Okay. So you were</p> <p>3 advertising narcotics?</p> <p>4 MS. HENN: Objection to</p> <p>5 form.</p> <p>6 THE WITNESS: Not myself.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. But McKesson?</p> <p>9 A. I don't --</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 THE WITNESS: I don't know</p> <p>13 that they were. I know they do</p> <p>14 sales so by saying marketing and</p> <p>15 sales as one, I'm not aware of</p> <p>16 them marketing controls and</p> <p>17 pushing controls.</p> <p>18 If a pharmacy isn't going to</p> <p>19 be able to fill a prescription,</p> <p>20 they are not going to buy</p> <p>21 something simply to buy it and put</p> <p>22 it on their shelf.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Sir, let me cut right to it,</p>

Page 274	Page 276
<p>1 okay.</p> <p>2 You as a regulator, as you</p> <p>3 sit here today, had no idea that your</p> <p>4 company was out marketing narcotics. Is</p> <p>5 that a yes or a no?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: As I stated,</p> <p>9 McKesson is selling products that</p> <p>10 a pharmacy needs to fill</p> <p>11 prescriptions.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Narcotics is one of them?</p> <p>14 A. Yes.</p> <p>15 Q. Correct?</p> <p>16 Okay. You did know that</p> <p>17 they were marketing narcotics then,</p> <p>18 correct?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. I want to be clear on this,</p> <p>23 because I'm getting ready to go through</p> <p>24 some documents here. And I want to be</p>	<p>1 that your company is marketing, you have</p> <p>2 no way to keep up with why there are so</p> <p>3 many sales at a particular pharmacy, you</p> <p>4 kind of have to know a correlation, don't</p> <p>5 you?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: In the</p> <p>9 regulatory area, we would request</p> <p>10 information from the pharmacy that</p> <p>11 would explain why their increase</p> <p>12 in business.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. All right. And you knew</p> <p>15 that -- or maybe you didn't know. But do</p> <p>16 you have any opinion as far as your</p> <p>17 experience as a regulator, that marketing</p> <p>18 increases sales?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: I would say</p> <p>22 not in the case for controlled</p> <p>23 substances, because a prescription</p> <p>24 has to be written by a doctor in</p>
<p>1 clear, you knew that McKesson was</p> <p>2 marketing narcotics, yes or no?</p> <p>3 MS. HENN: Objection to</p> <p>4 form.</p> <p>5 THE WITNESS: Yes, McKesson</p> <p>6 is selling narcotics.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Okay. And for example --</p> <p>9 MR. PAPANTONIO: 1154, would</p> <p>10 you put up 1154.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. You knew, sir, didn't you,</p> <p>13 that McKesson -- let me -- before I ask</p> <p>14 this question.</p> <p>15 If you see upticks in</p> <p>16 sales -- for example, we went through a</p> <p>17 few of the pharmacies that you were in</p> <p>18 charge with, right? And there is a lot</p> <p>19 of factors that affect upticks in sales.</p> <p>20 You would agree with that?</p> <p>21 A. Yes.</p> <p>22 Q. I think you explained a few.</p> <p>23 A. Yes, there are some.</p> <p>24 Q. And -- and if you don't know</p>	<p>1 order for that increase in sales</p> <p>2 to take place.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. When -- after your</p> <p>5 president, Mr. Hambergren, CEO, testified</p> <p>6 that your company didn't do any</p> <p>7 marketing, do you remember any e-mails</p> <p>8 flying around -- flying around at</p> <p>9 McKesson saying he just -- he just</p> <p>10 committed perjury?</p> <p>11 MS. HENN: Objection to</p> <p>12 form.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Was there any kind of</p> <p>15 e-mails like that that were flying around</p> <p>16 the McKesson headquarters?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: I did not see</p> <p>20 any e-mails pertaining to that,</p> <p>21 no.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. But it wasn't true. What he</p> <p>24 said was not true. You agreed to that</p>

Page 278	Page 280
<p>1 already, I think?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: I don't know</p> <p>5 what his definition of</p> <p>6 marketing -- what he was referring</p> <p>7 to on that.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Yeah. Well, as a matter of</p> <p>10 fact, sir, you were marketing with</p> <p>11 Purdue. You had --</p> <p>12 MR. PAPANTONIO: 1154.</p> <p>13 Could you put up 1154.</p> <p>14 MS. MOORE: It's MCK Oriente</p> <p>15 144.</p> <p>16 MS. HENN: Do you want 1154,</p> <p>17 or would you like him to see 144?</p> <p>18 MR. PAPANTONIO: 1154. The</p> <p>19 number she is giving is just for</p> <p>20 identification.</p> <p>21 (Document marked for</p> <p>22 identification as Exhibit</p> <p>23 MCK-Oriente-144.)</p> <p>24 BY MR. PAPANTONIO:</p>	<p>1 form.</p> <p>2 THE WITNESS: I was not</p> <p>3 aware, nor have I ever seen this.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Is this the first time that</p> <p>6 you've seen this marketing arrangement</p> <p>7 between McKesson and Purdue where they</p> <p>8 were marketing narcotics?</p> <p>9 A. Yes. As I --</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 THE WITNESS: Yes. As I</p> <p>13 stated earlier, I did not get</p> <p>14 involved with the sales side of</p> <p>15 the business. I have never seen</p> <p>16 this document.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Do you know what loyal --</p> <p>19 what the term "loyalty script" is? Have</p> <p>20 you ever heard that?</p> <p>21 A. No, I have not.</p> <p>22 Q. Okay. Did you know that</p> <p>23 Purdue and McKesson actually, as early as</p> <p>24 2010, had a marketing program, an</p>
<p style="text-align: center;">Page 279</p> <p>1 Q. You've seen -- have you ever</p> <p>2 seen this document --</p> <p>3 MS. HENN: Wait, wait.</p> <p>4 Counsel, I just want to make</p> <p>5 sure we're clear. The witness has</p> <p>6 been handed a document that's</p> <p>7 labeled and marked McKesson</p> <p>8 Oriente 144. So we need to make</p> <p>9 sure that the record's clear about</p> <p>10 that. I don't know what number</p> <p>11 you're using, but that's what he</p> <p>12 has.</p> <p>13 MS. O'GORMAN: Can I have a</p> <p>14 copy of that document.</p> <p>15 MS. HENN: And we're --</p> <p>16 MR. PAPANTONIO: So --</p> <p>17 MS. HENN: And we need</p> <p>18 another copy of the document.</p> <p>19 MR. PAPANTONIO: Yeah.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. So McKesson had a marketing</p> <p>22 arrangement with Purdue. Did you know</p> <p>23 that?</p> <p>24 MS. HENN: Objection to</p>	<p style="text-align: center;">Page 281</p> <p>1 agreement with something called Butrans.</p> <p>2 Do you know what Butrans is?</p> <p>3 A. No, I've never heard of --</p> <p>4 Q. B-U-T-R-A-N-S?</p> <p>5 A. No, sir, never heard of it.</p> <p>6 Q. You don't know if it's a</p> <p>7 narcotic or not?</p> <p>8 A. Butrans? I've never heard</p> <p>9 that word before.</p> <p>10 Q. Yeah, okay. And so nobody</p> <p>11 told you as you were out trying to figure</p> <p>12 out regulatory aspects of what was going</p> <p>13 on with your pharmacies, when were they</p> <p>14 selling more, when were they selling</p> <p>15 less, nobody told you that while all that</p> <p>16 was going on, Purdue and McKesson had a</p> <p>17 marketing program put together?</p> <p>18 MS. HENN: Objection.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Nobody told you that, right?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Correct?</p>

Page 282	Page 284
<p>1 A. You mentioned that, and I 2 was unaware that there was any program 3 between the two.</p> <p>4 Q. And apparently your CEO, the 5 highest man in this company, must have 6 been unaware of it too, because he told 7 Congress there was no such thing as 8 marketing between -- for McKesson 9 marketing?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. That's what we -- that's 14 what we listened to on the video, didn't 15 we?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Right?</p> <p>20 A. I don't know what he was 21 exactly referring to, sir.</p> <p>22 Q. Well, you knew that you were 23 marketing -- do you know what Teva is? 24 Have you ever heard the company Teva?</p>	<p>1 in order to answer this question.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Tell the jury what fentanyl 4 is.</p> <p>5 MS. HENN: Do you want him 6 to look at it?</p> <p>7 MR. PAPANTONIO: I do want 8 him to look at it. I'm not asking 9 about the document.</p> <p>10 MS. HENN: I just want to 11 make sure he's doing one thing at 12 a time. If you have a question or 13 you'd like --</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. This is a clear question. 16 Tell the jury what fentanyl is.</p> <p>17 A. Fentanyl is a controlled 18 substance used to control pain.</p> <p>19 Q. And tell us about the 20 potency of fentanyl, as you understand 21 it?</p> <p>22 A. It's highly potent and 23 usually is administered in a patch.</p> <p>24 Q. Is it -- would you agree</p>
<p>1 A. Teva Pharmaceutical, they're 2 another manufacturer.</p> <p>3 Q. Okay. And you had -- nobody 4 told you that --</p> <p>5 MR. PAPANTONIO: Would you 6 put up 1317, please.</p> <p>7 MS. HENN: Could we get a 8 copy for the witness, please?</p> <p>9 MR. PAPANTONIO: We're 10 getting a copy right now. 1317. 11 Carol give the identification on 12 this.</p> <p>13 MS. MOORE: MCK Oriente 279. 14 (Document marked for 15 identification as Exhibit 16 MCK-Oriente-279.)</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Tell the jury what Fentanyl 19 is.</p> <p>20 MS. HENN: Counsel, can you 21 wait until the witness has the 22 document, please? Thank you.</p> <p>23 MR. PAPANTONIO: Well, he 24 doesn't have to have the document</p>	<p>1 that it is the most potent narcotic on 2 the market?</p> <p>3 A. I'm not a pharmacist, but I 4 know it's one of the higher potency -- 5 excuse me -- potency controlled 6 substances, yes.</p> <p>7 Q. Again, we heard that your 8 CEO say that you don't market, McKesson 9 doesn't market. What is -- the title on 10 this is "McKesson Manufacturer Marketing 11 Contract." And then it goes on and it 12 talks about Actiq and Fentora. Would you 13 tell the jury what Actiq and Fentora is.</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 THE WITNESS: I know Actiq. 17 Fentora I'm not 100 percent clear 18 or familiar with that specific 19 brand.</p> <p>20 The Actiq, I believe, is 21 like a lollipop dispenser type for 22 fentanyl.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. So you've got a fentanyl</p>

<p style="text-align: right;">Page 286</p> <p>1 lollipop that you would agree is the most 2 potent narcotic ever sold in America. 3 You would agree with that, wouldn't you? 4 A. Not necessarily, sir. I'm 5 not a pharmacist. I can't say that it's 6 more or less potent than another drug. 7 Q. Have you ever seen the 8 comparison between how potent fentanyl is 9 compared to other narcotics?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 THE WITNESS: No. No.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. I'll put this up in a 15 minute. Have you ever seen that?</p> <p>16 MS. HENN: Are you going to 17 hand him --</p> <p>18 MR. PAPANTONIO: I'm going 19 to in just a second.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Have you ever seen that?</p> <p>22 MS. HENN: What are you 23 referring to, Counsel?</p> <p>24 BY MR. PAPANTONIO:</p>	<p style="text-align: right;">Page 288</p> <p>1 Q. When you -- what was your 2 involvement with Fentora and Actiq, the 3 fentanyl products?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: Fentanyl is 7 one of the base codes under -- 8 there are 82 different base codes 9 that we monitor.</p> <p>10 They were under the fentanyl 11 base code. They would have had a 12 monthly threshold amount. So it 13 was one of 82 products that we -- 14 or, excuse me -- 82 base codes 15 that we looked at on a daily 16 basis.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Okay. We already heard that 19 you were aware of the Department of 20 Justice going after Purdue and making 21 them pay a fine for the way they sold 22 their product, correct?</p> <p>23 MS. HENN: Objection to 24 form.</p>
<p style="text-align: right;">Page 287</p> <p>1 Q. I'm looking at a picture 2 that makes a comparison between heroin 3 and fentanyl.</p> <p>4 Have you ever seen any kind 5 of comparisons between fentanyl and 6 heroin? Ever seen any comparisons 7 between fentanyl and heroin?</p> <p>8 A. Not that specific one. But 9 yes, that fentanyl is one of the 10 stronger, you know, drugs.</p> <p>11 Q. Okay. And so when your CEO 12 was testifying before Congress and said 13 we don't market, he didn't mention 14 anything that, oh, by the way, we are 15 marketing the most potent narcotic sold 16 in America, which is fentanyl, along with 17 Teva. You never heard that out of that 18 discussion that we saw on the screen, did 19 you?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: I did not hear 23 that on -- on video, no.</p> <p>24 BY MR. PAPANTONIO:</p>	<p style="text-align: right;">Page 289</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. We already heard that 3 earlier, right?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 MS. O'GORMAN: Same 7 objection.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Earlier in the deposition, 10 we talked about that.</p> <p>11 Do you remember that?</p> <p>12 A. Yes, I do.</p> <p>13 Q. Okay. And you were aware of 14 it, correct?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 MS. O'GORMAN: Same 18 objection.</p> <p>19 THE WITNESS: I was aware 20 that there was a lawsuit against 21 Purdue for their advertising 22 practices.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. So you decide, even though</p>

Page 290	Page 292
<p>1 there was a lawsuit against Purdue for 2 advertising in a way that misled the 3 public about the addictive nature of 4 their products, you were aware that 5 McKesson chose to do business with them 6 anyway, true?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 MS. O'GORMAN: Objection to 10 form.</p> <p>11 THE WITNESS: McKesson did 12 business with Purdue to sell a 13 product that, you know, when used 14 in the correct or medical 15 purposes, is beneficial to 16 fighting pain. That, I knew.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. And you know enough to know 19 that if you don't tell the truth about 20 the qualities of your product, if you lie 21 about the qualities of your product when 22 consumers are buying that product, that 23 can cause real harm. You're aware of 24 that, aren't you, as -- in your business</p>	<p>1 date, sir.</p> <p>2 Q. And so now we're talking 3 about another company, not Purdue. We're 4 now talking about a company Teva, and 5 McKesson is marketing a fentanyl product 6 for them, two fentanyl products. And you 7 are aware, sir, aren't you that the 8 Department of Justice actually brought 9 criminal charges against them for also 10 not telling the truth about information 11 of their product. Did you know that?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 THE WITNESS: No, I did not. 15 I did not know Teva had --</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Okay. Had you ever -- let 18 me just -- let me see if this ever -- you 19 ever remember this knocking around the 20 office. 13 -- excuse me, 1381.</p> <p>21 MS. MOORE: MCK Oriente 322. 22 (Document marked for 23 identification as Exhibit 24 MCK-Oriente-322.)</p>
<p>1 for this many years?</p> <p>2 MS. HENN: Objection to 3 form.</p> <p>4 THE WITNESS: If -- if the 5 person taking the product does not 6 have all the truthful information, 7 it could be detrimental.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. And you know that the 10 people, the very people that you were 11 buying products from, which was Purdue, 12 was not giving truthful information to 13 doctors and to patients. You know that 14 now, correct?</p> <p>15 MS. O'GORMAN: Objection.</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: I know that 19 now. When I learned of it, it was 20 still ongoing.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. When did you learn about it, 23 sir?</p> <p>24 A. I don't remember the exact</p>	<p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Do you see where it says up 3 in the left-hand corner there, sir -- I 4 know this is not your document. Here's 5 what I'm interested in. You had a system 6 at McKesson where information was sent 7 around about issues involving narcotics 8 that involved other companies besides 9 your own, correct?</p> <p>10 MS. HENN: Objection to 11 form.</p> <p>12 THE WITNESS: I'm not 13 familiar with this. You said 14 there's a system.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Yeah. I mean, you had an -- 17 you had an entire system that kept you 18 informed about what was happening in 19 the -- in the drug business, right?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: No, not to my 23 knowledge.</p> <p>24 BY MR. PAPANTONIO:</p>

Page 294	Page 296
<p>1 Q. Had you ever heard of Rx 2 News?</p> <p>3 A. That's not a McKesson 4 system, is it?</p> <p>5 Q. It's a system that you were 6 a member of, McKesson -- Rx News. Do you 7 know you were a member that?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: Was I on that 11 e-mail distribution?</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Yeah. Did you know that? I 14 don't want to speak for you. Do you have 15 any memory of getting news from Rx News?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: I don't have a 19 recollection of getting news from 20 Rx News.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. And so is it your testimony 23 that when something would happen with 24 another company, when they've involved</p>	<p>1 THE WITNESS: The decision 2 to do business at that level would 3 not have been my responsibility. 4 My responsibility was to monitor 5 what the customers purchased, not 6 to determine if McKesson would use 7 a wholesaler -- excuse me, a 8 manufacturer or not.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Well, you don't want to do 11 business with a manufacturer that is 12 guilty of criminal conduct, do you?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Or is that okay with you?</p> <p>17 A. That decision was not left 18 up to me, sir.</p> <p>19 I -- again, I would monitor 20 what our customers purchased. But 21 whether or not McKesson did business with 22 a manufacturer was above my level.</p> <p>23 Q. Wouldn't you want to know as 24 a regulator, sir, that's working every</p>
Page 295	Page 297
<p>1 themselves in criminal conduct, when 2 they've been -- they've been hit by the 3 DOJ for doing something illegal, that you 4 had no way of knowing that? Is that your 5 testimony?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 THE WITNESS: I don't recall 9 getting updates via Rx News.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Isn't that important 12 information for you to know as a 13 regulator? I mean, you're in -- you're 14 in regulatory. You're selling narcotics 15 all over the country. And you're buying 16 those products from people that you don't 17 know anything about?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Is that what you're telling 22 me?</p> <p>23 MS. HENN: Objection to 24 form.</p>	<p>1 day to try to regulate the amount of 2 narcotics that are being spread out all 3 over this country, wouldn't you know -- 4 wouldn't you want to know if you're doing 5 business with a criminal?</p> <p>6 MS. HENN: Objection to 7 form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Buying products from a 10 criminal, is that important to you?</p> <p>11 MS. HENN: Same objection.</p> <p>12 THE WITNESS: It's important 13 to me. It was handled at a higher 14 level than myself.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Okay. Let me ask you. 17 You've been in regulatory how many years?</p> <p>18 A. 11 years, sir.</p> <p>19 Q. 11 years. And after 20 11 years of experience, you would have to 21 agree with me, sir, wouldn't you, that it 22 is pretty important to know that the 23 people that you're doing business with 24 have been hit for criminal conduct.</p>

Page 298	Page 300
<p>1 That's pretty important information to 2 you, isn't it? 3 MS. HENN: Objection to 4 form. 5 THE WITNESS: The 6 information would be good to know. 7 The decision on whether or not to 8 do business with that company 9 would not be under my 10 responsibility to continue or to 11 cease.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Yeah, you -- but -- and 14 you --</p> <p>15 This is the first time that 16 you've seen this document. The left-hand 17 corner it says Department of Justice, and 18 it talks about Teva has to pay 19 \$425 million for what they call criminal 20 information plea. Did you know that?</p> <p>21 MS. HENN: Counsel, is this 22 about Teva? I don't see anything 23 about Teva.</p> <p>24 BY MR. PAPANTONIO:</p>	<p>1 actions of our -- of our 2 manufacturers that we were buying 3 from.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Sir, so you felt like -- 6 your testimony here today is you felt 7 like you had no responsibility to 8 understand where all these narcotics were 9 coming from that was being distributed 10 through your distribution operation in 11 Landover. Is that what you're telling 12 me?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 THE WITNESS: No, sir. 16 That's not what I'm telling you.</p> <p>17 What I'm saying is my 18 responsibility was in what was 19 being sold by McKesson to these 20 licensed pharmacies and to watch 21 what products they were 22 purchasing.</p> <p>23 It was not my responsibility 24 to follow what lawsuits or actions</p>
<p>1 Q. Sir, you know what Cephalon 2 is. Counsel may not be. You know who 3 Cephalon. Cephalon is Teva, isn't it?</p> <p>4 A. I do not know that for sure, 5 sir.</p> <p>6 Q. Sir, how much information 7 were you given day to day about all the 8 people that you were buying drugs from 9 and then distributing in the company, 10 like Purdue or Teva or Cephalon? How 11 much information were you given by people 12 in management that said we have a 13 relationship with somebody who has been 14 hit and fined for criminal conduct?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Who is it that would tell 19 you that?</p> <p>20 MS. O'GORMAN: Objection.</p> <p>21 THE WITNESS: We -- in the 22 regulatory that I was responsible 23 for was for what our customers 24 were purchasing, not for the</p>	<p>1 were going against manufacturers.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. The jury is going to hear, 4 sir, about how potent fentanyl is, right.</p> <p>5 How would you describe the potency of 6 fentanyl?</p> <p>7 A. Again, sir, I'm not a 8 pharmacist. So a potency of fentanyl 9 versus other products, I don't have that 10 scientific knowledge.</p> <p>11 Q. You know by the time -- by 12 the time that 2011 rolled around, you 13 knew that on the street people were 14 taking all three of your drugs that 15 McKesson distributed, and they were 16 mixing it in cocktails. You'd heard 17 about that, correct?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 THE WITNESS: That, I was 21 aware.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. You were aware of that.</p> <p>24 When did you become aware of that?</p>

<p style="text-align: right;">Page 302</p> <p>1 A. The exact time frame, I 2 don't know. 3 Q. When did you become aware of 4 the number of people who were dying every 5 day from overdoses from narcotics, opioid 6 narcotics? 7 MS. HENN: Objection to 8 form. 9 THE WITNESS: That would 10 have been early on, say 2008. 11 BY MR. PAPANTONIO: 12 Q. You knew in 2000 though -- 13 no. You weren't there in 2000? 14 A. No, sir. 15 Q. Yeah, okay. 2008 is the 16 first time that you heard that A, there's 17 a crisis, an opioid crisis. You agree? 18 A. About that, yes, sir. 19 Q. 2008 is the first time that 20 you heard that more than 100 people were 21 dying every day from opioid overdoses, 22 correct? 23 MS. HENN: Objection to 24 form.</p>	<p style="text-align: right;">Page 304</p> <p>1 have a different number. That 116 people 2 were dying. I think that number rises 3 around 2007, as you said. 4 Once you learned that 116 5 people were dying every day from opioids, 6 did your company make any adjustment in 7 the way that they were selling opioids? 8 MS. HENN: Objection to 9 form. 10 THE WITNESS: We were 11 continuously adjusting and looking 12 at purchases. As I said, we 13 looked at it on a daily basis as 14 to what customers were purchasing 15 and what quantities, and in what 16 percentage of controls to Rx, how 17 much the business was growing, 18 wasn't growing, again, working 19 with the pharmacies to find out 20 which doctors they were filling 21 these prescriptions for, to try 22 and understand if it was for a 23 legitimate medical purpose. 24 BY MR. PAPANTONIO:</p>
<p style="text-align: right;">Page 303</p> <p>1 THE WITNESS: About that 2 time, yes. 3 BY MR. PAPANTONIO: 4 Q. And as you were hearing that 5 information, you were watching the sales 6 tick up higher and higher for every 7 pharmacy that was under your control at 8 Landover. Is that a correct statement? 9 A. No, sir, it's not. 10 MS. HENN: Objection to 11 form. 12 THE WITNESS: It wasn't 13 every pharmacy. 14 BY MR. PAPANTONIO: 15 Q. Well, how many pharmacies 16 was it? 17 A. I don't have that exact 18 amount. There were hundreds of 19 customers, sir, so I wouldn't know 20 exactly how many increased versus did not 21 increase. 22 Q. Well, during the time that 23 you had learned that people, more than -- 24 I think it's 116 people. Tell me if you</p>	<p style="text-align: right;">Page 305</p> <p>1 Q. So let me take you back to 2 marketing again, because marketing is, 3 whether you agree or not -- I'm not -- 4 it's still not clear to me whether you 5 agree that if you market a product, 6 you're going to sell more product. At 7 this point you have no opinion on that, 8 right? 9 MS. HENN: Objection to 10 form. 11 THE WITNESS: Again, you 12 cannot sell something to a 13 pharmacy if they're not going to 14 use it to fill a prescription. 15 BY MR. PAPANTONIO: 16 Q. Tell us what Actavis is. 17 A. I believe it's pronounced 18 Actavis. 19 Q. Tell us what Actavis is. 20 A. I'm not sure if it's another 21 company, I believe. 22 Q. Well, let's take a look at 23 it. 24 MR. PAPANTONIO: Would you</p>

Page 306	Page 308
<p>1 give us Document 113, please.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Because I'm still on this</p> <p>4 topic dealing your CEO testifying in</p> <p>5 front of Congress saying that your</p> <p>6 company did not market, okay. I'm still</p> <p>7 on this topic. Stay with me here.</p> <p>8 A. I'm with you.</p> <p>9 Q. All right. Do you see this</p> <p>10 document right here?</p> <p>11 MS. HENN: So the document.</p> <p>12 MR. PAPANTONIO: Carol, give</p> <p>13 them the number.</p> <p>14 MS. MOORE: MCK Oriente 20.</p> <p>15 MS. HENN: Thank you.</p> <p>16 (Document marked for</p> <p>17 identification as Exhibit</p> <p>18 MCK-Oriente-020.)</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. So this document, if you</p> <p>21 will look, first of all, tell me, who is</p> <p>22 John Hansen? Do you know?</p> <p>23 A. I do not know who John</p> <p>24 Hansen is.</p>	<p>1 A. Yes, McKesson carried that</p> <p>2 product.</p> <p>3 Q. All right. And here they</p> <p>4 are talking about marketing that product</p> <p>5 that McKesson sold with Actavis.</p> <p>6 Do you see that?</p> <p>7 MS. HENN: Let's give the</p> <p>8 witness a chance to read it,</p> <p>9 please.</p> <p>10 MR. PAPANTONIO: Sir, are</p> <p>11 you a little --</p> <p>12 MS. HENN: Just let --</p> <p>13 MR. PAPANTONIO: No, no.</p> <p>14 I'm going to ask questions.</p> <p>15 He's -- you're welcome to read</p> <p>16 anything you want. I'm amazed</p> <p>17 that these documents haven't been</p> <p>18 shown to this witness. So don't</p> <p>19 waste my time here. Now,</p> <p>20 here's --</p> <p>21 MS. HENN: Counsel, I'd just</p> <p>22 like to again reiterate --</p> <p>23 MR. PAPANTONIO: That's</p> <p>24 fine.</p>
Page 307	Page 309
<p>1 Q. You see the -- you see Page</p> <p>2 2 of this document right here.</p> <p>3 MS. HENN: Just to remind</p> <p>4 the witness, you can take your</p> <p>5 time to read the document.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, I want you to read it,</p> <p>8 because nobody is showing it to you</p> <p>9 before you came in here today, did you?</p> <p>10 A. No, I've never seen this.</p> <p>11 Q. Yeah, this is -- this is a</p> <p>12 McKesson document, right?</p> <p>13 A. I don't know. Is it?</p> <p>14 Q. Well, let's take a look at</p> <p>15 the top of it. It says, at the top of</p> <p>16 this page on Page 2 --</p> <p>17 MR. PAPANTONIO: How about</p> <p>18 blowing that up for me.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. It says, "Subject: McKesson</p> <p>21 marketing opportunities. Actavis." And</p> <p>22 we are talking about oxymorphone and that</p> <p>23 is a narcotic that McKesson sold,</p> <p>24 correct?</p>	<p>1 MS. HENN: -- as you agreed,</p> <p>2 that if the witness needs to read</p> <p>3 the document to answer your</p> <p>4 questions, you need to give him</p> <p>5 time to do that.</p> <p>6 MR. PAPANTONIO: I'm fine</p> <p>7 with that. And I am appalled that</p> <p>8 you never -- or anybody with</p> <p>9 McKesson never showed him this</p> <p>10 document before you put him in</p> <p>11 that chair to be cross-examined.</p> <p>12 I'm appalled.</p> <p>13 MS. HENN: Noted.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. So with that, read the</p> <p>16 document. Do you see it?</p> <p>17 The top of the page says,</p> <p>18 "Subject: McKesson marketing</p> <p>19 opportunities." And you didn't even know</p> <p>20 prior to coming in here, and obviously</p> <p>21 either your CEO did know and lied to</p> <p>22 Congress or he didn't know, but it says</p> <p>23 right here, "McKesson marketing</p> <p>24 opportunities. Actavis, oxymorphone,"</p>

Page 310	Page 312
<p>1 right there, correct? And that's a 2 product -- that's a product that you 3 distributed?</p> <p>4 A. Yes.</p> <p>5 Q. All right. And it says, 6 "Hi, Ara. I'm the marketing director for 7 the McKesson one-stop generics program. 8 In collection" -- "in collaboration with 9 Amber Kehoe's product management team 10 I've put together a marketing plan" --</p> <p>11 MR. PAPANTONIO: Please 12 underline "marketing plan."</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. -- "put together a marketing 15 plan to promote awareness of your 16 recently launched oxymorphone ER 17 tablets."</p> <p>18 And, sir, is there anything 19 equivocal about what I just read? Do you 20 understand what this is talking about in 21 regard to marketing oxymorphone that your 22 company distributed all over this 23 country?</p> <p>24 MS. HENN: Objection to</p>	<p>1 marketing if it's not important? Why 2 would he do that? Do you know? 3 MS. HENN: Objection to 4 form.</p> <p>5 THE WITNESS: I'm not aware 6 of what Mr. Hambergren's testimony 7 was based on.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. It was based on a lie, 10 wasn't it?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: I don't agree 14 with that.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Let's read the next 17 paragraph. It says, "I understand that 18 you're looking to target this to 19 approximately 500 accounts with 20 significant brand purchase history and 21 have accounted for in the proposal. 22 "Please note, however, that 23 many of our communication vehicles can 24 reach a larger population at no</p>
<p>1 form.</p> <p>2 THE WITNESS: This document, 3 from what I'm reading, says that 4 McKesson is looking at promoting 5 awareness for this new product.</p> <p>6 What I was involved in is 7 the threshold amount that a 8 customer could order. So with a 9 threshold amount remaining the 10 same, the customer could not get 11 any more product unless I made a 12 threshold adjustment.</p> <p>13 So, you know, they would 14 have had to have business increase 15 to justify that.</p> <p>16 The amount that a pharmacy 17 could purchase was not just 18 increased based on any marketing 19 that was done. We looked at 20 different factors than -- than the 21 marketing.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. So why would the CEO of 24 McKesson get up and lie to Congress about</p>	<p>1 additional charge."</p> <p>2 Did I just read that right, 3 or is there anything that you want to add 4 to it before we move on?</p> <p>5 A. You read that right. As I 6 stated earlier, being in regulatory and 7 looking at different factors that go into 8 threshold setting, I'm not familiar with 9 what they would be referring to 10 regarding, you know, marketing and sales 11 and things of that nature here.</p> <p>12 So, again, the threshold 13 that I was responsible for and what I 14 would look at would not be affected by if 15 they were doing this -- these promotions.</p> <p>16 Q. In other words, promotions 17 don't make any difference to sales of 18 McKesson. Is that what you're telling 19 me?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: No, what I 23 said was promotion -- these 24 promotions would not have an</p>

Page 314	Page 316
<p>1 effect on a customer being able to 2 order more product.</p> <p>3 MR. PAPANTONIO: Look, I'm 4 going to close and I'm going to 5 let my partner take over from 6 here, Mr. Kennedy.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. But I want to ask you 9 something. If you're -- if you are in 10 the position of having to tell the DEA 11 about suspicious orders, that's something 12 that you take very seriously, right?</p> <p>13 A. Yes, sir, I do.</p> <p>14 Q. And the term "suspicious 15 orders" is pretty clear. If an order is 16 suspicious, you -- you need to report it, 17 correct? We've established that.</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 THE WITNESS: That is 21 correct.</p> <p>22 MR. PAPANTONIO: Okay. 23 Would you please show him 24 Document 345, please.</p>	<p>1 turning over to .23, Page 23. It's at 2 the top right-hand corner. Oh, excuse 3 me. No. 20 -- yeah, Page 23. It's at 4 the top right-hand corner.</p> <p>5 A. Okay.</p> <p>6 Q. Are you there?</p> <p>7 A. Yes, sir.</p> <p>8 MR. PAPANTONIO: Would you 9 please blow up that paragraph that 10 says "customer communications" for 11 me, Evan.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. This is out of -- this is 14 right out of your manual, true?</p> <p>15 A. Yes. That's -- that's 16 written here in the document.</p> <p>17 Q. All right. Do you see where 18 it says under -- let's see, one, two, 19 three, four, five, six -- under 5, do you 20 see that fifth dot?</p> <p>21 A. Yes, sir.</p> <p>22 Q. It says, "Refrain from using 23 the word 'suspicious' in communication. 24 Once McKesson deems an order or customer</p>
<p>1 MS. MOORE: MCK Oriente 62. 2 (Document marked for 3 identification as Exhibit 4 MCK-Oriente-062.)</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Sir, take a minute and look 7 at this. Do you see where it says 8 McKesson operations manual. Have you 9 ever seen this before?</p> <p>10 A. Yes, sir.</p> <p>11 Q. When have you seen it?</p> <p>12 A. I wouldn't remember the 13 exact date. It would have been when it 14 was established and -- and sent out to 15 us.</p> <p>16 Q. So you are familiar with the 17 document, right?</p> <p>18 A. Yes.</p> <p>19 Q. You're familiar -- you were 20 familiar with the document before you 21 came in here to testify today, correct?</p> <p>22 A. I've seen this document 23 prior. It's a few years old.</p> <p>24 Q. How about -- how about</p>	<p>1 suspicious, McKesson is required to act."</p> <p>2 MR. PAPANTONIO: Now I want 3 you to underline that, because 4 we're going to talk about that in 5 just a minute.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. This is telling you, this is 8 telling everybody who reads this document 9 to refrain from using the word 10 "suspicious" in communication because 11 once McKesson deems an order suspicious, 12 McKesson is required to act.</p> <p>13 Isn't it a good thing that 14 McKesson should act when they find out an 15 order is suspicious, do you have any 16 problems with that?</p> <p>17 A. Sir, when we find an order 18 to be suspicious and a customer to be 19 suspicious, we would act. But when we 20 first see a customer and we might call 21 them a customer of interest, as we 22 conduct our review and due diligence, so 23 for instance, while I'm doing my research 24 of a customer and I'm doing my research</p>

Page 318	Page 320
<p>1 of his purchase patterns, okay, I don't 2 call them suspicious until I deem that 3 there is actual suspicious activity. And 4 at that point I would say there is 5 suspicious customer intake action. 6 But prior to that, they were 7 a customer of -- of interest that I would 8 be reviewing.</p> <p>9 Q. Now, sir, let me ask you. I 10 want -- I want to -- read this with me 11 one time. Would you read that out loud 12 where it says refrain. Please read that 13 to me.</p> <p>14 A. "Refrain from using the word 15 'suspicious' in communications."</p> <p>16 Q. Go ahead.</p> <p>17 A. Oh.</p> <p>18 "Once McKesson deems an 19 order and/or customer suspicious, 20 McKesson is required to act. This means 21 all controlled substance sales to that 22 customer must cease and the DEA must be 23 notified."</p> <p>24 Which is what we did.</p>	<p>1 going to require McKesson to do 2 something. Right? McKesson is required 3 to act?</p> <p>4 MR. PAPANTONIO: Would you 5 underline "required to act"?</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Required to act. Right?</p> <p>8 A. Right. The date on this 9 document is 2013.</p> <p>10 Q. So what? Who cares? Is 11 that important?</p> <p>12 MS. HENN: Counsel.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. I'm interested to know, why 15 is that important?</p> <p>16 A. Only that if this was given 17 to us in 2013 and you are referring to 18 actions that took place in 2011.</p> <p>19 Q. You knew you were supposed 20 to report suspicious orders all the way 21 back to the first time you sold your 22 first pill, didn't you?</p> <p>23 A. That is correct. And we 24 always did and -- and do. And that's why</p>
<p style="text-align: center;">Page 319</p> <p>1 Q. Well, here you're saying 2 don't use the word "suspicious," because 3 once you do that, it kicks into play the 4 fact that you have a responsibility, is 5 that correct?</p> <p>6 Once the word "suspicious" 7 is used, McKesson has responsibility to 8 get control of the problem, is that a yes 9 or a no?</p> <p>10 A. Once we deem them suspicious 11 we took action on them.</p> <p>12 Q. And we saw earlier, 318 13 times, where -- where there was no -- 14 there was no suspicious order that was -- 15 that was given to the DEA, right, 318 16 times?</p> <p>17 MS. HENN: Objection to 18 form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. We saw that, right?</p> <p>21 A. It was in the document.</p> <p>22 Q. And here, this document 23 we're looking at, says don't use the word 24 "suspicious," because if you do, that's</p>	<p style="text-align: center;">Page 321</p> <p>1 we had a manual system when I came into 2 regulatory in '07, and it has since been 3 automated for us to be able to review 4 more customers more quickly.</p> <p>5 Q. Sir, we're going to have my 6 partner Eric Kennedy talk to you about 7 what you did and didn't do. Give us a 8 minute. We're going to change positions; 9 okay?</p> <p>10 A. All right.</p> <p>11 MR. PAPANTONIO: Take a 12 break for five minutes.</p> <p>13 THE VIDEOGRAPHER: All 14 right. Take off your microphone.</p> <p>15 MR. PAPANTONIO: Yep.</p> <p>16 THE VIDEOGRAPHER: The time 17 is 1:43 p.m. Going off the 18 record.</p> <p>19 (Short break.)</p> <p>20 THE VIDEOGRAPHER: We are 21 back on the record. The time is 22 1:49 p.m.</p> <p>23 - - -</p> <p>24 EXAMINATION</p>

Page 322	Page 324
	1 when we start off, I want to understand 2 your position from everything that we 3 have heard, McKesson played zero role in 4 causing the opioid crisis that we have in 5 America today?
1 - - - 2 BY MR. KENNEDY: 3 Q. Mr. Oriente, my name is Eric 4 Kennedy, I also represent the plaintiffs 5 in this case. All right? 6 A. Mm-hmm. 7 Q. And I'm going to ask you a 8 few questions. I'm going to try not to 9 be repetitious of -- of what you've 10 already answered. 11 All right? 12 A. Okay. Thank you. 13 Q. Let me start by asking 14 this -- this relatively simple question. 15 From -- from everything that 16 you've heard this morning, from 17 everything that you have answered this 18 morning, can we agree that McKesson 19 played some role in causing the opioid 20 crisis that we have in this country? 21 MS. HENN: Objection to 22 form. 23 THE WITNESS: I would say 24 that we did our due diligence to	6 MS. HENN: Objection to 7 form. 8 BY MR. KENNEDY: 9 Q. Is that correct? And that's 10 a clear yes or no. 11 A. I don't believe we caused 12 it. 13 Q. I didn't say that. Did you 14 play a role -- 15 MS. HENN: Counsel. 16 BY MR. KENNEDY: 17 Q. My question is very simple. 18 Would you agree that McKesson played a 19 role, they didn't cause it all, but 20 played a role in the crisis that we have 21 in America today as it relates to 22 prescription opioids? 23 MS. HENN: And, Counsel, I 24 would just ask that you let the
	1 witness finish his answers. 2 MR. KENNEDY: I'm sorry. 3 THE WITNESS: We did play a 4 role as a distributor, yes. 5 MR. KENNEDY: That's all I'm 6 asking. 7 MS. HENN: Are you done with 8 your answer? 9 THE WITNESS: Yes, I am. 10 Thank you. 11 BY MR. KENNEDY: 12 Q. Now, let me ask you -- I 13 want to -- there may be some things that 14 we can very easily agree upon. All 15 right? Because I want to ask you about 16 what McKesson knew or should have known 17 what was going on in America as we 18 continue to discuss what they did and 19 didn't do. All right? 20 A. All right. 21 Q. Late '90s, early 2000s, we 22 have an opioid crisis in the United 23 States of America. True? 24 A. I'm not familiar that far
1 the best of our ability with the 2 information we had and made sure 3 that what we were distributing to 4 pharmacies was going towards 5 medical purposes and that they 6 were going towards filling 7 prescriptions that were written by 8 doctors. 9 And in -- if and when we 10 determined they weren't, we took 11 action to not ship additional 12 product, as demonstrated by the 13 pharmacies that -- that I closed. 14 BY MR. KENNEDY: 15 Q. So is the answer to my 16 question "yes"? 17 MS. HENN: Objection to 18 form. 19 BY MR. KENNEDY: 20 Q. Is the answer to my question 21 "yes"? 22 A. I would say no, it isn't a 23 yes. 24 Q. So it's your position, just	

Page 326	Page 328
<p>1 back, because I wasn't in regulatory in 2 the late '90s. 3 Q. Well, let me ask you this, 4 sir. You've been in the pharmacy 5 industry since 1999, have you not? 6 A. I worked for Eckerd Drug at 7 that time, yes. 8 Q. And they are in the pharmacy 9 industry, are they not? 10 A. Yes. 11 Q. And then you came to 12 McKesson in '04, correct? 13 A. That is correct. 14 Q. And into regulatory in '07, 15 correct? 16 A. That is correct. 17 Q. You read newspapers in the 18 2000s, did you not? 19 A. I was not aware that there 20 was the epidemic that existed when I 21 moved into regulatory in '07. 22 Q. You knew that by 2001, 23 4.8 million Americans had reported in the 24 media and to the CDC, 4.8 million</p>	<p>1 correspondence. 2 MR. KENNEDY: Would you give 3 me 5015, please. 4 Exhibit -- McKesson exhibit, 5 I'm sorry, 545. 6 MS. ROZMAN: No, it's MCK 7 Oriente 545. I'm sorry. 8 MS. HENN: And just for the 9 record, I'd note that these 10 documents have highlighting, is 11 that -- 12 MR. KENNEDY: Yes, 13 highlighting is all by me and 14 there will be writing and it's all 15 by me. 16 MS. HENN: Thank you. 17 (Document marked for 18 identification as Exhibit 19 MCK-Oriente-545.) 20 BY MR. KENNEDY: 21 Q. McKesson document, sir, is 22 McKesson up in the right-hand corner? 23 A. Yes. 24 Q. It looks like it's a</p>
<p style="text-align: center;">Page 327</p> <p>1 admitted to abusing prescription opioids 2 by 2001? 3 MS. HENN: Objection to 4 form. 5 BY MR. KENNEDY: 6 Q. You didn't understand that? 7 A. It wasn't that I didn't 8 understand that. I wasn't aware that 9 that was the number at 2001, sir. 10 Q. By 2007, when you went into 11 regulatory, McKesson was already 12 admitting internally, were they not, they 13 were already admitting internally that 14 opioids, prescription opioids that you 15 were selling, were killing more Americans 16 than cocaine and heroin combined, true? 17 MS. HENN: Objection to 18 form. 19 THE WITNESS: I don't know 20 that McKesson was admitting that. 21 I have -- I heard it in the 22 newspapers and such and on the 23 news. But I did not hear it 24 internally with McKesson</p>	<p style="text-align: center;">Page 329</p> <p>1 national operations conference from 2007, 2 true? A national conference? 3 A. Yes, sir. 4 Q. And who is Don Walker? 5 A. Don Walker was the senior 6 vice president in distribution 7 operations. 8 Q. Did you work in operations? 9 A. I did from '04 through late 10 '07. 11 Q. Go to Page .3, if you would. 12 This is a McKesson document. 13 Are they telling all folks, 14 at this national conference, "Opioid 15 painkillers kill more than cocaine and 16 heroin combined," on .3? 17 A. Yes, that's highlighted 18 here. 19 Q. So McKesson knows it, and 20 they are telling their folks internally 21 by 2007, true? 22 A. Yes. That's noted here. 23 Q. And certainly, sir, given 24 the fact that you work in the pharmacy</p>

Page 330	Page 332
<p>1 industry since 1999, you knew and 2 understood that the opioid crisis in 3 America was addicting and killing more 4 Americans every single year, '01, '02, 5 '04, '05, right up to the time that you 6 moved into regulatory, sir, correct?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: I see it here. 10 I didn't recall it previously that 11 that statement was made.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. As someone in the industry, 14 sir, since 1999, McKesson since '04, you 15 did not understand that the crisis was 16 getting worse every year?</p> <p>17 MS. HENN: Objection to 18 form.</p> <p>19 THE WITNESS: I did know 20 that the crisis was increasing. I 21 just don't recall having seen it 22 in a document that you're 23 presenting here.</p> <p>24 BY MR. KENNEDY:</p>	<p>1 we were aware that there -- 2 certainly there was some diversion 3 going on.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. It was a significant problem 6 in America. It wasn't some going on. It 7 was a big problem in America that was 8 contributing to the crisis, was it not?</p> <p>9 MS. HENN: Objection to 10 form.</p> <p>11 THE WITNESS: There was 12 diversion going on, sir. I didn't 13 measure the amount of total 14 diversion going on.</p> <p>15 MR. KENNEDY: Give me 1076 16 please.</p> <p>17 MS. ROZMAN: This is MCK 18 Oriente 515.</p> <p>19 (Document marked for 20 identification as Exhibit 21 MCK-Oriente-515.)</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Sir, you've -- you've heard 24 of the -- the General Accounting Office</p>
Page 331	Page 333
<p>1 Q. Let's talk about diversion. 2 Tell us what diversion is.</p> <p>3 A. Diversion would be the 4 misuse of controlled substances for 5 nonmedical purposes.</p> <p>6 Q. A lot of diversion occurs at 7 the pharmacy level, true?</p> <p>8 A. There -- I can't say what 9 percent occurs at the pharmacy level. 10 There is internal diversion and theft as 11 well as, you know, external diversion 12 where scripts are filled for nonmedical 13 reasons.</p> <p>14 Q. And McKesson certainly knew, 15 understood, as you did, as early as 2002 16 that diversion, the movement of opioids, 17 of narcotics into illegal markets was 18 occurring in the United States, they 19 understood that, did they not?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: I can't speak 23 for all of McKesson. But I would 24 say that in that time frame, yes,</p>	<p>1 of the United States government, have you 2 not?</p> <p>3 A. Yes, I've heard of the GAO.</p> <p>4 Q. This is a May 2002 report, 5 titled "Prescription Drugs: State 6 Monitoring Programs Provide Useful Tool 7 to Reduce Diversion." Do you see that?</p> <p>8 A. Are you referring to the 9 highlighted paragraph on Page 2?</p> <p>10 Q. I'm referring to the title 11 of it, sir.</p> <p>12 A. Okay.</p> <p>13 Q. That's what it's titled, 14 "Prescription Drugs"?</p> <p>15 A. Yes.</p> <p>16 Q. If you look at the next page 17 which is .6, do you see the highlighted 18 portion? And this is 2002. "The 19 diversion and abuse of prescription drugs 20 are associated with incalculable costs to 21 society in terms of addiction, overdose, 22 death, and related criminal activities."</p> <p>23 Did I read that right? Sir?</p> <p>24 A. Yes.</p>

Page 334	Page 336
<p>1 Q. And it continues, "DEA has 2 stated that the diversion and abuse of 3 legitimately produced controlled 4 pharmaceuticals constitutes a 5 multibillion-dollar illicit market 6 nationwide." Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. And if your company McKesson 9 is the largest distributor of these 10 narcotics in the country, they certainly 11 should know about what's going on with 12 diversion of the drugs that they are 13 selling to pharmacies, can we agree with 14 that?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. Can we agree with that, sir?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: Yes, they...</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. They should know that?</p> <p>24 A. They should know about the</p>	<p>1 can you agree that by the -- by the early 2 2000s, it had become evident that the DEA 3 by itself could not monitor and prevent 4 diversion of narcotics into our 5 communities. They couldn't do it by 6 themselves. Correct?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: I don't know 10 what they can and couldn't do. 11 I know that the requirement 12 was for a distributor to have a 13 program in place to monitor -- 14 monitor and detect suspicious 15 ordering.</p> <p>16 MR. KENNEDY: Give me 1086.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. I'm asking about the DEA and 19 their abilities and -- and what McKesson 20 knew and understand about the DEA's 21 ability to handle the problem by 22 themselves. All right? And it was known 23 by the early 2000s that the DEA by 24 themselves could not prevent the</p>
Page 335	Page 337
<p>1 diversion. This document was from I 2 believe '02.</p> <p>3 Q. Yes, sir.</p> <p>4 A. I was not at McKesson at the 5 time.</p> <p>6 Q. But you're part of the 7 industry.</p> <p>8 A. When --</p> <p>9 Q. Are you denying the fact 10 that McKesson is the largest distributor 11 of opioids in this country, are you 12 denying the fact that they ought to know 13 about the extent of diversion, sir?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 THE WITNESS: No, I did not 17 say that they should not know 18 about it. I'm just stating that 19 in '02 when this document came out 20 I did not work for McKesson.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. Can you agree with me, sir, 23 as part of this industry, and someone who 24 has dealt with the DEA his entire career,</p>	<p>1 diversion of narcotics into our 2 communities. It was known, was it not?</p> <p>3 MS. HENN: Objection to 4 form.</p> <p>5 THE WITNESS: Sir, I -- I 6 could not say whether the -- what 7 resources the DEA has for them to 8 do their ability. 9 So I really can't comment 10 whether they could do it alone or 11 not, sir. I know our requirement 12 is to have a system in place to 13 report --</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. We'll talk about that. I 16 just want to ask about --</p> <p>17 MS. HENN: Counsel, let's 18 let him answer the question 19 please.</p> <p>20 MR. KENNEDY: Go ahead.</p> <p>21 MS. ROZMAN: This is Exhibit 22 MCK Oriente 518.</p> <p>23 MS. HENN: Did you have any 24 more you wanted to add?</p>

Page 338	Page 340
<p>1 THE WITNESS: No.</p> <p>2 MS. HENN: All right. So</p> <p>3 I'm handing the witness MCK</p> <p>4 Oriente 518.</p> <p>5 (Document marked for</p> <p>6 identification as Exhibit</p> <p>7 MCK-Oriente-518.)</p> <p>8 BY MR. KENNEDY:</p> <p>9 Q. See this -- this stated</p> <p>10 memorandum for ASA Hutchinson,</p> <p>11 administrator, Drug Enforcement</p> <p>12 Administration. Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. And it's from the Inspector</p> <p>15 General. Have you ever heard of the</p> <p>16 Inspector General of the United States of</p> <p>17 America?</p> <p>18 A. Yes, I have.</p> <p>19 Q. "Subject, review of Drug</p> <p>20 Enforcement Administration's</p> <p>21 investigations of the diversion of</p> <p>22 controlled pharmaceuticals. Report</p> <p>23 number I-2002-010." Do you see that,</p> <p>24 sir?</p>	<p>1 document here. Where is that on this</p> <p>2 document?</p> <p>3 Q. It's on .4, Page .4 up in</p> <p>4 the right corner, right upper corner,</p> <p>5 sir.</p> <p>6 A. Okay.</p> <p>7 MS. HENN: And you can take</p> <p>8 your time to review it.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. Does the Inspector General</p> <p>11 state here in 2002, "Our review found</p> <p>12 that DEA's enforcement efforts have not</p> <p>13 adequately addressed the problem of</p> <p>14 controlled pharmaceutical diversion"?</p> <p>15 Does it state that, sir?</p> <p>16 A. It does.</p> <p>17 Q. "Despite the widespread</p> <p>18 problem of pharmaceutical abuse, the DEA</p> <p>19 has dedicated only 10 percent of its</p> <p>20 field investigator positions to diversion</p> <p>21 investigations," sir. Do you see that?</p> <p>22 A. Yes. It says only</p> <p>23 10 percent.</p> <p>24 Q. McKesson is the largest</p>
<p>1 A. Yes, that's in the subject</p> <p>2 line.</p> <p>3 Q. Does the first title state,</p> <p>4 "Attached is the final report covering</p> <p>5 our review of the Drug Enforcement</p> <p>6 Administration's, DEA, efforts to</p> <p>7 investigate cases of controlled</p> <p>8 pharmaceutical diversion"? Does it state</p> <p>9 that, sir?</p> <p>10 A. It does.</p> <p>11 Q. If you'll go to --</p> <p>12 MS. HENN: Counsel, does</p> <p>13 this document have a date?</p> <p>14 MR. KENNEDY: This is from</p> <p>15 2002.</p> <p>16 MS. HENN: Thank you.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. And if you'll go, sir, to</p> <p>19 .4.</p> <p>20 A. 10 percent is all they are</p> <p>21 diverting.</p> <p>22 Q. Are you on .4? It's up on</p> <p>23 the screen.</p> <p>24 A. Yeah, I'm looking at the</p>	<p>1 distributor of pharmaceuticals,</p> <p>2 controlled substances in the country.</p> <p>3 Shouldn't they understand the abilities,</p> <p>4 inabilities of the DEA in fighting this</p> <p>5 problem of diversion? Shouldn't they</p> <p>6 understand that?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: Sir, I'm --</p> <p>10 I'm not, you know, in a position</p> <p>11 to determine what abilities the</p> <p>12 DEA has.</p> <p>13 As far as McKesson, we took</p> <p>14 our responsibilities, you know,</p> <p>15 seriously as a distributor and we</p> <p>16 had our programs in place.</p> <p>17 And to -- here I'm reading</p> <p>18 that the DEA only used 10 percent</p> <p>19 of its field investigators to look</p> <p>20 at the problem, and that the</p> <p>21 overall investigators decreased</p> <p>22 3 percent during this problem.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Do you have --</p>

Page 342	Page 344
<p>1 A. So for me to say what the 2 DEA should be doing is not in -- is 3 really not my place, sir.</p> <p>4 Q. I'm just -- I'm just asking 5 you what the largest distributor in the 6 world should understand about the 7 limitations of the DEA. All right?</p> <p>8 A. Mm-hmm.</p> <p>9 Q. But you said something, and 10 I'm going to write it down.</p> <p>11 I started to write it down.</p> <p>12 Because we're going to talk about this in 13 a minute.</p> <p>14 You just said that McKesson 15 took our -- quote, "took our 16 responsibilities very seriously."</p> <p>17 Is that what you just told 18 me?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. "McKesson took our 23 responsibilities very seriously." Is 24 that what you just told me?</p>	<p>1 on in the -- in the industry 2 that -- that we're regulated in.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. And they are being regulated 5 by the DEA, right?</p> <p>6 A. That is correct.</p> <p>7 MR. KENNEDY: Give me 1088, 8 please.</p> <p>9 MS. HENN: I'm sorry, did 10 you --</p> <p>11 THE WITNESS: I said one of 12 the agencies that regulates us. 13 We also have FDA.</p> <p>14 MS. ROZMAN: This is MCK 15 Oriente Exhibit 519.</p> <p>16 THE WITNESS: Thank you. 17 (Document marked for 18 identification as Exhibit 19 MCK-Oriente-519.)</p> <p>20 BY MR. KENNEDY:</p> <p>21 Q. Does it say up here on the 22 left of the cover page, "U.S. Department 23 of Justice, Office of the Inspector 24 General, Evaluation and Inspections</p>
<p>1 A. I believe that's what I 2 said, yes.</p> <p>3 Q. We'll come back to that, all 4 right.</p> <p>5 The United States of America 6 was so concerned about this crisis and 7 about the DEA's ability, they did another 8 follow-up study in 2006.</p> <p>9 Can we agree that if the 10 federal government is reporting a study 11 with respect to the DEA's ability to 12 fight diversion, McKesson as the largest 13 distributor of these narcotics should 14 know and understand that, sir?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 THE WITNESS: Sir, it --</p> <p>18 BY MR. KENNEDY:</p> <p>19 Q. I'm just -- can you agree 20 they should know that?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 THE WITNESS: I believe 24 McKesson should know what is going</p>	<p>1 Division." Is that what it states?</p> <p>2 A. It does say that.</p> <p>3 Q. Is the title of this report, 4 "Follow-up of the Drug Enforcement 5 Administration's efforts to control the 6 diversion of controlled pharmaceuticals"? 7 Does it state that, sir, is that the 8 title of this program?</p> <p>9 A. Yes, it is.</p> <p>10 Q. And this is July of 2006.</p> <p>11 Would that be correct?</p> <p>12 A. That's what's stated here, 13 yes.</p> <p>14 Q. And if you go to Page .5 in 15 the upper right-hand corner. Now, this 16 is the follow-up of the DEA by the 17 federal government.</p> <p>18 And this follow-up in '06, 19 they state, "Despite these positive 20 actions, we identified several continuing 21 concerns. We found that although the 22 need for special agent assistance in 23 diversion investigations had increased 24 significantly since our previous review,</p>

<p style="text-align: right;">Page 346</p> <p>1 the time spent by special agents 2 assisting diversion investigations still 3 constitutes a small share of their total 4 investigative effort."</p> <p>5 Do they state that, sir?</p> <p>6 A. Yes, that's written here.</p> <p>7 Q. They continue to state: "In 8 addition, we've found that the DEA still 9 had not resolved the complicated issue of 10 providing law enforcement authority for 11 diversion investigators, although it is 12 actively pursuing this matter. Further, 13 we found that few DEA special agents had 14 received diversion control training 15 beyond the two-hour module provided 16 during basic agent training."</p> <p>17 And finally: "In addition, 18 the support provided by intelligence 19 analysts to diversion groups in the field 20 has continued to be limited, and 21 intelligence analysts still received 22 minimal diversion control training."</p> <p>23 Tell me, '06, you're working 24 at McKesson. Who read this report at</p>	<p style="text-align: right;">Page 348</p> <p>1 understand that the DEA alone could not 2 monitor 40-, 50-, 60,000 pharmacies, 3 true?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: I'm sorry. I 7 can't comment on what the DEA's 8 abilities are.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. You talked a lot with 11 Mr. Papantonio. You talked a lot about 12 suspicious orders. Do you remember all 13 that discussion?</p> <p>14 A. Yes.</p> <p>15 Q. And I think you agreed with 16 him that -- that legally, the law 17 requires that McKesson, number one, 18 identify suspicious orders from 19 pharmacies, correct?</p> <p>20 A. Yes.</p> <p>21 Q. And number two, I think you 22 agreed that the law requires that 23 McKesson, when it identifies a suspicious 24 order, that they report that to the DEA,</p>
<p style="text-align: right;">Page 347</p> <p>1 McKesson to understand the limitations of 2 the DEA in assisting and controlling the 3 flow of narcotics to pharmacies?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Who?</p> <p>8 MS. HENN: Same objection.</p> <p>9 THE WITNESS: I cannot tell 10 you who read this report. I know 11 that I did not.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. And at this point in time, 14 you understand, you've been in the 15 industry since '99. What do we have, 16 40-, 50-, 60,000 pharmacies in the United 17 States at this time, correct, in '06?</p> <p>18 MS. HENN: Objection to 19 form.</p> <p>20 THE WITNESS: I don't know 21 the exact amount of pharmacies in 22 the United States in '06, sir.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Certainly McKesson knew and</p>	<p style="text-align: right;">Page 349</p> <p>1 correct?</p> <p>2 A. Yes, sir.</p> <p>3 Q. And when this new program, 4 this enhanced program came in in 2008, 5 can we agree that McKesson knew and 6 understood not only did they have to 7 recognize suspicious orders, not only is 8 it their lawful duty to report those to 9 the DEA, but they knew and understood 10 that the DEA expected them to not ship 11 suspicious orders?</p> <p>12 A. Yes. Once an order was 13 identified as suspicious, it should not 14 be shipped.</p> <p>15 Q. Sir, I'm going to ask you 16 some questions now about -- that maybe 17 will explain some -- some things.</p> <p>18 We talked about a lot of 19 suspicious orders that you didn't report 20 to the DEA this morning, correct?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Correct, sir?</p>

Page 350	Page 352
<p>1 A. They -- they were noted in 2 the report. I'm -- I'm not familiar with 3 which ones the DEA is saying suspicious 4 that I did not report.</p> <p>5 Q. I understand. But you -- 6 you weren't questioning the accuracy of 7 those DEA reports this morning, they 8 weren't making that stuff up, right?</p> <p>9 A. I don't believe they were, 10 no.</p> <p>11 Q. And I want to take a look, 12 maybe with a little bit of detail, as to 13 why that happened. All right?</p> <p>14 A. Yes.</p> <p>15 Q. As I ask you questions 16 though, and as we talk about what 17 McKesson did and didn't do, as we talk 18 about the decisions that McKesson has 19 made along the way, can we agree that 20 it's important to evaluate McKesson's 21 decisions within the framework of what 22 was going on in America at the time, can 23 we agree to that?</p> <p>24 MS. HENN: Objection to</p>	<p>1 2008. All right. That's where I want to 2 focus maybe the rest of the afternoon. 3 All right?</p> <p>4 A. Mm-hmm.</p> <p>5 Q. You were a director of 6 regulatory affairs when this new program 7 came into place, true?</p> <p>8 A. Yes.</p> <p>9 Q. A national program, true?</p> <p>10 A. Yes.</p> <p>11 Q. Managed and implemented in 12 the same fashion nationally, correct?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 THE WITNESS: It was rolled 16 out on a national level. 17 Depending on the region where we 18 administered it, different regions 19 in the country had different 20 controlled substance problems. 21 Some being hydrocodone, others 22 being oxycodone. 23 So there would be some 24 differences within a regional area</p>
Page 351	Page 353
<p>1 form.</p> <p>2 THE WITNESS: You're saying 3 looking back at it now?</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. That's what we're going to 6 do. We're going to -- we're going to 7 look back at that new program in '08, and 8 when we look at the decisions that 9 McKesson made along the way, it's 10 important to look at those decisions 11 within the context of what was going on 12 in America; number one, a crisis, number 13 two, diversion, and number three, a DEA 14 that needed help. All right?</p> <p>15 MS. HENN: Objection to 16 form.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. Can we do that?</p> <p>19 MS. HENN: Same objection.</p> <p>20 THE WITNESS: Okay.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. And let's look at the 23 controlled substances monitoring program 24 that came into effect at McKesson in</p>	<p>1 of what base codes were being 2 identified as problematic.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. That might have been 5 different, sir. But the program, the 6 printed program that -- that we have 7 looked at, that you have in front of you, 8 Exhibit 62, this program was a national 9 program, correct?</p> <p>10 A. Yes. One program.</p> <p>11 Q. There wasn't a different 12 detailed and documented McKesson 13 operation manual -- manual for controlled 14 substances. There wasn't a different one 15 in the West, and the East and Midwest, 16 true?</p> <p>17 A. That's correct.</p> <p>18 Q. It was the same program and 19 the intention and actuality was, this was 20 implemented and managed uniformly across 21 this country, sir --</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: Yes.</p>

<p style="text-align: right;">Page 354</p> <p>1 BY MR. KENNEDY:</p> <p>2 Q. Now, this monitoring program</p> <p>3 of 2008, it was structured around the</p> <p>4 creation of thresholds, true?</p> <p>5 A. Yes.</p> <p>6 Q. Thresholds or -- or</p> <p>7 limitations, we're going to call them.</p> <p>8 Threshold limitations, all right?</p> <p>9 A. Yes.</p> <p>10 Q. And a threshold was a</p> <p>11 limitation that was put on each specific</p> <p>12 opioid that you sold, true?</p> <p>13 A. It was a monthly threshold</p> <p>14 set on all base codes, not just opioids.</p> <p>15 Q. All right. But we're going</p> <p>16 to talk about opioids.</p> <p>17 A. Okay.</p> <p>18 Q. We're going to talk about</p> <p>19 narcotics. All right?</p> <p>20 A. Okay.</p> <p>21 Q. We're going to talk about</p> <p>22 painkilling neurotics -- narcotics and</p> <p>23 opiates. So you understand what I am</p> <p>24 talking about, right?</p>	<p style="text-align: right;">Page 356</p> <p>1 Q. And each one of your</p> <p>2 customers, each different pharmacy would</p> <p>3 have a different threshold for oxycodone?</p> <p>4 A. It -- some may have the same</p> <p>5 threshold. It wasn't different --</p> <p>6 Q. And that would -- that would</p> <p>7 be just coincidence, correct?</p> <p>8 A. Well, they could have --</p> <p>9 with -- with hundreds and hundreds of</p> <p>10 customers, customers could have the same</p> <p>11 threshold, sir.</p> <p>12 Q. Absolutely. But every</p> <p>13 customer -- well, we'll take a look and</p> <p>14 go through this.</p> <p>15 Oxycodones, each customer</p> <p>16 would have a threshold for oxycodones?</p> <p>17 A. Their threshold would be</p> <p>18 based off of their previous purchasing.</p> <p>19 Q. I'm not asking what -- would</p> <p>20 you just listen to my questions?</p> <p>21 A. I'm --</p> <p>22 Q. Every -- I'm going to ask</p> <p>23 you. When I want an explanation I'll ask</p> <p>24 for one.</p>
<p style="text-align: right;">Page 355</p> <p>1 A. Mm-hmm. Yes.</p> <p>2 Q. And the threshold for the</p> <p>3 system that McKesson set up as part of</p> <p>4 its 2008 program whereby you would set a</p> <p>5 threshold or a limitation on each</p> <p>6 specific narcotic, true?</p> <p>7 A. It would be on a base code</p> <p>8 level. So for instance, all your</p> <p>9 oxycodone-based products that the DEA</p> <p>10 deemed the base ingredient being</p> <p>11 oxycodone would be under one base code,</p> <p>12 and that's base code 9143 oxycodone, and</p> <p>13 all strengths within oxycodone were in</p> <p>14 that base code.</p> <p>15 So whether you were</p> <p>16 10-milligram, 15-milligram, 30-milligram,</p> <p>17 it all got added up, and they had one</p> <p>18 base code for oxycodone.</p> <p>19 Q. Okay. Base code for</p> <p>20 oxycodone.</p> <p>21 A. And one threshold.</p> <p>22 Q. So you've got a threshold</p> <p>23 for oxycodone, correct?</p> <p>24 A. Mm-hmm. Yes, sir.</p>	<p style="text-align: right;">Page 357</p> <p>1 Every customer, every</p> <p>2 customer would have a threshold for</p> <p>3 oxycodone, correct?</p> <p>4 A. Yes.</p> <p>5 Q. And every customer would</p> <p>6 have a threshold for hydrocodone,</p> <p>7 correct?</p> <p>8 A. Correct.</p> <p>9 Q. And each grouping of</p> <p>10 different narcotic would have a threshold</p> <p>11 for each customer, correct?</p> <p>12 A. Correct.</p> <p>13 Q. All right. It was the</p> <p>14 monthly limitation, correct?</p> <p>15 A. Yes.</p> <p>16 Q. It was done on a monthly</p> <p>17 basis, correct?</p> <p>18 A. Yes. It would reset after</p> <p>19 each month.</p> <p>20 Q. All righty. If we can look</p> <p>21 at 62. I believe you -- you have 62,</p> <p>22 Exhibit 62, which is 345.</p> <p>23 MS. HENN: That's the</p> <p>24 McKesson operations manual. The</p>

Page 358	Page 360
<p>1 sticker with 62 on it.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. Yes, this is the -- sir,</p> <p>4 we're going to use this a lot. This is</p> <p>5 the McKesson operations manual, correct?</p> <p>6 A. Yes, sorry, I have it in</p> <p>7 front of me.</p> <p>8 Q. Came into place in 2008,</p> <p>9 correct?</p> <p>10 A. I believe that was the time</p> <p>11 frame. This one is dated 2013. But it</p> <p>12 may have just been an update, I'm not</p> <p>13 sure.</p> <p>14 Q. Well, if you -- if you look</p> <p>15 at .27, you'll see that this comes into</p> <p>16 play in February of 2008, correct, Page</p> <p>17 27 up in the right.</p> <p>18 A. Page 27, did you say?</p> <p>19 Q. .27, upper right.</p> <p>20 A. Okay. Sorry about that.</p> <p>21 Revision 1, February 2008.</p> <p>22 Yes, sir.</p> <p>23 Q. And if you go to page .2, if</p> <p>24 you would, of your manual.</p>	<p>1 pharmacy volume.</p> <p>2 Q. And --</p> <p>3 MR. KENNEDY: If you'll give</p> <p>4 me 509 please -- 5009.</p> <p>5 MS. ROZMAN: Which is MCK</p> <p>6 Oriente 539.</p> <p>7 (Document marked for</p> <p>8 identification as Exhibit</p> <p>9 MCK-Oriente-539.)</p> <p>10 BY MR. KENNEDY:</p> <p>11 Q. This is something we</p> <p>12 created, sir, because I want to be very</p> <p>13 clear about these thresholds.</p> <p>14 Number one, thresholds with</p> <p>15 respect to this 2008 monitoring program,</p> <p>16 they were a critical component of that</p> <p>17 program, were they not?</p> <p>18 MS. HENN: Counsel, what's</p> <p>19 that quoting? It's not clear from</p> <p>20 the document.</p> <p>21 MR. KENNEDY: We'll go to</p> <p>22 each document if you want to look</p> <p>23 at the quote. All right?</p> <p>24 MS. HENN: I'm -- I'm</p>
<p style="text-align: center;">Page 359</p> <p>1 A. Yes.</p> <p>2 MR. KENNEDY: Do we have .2?</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Your manual states, "All</p> <p>5 McKesson customers are evaluated and</p> <p>6 classified into like business segments</p> <p>7 based upon type of business and monthly</p> <p>8 dollar prescription sales." And this is</p> <p>9 all under threshold limits, correct?</p> <p>10 A. Yes, it is.</p> <p>11 Q. "Additionally, Six Sigma</p> <p>12 analysis helped to identify appropriate</p> <p>13 threshold amounts for every controlled</p> <p>14 substance for all and every family type."</p> <p>15 Correct?</p> <p>16 A. Yes, sir.</p> <p>17 Q. "Out of that information, a</p> <p>18 matrix of family codes and threshold</p> <p>19 amounts were developed." Correct?</p> <p>20 A. Yes, sir.</p> <p>21 Q. So it was an entire process</p> <p>22 that you would go through to establish</p> <p>23 thresholds, true?</p> <p>24 A. Yes. By business type and</p>	<p style="text-align: center;">Page 361</p> <p>1 just --</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. Can you agree with that</p> <p>4 statement, sir, that thresholds with</p> <p>5 respect to your program that McKesson</p> <p>6 implemented, that you managed, thresholds</p> <p>7 were a critical part of the program,</p> <p>8 true?</p> <p>9 A. Thresholds -- excuse me.</p> <p>10 Thresholds were a critical aspect of --</p> <p>11 part of the program, yes.</p> <p>12 Q. And from what we just looked</p> <p>13 at, McKesson took great care in setting</p> <p>14 those thresholds for each of its</p> <p>15 customers for each of the controlled</p> <p>16 substances, correct?</p> <p>17 A. We took great care in</p> <p>18 setting thresholds based off of the</p> <p>19 customer's past historical volume and</p> <p>20 also by base code, yes.</p> <p>21 Q. And with respect to each</p> <p>22 customer, you considered, in creating</p> <p>23 those thresholds, you considered each</p> <p>24 customer to be unique so their threshold</p>

<p style="text-align: right;">Page 362</p> <p>1 was specific to each customer's business 2 needs, correct? 3 MS. HENN: Objection to 4 form. 5 THE WITNESS: They were 6 unique and we also had what is 7 known as default thresholds, which 8 is a minimum amount that a 9 customer would be assigned, if 10 they were -- they were a new 11 customer or hadn't purchased a 12 significant amount and a default 13 number was used.</p> <p>14 BY MR. KENNEDY: 15 Q. And McKesson would make 16 informed decisions based upon the 17 established threshold information, true? 18 A. We used their past 12-month 19 history. 20 Q. Is that true, sir? Is that 21 statement true? 22 A. Yes, we used their 12-month 23 history. 24 Q. And you used the threshold</p>	<p style="text-align: right;">Page 364</p> <p>1 BY MR. KENNEDY: 2 Q. Let me ask you. You were in 3 charge of this program. Nobody told you 4 that one of the agreements with the DEA 5 is that you would create a system of 6 thresholds going forward? 7 A. We -- we -- 8 Q. I'm only asking. Did 9 anybody tell you that that was part of 10 the agreement with the DEA in 2008, that 11 you would establish thresholds? 12 A. Yes. That's how we created 13 the thresholds to start. 14 Q. And when you first put this 15 program in place in 2008, sir, would I be 16 correct that you represented to the DEA 17 that if McKesson were to change a 18 threshold, increase a threshold, you 19 represented to the DEA that McKesson 20 would require documentation to support 21 the increase?</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: I am</p>
<p style="text-align: right;">Page 363</p> <p>1 to make informed decisions, correct, sir? 2 A. It was one of the -- 3 MS. HENN: Objection to 4 form. Go ahead. 5 THE WITNESS: It was one of 6 the decision points, yes.</p> <p>7 BY MR. KENNEDY: 8 Q. And in 2008, after paying 9 \$13 million -- a \$13 million fine with 10 respect to your settlement with the DOJ 11 and the DEA, at that point in time you 12 agreed, you agreed with the DEA that you 13 would establish a system with thresholds 14 to monitor the flow of opioids, did you 15 not, sir?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: I believe that 19 was the -- a statement made. Yes, 20 I did not deal directly with DEA, 21 so I can't say exactly what was 22 committed to with them. But I 23 know that we set thresholds for monitoring.</p>	<p style="text-align: right;">Page 365</p> <p>1 unfamiliar with what was said to 2 DEA regarding threshold increases. 3 I know when we made threshold 4 increases we did reviews --</p> <p>5 BY MR. KENNEDY: 6 Q. Sir, I'm just asking was 7 that represented --</p> <p>8 MS. HENN: Counsel, please. 9 MR. KENNEDY: He's not 10 answering my question.</p> <p>11 BY MR. KENNEDY: 12 Q. Was that represented to the 13 DEA, that if you were to increase a 14 threshold, documentation would be 15 required, was that what you told them?</p> <p>16 MS. HENN: Objection to 17 form. And I just really would 18 appreciate if he were permitted to 19 finish his answers, Counsel.</p> <p>20 BY MR. KENNEDY: 21 Q. Is that what was 22 represented, sir?</p> <p>23 A. I -- I did not speak to DEA 24 so I don't know what was conveyed to</p>

Page 366	Page 368
<p>1 them. I know that when we did a 2 threshold review, part of our 3 documentation was to have a report 4 outlining the details that we used to 5 review the threshold and what the 6 threshold was, what it was going to, and 7 why we made that threshold change. 8 But I don't know what was 9 conveyed to the DEA, because I did not 10 communicate with them.</p> <p>11 Q. Sir, I just -- I just 12 listened to your answer. Let me write 13 something down if I could have the Elmo 14 again.</p> <p>15 You just told us that when 16 you made an increase in the threshold you 17 would have a report as to the reason; is 18 that correct?</p> <p>19 A. There would be a reason -- 20 MS. HENN: Objection to 21 form. Go ahead.</p> <p>22 THE WITNESS: There would be 23 a reason asking why -- what -- 24 what type of business change</p>	<p>1 Q. Basically, sir, you're -- 2 you're required to document why you are 3 making the change, true?</p> <p>4 A. We would have a reason as to 5 why, yes, sir.</p> <p>6 Q. All right. Thanks. We're 7 going to come back to that.</p> <p>8 Now, sir, and I'm going to 9 ask you this a variety of times. Sir, 10 this whole threshold system that you set 11 up, that you told the DEA that you would 12 do, that the DEA required you to do, and 13 that you did put in place. The reason 14 that's important is because under your 15 monitoring program that came in in '08, 16 the enhanced program, basically the way 17 it was structured is if a customer would 18 place an order in any given month over 19 their threshold, that would trigger a 20 Level 1 review or investigation, correct?</p> <p>21 A. Yes, sir.</p> <p>22 Q. And if after Level 1 the 23 person that did the review wasn't really 24 satisfied, it could move to Level 2 and</p>
<p>1 required the -- the pharmacy to 2 request additional product.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. So business change, right?</p> <p>5 What else, report as to the reason.</p> <p>6 You're looking for a business change.</p> <p>7 Like for example, like one of our main</p> <p>8 customers are -- one of our main</p> <p>9 competitors down the street closed,</p> <p>10 correct?</p> <p>11 A. Correct, that would be an</p> <p>12 example.</p> <p>13 Q. Or a new hospital moved into</p> <p>14 the community so we need more opioids,</p> <p>15 right?</p> <p>16 A. Correct.</p> <p>17 Q. That's the kind of thing you</p> <p>18 were looking for?</p> <p>19 A. Yes, sir.</p> <p>20 Q. What else for a change, an</p> <p>21 increase in that threshold?</p> <p>22 A. If there was an acquisition</p> <p>23 made where the pharmacy bought another</p> <p>24 pharmacy.</p>	<p>1 it could even move to Level 3, correct?</p> <p>2 A. That is correct.</p> <p>3 Q. So you start with Level 1,</p> <p>4 you start with Level 2, and at Level 2</p> <p>5 and 3, that's where -- that's where an</p> <p>6 order might get identified as suspicious</p> <p>7 and then reported, correct?</p> <p>8 A. It had the potential to be</p> <p>9 identified as such, yes. It not always</p> <p>10 was.</p> <p>11 Q. But if a customer didn't</p> <p>12 order over their threshold, there would</p> <p>13 not be an automatic triggering of the</p> <p>14 Level 1 investigation, correct?</p> <p>15 A. That is correct. Because</p> <p>16 the Level 1 would get triggered when the</p> <p>17 customer had what we called an omit,</p> <p>18 which is a stopping of an order from</p> <p>19 going through.</p> <p>20 Q. That's an order over the</p> <p>21 threshold?</p> <p>22 A. Correct.</p> <p>23 Q. So that's what the</p> <p>24 importance of this system is. The</p>

<p style="text-align: right;">Page 370</p> <p>1 thresholds are the beginning step for you 2 folks to identify suspicious orders, 3 correct? 4 A. It would block a customer 5 from ordering above their threshold. 6 Q. It was -- listen to my 7 question. I didn't ask you anything 8 about a block. Would you listen to my 9 questions.</p> <p>10 The threshold was the 11 beginning step in the identification of 12 the suspicious orders, correct?</p> <p>13 A. No. I would say no, sir, 14 because a customer hitting their 15 threshold on the last day of the month 16 for one bottle of 100 pills would not 17 necessarily be deemed suspicious 18 because --</p> <p>19 Q. I'm not talk -- I'm talking 20 about -- I'm talking about triggering. 21 I'm talking about the beginning.</p> <p>22 The threshold is what 23 triggers the Level 1, which then moves to 24 Level 2 and Level 3, correct? So the</p>	<p style="text-align: right;">Page 372</p> <p>1 McKesson took its responsibilities with 2 respect to monitoring controlled 3 substances, they took that responsibility 4 back in '08 very seriously. Do you 5 remember that?</p> <p>6 A. I remember hearing that, 7 yes.</p> <p>8 Q. And that is what you've told 9 us here today?</p> <p>10 A. I did say that, yes.</p> <p>11 Q. All right. Now, when 12 somebody, when a customer would want 13 to -- let's talk a little bit about how 14 serious y'all took this.</p> <p>15 Customers weren't told what 16 their threshold was in any particular 17 drug, right?</p> <p>18 A. That is correct. They were 19 blind to it.</p> <p>20 Q. Why is that important?</p> <p>21 A. Because if a customer knew 22 what their threshold was, they would have 23 the ability to order up to and stay just 24 below the threshold and never sort of</p>
<p style="text-align: right;">Page 371</p> <p>1 first step is the customer orders over 2 the threshold. If they do, that triggers 3 a Level 1 investigation.</p> <p>4 A. That is true.</p> <p>5 Q. All righty.</p> <p>6 MR. KENNEDY: Now, can I 7 have the Elmo for a second, 8 please.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. I want to go back to your 11 statement here, sir.</p> <p>12 "McKesson took our 13 responsibilities very seriously." That's 14 your statement, sir?</p> <p>15 A. Right, sir.</p> <p>16 Q. And do you know that the 17 president/CEO of McKesson, you talked 18 about earlier, he testified on May 18th 19 of this year in front of Congress.</p> <p>20 You've seen some clips of that?</p> <p>21 A. Yes, I did.</p> <p>22 Q. And do you know -- and you 23 watched it. Do you remember him saying, 24 just like you just said, he said that</p>	<p style="text-align: right;">Page 373</p> <p>1 trip on one of the red flags which was an 2 omit.</p> <p>3 Q. So they don't order above, 4 you are not going to trigger a Level 1 5 investigation, right?</p> <p>6 A. That is correct, because 7 they --</p> <p>8 Q. So you didn't -- you didn't 9 tell them their thresholds?</p> <p>10 A. That is correct. Because 11 they were authorized on the size of their 12 pharmacy to have a monthly threshold set. 13 For instance, a customer may be 14 authorized to order 5,000 doses a month. 15 So if they are ordering 4,800 doses, they 16 are authorized to order 5,000 --</p> <p>17 Q. Sir, sir, I asked you a very 18 simple question. I asked you a simple 19 question.</p> <p>20 MS. HENN: Counsel --</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. If they don't order above, 23 you don't trigger the Level 1 24 investigation; is that right?</p>

	Page 374	Page 376
	<p>1 A. That's correct.</p> <p>2 Q. Thank you.</p> <p>3 MS. HENN: And I'll just</p> <p>4 remind the witness that he is</p> <p>5 entitled to give his answer to the</p> <p>6 question.</p> <p>7 MR. KENNEDY: He's entitled</p> <p>8 to answer my question.</p> <p>9 MS. HENN: Right.</p> <p>10 MR. KENNEDY: Not the</p> <p>11 question he wants to answer.</p> <p>12 MS. HENN: Well, we can --</p> <p>13 MR. KENNEDY: That's what</p> <p>14 he's entitled to. And nothing</p> <p>15 more.</p> <p>16 MS. HENN: And we can</p> <p>17 disagree about whether you are</p> <p>18 allowing him to do that.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. You didn't tell the customer</p> <p>21 what their threshold was, but you</p> <p>22 certainly warned them when they got close</p> <p>23 to their threshold in any given month</p> <p>24 for, say, OxyContin, correct?</p>	<p>1 threshold. If they call up on the</p> <p>2 telephone, somebody answers the phone,</p> <p>3 usually a sales rep, they are told that</p> <p>4 they are getting close to their threshold</p> <p>5 if they make that call, correct, they</p> <p>6 already know, they've seen it on their</p> <p>7 bill, right?</p> <p>8 A. It is --</p> <p>9 MS. HENN: Objection to</p> <p>10 form. Go ahead.</p> <p>11 THE WITNESS: If it was on</p> <p>12 the invoice, they would have that.</p> <p>13 Sales did not have visibility to</p> <p>14 thresholds.</p> <p>15 BY MR. KENNEDY:</p> <p>16 Q. Let me ask you this. When</p> <p>17 they would call McKesson after seeing</p> <p>18 they were close to their threshold, they</p> <p>19 would be asked whether they wanted to</p> <p>20 increase their threshold, right?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 THE WITNESS: That I'm not</p> <p>24 aware, sir. Usually if a customer</p>
	Page 375	Page 377
	<p>1 A. There was --</p> <p>2 Q. Is that correct?</p> <p>3 A. There was a percentage</p> <p>4 warning report -- or not warning report.</p> <p>5 But on the invoice --</p> <p>6 Q. Sir, listen to my question.</p> <p>7 A. Yes.</p> <p>8 Q. The answer is yes, correct?</p> <p>9 A. Yes.</p> <p>10 Q. And the first warning that</p> <p>11 you would give to the customer each month</p> <p>12 would be right on their invoice, correct?</p> <p>13 A. Yes.</p> <p>14 Q. Letting them know they are</p> <p>15 getting close to their threshold, right?</p> <p>16 A. Yes.</p> <p>17 Q. But that's not the only</p> <p>18 warning you gave customers, is it?</p> <p>19 A. I'm not familiar with other</p> <p>20 warnings, sir.</p> <p>21 Q. Let me ask you this. The</p> <p>22 customer sees on their -- on their</p> <p>23 statement, on their -- on their billing</p> <p>24 that they are getting close to their</p>	<p>1 called in, the customer would</p> <p>2 request the review.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Sir, if they don't ask, they</p> <p>5 are told that they can increase their</p> <p>6 threshold, were they not?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: I'm not aware</p> <p>10 of sales saying that they can</p> <p>11 increase it, no, sir.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Sir, when -- if a customer</p> <p>14 were to call on the telephone who was</p> <p>15 getting close to their threshold and if</p> <p>16 they were to request a threshold</p> <p>17 increase, right over the telephone, in</p> <p>18 five minutes, that McKesson employee</p> <p>19 could ask him a few questions and fill</p> <p>20 out, in five minutes, a one-page</p> <p>21 threshold change request, correct?</p> <p>22 A. They --</p> <p>23 Q. They could do it in five</p> <p>24 minutes?</p>

Page 378	Page 380
<p>1 A. They could -- it may take 2 five minutes, yes, sir. 3 Q. And, sir, in fact, these 4 thresholds, which are the foundation of 5 your entire program to control the flow, 6 if somebody asked for a threshold 7 increase, it was such a sure thing that 8 the customer would -- would be told, the 9 customer would be told, if you don't hear 10 back from us, consider the threshold 11 increase approved, right, right over the 12 phone they would be told that?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 THE WITNESS: I'm not aware 16 of that statement, sir.</p> <p>17 MR. KENNEDY: If you can 18 give us 5011 please.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. Are you surprised at that 21 statement?</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: I am.</p>	<p>1 Q. Sir, this -- look to the 2 next page. This is the audience who 3 this -- this is directed towards. Do you 4 see the audience says, "First service 5 representatives, including specialty and 6 support."</p> <p>7 Can you tell us who first 8 service -- or ServiceFirst 9 representatives, who are those folks at 10 McKesson?</p> <p>11 A. ServiceFirst representatives 12 are customer service down in the Texas 13 office.</p> <p>14 Q. And these folks, they are 15 sales assistants, right?</p> <p>16 A. They are customer serve 17 reps, I don't know if they are sales 18 assistants. They handled customer 19 inquiries when they were called in.</p> <p>20 Q. They handled threshold 21 increases, did they not?</p> <p>22 A. They would -- they didn't -- 23 well, when you say handle them, they 24 would take the information, send it to</p>
<p style="text-align: center;">Page 379</p> <p>1 MS. ROZMAN: Which is MCK 2 Oriente 541. 3 (Document marked for 4 identification as Exhibit 5 MCK-Oriente-541.)</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Sir, this is titled 8 "Controlled Substances Substance 9 Monitoring Program," CSMP, correct?</p> <p>10 A. Yes.</p> <p>11 Q. Second paragraph, it states, 12 "McKesson's technology monitors their 13 purchases and alerts customers when they 14 near their threshold." Do you see that, 15 sir?</p> <p>16 A. Yes.</p> <p>17 Q. They are getting alerted, 18 right?</p> <p>19 A. Yes. There's a warning 20 printed on the invoice.</p> <p>21 Q. Now, you told us these 22 thresholds are critical, right? They are 23 critical, correct?</p> <p>24 A. Yes.</p>	<p style="text-align: center;">Page 381</p> <p>1 the -- in each distribution center there 2 is a sales administrator who would then 3 submit the TCR to the McKesson regulatory 4 person for review.</p> <p>5 Q. Right. They filled out the 6 threshold change request over the 7 telephone in five minutes, a customer 8 assistance rep, right?</p> <p>9 MS. HENN: Objection to 10 form.</p> <p>11 BY MR. KENNEDY:</p> <p>12 Q. Is that right, sir?</p> <p>13 A. I'm not familiar with the 14 customer ServiceFirst representative 15 filling them out. The ones that -- that 16 I would review would come through the 17 sales administrator at the distribution 18 center and fill out what we called a TCR 19 form, or a threshold request form.</p> <p>20 Q. Well, we're going to talk 21 about -- a threshold change request, 22 right?</p> <p>23 A. Yes.</p> <p>24 Q. And they filled that out</p>

Page 382	Page 384
<p>1 over the phone, correct?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: When you say</p> <p>5 they filled that out over the</p> <p>6 phone, they would get the</p> <p>7 information from the customer</p> <p>8 and --</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. And fill out the form over</p> <p>11 the telephone?</p> <p>12 A. -- fill it out -- yes. And</p> <p>13 then would submit it to regulatory for</p> <p>14 review.</p> <p>15 Q. Excellent. Now look at .3.</p> <p>16 This is what is being told to the people</p> <p>17 who are answering the phone and receiving</p> <p>18 requests from pharmacies.</p> <p>19 This is the script they are</p> <p>20 given. Look at .3. Do you see this,</p> <p>21 sir, on .3?</p> <p>22 A. I'm looking for .3.</p> <p>23 Q. Up in the right-hand corner.</p> <p>24 A. Oh, okay, third page.</p>	<p>1 Q. Sir, you say you wouldn't</p> <p>2 see this?</p> <p>3 A. Yeah.</p> <p>4 Q. You are the one in charge of</p> <p>5 attempting to regulate the flow of</p> <p>6 narcotics to pharmacies. And the way</p> <p>7 you're doing it is putting into place a</p> <p>8 threshold system, correct? That's how</p> <p>9 you were doing it.</p> <p>10 A. Correct. And I would watch</p> <p>11 that threshold process. But as far as</p> <p>12 the communication of a customer hearing</p> <p>13 back that it was approved or not? I did</p> <p>14 not get involved.</p> <p>15 MR. KENNEDY: Can you give</p> <p>16 me the Elmo again please, sir.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. You told us earlier, and so</p> <p>19 did the president of your company, that</p> <p>20 "McKesson took our responsibility very</p> <p>21 seriously." And this threshold system</p> <p>22 was taken so seriously that if somebody</p> <p>23 wanted to increase their threshold, they</p> <p>24 were told just to assume. It's so easy,</p>
Page 383	Page 385
<p>1 Q. This is what they're --</p> <p>2 they're instructed to tell a pharmacy who</p> <p>3 wants to increase this all-important</p> <p>4 threshold.</p> <p>5 "Tell caller that you will</p> <p>6 forward the request and that someone from</p> <p>7 McKesson distributor center will call if</p> <p>8 the request is denied. Otherwise, the</p> <p>9 caller can consider the request</p> <p>10 approved."</p> <p>11 That's what they are</p> <p>12 instructed to tell pharmacies. You are</p> <p>13 surprised by that, aren't you?</p> <p>14 A. Well, since this is a --</p> <p>15 Q. My question is real simple.</p> <p>16 Surprised by that?</p> <p>17 MS. HENN: And the witness</p> <p>18 should answer the question as he</p> <p>19 deems fit.</p> <p>20 THE WITNESS: Since this is</p> <p>21 a customer care document and not a</p> <p>22 regulatory document that I would</p> <p>23 have seen, I am surprised at that.</p> <p>24 BY MR. KENNEDY:</p>	<p>1 just assume that it's been approved.</p> <p>2 Correct? Is that what they were told?</p> <p>3 A. Not -- not to assume, no.</p> <p>4 Consider the request approved if you</p> <p>5 don't hear that it's denied.</p> <p>6 Q. Thank you. But that wasn't</p> <p>7 all, sir, that wasn't all you were doing</p> <p>8 with respect to these thresholds. You</p> <p>9 were actually proactive about it. If the</p> <p>10 customer got near their threshold and</p> <p>11 they didn't call McKesson, if they didn't</p> <p>12 call McKesson to say increase my</p> <p>13 threshold, you folks actually put into</p> <p>14 place a system where you would call the</p> <p>15 customer and say, "Do you want to</p> <p>16 increase your threshold?" Are you aware</p> <p>17 of that program, sir?</p> <p>18 MS. HENN: Objection to</p> <p>19 form.</p> <p>20 THE WITNESS: I am -- I am</p> <p>21 not.</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. You were the head of</p> <p>24 regulatory, weren't you?</p>

<p style="text-align: right;">Page 386</p> <p>1 A. Yes, sir.</p> <p>2 MR. KENNEDY: Give me 5012</p> <p>3 please.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. This -- this document is</p> <p>6 titled "ISMC Controlled Substance</p> <p>7 Monitoring Program, CSMP Outbound Calls."</p> <p>8 Those are calls McKesson is making,</p> <p>9 outbound, correct? Is that what outbound</p> <p>10 means?</p> <p>11 A. Yes.</p> <p>12 Q. First sentence, first</p> <p>13 service assists -- and I suggested to you</p> <p>14 before that first service sales. Does</p> <p>15 this say first service -- "ServiceFirst</p> <p>16 assists RSMs." Is that what it says?</p> <p>17 A. That is what it says.</p> <p>18 Q. And what does RSM stand for?</p> <p>19 A. Retail sales manager.</p> <p>20 Q. "ServiceFirst assists retail</p> <p>21 sales managers housed out of the</p> <p>22 following distribution centers by</p> <p>23 generating outbound calls."</p> <p>24 So they are making the calls</p>	<p style="text-align: right;">Page 388</p> <p>1 Q. And they are assisting the</p> <p>2 sales folks, correct?</p> <p>3 A. Yes. That's -- again, this</p> <p>4 document I would not have seen because</p> <p>5 the audience was the customer care</p> <p>6 section. It was not regulatory. And</p> <p>7 with these six DCs not being my DCs, I</p> <p>8 was unaware that that's how these six DCs</p> <p>9 were handling this.</p> <p>10 Q. Let me ask you, sir.</p> <p>11 McKesson, McKesson is sitting here in the</p> <p>12 United States of America at this point in</p> <p>13 time, and there's an opioid crisis, there</p> <p>14 is diversion that is feeding this crisis.</p> <p>15 And are you telling me that -- that with</p> <p>16 respect to your monitoring obligations,</p> <p>17 you've got this regulatory department</p> <p>18 going on and at the same time you have</p> <p>19 sales in the middle of it and you don't</p> <p>20 even know about it, you don't even know</p> <p>21 about this program?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 THE WITNESS: My</p>
<p style="text-align: right;">Page 387</p> <p>1 to independent customers nearing their</p> <p>2 CSMP thresholds. So these folks are</p> <p>3 being told, these assistants to the sales</p> <p>4 folks are being told, you call pharmacies</p> <p>5 if they get close to their thresholds.</p> <p>6 Is that what it's saying, sir?</p> <p>7 A. So these distribution</p> <p>8 centers, these six of them, were not in</p> <p>9 my region, so I had no responsibilities</p> <p>10 for these six DCs.</p> <p>11 Q. That's fine. I'm talking</p> <p>12 about a national program, sir. All</p> <p>13 right. I'm talking about a national</p> <p>14 program.</p> <p>15 A. Mm-hmm.</p> <p>16 Q. Let me ask you this.</p> <p>17 Let's go down here.</p> <p>18 "Audience. This monitoring</p> <p>19 program, the audience is designated ISMC</p> <p>20 ServiceFirst representatives."</p> <p>21 What is ISMC? That is</p> <p>22 independent/small/medium-size customers,</p> <p>23 right?</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 389</p> <p>1 responsibility was six DCs in the</p> <p>2 Northeast, sir. And I knew my</p> <p>3 program. This was in the North</p> <p>4 Central region handled by another</p> <p>5 regulatory director.</p> <p>6 So if they were making these</p> <p>7 outbound calls, sir, I was not</p> <p>8 aware.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. So you are trying to control</p> <p>11 the flow of opioids into this country,</p> <p>12 and sales is trying to increase the</p> <p>13 opioids going in. And you have no idea</p> <p>14 that they are involved in your program?</p> <p>15 MS. HENN: Objection to</p> <p>16 form.</p> <p>17 THE WITNESS: The request</p> <p>18 from sales to review a threshold</p> <p>19 does not automatically mean that</p> <p>20 the threshold would have been</p> <p>21 increased.</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Sir, I'm just talking about</p> <p>24 now your sales folks making phone calls</p>

<p style="text-align: right;">Page 390</p> <p>1 to customers who are near their 2 thresholds to ask them if they want to 3 increase their threshold. And you don't 4 know about it, right?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Do you know about that going 9 on?</p> <p>10 MS. HENN: Same objection.</p> <p>11 THE WITNESS: I don't -- I 12 did not know that in the North 13 Central, these six distribution 14 center customers were getting 15 calls.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Sir, look at this. You told 18 us before that the sales folks never -- 19 they would never see the daily reports on 20 thresholds. Look at Page 2, .2.</p> <p>21 Yeah, this is Exhibit 542.</p> <p>22 Look at that second page 23 of -- of this protocol. Does it state -- 24 and this is under policy. Does it state,</p>	<p style="text-align: right;">Page 392</p> <p>1 they look at this report, when they look 2 at this report, first thing they are 3 supposed to do is verify if the customer 4 has already been contacted this month 5 regarding their threshold. So look at 6 that first. They are saying to these -- 7 these sales assistant. First look and 8 see if they've already been contacted. 9 Correct?</p> <p>10 A. Correct.</p> <p>11 Q. It says here that if the 12 customer has reached 96 percent of their 13 threshold, if yes, call the customer 14 again. Right? Is that right?</p> <p>15 A. That's what it states here, 16 yes.</p> <p>17 Q. So a customer might get two 18 phone calls in one month from your sales 19 assistant, right?</p> <p>20 A. In this region, yes. Not in 21 mine.</p> <p>22 Q. Number 8, "Call the 23 customer, referring the point of contact 24 provided on the contact spreadsheet," see</p>
<p style="text-align: right;">Page 391</p> <p>1 "Designated ISMC," so that's 2 independent/small/medium pharmacies, 3 "SFRs," ServiceFirst reps who are -- who 4 are assisting sales, "they will review 5 Department of Regulatory Affairs, DRA, 6 daily reports."</p> <p>7 You just said the sales 8 folks didn't see the regulatory reports. 9 This is saying something different, 10 correct?</p> <p>11 A. I said the customers don't 12 see their reports.</p> <p>13 Q. "And proactively," next 14 sentence. "And proactively contact." So 15 we want you folks to be proactive. We 16 want you to call the customer who reached 17 90 percent of their threshold. "ISMC SFR 18 assistant sales will document the 19 customer's response and e-mail requests 20 for increases of thresholds." Do you see 21 that?</p> <p>22 Do you see that, sir?</p> <p>23 A. Yes.</p> <p>24 Q. Go down to Number 6. When</p>	<p style="text-align: right;">Page 393</p> <p>1 that?</p> <p>2 A. Yes.</p> <p>3 Q. Number 9. This is the ninth 4 step of the instruction to these sales 5 assistants.</p> <p>6 "Advise pharmacy that they 7 are nearing their CSMP threshold." 8 Right? And -- right?</p> <p>9 A. Yes, that's what Number 9 10 says.</p> <p>11 Q. It says tell them what 12 percentage they are at, correct?</p> <p>13 Does it say that, provide 14 percentage?</p> <p>15 A. It does.</p> <p>16 Q. So if I'm a customer and I 17 know I've -- I've purchased 9,000 18 oxycodones and the sales assistant says, 19 you know, Mr. Kennedy, Mr. Pharmacist, 20 you're at 90 percent of your threshold, 21 it's pretty easy for me now to know my 22 threshold, right? Is that right, sir?</p> <p>23 A. The customer may be able to 24 back into that number, yes.</p>

Page 394	Page 396
<p>1 Q. Pretty easy math, isn't it?</p> <p>2 A. They -- they could do the</p> <p>3 math to determine it. They --</p> <p>4 Q. Didn't you tell us earlier</p> <p>5 that you never told the customer their</p> <p>6 threshold because you don't want to do</p> <p>7 that, because then they are going to be</p> <p>8 able to play underneath their threshold</p> <p>9 and they are going to be able to divert</p> <p>10 opioids and narcotics into the community.</p> <p>11 Isn't that what you told us earlier, sir?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: That's --</p> <p>15 BY MR. KENNEDY:</p> <p>16 Q. Didn't you tell us that?</p> <p>17 A. That's what I said for the</p> <p>18 area that I was responsible for which is</p> <p>19 not any of these six DCs receiving these</p> <p>20 phone calls, sir.</p> <p>21 Q. The national program that --</p> <p>22 that McKesson was implementing, right?</p> <p>23 A. I -- I said it was regional</p> <p>24 in my area of the Northeast. My six DCs</p>	<p>1 Q. So this program of</p> <p>2 thresholds that you folks are taking so</p> <p>3 serious on any given month, if -- if</p> <p>4 Mr. Pharmacist is getting close to that</p> <p>5 threshold that's going to trigger an</p> <p>6 investigation, if he gets close, number</p> <p>7 one, you are going to notify him on his</p> <p>8 bill, correct?</p> <p>9 A. That is correct.</p> <p>10 Q. And by these programs,</p> <p>11 number two, sir, if he calls he's going</p> <p>12 to be told he can increase his threshold.</p> <p>13 And number three, if he doesn't call, you</p> <p>14 are going to call him once or twice,</p> <p>15 correct?</p> <p>16 MS. HENN: Objection.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. Correct, under this program,</p> <p>19 correct?</p> <p>20 MS. HENN: Objection to</p> <p>21 form.</p> <p>22 THE WITNESS: This program</p> <p>23 would start the review, yes. It</p> <p>24 doesn't mean that the review would</p>
<p>1 did not do this and that's why I said it</p> <p>2 was regional.</p> <p>3 Q. Let's go down to Number 12.</p> <p>4 Number 12, this is the 12th step for the</p> <p>5 sales assistant. After they've made one</p> <p>6 or two calls does it say there, if the</p> <p>7 customer doesn't want to increase their</p> <p>8 threshold, does it say, "Advise the</p> <p>9 customer to contact ServiceFirst if</p> <p>10 threshold needs change. Provide your</p> <p>11 direct phone number." Is that what it</p> <p>12 says?</p> <p>13 A. That is what it says.</p> <p>14 Q. Sir, what we've got here,</p> <p>15 we've got a system. Again, you told us</p> <p>16 you were taking this very seriously.</p> <p>17 You've got a system whereby, number one,</p> <p>18 let's say a pharmacy is getting low on</p> <p>19 OxyContin, oxycodone, dangerous drug,</p> <p>20 right?</p> <p>21 A. Strong painkiller.</p> <p>22 Q. In the middle of the</p> <p>23 epidemic, right?</p> <p>24 A. That is correct.</p>	<p>1 actually get approved.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. And you're -- and you're</p> <p>4 going to then ask him, do we -- do I want</p> <p>5 to increase -- do you want to increase</p> <p>6 your thresholds in one of these two</p> <p>7 calls, and then if he says no, you're</p> <p>8 going to say hey, here is a direct dial</p> <p>9 number. If you want to increase your</p> <p>10 threshold, call us back.</p> <p>11 Isn't that what this program</p> <p>12 says, that is what was going on?</p> <p>13 A. This -- this program says</p> <p>14 that the service rep would get the call</p> <p>15 back, yes.</p> <p>16 Q. And, sir, and if the</p> <p>17 customer says to you, you know what, I do</p> <p>18 want to increase my threshold. He's told</p> <p>19 you know what, consider your threshold</p> <p>20 raised unless we get back to you.</p> <p>21 And this was you folks at</p> <p>22 McKesson, according to you, and the CEO</p> <p>23 in his testimony to Congress, this was</p> <p>24 you folks taking your responsibilities</p>

Page 398	Page 400
<p>1 very seriously since 2008, right?</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. Is that right?</p> <p>6 A. As I stated, this was not a</p> <p>7 practice in my area of responsibility.</p> <p>8 Q. You know what, these</p> <p>9 thresholds that we are talking about</p> <p>10 here, if we can go back a second, to 5009</p> <p>11 I think.</p> <p>12 MS. HENN: And, Counsel, the</p> <p>13 deposition protocol requires</p> <p>14 demonstratives to be entered as</p> <p>15 exhibits, just to make sure we</p> <p>16 take back --</p> <p>17 MR. KENNEDY: 5009 is</p> <p>18 Exhibit 539.</p> <p>19 MS. ROZMAN: This is that</p> <p>20 one.</p> <p>21 MS. HENN: I'm talking about</p> <p>22 the Elmo demonstratives.</p> <p>23 MS. ROZMAN: Oh, I'm sorry.</p> <p>24 MS. HENN: Those need to be</p>	<p>1 use it to make informed decisions based</p> <p>2 upon established threshold information,</p> <p>3 that's what you were going to use it for?</p> <p>4 A. Correct.</p> <p>5 Q. And if you were going to</p> <p>6 change them, if you were going to change</p> <p>7 it, it was required that you document it,</p> <p>8 right?</p> <p>9 A. We did a -- what was called</p> <p>10 a threshold change review by regulatory</p> <p>11 to see if the threshold should be</p> <p>12 increased.</p> <p>13 Q. Let's take a look at some</p> <p>14 change. Let's look at that process that</p> <p>15 you were talking about. If we'll --</p> <p>16 we'll mark that exhibit.</p> <p>17 MR. KENNEDY: Keep the Elmo</p> <p>18 up for a second. If we can go back.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. I wrote this down, because</p> <p>21 this is what you told me earlier.</p> <p>22 If you were going to</p> <p>23 increase a threshold you needed to report</p> <p>24 the reason, correct?</p>
<p>1 labeled as exhibits at some point.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. I want to go back a second</p> <p>4 here, because we -- we just need to be</p> <p>5 reminded of this as we go forward.</p> <p>6 This -- this threshold</p> <p>7 system we are going to continue to talk</p> <p>8 about. It was a critical compart -- part</p> <p>9 of your program to monitor the flow of</p> <p>10 narcotics into the community, correct,</p> <p>11 critical, correct?</p> <p>12 A. I would say yes, it was.</p> <p>13 Q. And you took great care in</p> <p>14 setting it, right?</p> <p>15 A. I did, yes.</p> <p>16 Q. And it had to be unique for</p> <p>17 your customers, each one of them was</p> <p>18 going to get a specific threshold because</p> <p>19 the customers were different, correct?</p> <p>20 A. It was based off of their</p> <p>21 historical data unless the full</p> <p>22 thresholds were used when setting up new</p> <p>23 customers.</p> <p>24 Q. And McKesson was going to</p>	<p>1 A. Right, sir.</p> <p>2 Q. And you are looking for a</p> <p>3 business change, some kind of business</p> <p>4 change at the pharmacy to document and</p> <p>5 explain and justify the increase, right?</p> <p>6 A. Yes.</p> <p>7 Q. And we talked about you've</p> <p>8 got a competitor that's closed down,</p> <p>9 you've got a new group of doctors, right?</p> <p>10 A. Mm-hmm. Right.</p> <p>11 Q. All right. Threshold change</p> <p>12 request, that was the standard form</p> <p>13 utilized by McKesson to initiate a</p> <p>14 change, true?</p> <p>15 A. Yes.</p> <p>16 Q. Standard form used across</p> <p>17 the country, right?</p> <p>18 A. I believe it was standard.</p> <p>19 Yes.</p> <p>20 Q. And we're trying to get an</p> <p>21 understanding of why no suspicious orders</p> <p>22 were reported earlier, right? Some --</p> <p>23 understand that's why we're doing this.</p> <p>24 So let's look at a threshold change</p>

Page 402	Page 404
<p>1 request.</p> <p>2 MR. KENNEDY: If you can</p> <p>3 give me 5016, please.</p> <p>4 MS. ROZMAN: MCK Oriente</p> <p>5 546.</p> <p>6 (Document marked for</p> <p>7 identification as Exhibit</p> <p>8 MCK-Oriente-546.)</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. This is a standard form</p> <p>11 threshold change request at McKesson.</p> <p>12 True?</p> <p>13 A. This is the form that was</p> <p>14 used in 2008, yes.</p> <p>15 Q. Across the country?</p> <p>16 A. In 2008, yes.</p> <p>17 Q. Up in that left hand it</p> <p>18 gives us the date that this was filled</p> <p>19 out, right, 11/28/08?</p> <p>20 A. Mm-hmm.</p> <p>21 Q. Customer name. That's going</p> <p>22 to be the name of the customer that wants</p> <p>23 the change, true?</p> <p>24 A. Yes.</p>	<p>1 A. On here it says various,</p> <p>2 yes.</p> <p>3 Q. It says, "Increase amount</p> <p>4 30 percent." True?</p> <p>5 A. Yes.</p> <p>6 Q. So you're asking for a</p> <p>7 30 percent increase on various different</p> <p>8 controlled substances for various</p> <p>9 different customers. True?</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Is that true? Is that what</p> <p>14 it says?</p> <p>15 A. This document says that,</p> <p>16 yes.</p> <p>17 Q. "Reason for change,</p> <p>18 parentheses, attach supporting</p> <p>19 documentation." Do you see that, sir?</p> <p>20 A. Yes.</p> <p>21 Q. What's the stated reason by</p> <p>22 McKesson for this change?</p> <p>23 A. The -- this says, "Increase</p> <p>24 due to the Thanksgiving holiday."</p>
<p>1 Q. Various RNA customers it</p> <p>2 says. This -- this threshold is being</p> <p>3 requested, the change, by various RNA</p> <p>4 customers, see attachment. And I suppose</p> <p>5 there's an attachment and there's a list</p> <p>6 of all the customers that this would</p> <p>7 apply to, correct?</p> <p>8 A. According to this it says</p> <p>9 that there is an attachment, yes. That</p> <p>10 attachment isn't here.</p> <p>11 Q. And RNA would be retail</p> <p>12 national accounts, true?</p> <p>13 A. That is correct.</p> <p>14 Q. That's the big accounts,</p> <p>15 those are the big national chains, right?</p> <p>16 A. Those are the chain stores,</p> <p>17 yes.</p> <p>18 Q. That's the CVS, that's the</p> <p>19 Walmart, that's the Walgreens, correct?</p> <p>20 A. Yes.</p> <p>21 Q. And down here then with</p> <p>22 respect to what narcotic or what</p> <p>23 controlled substances you're asking the</p> <p>24 increase for, it says, "Various." True?</p>	<p>1 Q. Thanksgiving?</p> <p>2 A. That's what it says here,</p> <p>3 because of the DCs being closed.</p> <p>4 Q. That's -- is that what it</p> <p>5 says, Thanksgiving?</p> <p>6 A. Says Thanksgiving holiday.</p> <p>7 Q. 30 percent increase. Is</p> <p>8 that what it says?</p> <p>9 A. That's what this document</p> <p>10 says, yes. This was not one of mine.</p> <p>11 Q. Want to go back to that --</p> <p>12 if we can go back to the Elmo for a</p> <p>13 second here. I just want to put this all</p> <p>14 in context, about what you've been</p> <p>15 telling us here today.</p> <p>16 A. Mm-hmm.</p> <p>17 Q. When we make an increase in</p> <p>18 the threshold, we report the reason, and</p> <p>19 we're looking for a business change. Is</p> <p>20 that what you told me?</p> <p>21 Is that what you told me?</p> <p>22 A. A change -- a change in</p> <p>23 business would be one of the reasons that</p> <p>24 we would look for. So in this case, with</p>

Page 406	Page 408
<p>1 the increase due to the Thanksgiving 2 holiday, that either distribution centers 3 are closed today so customers can't get 4 their -- their product, they may need to 5 order earlier in the month, things of 6 that nature.</p> <p>7 This was not one of my 8 requests, so I cannot say exactly what 9 was reviewed and such. It was done by 10 another director.</p> <p>11 Q. Sir, whoa, one second here. 12 Doesn't this say, that -- that 13 justification, thanks. Doesn't this say 14 permanent or temporary threshold change? 15 Is that what it says?</p> <p>16 A. This one says perm 17 underlying, yes.</p> <p>18 Q. You -- you're talking about 19 a permanent 30 percent change for 20 Thanksgiving. Is that what it says?</p> <p>21 A. This document does say that. 22 I cannot say why it was written up. I -- 23 I don't know because this is not one of 24 mine.</p>	<p>1 THE WITNESS: I believe he 2 did, sir.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. And he's -- he's going to 5 follow the rules in the approach that 6 McKesson is taking with respect to these 7 things, isn't he?</p> <p>8 A. He would in his 9 interpretation of the program, sir.</p> <p>10 Q. Let me ask you this. 11 When -- when this program got put into 12 place in the beginning, when you folks 13 made the commitment to the DEA and the 14 department of justice in the settlement 15 agreement after paying \$13 million and 16 you said we're going to put a program in 17 place, and we're going to foundation this 18 program on thresholds, did you tell them 19 that you would be making 30 percent 20 increases for various different 21 pharmacies because of Thanksgiving and 22 that they would be permanent? Did you 23 represent that to the DEA, the DOJ, when 24 you agreed to put in a threshold system?</p>
<p>1 Q. That was approved the same 2 day the request was -- was being made, 3 right?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Right?</p> <p>8 A. This -- this looks like it 9 was approved by another regulatory 10 director. I don't know what decisions 11 were made to approve this.</p> <p>12 Q. Well, that's Dave Gustin, 13 that DG, right?</p> <p>14 A. I believe it is, yes.</p> <p>15 Q. You know him, right?</p> <p>16 A. I worked with Dave, yes.</p> <p>17 Q. He is a good guy?</p> <p>18 A. That's a commentary, sir. I 19 mean Dave was --</p> <p>20 Q. Well, do you like him, a 21 competent guy, he did a good job for 22 McKesson?</p> <p>23 MS. HENN: Objection to 24 form.</p>	<p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Did you tell them that?</p> <p>5 A. Sir, you are asking me what 6 was said to the DEA and I was not there, 7 so I cannot comment on what was said to 8 the DEA.</p> <p>9 Q. And, sir, I said before, 10 when I asked you about your system, I 11 thought it was really important that we 12 look at all of the decisions that being 13 made by McKesson, I thought it was 14 important that we look at these decisions 15 within the framework of what is going on 16 in America. And while you folks are 17 making the decision to increase the sales 18 of controlled substances to various 19 pharmacies on a permanent basis for 20 Thanksgiving, at this point in time, 21 controlled substances are killing more 22 people in this country, sir, at that 23 point in time than coke and heroin 24 combined. Isn't that the fact?</p>
Page 407	Page 409

Page 410	Page 412
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. True? This is '08.</p> <p>5 MS. HENN: Same objection.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Isn't that true, sir?</p> <p>8 A. That's what the other 9 document had in it, yes, sir.</p> <p>10 Q. Let's continue on. Let's 11 how serious we are all taking this, 12 what's going on.</p> <p>13 MS. HENN: Counsel, it's 14 been about an hour since you got 15 started. So I'd ask if it's an 16 okay time to take a ten-minute 17 break?</p> <p>18 MR. KENNEDY: Sure.</p> <p>19 THE VIDEOGRAPHER: Stand by 20 please. The time is 2:57 p.m. Off 21 the record.</p> <p>22 (Short break.)</p> <p>23 THE VIDEOGRAPHER: We are 24 back on the record. The time is</p>	<p>1 "not truthful" pointing to words. 2 MR. KENNEDY: Yeah.</p> <p>3 Correct. And there's a numbering 4 system.</p> <p>5 BY MR. KENNEDY:</p> <p>6 Q. All the red handwriting is 7 mine, all right?</p> <p>8 And if -- if this -- 9 attached to this threshold change 10 request, I'm going to start by talking 11 about the e-mails leading up to that 12 threshold change request. All right.</p> <p>13 And I put numbers on these, 14 one, two, three, four, five. And that's 15 so we can follow it through 16 chronologically. All right.</p> <p>17 So if you'll go to Page .4.</p> <p>18 MS. HENN: And you can take 19 your time reading the whole 20 document if you need to.</p> <p>21 THE WITNESS: Okay.</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. We're going to read the 24 entire document, sir. All right. You</p>
Page 411	Page 413
<p>1 3:12 p.m.</p> <p>2 MR. KENNEDY: We all set?</p> <p>3 THE VIDEOGRAPHER: All set.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. All right, Mr. Oriente, I 6 want to continue to talk about threshold 7 change requests.</p> <p>8 Let me show you 5014.</p> <p>9 MS. ROZMAN: Which is MCK 10 Oriente 544.</p> <p>11 (Document marked for 12 identification as Exhibit 13 MCK-Oriente-544.)</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. This is another threshold 16 change request, threshold change form, 17 correct?</p> <p>18 A. Yes.</p> <p>19 Q. All right. And you can see 20 that attached to this threshold change 21 request are two pages of e-mails. True?</p> <p>22 MS. HENN: And, Counsel, I 23 just want to point out there is 24 red handwriting with the words</p>	<p>1 all set?</p> <p>2 A. Almost. Okay. Thank you.</p> <p>3 Q. All right. E-mail Number 1. 4 Let's start with the first e-mail that's 5 written. Number 1. Do you see that on 6 Page .4?</p> <p>7 A. Yes, sir.</p> <p>8 Q. Now, down at the bottom, on 9 .4, we have an e-mail from Dave Gustin, 10 correct?</p> <p>11 A. Yes. He's the --</p> <p>12 Q. And he is -- he is a 13 director of regulatory affairs just like 14 you, true?</p> <p>15 A. Yes. He handled the 16 Northeast region.</p> <p>17 Q. And you are in the Northeast 18 region?</p> <p>19 A. I'm sorry, I misspoke. He 20 was in the North Central. Thank you.</p> <p>21 Q. All right. North Central?</p> <p>22 A. Yeah. Thank you.</p> <p>23 Q. He sends an e-mail on 24 May 28, '08. Correct?</p>

	Page 414	Page 416
<p>1 A. Yes.</p> <p>2 Q. And he sends it to you,</p> <p>3 correct?</p> <p>4 A. Yes. Michael, Blaine and</p> <p>5 Rex and Joel.</p> <p>6 Q. He sends it to Snider,</p> <p>7 correct?</p> <p>8 A. Yes.</p> <p>9 Q. Who is Snider?</p> <p>10 A. Blaine Snider is the DC</p> <p>11 manager at the New Castle distribution</p> <p>12 center.</p> <p>13 Q. And he says it to Catton,</p> <p>14 correct?</p> <p>15 A. Rex Catton.</p> <p>16 Q. Catton. And he's in sales,</p> <p>17 true?</p> <p>18 A. Yes, he was vice president</p> <p>19 of sales.</p> <p>20 Q. And the subject on this is</p> <p>21 New Castle CSMP report. New Castle is in</p> <p>22 your region, true?</p> <p>23 A. Yes.</p> <p>24 Q. And New Castle is what</p>		<p>1 have. You folks didn't produce</p> <p>2 it.</p> <p>3 MS. HENN: Okay.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. So the subject then is a</p> <p>6 75 percent report as of 5/28/08. And</p> <p>7 that -- that would be a report that is</p> <p>8 identifying all of your customers who</p> <p>9 have purchased at least 75 percent of</p> <p>10 their threshold as of that day in the</p> <p>11 month. True?</p> <p>12 A. Yes, sir.</p> <p>13 Q. And Dave Gustin is saying to</p> <p>14 Rex who is in sales, "Rex, I await your</p> <p>15 input." So now we've got a -- we've got</p> <p>16 a regulatory director asking Rex in sales</p> <p>17 for his input, correct? That's the first</p> <p>18 sentence?</p> <p>19 A. Yeah. Dave is asking Rex</p> <p>20 for comment.</p> <p>21 Q. Is that the -- that's</p> <p>22 correct, he's asking sales for some</p> <p>23 input, true?</p> <p>24 A. He's asking Rex for input.</p>
<p>1 services Cayahouga County, Cleveland,</p> <p>2 Ohio, Summit County, Akron, Ohio, true?</p> <p>3 A. They handle all the -- this</p> <p>4 one regarded Giant -- Giant Eagle. So</p> <p>5 they would handle all the Giant Eagle</p> <p>6 stores.</p> <p>7 Q. In that area that I just</p> <p>8 mentioned, that geographic area?</p> <p>9 A. I believe so, yes.</p> <p>10 Q. All right. So the answer to</p> <p>11 my question is yes, right?</p> <p>12 A. Yes.</p> <p>13 Q. And the subject then is New</p> <p>14 Castle CSMP. So that's controlled</p> <p>15 substance monitoring report. 75 percent</p> <p>16 plus with a date 5/28/08. Is that the</p> <p>17 subject?</p> <p>18 A. Yes.</p> <p>19 Q. And so --</p> <p>20 MS. HENN: Counsel, just a</p> <p>21 note. It looks like this is a</p> <p>22 reply to a prior e-mail. Do we</p> <p>23 not have that e-mail?</p> <p>24 MR. KENNEDY: We do not</p>	Page 415	<p>1 Yes.</p> <p>2 Q. The second sentence is, "I</p> <p>3 can bump it if you agree to a small</p> <p>4 bump."</p> <p>5 And he's asking, and he's</p> <p>6 talking about bumping up the threshold.</p> <p>7 True?</p> <p>8 A. That is what Dave is</p> <p>9 referring to, yes.</p> <p>10 Q. So now we've got a director</p> <p>11 of regulatory affairs is asking sales for</p> <p>12 their input about an increase of a</p> <p>13 threshold. True?</p> <p>14 A. He's asking Rex for his</p> <p>15 opinion on bumping the threshold, yes.</p> <p>16 Q. He says, "I know RNA,"</p> <p>17 regional or retail national accounts,</p> <p>18 "should make the contact initially, but</p> <p>19 it looks like the customer called the</p> <p>20 description center so let me know."</p> <p>21 Right? Is that the e-mail?</p> <p>22 A. Yes, sir. That's what it</p> <p>23 says.</p> <p>24 Q. Okay. So we've got a</p>

Page 418	Page 420
<p>1 regulatory affairs director asking sales 2 for their input on an increase in the 3 threshold. And then next, if we go up to 4 e-mail Number 2, about an hour later. 5 Rex Catton, Catton, he e-mails back to 6 Gustin, he e-mails you, and Snider, the 7 same folks, right, and we -- we've got 8 the same subject line, New Castle CSMP 9 report 75 percent, 5/28/08, correct? 10 A. Yes. 11 Q. And sales is saying, "Yes. 12 Please bump it up." So increase the 13 threshold. "There were other stores in 14 the list that was sent yesterday. We 15 spoke to Greg Carlson yesterday, and he 16 asked us to increase those above 17 80 percent." 18 First of all, who is -- who 19 is Greg Carlson? 20 A. I don't know who Greg 21 Carlson is. 22 Q. Anyway, Greg Carlson, 23 somebody at McKesson, he is asking that 24 you bump up everybody on this list,</p>	<p>1 of regulatory, an hour later. 2 A. Mm-hmm. 3 Q. He sends an e-mail back to 4 sales, and to you and to other folks, and 5 he says, "The list, by the way, is a long 6 one." 7 That's the lists of all the 8 folks, all the pharmacies, all the 9 customers he wants to get a bump in their 10 threshold. He says, "The list, by the 11 way, is a long one. 12 "I need a reason to go in 13 and bump all those stores thresholds." 14 Is that what he said? 15 A. That's what's written here. 16 Q. And let me ask you, sir. 17 Mr. Gustin, he is right, isn't he? When 18 he says, I need a reason to bump up the 19 thresholds of a long list of pharmacies, 20 he's right when he says that, isn't he? 21 Isn't he? 22 A. Yes. Yes, he would need a 23 reason. What's the reason for the 24 increase.</p>
Page 419	Page 421
<p>1 increase the threshold for everybody on 2 the list that has already purchased 3 80 percent or more of their threshold. 4 Isn't that what he's asking? Isn't that 5 what he's asking, sir? 6 A. He's ask -- what I'm reading 7 here is he's asking for customers who are 8 at 80 percent to be given an increase so 9 they don't hit their threshold. 10 Q. That's what he's asking, 11 right? Is that what he's asking? 12 A. I just said I believe he is 13 asking for an increase so that the 14 customers won't get the omits and not be 15 able to order product. 16 Q. Across the board, let's 17 increase everybody that's already got to 18 80 percent, that's what he's asking? 19 A. Right. We don't know from 20 this e-mail how many they are talking 21 about. It could be a couple or more. 22 Q. Well, we'll go to the next 23 e-mail. We're going to find out. 24 So Dave Gustin, the director</p>	<p>1 Q. That's the way things are 2 supposed to be done at McKesson, right? 3 A. That's part of the procedure 4 to understand why the thresholds are 5 being made. 6 Q. That's the right way to do 7 it, isn't it, sir? Isn't that the right 8 way to do it, exactly what he's 9 suggesting there. That's the right way 10 to do it. 11 A. It's -- it's part of the 12 process to review a threshold, the 13 reason. 14 Q. He goes on and next he says, 15 "They," they meaning everybody on this 16 list, all these pharmacies, "They are all 17 purchasing at well past their historic 18 trends or they would not be on the 19 report." 20 He next says, "The question 21 is why, and until it is answered, the 22 response should not just be going in and 23 changing their thresholds to keeping them 24 off the report."</p>

Page 422	Page 424
<p>1 And when he says, "The 2 question is why, and until we answer it," 3 we can't just go in and bump up a whole 4 long list of thresholds. When he says 5 that, he was right, wasn't he?</p> <p>6 A. Yes. We wouldn't want to 7 just make changes for the sake of making 8 changes.</p> <p>9 Q. He's right, isn't he?</p> <p>10 A. Yes.</p> <p>11 Q. And you agreed with him at 12 that point?</p> <p>13 A. Well, I don't know if I 14 agreed with him at that point. I'm 15 agreeing with what I'm reading here. 16 This is a ten-year-old e-mail.</p> <p>17 Q. And, sir, I'll tell you 18 what. Mr. Gustin was right. And you 19 agree he was right. But guess what? 20 That entire long list of pharmacies all 21 got their bump, every single one of them, 22 despite no reason. They all got an 23 increase in their thresholds, sir. You 24 know that?</p>	<p>1 to what you represented to the DEA as to 2 what you were going to do pursuant to the 3 2008 settlement.</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Is that right?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: When you said 11 you made an increase, are you 12 saying me personally or you 13 McKesson?</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. I'm saying you McKesson, 16 your company.</p> <p>17 A. Oh.</p> <p>18 Q. That's wrong, isn't it?</p> <p>19 MS. HENN: Objection to 20 form.</p> <p>21 THE WITNESS: Not 22 necessarily. You would need to 23 know what the reason was.</p> <p>24 BY MR. KENNEDY:</p>
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. You were on this e-mail, 5 sir.</p> <p>6 A. Excuse me?</p> <p>7 Q. You were on this e-mail.</p> <p>8 A. Right, I was on the e-mail.</p> <p>9 I don't know if I was in the office or on 10 vacation or what, on May 28th of 2008. 11 I'd have to see.</p> <p>12 Yes, I got the e-mail.</p> <p>13 Again, if this account -- I was on the 14 e-mail because I had the New Castle 15 distribution center.</p> <p>16 Q. Yep.</p> <p>17 A. Dave Gustin may have had the 18 customer we're referring to on here which 19 I believe was Giant Eagle. So Dave would 20 have made the increases based off of the 21 customer.</p> <p>22 Q. I tell you what. You 23 increased a long list of pharmacies with 24 no reason. That is absolutely contrary</p>	<p>1 Q. He's asking for the reason.</p> <p>2 A. Right. And until we know 3 what the reason, which we haven't gotten 4 to yet, we wouldn't know.</p> <p>5 Q. Well, let's go to the next 6 page. Turn that page. Let's go to 7 e-mail Number 4 then, sir.</p> <p>8 Now we are on Page .3. I'm 9 sorry, .3 is e-mail Number 4. Now it's 10 four months later. It's four months 11 after, after Mr. Gustin, you agreed, 12 said, hey, unless you give us a reason we 13 can't increase these thresholds because 14 that's not right.</p> <p>15 Four months later, Diane 16 Martin -- who is Diane Martin?</p> <p>17 A. She worked in the 18 distribution center. I'm not sure what 19 her position was.</p> <p>20 Q. She sends an e-mail now on 21 September 22, 2008, correct?</p> <p>22 A. Yes.</p> <p>23 Q. She sends it to Gustin. She 24 sends it to Catton in sales. She sends</p>

Page 426	Page 428
<p>1 it to Snider. Same subject line: New 2 Castle CSMP report 75 percent, dated 3 5/28/08. Right? Correct? 4 A. Yes. 5 Q. And this is a part of the 6 same e-mail string, sir. And she writes 7 Dave -- she's talking about what occurred 8 four months earlier. And she says, 9 "Dave, since we" -- "since these were 10 bumped up without a threshold change 11 request in late May, what is the reason 12 for the increase in dosages? I'll have 13 to create some sort of threshold change 14 request for each of them and then we will 15 need some details for the action taken." 16 Is that what she wrote, sir? 17 A. That is what's written here. 18 Q. And she's talking about the 19 fact that those thresholds and that long 20 list were increased four months earlier 21 without any reason, isn't she? 22 MS. HENN: Objection to 23 form. 24 THE WITNESS: She's asking</p>	<p>1 given? Is that what they were doing? 2 A. Absolutely not. I'm not 3 sure why Dave did not have a threshold 4 change request form at the time of the 5 increase. I can't say why he did not 6 make one out. 7 Q. Well, let's -- let's look 8 further, sir. We have Diane Martin 9 asking him, asking Dave Gustin, what's 10 the reason we made all these increases 11 four months earlier. 12 If we look up above, you see 13 that he e-mails -- e-mails her back three 14 hours later. "Reason..... RNA 15 reasonable request for a small increase." 16 And then cites Rex Catton from sales, 17 right? 18 A. Mm-hmm, right. 19 Q. So we're increasing a whole 20 bunch of people four months earlier. And 21 the reason is because somebody from sales 22 just says it's reasonable. 23 Let me ask you. Sales says 24 reasonable request for a whole bunch of</p>
<p>1 what is the reason. There was a 2 reason which is -- 3 BY MR. KENNEDY: 4 Q. Well, no. I'll ask about 5 that. She's asking, what is the reason 6 we increased that long list of thresholds 7 four months earlier. Isn't that what she 8 is asking, sir? 9 A. Diane is asking for the 10 reason, yes. 11 Q. And she said she's going to 12 have to create a threshold change request 13 four months after the thresholds were 14 changed, right? 15 A. She wrote here that she 16 needs some sort of threshold change 17 request for each of them and will need 18 details. 19 Q. Sir, I'm -- let me ask you 20 this. Was it the policy and procedure at 21 McKesson at this point in time, something 22 they were taking very seriously, was it 23 their policy and procedure to create the 24 request four months after the increase is</p>	<p>1 people. Is that what you considered to 2 be the required documentation for an 3 increase in a threshold? 4 A. I don't know what reason. 5 It's not spelled out here. It could have 6 been a business increase that -- I 7 believe this was Giant Eagle was on here. 8 That Giant Eagle was seeing a business 9 growth in their pharmacies and needed 10 increases. 11 Q. Do you know that? Do you 12 know that? 13 A. I know -- no. What I'm 14 saying is there's no reason stated here. 15 Q. Okay. Well, there's not 16 only no reason stated there. But let's 17 look at -- let's look at the page before 18 that's attached. .2. 19 This is the threshold change 20 request that got created four months 21 after the fact, right? She says, "I'm 22 going to have to put one together to 23 explain what we did four months earlier." 24 And now here it is. Do you see that?</p>

Page 430	Page 432
<p>1 Giant Eagle?</p> <p>2 A. Right, I see Giant Eagle</p> <p>3 and --</p> <p>4 Q. Do you see the date on</p> <p>5 there?</p> <p>6 A. 5/28.</p> <p>7 Q. 5/28/08. Sir, 5/28/08,</p> <p>8 that's not the date that this threshold</p> <p>9 change request was made, is it?</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. That's not the date that</p> <p>14 this request was made.</p> <p>15 A. No, it was made on the 28th,</p> <p>16 the request. The request was made on the</p> <p>17 28th.</p> <p>18 Q. Oh, but the form wasn't made</p> <p>19 on that date, correct?</p> <p>20 A. I don't know what date the</p> <p>21 form was made.</p> <p>22 Q. Sir --</p> <p>23 A. It looks like -- right.</p> <p>24 It's Diane saying that she didn't have</p>	<p>1 Q. And they are talking about</p> <p>2 changes for hydrocodone, correct?</p> <p>3 A. Correct.</p> <p>4 Q. And hydrocodone is at the</p> <p>5 center of the opioid crisis that's going</p> <p>6 on in '08, correct?</p> <p>7 A. That is correct.</p> <p>8 Q. And look at the change.</p> <p>9 Look at the reason for the change.</p> <p>10 Reasonable request for a small increase</p> <p>11 per Rex Catton from sales.</p> <p>12 A. Right. Most of the requests</p> <p>13 for increases would come from sales</p> <p>14 because they are interacting with the</p> <p>15 customer.</p> <p>16 Q. Exactly.</p> <p>17 A. So sales would send them</p> <p>18 into regulatory. Regulatory would do the</p> <p>19 review and either approve or deny based</p> <p>20 off of their review. So the fact that</p> <p>21 this request came from sales is not</p> <p>22 atypical.</p> <p>23 Q. Oh, I'm not talking -- sir,</p> <p>24 I'm not talking about sales filling out a</p>
<p>1 one based in September.</p> <p>2 Q. On September 22 of '08, and</p> <p>3 now attached to that, and now the form</p> <p>4 gets made, and it's dated -- it's dated</p> <p>5 now 5/28/08, correct?</p> <p>6 A. It is.</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. Whoever put 5/28/08 on this</p> <p>11 threshold change request knew that this</p> <p>12 threshold change request form was not</p> <p>13 filled out on 5/28/08. They knew it.</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Is that right, sir?</p> <p>18 A. I -- I -- looking at what</p> <p>19 this is saying with the September request</p> <p>20 for a TCR form, it appears that way.</p> <p>21 Q. Then let's go down here. We</p> <p>22 were talking about Giant Eagle, correct.</p> <p>23 And that's the customer name, correct?</p> <p>24 A. Yes.</p>	<p>1 request form. I'm talking about sales</p> <p>2 giving you the reason for the change.</p> <p>3 That's what we are talking about right</p> <p>4 here.</p> <p>5 A. Well, sales would provide</p> <p>6 the reason for the change. They would --</p> <p>7 they would tell us that the customer had</p> <p>8 a -- a business increase or their</p> <p>9 competitor closed or something like that.</p> <p>10 And then we would take that information,</p> <p>11 do our review and either make -- approve</p> <p>12 or deny the request.</p> <p>13 Q. All right. I'm going to</p> <p>14 write that one down too. Because we're</p> <p>15 going to come back to it. You're telling</p> <p>16 us sales is providing you with the reason</p> <p>17 for increasing your thresholds.</p> <p>18 A. The reason, not the</p> <p>19 justification.</p> <p>20 Q. Oh, okay. So they are</p> <p>21 giving you the reason, but not the</p> <p>22 justification.</p> <p>23 A. We decide, regulatory</p> <p>24 decides if the reason given is justified.</p>

Page 434	Page 436
<p>1 Q. Coming from sales?</p> <p>2 A. Coming from sales. And we</p> <p>3 deny some when the reason is not</p> <p>4 substantial. Or we'll go back to the</p> <p>5 customer and ask for additional</p> <p>6 information to support the business</p> <p>7 change.</p> <p>8 Q. Let's look down here. This</p> <p>9 says approved. And there's a signature</p> <p>10 by Blaine Snider. He dates his signature</p> <p>11 5/28/08. Do you see that?</p> <p>12 A. Yes.</p> <p>13 Q. That ain't true, is it? He</p> <p>14 didn't sign this on 5/28/08, did he, sir?</p> <p>15 MS. HENN: Objection to</p> <p>16 form.</p> <p>17 THE WITNESS: From the</p> <p>18 e-mail chain I can say that it</p> <p>19 looks like it may have been</p> <p>20 created in September.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. And, sir, was it the -- was</p> <p>23 it the practice at McKesson to backdate</p> <p>24 documents so that if the DEA came in, it</p>	<p>1 Q. In your region, right?</p> <p>2 A. Yes.</p> <p>3 Q. And you were part of an</p> <p>4 e-mail chain, weren't you?</p> <p>5 A. Yes.</p> <p>6 Q. And did you stand up when --</p> <p>7 when Dave Gustin said we can't send this,</p> <p>8 and we can't increase this entire list</p> <p>9 unless we have a reason. I don't see an</p> <p>10 e-mail back from you, saying you're</p> <p>11 absolutely right, don't let this go</p> <p>12 forward, this is my region.</p> <p>13 Where is that e-mail?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. I don't see it on the e-mail</p> <p>18 chain.</p> <p>19 A. Again, the request came from</p> <p>20 sales to Dave. And Dave had this chain.</p> <p>21 And he is the one that increased it.</p> <p>22 Q. Now, let's -- I'm going to</p> <p>23 show you some more -- more threshold</p> <p>24 change requests. This is a series of</p>
Page 435	Page 437
<p>1 would look like you were fulfilling your</p> <p>2 legal responsibilities, sir, was that the</p> <p>3 practice at McKesson?</p> <p>4 A. No, sir. That was not the</p> <p>5 practice.</p> <p>6 How -- how do I know this</p> <p>7 one from Giant Eagle is on the list that</p> <p>8 Rex approved? Is there something that</p> <p>9 shows that?</p> <p>10 Q. Sir --</p> <p>11 A. I'm just asking.</p> <p>12 Q. -- it's part of the same</p> <p>13 e-mail chain, and they were all produced</p> <p>14 together by your lawyer.</p> <p>15 A. Okay. Because again, this</p> <p>16 was done by -- not by myself. So for me</p> <p>17 to speculate what took place, you're not</p> <p>18 asking me of actions that I did. You're</p> <p>19 asking me actions that others did.</p> <p>20 Q. It was in your region,</p> <p>21 wasn't it?</p> <p>22 A. The distribution center was?</p> <p>23 Q. Yeah.</p> <p>24 A. Yes.</p>	<p>1 different exhibits.</p> <p>2 And we're not going to use</p> <p>3 the screen on this one.</p> <p>4 MR. KENNEDY: This is a</p> <p>5 package of different exhibits.</p> <p>6 MS. ROZMAN: Collectively we</p> <p>7 have MCK Oriente 525, 526, 527,</p> <p>8 528, and 529.</p> <p>9 (Document marked for</p> <p>10 identification as Exhibit</p> <p>11 MCK-Oriente-525.)</p> <p>12 (Document marked for</p> <p>13 identification as Exhibit</p> <p>14 MCK-Oriente-526.)</p> <p>15 (Document marked for</p> <p>16 identification as Exhibit</p> <p>17 MCK-Oriente-527.)</p> <p>18 (Document marked for</p> <p>19 identification as Exhibit</p> <p>20 MCK-Oriente-528.)</p> <p>21 (Document marked for</p> <p>22 identification as Exhibit</p> <p>23 MCK-Oriente-529.)</p> <p>24 BY MR. KENNEDY:</p>

Page 438	Page 440
<p>1 Q. Take a look at these if you 2 would, sir. These are five different 3 threshold change requests for 2009. 4 The attachments I believe 5 are the same for each one. Take a 6 look -- more threshold requests. Five 7 different threshold change requests. 8 Correct? 9 A. Yes. 10 Q. All dated 12/30/09. 11 A. Mm-hmm. 12 Q. Correct? 13 A. Yes. End of month. 14 Q. Five different pharmacies, 15 correct? 16 A. Yes. 17 Q. All five threshold change 18 requests have a 3,000-unit increase of a 19 controlled substance, correct? 20 A. Yes. 21 Q. And the reason for the 22 requested change, be specific it says, 23 include documentation, four words: 24 "End-of-the-year buffers." Is that what</p>	<p>1 chain, this all happened in less than 2 three hours. Five requests, five 3 different pharmacies, same amount 4 requested, same amount granted, same 5 four-word reason. Right? 6 A. Mm-hmm. 7 Q. Do you know who Mr. Boggs 8 is? 9 A. Yes. 10 Q. Dave Boggs? Is he above you 11 in the chain, he's a senior regulatory 12 affairs? 13 A. Not -- not Dave Boggs. 14 Q. Dave Boggs, what is it? 15 A. Gary Boggs. 16 Q. I'm sorry. Gary Boggs. He 17 is up above you -- 18 A. Yes. 19 Q. In fact, he is a senior 20 regulatory -- 21 A. Yes, he is a senior director 22 over the eastern half of the country. 23 Q. Do you know that he gave 24 testimony on behalf of McKesson on</p>
<p>1 it says for all five, all five different 2 pharmacies? 3 A. End of month and end of -- 4 end of year. 5 Q. Same documents attached to 6 every single one of these requests, 7 correct? 8 A. As they were hitting their 9 monthly threshold. 10 Q. So what we have on the same 11 date, five different pharmacies are 12 getting the same increase for the same 13 four-year reason, true? 14 A. It -- it was the end of the 15 month. So customers were obviously more 16 apt to hit their threshold near the end 17 of the month. 18 Q. So the answer is true. Five 19 different pharmacies for the same 20 four-year -- four-word reason, on the 21 same date, are getting the same 3,000 22 increase, correct? 23 A. Yes. 24 Q. And if you follow the e-mail</p>	<p>1 May 23, 2018, so a month ago about? 2 A. I knew that he did. Yes. 3 Q. And with respect to these 4 thresholds, he testified, and I'm going 5 to quote, on behalf of the company, he 6 testified, "I think it's important to 7 understand that we have a very large, 8 diverse customer base and that the 9 customer base is very nuanced in terms of 10 individual sizes, individual needs, based 11 upon their business models, and, 12 therefore, there's no size one" -- or 13 "one size that fits all of that." Did 14 you know about that testimony? 15 A. I didn't know -- 16 MS. HENN: Objection to 17 form. Go ahead. 18 THE WITNESS: I didn't know 19 specifically what he said. But 20 what he's talking about took place 21 in 2018. And this document is 22 talking about increases that were 23 done in 2009. 24 BY MR. KENNEDY:</p>

Page 442	Page 444
<p>1 Q. So you don't think that 2 applies? 3 A. No, sir, that's not what I 4 said. I said that the increase in 2009 5 is not what Gary Boggs is referring to. 6 Q. Well, he was referring back 7 to your programs over the years. And yet 8 if they are all different, and you folks 9 are taking great care to set these 10 specific thresholds, we've got a 11 situation here that in one day in a 12 three-hour period, five different 13 pharmacies for the same four-word -- 14 four-word reason are getting the same 15 3,000 increase. Right?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: These 19 pharmacies received 3,000 doses 20 each in order for them to get 21 additional product that they 22 needed within that month, yes.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Well, let's go back then.</p>	<p>1 increase was made permanent for them to 2 get additional product because they were 3 bumping up against their threshold. 4 Q. Permanent increase for the 5 end-of-the-year buffer. Is that what 6 happened here, sir? 7 A. Well, it says end of the 8 year. It would -- in my opinion it would 9 be an end of month because they need more 10 in the month. It's not an end-of-year 11 buffer. We don't have an end of -- 12 end-of-year threshold. 13 Q. Does it say end of year? 14 A. It says end-of-year buffers. 15 Q. Right. And if you look at 16 the e-mail that it's attached to it says, 17 "Customers are calling about end of 18 year," does it not, on the e-mails? And 19 then on the reason it says end of year, 20 but you're giving them a 3,000 permanent 21 increase. 22 A. Mm-hmm. 23 Q. Let me show you another 24 exhibit, another threshold change</p>
<p>1 Look at that -- look at that Number 3 on 2 this form. That Number 3 in that form? 3 A. Where -- where are you, sir? 4 Q. Number 3. It says, "For 5 reasons requested, end-of-year buffer," 6 and then 3 says, "Permanent or temporary 7 threshold increase." 8 And what is written there, 9 sir, as to whether or not this end of the 10 year is permanent or temporary? 11 A. It says permanent. 12 Q. Do you see any documented 13 reason as you required, any documented 14 reason as you represented to the DEA you 15 would do for a permanent increase in 16 these threshold change requests? 17 Permanent. You told us this was end of 18 the year, but they are giving these folks 19 a 3,000 increase permanent. Is that 20 true? 21 A. The increase was made 22 permanent -- 23 Q. Is that true? 24 A. -- for them to make -- the</p>	<p>1 request. All right. 2 MR. KENNEDY: 5017. This 3 one we'll bring up please. 4 MS. ROZMAN: This is MCK 5 Oriente 547. 6 (Document marked for 7 identification as Exhibit 8 MCK-Oriente-547.) 9 BY MR. KENNEDY: 10 Q. And I put numbers on this so 11 we could -- we can follow through in the 12 right order, in the right order of these 13 e-mails. 14 First e-mail chronologically 15 is on the first page. Now, Dave Gustin, 16 we know Dave Gustin, he is a director of 17 regulatory affairs like you, correct? 18 A. Yes. 19 Q. And he is in charge of the 20 entire region? 21 A. He was in charge of the 22 North Central. He I believe has since 23 retired. 24 Q. And you wouldn't expect him</p>

Page 446	Page 448
<p>1 to be doing things that weren't 2 consistent with the policies of this 3 company, would you? You wouldn't expect 4 Dave to be doing that, he is a good guy, 5 a good employee. He is going to -- he is 6 going to follow what McKesson does, won't 7 he?</p> <p>8 A. He should -- he should 9 follow the proper procedure, yes.</p> <p>10 Q. So Dave Gustin, on 11 December 16, 2008, he sends an e-mail to 12 Michael Bishop. Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. Do you know who Michael 15 Bishop is?</p> <p>16 A. Michael Bishop was a 17 regulatory affairs manager. But at this 18 time he was in the -- in 2008 when this 19 was written, he was in the retail 20 national accounts team.</p> <p>21 Q. And what's that? Does that 22 make him sales?</p> <p>23 A. He would have been involved 24 with customer support and sales.</p>	<p>1 he's writing that. So he's probably 2 talking about November 30th, two weeks or 3 so ago. Is that what he says?</p> <p>4 A. It -- it doesn't say 5 November 30th. But since he has the 6 30th, it would seem to be November 30th.</p> <p>7 Q. And Gustin says, "I will use 8 it for the 30 percent increases I made 9 for the regional national accounts" -- 10 those are the big chains, right?</p> <p>11 A. Correct.</p> <p>12 Q. He says, "I'm going to use 13 this threshold change request, I will use 14 it for the 30 percent increases I made 15 for the RNAs that day after you e-mailed 16 me all those reports. Thanks." Do you 17 see that?</p> <p>18 A. Yeah -- yes. It doesn't say 19 how many were on those reports, but yes.</p> <p>20 Q. It doesn't really matter, 21 does it, how many is on the reports. You 22 shouldn't be making out threshold change 23 requests more than two weeks after you 24 make the changes, should you, sir?</p>
<p>1 Q. So now we got a -- again, we 2 got a regulatory guy writing an e-mail to 3 sales. And the subject is could you do 4 me a favor. Do you see that?</p> <p>5 A. Yes.</p> <p>6 Q. And he e-mails to Bishop, 7 and he says, "Are you in" -- "are you in 8 today?" Correct?</p> <p>9 A. Yes.</p> <p>10 Q. Now, we turn the page. And 11 it's the same day. We look at the next 12 e-mail, it's at the top of the page. And 13 Gustin sends a second e-mail to Bishop on 14 the same day, same subject, could you do 15 me a favor. Right?</p> <p>16 A. Yeah. Same subject on the 17 e-mail.</p> <p>18 Q. Dave Gustin, again you would 19 expect him to follow the policies. He 20 says, "I just need a threshold change 21 request from you signed and dated the 22 30th." Do you see where he says that?</p> <p>23 A. Yes.</p> <p>24 Q. And it's December 16th when</p>	<p>1 A. He should have had the 2 documentation when he made the changes.</p> <p>3 Q. He's asking him to approve a 4 30 percent increase that was made two 5 weeks earlier. Right?</p> <p>6 A. He's asking for the 7 follow-up paperwork. Yeah. Dave made 8 the -- the increase. He's asking Michael 9 to make out the TCR form. It appears 10 Dave made the increase without having the 11 paperwork.</p> <p>12 Q. Look down to the next -- we 13 look down to the next e-mail. It's 14 Bishop's -- he e-mails back and says, 15 "I'm in a meeting for the next 30." Do 16 you see that? It says I'm in a meeting 17 for the next 30, right?</p> <p>18 A. Yes.</p> <p>19 Q. Turn to the next page, and 20 it's -- it's a day later, correct?</p> <p>21 A. Yeah. The 17th.</p> <p>22 Q. And Bishop e-mails back 23 to Gustin. He says, "This is the 24 Thanksgiving increases." So now we're</p>

Page 450	Page 452
<p>1 back to increases for Thanksgiving, 2 right? 3 A. Right. This references 4 that -- that other e-mail that was -- or 5 that TCR form that was done on 6 Thanksgiving.</p> <p>7 Q. Gustin e-mails him back and 8 says, "Yep. 11/28, right? So now we are 9 talking about more increases for 10 Thanksgiving," correct?</p> <p>11 A. I believe this references 12 the same increase that the Thanksgiving 13 TCR referenced from Rex.</p> <p>14 Q. And now we go to the next 15 page. And we see Bishop, it looks like 16 he sends and encloses a threshold change 17 form. Now it looks like he filled it out 18 and signed it, right? Is that correct?</p> <p>19 A. Well --</p> <p>20 Q. Threshold change form, see 21 that?</p> <p>22 A. Yeah. Right. It just shows 23 a Word attachment. It doesn't show 24 the -- what was actually sent.</p>	<p>1 and sign it for me and send it back. And 2 he's not saying I'm not doing that. It's 3 two and a half weeks late. I'm not doing 4 that. Do you find that unusual?</p> <p>5 MS. HENN: Objection to 6 form.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Is that unusual, sir? Very 9 simple question.</p> <p>10 MS. HENN: Same objection.</p> <p>11 BY MR. KENNEDY:</p> <p>12 Q. Was that the culture here at 13 your company?</p> <p>14 A. No. No, that's not the 15 culture. Our typical process is to have 16 the paperwork when we're making the 17 increase. Dave realized he didn't have 18 the form. He asked Michael to make one 19 out so that we had a copy to support the 20 increase that was done on Thanksgiving.</p> <p>21 Q. Not typical? Go up to the 22 next e-mail, please. Go up to the next 23 e-mail.</p> <p>24 A. Number 7?</p>
<p>1 Q. Well, you ask him to send 2 him back one signed. So do you think he 3 probably was sending one back signed?</p> <p>4 MS. HENN: Objection to 5 form.</p> <p>6 THE WITNESS: I can't tell 7 from what I'm looking at, though.</p> <p>8 BY MR. KENNEDY:</p> <p>9 Q. Sir, don't you find it 10 unusual that -- that Michael Bishop, 11 instead of e-mailing Gustin back and 12 saying look it, I -- I can't sign and 13 date a threshold two and a half weeks 14 late, that's -- that's not honest. But 15 he just -- do you find it unusual, he 16 just sends it back, without objecting?</p> <p>17 MS. HENN: Objection to 18 form.</p> <p>19 THE WITNESS: Well, in -- in 20 number --</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. Sir, I'm just asking, did 23 you find it unusual that you have -- you 24 have Gustin saying put something together</p>	<p>1 Q. Number 7. We've got Gustin 2 now sending another e-mail. And it's -- 3 it's to a different group of people. And 4 he's sending it to you also, is he not?</p> <p>5 A. Yes. I'm on -- I'm on 6 the --</p> <p>7 Q. December 17th?</p> <p>8 A. I'm cc'd.</p> <p>9 Q. Okay. And again, could you 10 do me a favor. This one isn't -- this is 11 different. This is not to Bishop. Now, 12 this is to a different group of people 13 saying, can you do me a favor, right?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Right?</p> <p>18 A. Well, I'm -- I'm reading it, 19 sir.</p> <p>20 Q. I'll -- we'll -- you want 21 to -- we'll go through it. I'm going to 22 go through it.</p> <p>23 A. Yeah, but you asked me a 24 question that I can't answer until I read</p>

Page 454	Page 456
<p>1 it.</p> <p>2 Q. I'm saying, was this to a</p> <p>3 different group of people?</p> <p>4 MS. HENN: Counsel, if you</p> <p>5 give him a moment he'll answer</p> <p>6 your question.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Was this to a different</p> <p>9 group of people?</p> <p>10 A. It -- this one is sent to</p> <p>11 the pharmacy group DC managers. DCM.</p> <p>12 Q. And it's sent to you?</p> <p>13 A. I'm cc'd along with the</p> <p>14 other directors, Tracy and Bill.</p> <p>15 Q. And he is attaching</p> <p>16 threshold change form, is he not?</p> <p>17 A. It says, "The attached TCR</p> <p>18 form covers all RNA increases made on</p> <p>19 that date" --</p> <p>20 Q. Stop. The attachment. Do</p> <p>21 you see the line,</p> <p>22 thresholdchangeform.doc, is that the</p> <p>23 attachment?</p> <p>24 A. Yes.</p>	<p>1 30 percent on one day. True? Is that</p> <p>2 what he's talking about?</p> <p>3 A. That's what he wrote here,</p> <p>4 yes.</p> <p>5 Q. And he's talking about doing</p> <p>6 it without any threshold change request</p> <p>7 forms. Correct? Is that true, sir?</p> <p>8 A. He -- yes.</p> <p>9 Q. And now, even further, he's</p> <p>10 asking these folks to sign them two weeks</p> <p>11 after the date.</p> <p>12 And I'm going to ask you</p> <p>13 again. Is that the way things were done?</p> <p>14 Is that the culture at your company with</p> <p>15 respect to threshold changes?</p> <p>16 A. No, sir. It's not. And</p> <p>17 when it says please sign and file, they</p> <p>18 could have signed them, filed them. They</p> <p>19 did not need to date them for November or</p> <p>20 they could have put per -- for December</p> <p>21 change and dated it December.</p> <p>22 Q. Well, they could have done a</p> <p>23 lot of things, sir, but they put the</p> <p>24 wrong date on it, sir. They put the</p>
<p>1 Q. And does he state that</p> <p>2 you're included, "On November 28th, I</p> <p>3 sent request" -- "I was sent requests by</p> <p>4 Michael for over 200 thresholds to get</p> <p>5 30 percent increases for various national</p> <p>6 accounts. The attached TCR form covers</p> <p>7 all RNA increases made that date. Please</p> <p>8 sign and file. This is not routine, but</p> <p>9 I was the only DRA on and so my time was</p> <p>10 spent making the changes. And I may have</p> <p>11 missed some e-mails to DCs."</p> <p>12 Sir, he's talking about 200</p> <p>13 threshold changes at 30 percent, is he</p> <p>14 not, in this e-mail? Is he not talking</p> <p>15 about --</p> <p>16 A. He is, but I'm not the</p> <p>17 Michael he's referring to.</p> <p>18 Q. Oh, but you are copied on</p> <p>19 the e-mail, aren't you, sir?</p> <p>20 A. Yes, but he's -- but I did</p> <p>21 not send the request to him. By Michael,</p> <p>22 he's meaning Michael Bishop.</p> <p>23 Q. Real simple. He's talking</p> <p>24 about 200 threshold change requests of</p>	<p>1 dishonest date on every single one of</p> <p>2 them, for 200 changes in one day, right?</p> <p>3 MS. HENN: Objection to</p> <p>4 form.</p> <p>5 THE WITNESS: They put the</p> <p>6 date that the increase took place</p> <p>7 on.</p> <p>8 BY MR. KENNEDY:</p> <p>9 Q. You know what, you told us</p> <p>10 how serious you took this program</p> <p>11 considering we had a crisis going on in</p> <p>12 this country. And so did the president</p> <p>13 and CEO of your company when he testified</p> <p>14 in front of Congress. Let's take a look</p> <p>15 at that, sir, because I might want to ask</p> <p>16 you.</p> <p>17 MR. KENNEDY: If you can</p> <p>18 give us 8, please.</p> <p>19 (Document marked for</p> <p>20 identification as Exhibit</p> <p>21 MCK-Oriente-Video-8.)</p> <p>22 (Video playback.)</p> <p>23 REP. CASTOR:</p> <p>24 Mr. Hammergren, your company</p>

Page 458	Page 460
<p>1 McKesson distributed over 2 1.8 million opioid pills each year 3 in 20 -- 2006 and 2007 to Family 4 Discount Pharmacy. That's an 5 average of about 5,000 pills per 6 day in this rural small town.</p> <p>7 Based upon figures cited by 8 DEA, McKesson shipped Family 9 Discount approximately six times 10 the amount of hydrocodone that an 11 average pharmacy in west -- in 12 rural West Virginia would have 13 received during those years.</p> <p>14 So similar question to you, 15 McKesson delivered millions of 16 pills to the single pharmacy. 17 Clearly that's not reasonable and 18 you should have -- you should have 19 flagged that and stopped that 20 right away. Why didn't you?</p> <p>21 MR. HAMMERGREN: We did 22 terminate the relationship with 23 that pharmacy, and like 24 Mr. Barrett, I -- I would have</p>	<p>1 greater accountability. Thank 2 you, and I go back. 3 (Video playback ended.)</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. You heard him talk about 6 taking the settlement very seriously, 7 didn't you?</p> <p>8 A. Yes.</p> <p>9 Q. Let's look at another 10 threshold change request if we could. 11 This is 5018.</p> <p>12 MS. ROZMAN: MCK Oriente 13 548.</p> <p>14 (Document marked for 15 identification as Exhibit 16 MCK-Oriente-548.)</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. Is this another threshold 19 change request, sir?</p> <p>20 A. Yes, it is.</p> <p>21 Q. And this one, this one is 22 dated 11/26/08, is it not?</p> <p>23 A. Yes, it is.</p> <p>24 Q. And it was approved the same</p>
<p>1 liked to have made a decision 2 faster.</p> <p>3 REP. CASTOR: Don't you take 4 responsibility for what was 5 happening back then? Was it that 6 the -- the profit motive was -- 7 simply overcame the -- you saw 8 that paying the penalties on your 9 settlement agreements was a cost 10 worth paying because you were 11 making so much money?</p> <p>12 MR. HAMMERGREN: 13 Congresswoman, we take all these 14 matters very seriously. Any 15 settlement with a regulator we 16 take very seriously. Our systems 17 have evolved and we continue to 18 invest heavily to make sure that 19 situations like that don't happen 20 again.</p> <p>21 REP. CASTOR: I think this 22 was the opposite of due diligence 23 that was required under the law 24 and we're going to be looking for</p>	<p>1 day, do you see that? Same day?</p> <p>2 A. Yes.</p> <p>3 Q. And the customer on here is 4 a CVS pharmacy. True?</p> <p>5 A. Yes, it is.</p> <p>6 Q. And they are asking for a 7 30 percent increase. Correct?</p> <p>8 A. They are.</p> <p>9 Q. And as you told the DEA, if 10 we are going to increase the -- a 11 threshold, if we're going to increase a 12 threshold, we will require documentation, 13 does it not? Is that what it says?</p> <p>14 A. Yes.</p> <p>15 Q. What you agreed to with the 16 FDA (sic), we will require documentation 17 if we're going to increase a threshold. 18 True?</p> <p>19 A. Right. Threshold change 20 form.</p> <p>21 Q. The reason for change. And 22 it says, "Attach supporting 23 documentation."</p> <p>24 The reason for change is,</p>

Page 462	Page 464
<p>1 "Per the agreement between CVS and 2 McKesson, approved by Don Walker on 3 September 25th to temporarily withhold 4 threshold monitoring until CVS analyzed 5 the requested data." 6 And based on that statement, 7 this increase by 30 percent was approved. 8 Do you see that, sir? 9 A. Again, it was approved by 10 another regulatory director. Not myself. 11 Q. It states here that you made 12 an agreement, somebody made an agreement 13 with CVS to stop the monitoring of their 14 thresholds. Do you see that? 15 A. To temporarily withhold it, 16 yes. 17 Q. And so during this -- how 18 long this temporary -- how long -- 19 A. It doesn't say on this 20 document how long temporary was. 21 Q. Is that appropriate for any 22 period, whether it's a day or two or 10 23 or a hundred, to not monitor the 24 thresholds of CVS? Is it proper?</p>	<p>1 MS. HENN: Objection to 2 form. 3 THE WITNESS: We may have 4 still been monitoring them. We 5 were not looking at their 6 thresholds on what they were 7 ordering for this temporary 8 period. And again, I don't know 9 if this was a week or ten days or 10 how much. 11 And again, this was done in 12 the West region, which is not my 13 area of responsibility. 14 BY MR. KENNEDY: 15 Q. Sir, let me ask -- let me 16 ask you this. 17 A. Yes. 18 Q. At this point in time, 19 you're doing business with hundreds of 20 CVSs, right, hundreds of CVSs? 21 A. Yes. 22 Q. Who is Don Walker? 23 A. Don Walker was a senior vice 24 president distribution operations who we</p>
<p style="text-align: center;">Page 463</p> <p>1 A. I can't speak on the 2 agreement that was made, because this is 3 the first time I'm seeing that, this 4 agreement between Don Walker and CVS to 5 temporary withhold this while CVS 6 analyzed requested data. 7 Q. I'm going to ask you, sir, 8 when you said to the DEA -- let's start 9 from the beginning. When Congress passed 10 the Controlled Substances Act of 1970, 11 when the DEA issued its regulations in 12 '71, when you signed the agreement with 13 the DEA in '08, did you agree with them 14 and tell them that you were just going to 15 monitor some of the pharmacies some of 16 the time? 17 MS. HENN: Objection to 18 form. 19 BY MR. KENNEDY: 20 Q. Is that what you said? 21 A. No, sir. 22 Q. And the law says you've got 23 to monitor all of the pharmacies all the 24 time. Doesn't it? Isn't that the law?</p>	<p style="text-align: center;">Page 465</p> <p>1 reported into. 2 Q. He was a -- he is a national 3 guy, right? 4 A. Yes, sir. 5 Q. He makes agreements with 6 CVS, he's making national agreements, 7 right? 8 A. Yes, sir. 9 Q. Let me ask you. This 10 special arrangement that you seem to have 11 with CVS, did it have anything to do with 12 the fact that by 2008, when you had this 13 agreement not to monitor their 14 thresholds, did it have anything to do 15 with the fact that by 2008, CVS was a 16 12-billion, not million, a \$12-billion 17 customer of McKesson? 18 MS. HENN: Objection to 19 form. 20 THE WITNESS: Sir, I -- as I 21 said earlier, I don't get involved 22 with sales. So I would not even 23 know how much business McKesson 24 did with CVS on the dollar value.</p>

Page 466	Page 468
<p>1 So I can't say what the 2 decisionmaking was. 3 BY MR. KENNEDY: 4 Q. This is all very serious 5 because there was an opioid crisis going 6 on, correct? 7 A. Yes, sir. 8 Q. Is that right? 9 A. Yes, sir. 10 Q. And diversion from 11 pharmacies like CVS was going on, was it 12 not? 13 A. During this period, I don't 14 know when the CVS had their issues in 15 Florida at two stores. But yes, there 16 was -- there was an opioid crisis in '08. 17 Q. Let's look at -- let's 18 continue with CVS. Let's look at another 19 threshold change request. 20 This is 5013. 21 MS. ROZMAN: MCK Oriente 22 543. 23 (Document marked for 24 identification as Exhibit</p>	<p>1 Q. And the reason the 2 documented, be-specific reason, is quote, 3 "per the process agreed to with McKesson 4 and the CVS loss prevention team 2/6/09, 5 Michael Oriente," that's you," will 6 provide CVS a list of any location 7 requiring CVS validation prior to further 8 threshold change requests. For now, 9 these threshold increases are considered 10 reasonable." 11 Do you see that statement, 12 sir? 13 A. Yes, I do. 14 Q. Why is this statement in 15 quotes? 16 A. I don't know. I didn't 17 write this document. 18 Q. What it says, "for now, 19 these threshold increases are considered 20 reasonable." These, what these? What 21 threshold requests, anything by CVS? 22 What's that mean when it 23 says, "These threshold changes will be 24 considered reasonable for now"? What</p>
Page 467	Page 469
<p>1 MCK-Oriente-543.) 2 BY MR. KENNEDY: 3 Q. Another threshold change 4 request, sir? 5 A. Yes, sir. 6 Q. This is from 4/28/10, the 7 top one we're looking at. Do you see 8 that? 9 A. Yes, sir. April 28 of 2010. 10 Q. Customer name, it says, "See 11 list." Do you see that? 12 A. Yes. 13 Q. And they are looking for a 14 15 percent increase in a list of 15 different controlled substances. True? 16 A. Yes. 17 Q. Reason for requested change, 18 the required documentation. And it says 19 be specific. Do you see that, capital 20 letters, "be specific." Include 21 supporting documentation. 22 Right? That's what the form 23 states? 24 A. Yes.</p>	<p>1 does that mean? 2 A. Again, I did not write this 3 document so I can't speak on what it's 4 pertaining to. As you said under the 5 controlled substance requested, it says, 6 "See list." 7 So I don't know, since I 8 didn't create this document. It was 9 created by either Jake or -- and approved 10 by Tom McDonald, our West regional 11 director, again not myself. 12 Q. Sir, it looks like -- it 13 looks like CVS is getting preapproval, 14 right? 15 MS. HENN: Objection. 16 BY MR. KENNEDY: 17 Q. "For now, these threshold 18 increases are considered reasonable," in 19 quotes. 20 They are getting preapproval 21 of threshold increase requests. 22 A. What -- what -- 23 MS. HENN: Objection to 24 form.</p>

Page 470	Page 472
<p>1 BY MR. KENNEDY:</p> <p>2 Q. Isn't that what was going</p> <p>3 on?</p> <p>4 MS. HENN: Objection to</p> <p>5 form.</p> <p>6 THE WITNESS: No, sir. What</p> <p>7 it says here is that I will</p> <p>8 provide CVS a list of any location</p> <p>9 requiring CVS to validate prior to</p> <p>10 further TCRs. So it's --</p> <p>11 BY MR. KENNEDY:</p> <p>12 Q. What' the -- read the next</p> <p>13 sentence, sir. There's another sentence.</p> <p>14 A. And then the next sentence</p> <p>15 says, "For now, these threshold increases</p> <p>16 are considered reasonable."</p> <p>17 But again, I did not write</p> <p>18 this so I cannot speak on what that</p> <p>19 second sentence says.</p> <p>20 Q. You don't think this is a</p> <p>21 CVS getting threshold increased requests</p> <p>22 preapproved?</p> <p>23 A. No, sir. Not preapproved.</p> <p>24 Because it says, "For now, these</p>	<p>1 daily report that tells you where you are</p> <p>2 with respect to the threshold increases,</p> <p>3 true?</p> <p>4 A. This report is -- I'm trying</p> <p>5 to determine what -- what report this is.</p> <p>6 Q. Do you see down the end,</p> <p>7 threshold percentage, do you see that,</p> <p>8 threshold percentage?</p> <p>9 A. Where are you?</p> <p>10 Q. Threshold percentage, on</p> <p>11 that report, page .2.</p> <p>12 A. Threshold percentage. Yes,</p> <p>13 I -- right. It shows them what their</p> <p>14 monthly threshold is, how much they</p> <p>15 bought, the threshold that they are at</p> <p>16 and then a new threshold.</p> <p>17 Q. So that increase, that's</p> <p>18 getting approved on the same day that it</p> <p>19 is made with the statement, "For now,</p> <p>20 these threshold increases are considered</p> <p>21 reasonable."</p> <p>22 A. 2,000-dose increase on an</p> <p>23 11,000 threshold.</p> <p>24 Q. And that CVS store was at</p>
<p>1 threshold increases are considered</p> <p>2 reasonable." So a 15 percent increase,</p> <p>3 judging off of the list that was</p> <p>4 submitted, Jake would have submitted it</p> <p>5 and approved it and Tom McDonald in</p> <p>6 regulatory would have reviewed it and</p> <p>7 approved it.</p> <p>8 Q. Let's take a look -- let's</p> <p>9 see what's going on. Let's see what's</p> <p>10 going on, sir. Let's look at the next</p> <p>11 page.</p> <p>12 The next page is .2. Do you</p> <p>13 see that next page? We got the</p> <p>14 attachment here. Do you see that? It's</p> <p>15 one CVS store, right?</p> <p>16 A. Yes, sir.</p> <p>17 Q. And they are looking for an</p> <p>18 increase in oxycodone, correct?</p> <p>19 A. Yes. They are currently set</p> <p>20 at 11,000. They've reached 10,934 doses.</p> <p>21 Q. So the answer is yes,</p> <p>22 correct?</p> <p>23 A. Yes.</p> <p>24 Q. This page is kind of the</p>	<p>1 99.4 percent of their threshold, right?</p> <p>2 A. Correct.</p> <p>3 Q. Now look at the next page.</p> <p>4 We've got another threshold change</p> <p>5 request, right?</p> <p>6 A. This one is January 20th.</p> <p>7 Q. Right. Another one,</p> <p>8 January 20 of '10. And you've got the</p> <p>9 same statement. Another 15 percent</p> <p>10 increase and the same statement: "For</p> <p>11 now, these threshold increases are</p> <p>12 considered reasonable." Same statement,</p> <p>13 correct?</p> <p>14 A. Yes.</p> <p>15 Q. Now, this is 1/20/10.</p> <p>16 Right?</p> <p>17 A. Yes.</p> <p>18 Q. Now, if you look at what's</p> <p>19 attached to that. They said see list.</p> <p>20 If we look at this list, on this one, you</p> <p>21 can have 12 different threshold change</p> <p>22 requests. True?</p> <p>23 A. Yes. There's 12.</p> <p>24 Q. And if you look down the</p>

Page 474	Page 476
<p>1 list, every single one on the threshold 2 percentage down there at the end? 3 A. Mm-hmm. 4 Q. Every one of them is above 5 80 percent. 6 A. Right. This report would 7 only show those customers above 8 80 percent. 9 Q. Right. Exactly. Exactly. 10 That's what they are getting. They are 11 getting a report that says everybody is 12 above 80 percent. And now we've got -- 13 one second. Now we've got 12 different 14 CVS requests. Correct? Correct? 15 A. This -- this report is 16 showing 12 thresholds that they want 17 reviewed and the customers are on the 18 report because they are above 80 percent, 19 which is where the report would frame. 20 Q. Absolutely, they are all 21 attached to one form that says hey, for 22 now these threshold increases are 23 considered reasonable. 24 And, sir, let me ask you</p>	<p>1 True? Is that true, sir? 2 A. The fact that they were at 3 an 8,000 monthly threshold, which is our 4 base number, these stores were not 5 elevated to begin with. 6 Q. Sir, am I -- is it true that 7 the only statement that you see in your 8 explanation here that would even justify 9 this, is "for now these are all 10 reasonable," isn't that what a statement 11 under explanation or reason for the 12 increase of all 12 stores, right? 13 MS. HENN: Objection to 14 form. 15 BY MR. KENNEDY: 16 Q. All 12. 17 MS. HENN: Objection to 18 form. 19 THE WITNESS: This is saying 20 that these threshold increases are 21 considered reasonable, looking at 22 each of them to go up the amount 23 that they did. 24 BY MR. KENNEDY:</p>
<p>1 this. Look at the top one listed. CVS 2 8944A. Do you see that top one there? 3 MS. HENN: What page are you 4 on, sir? 5 THE WITNESS: He's on this 6 one. 7 MR. KENNEDY: We're on .4. 8 MS. HENN: .4? Thank you. 9 BY MR. KENNEDY: 10 Q. Do you see that? 11 A. Yes. 12 Q. Did they have a new group of 13 doctors move into the building of the 14 pharmacy? Did they? 15 A. I cannot tell from this 16 document. 17 Q. Did they have a competitor 18 go out of business down the street? 19 A. Again, I can't tell from 20 this document. 21 Q. Only thing you can see, sir, 22 with respect to all 12 is the single 23 statement, "For now, these are considered 24 reasonable," that's all you can tell.</p>	<p>1 Q. Look -- go down to the 2 fourth one. Did they have a competitor 3 go out of business? 4 A. The request for codeine with 5 oxide? 6 Q. Yeah, codeine, that's a 7 serious drug. Did they have a competitor 8 go out of business that's justifying this 9 increase? 10 A. I cannot tell from the 11 paperwork that this is showing, no. 12 Q. What we do know is that all 13 12 of these are above 80 percent of their 14 threshold, right, all 12? 15 A. Correct. 16 Q. Is that a coincidence? Is 17 that a coincidence? 18 A. No, because -- 19 Q. First group they are all 20 above -- 21 MS. HENN: Counsel, counsel. 22 THE WITNESS: You're asking 23 me -- you're asking me a question. 24 I'd like to answer.</p>

Page 478	Page 480
<p>1 BY MR. KENNEDY:</p> <p>2 Q. Very good.</p> <p>3 Is that a coincidence, sir?</p> <p>4 A. No, it's not a coincidence,</p> <p>5 but the report will only show customers</p> <p>6 that are above 80 percent. It's an</p> <p>7 80 percent threshold warning report.</p> <p>8 Q. Exactly. Somebody is asking</p> <p>9 for it, right? Somebody is asking for</p> <p>10 the 80 percent report, right?</p> <p>11 MS. HENN: Objection to</p> <p>12 form.</p> <p>13 BY MR. KENNEDY:</p> <p>14 Q. And they are attaching it to</p> <p>15 threshold change requests. That's what's</p> <p>16 going on, right?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: I don't know</p> <p>20 if they are asking for it or this</p> <p>21 report is what they used to</p> <p>22 generate the request.</p> <p>23 Again, this was, what, eight</p> <p>24 years ago. Our program was</p>	<p>1 They are all over 80 percent?</p> <p>2 A. Yes, but this -- this report</p> <p>3 from 4/16 which is Item 5 is -- is not</p> <p>4 even filled out. It's --</p> <p>5 Q. It's supposed --</p> <p>6 A. There's no DCMs. There's</p> <p>7 no -- there's no sales. There's no</p> <p>8 regulatory persons --</p> <p>9 Q. It's supposed to be filled</p> <p>10 out, isn't it?</p> <p>11 A. Well, I'm -- I'm not sure</p> <p>12 why it wasn't. I can only say what I'm</p> <p>13 seeing and it's blank.</p> <p>14 Q. Let's go to the next page.</p> <p>15 A. Do these -- do these three</p> <p>16 relate to this one?</p> <p>17 Q. Let's go to the next page.</p> <p>18 .8.</p> <p>19 A. Same thing. It's --</p> <p>20 Q. Sir, if they are all related</p> <p>21 to the first one, then what you've got</p> <p>22 going on here is someone is backdating</p> <p>23 again, right?</p> <p>24 MS. HENN: Counsel,</p>
<p>1 changed dramatically.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. I'm talking about what's</p> <p>4 going on there now. That's all I want to</p> <p>5 know about, what's going on --</p> <p>6 A. Now?</p> <p>7 Q. -- then.</p> <p>8 A. Oh, okay.</p> <p>9 Q. That's what we're asking</p> <p>10 about.</p> <p>11 Go to the next one. .5. .5,</p> <p>12 4/16/09. It says, "See list again." Do</p> <p>13 you see that?</p> <p>14 A. Yes.</p> <p>15 Q. It says down here again,</p> <p>16 reason, "For now, these threshold</p> <p>17 increases are considered reasonable." Do</p> <p>18 you see that?</p> <p>19 A. Mm-hmm.</p> <p>20 Q. And if we look at the form</p> <p>21 attached. Lo and behold, all, all of</p> <p>22 these CVS stores are over 80 percent,</p> <p>23 right? 86, 99, 88. All of them are</p> <p>24 over, right? Is -- is that correct?</p>	<p>1 objection to form.</p> <p>2 THE WITNESS: I can't tell</p> <p>3 from this document, sir.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. Go to the next page.</p> <p>6 A. I'm just saying that it's</p> <p>7 not filled out with who approved it. And</p> <p>8 there's no regulatory name or date.</p> <p>9 Q. Let's go to the next page,</p> <p>10 sir, .8. Do you see the next page?</p> <p>11 A. Yeah.</p> <p>12 Q. Dated 4/17/09?</p> <p>13 A. Yes, sir. That's the one</p> <p>14 that I'm referring to. It is -- there's</p> <p>15 no --</p> <p>16 Q. It says, "See list," again,</p> <p>17 right?</p> <p>18 A. Yes.</p> <p>19 Q. It says, "For now, these</p> <p>20 thresholds considered reasonable,"</p> <p>21 correct?</p> <p>22 A. Yes.</p> <p>23 Q. And attached to that, sir,</p> <p>24 now you've got seven different CVS</p>

Page 482	Page 484
<p>1 pharmacies, correct? Is that correct?</p> <p>2 A. Yes. Yes.</p> <p>3 Q. And every one of them is</p> <p>4 over 80 percent in their threshold so far</p> <p>5 that month, correct?</p> <p>6 A. Yes. I can't even tell</p> <p>7 who -- who approved this, because there's</p> <p>8 no name on the regulatory side of who</p> <p>9 approved it. So I don't know if it was</p> <p>10 Tom, Dave.</p> <p>11 Q. Sir, just -- please just</p> <p>12 answer my questions. All right?</p> <p>13 A. Well, the --</p> <p>14 Q. Just answer my questions --</p> <p>15 A. The document is so vague I</p> <p>16 can't comment on it.</p> <p>17 Q. And it's your document,</p> <p>18 isn't it --</p> <p>19 A. It's not mine personally.</p> <p>20 Yes, it is McKesson's.</p> <p>21 Q. Is this the way things were</p> <p>22 done at McKesson? That you were</p> <p>23 increasing thresholds without the</p> <p>24 documents even being completed?</p>	<p>1 Q. And all of them, all of them</p> <p>2 are over 80 percent of their thresholds,</p> <p>3 correct?</p> <p>4 A. Yes, or they wouldn't be on</p> <p>5 the report.</p> <p>6 Q. And go to the next one,</p> <p>7 Page 14, sir.</p> <p>8 A. Yes.</p> <p>9 Q. Another threshold change</p> <p>10 request dated 3/27/09, true?</p> <p>11 A. Yes. And again, filled out</p> <p>12 by Tom McDonald.</p> <p>13 Q. And it states -- right. And</p> <p>14 again states, "For now, these thresholds</p> <p>15 increases are considered reasonable." It</p> <p>16 says that again, right?</p> <p>17 A. It does.</p> <p>18 Q. And now you've got them</p> <p>19 attached to 31 different threshold change</p> <p>20 requests, right, 31 different ones, true,</p> <p>21 31?</p> <p>22 A. Without counting them it</p> <p>23 looks about 31, yes.</p> <p>24 Q. All of them are above</p>
<p>1 A. I was not aware of that --</p> <p>2 MS. HENN: Objection to</p> <p>3 form.</p> <p>4 THE WITNESS: -- nor have I</p> <p>5 done that.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. All right. Let go to the</p> <p>8 next one. Page 11.</p> <p>9 A. Mm-hmm.</p> <p>10 Q. Do you see the next one?</p> <p>11 4/14/09, do you see that?</p> <p>12 A. Yes.</p> <p>13 Q. 4/14/09 says, "See list."</p> <p>14 Right?</p> <p>15 A. Yes.</p> <p>16 Q. "For now, these thresholds</p> <p>17 increases are considered reasonable,"</p> <p>18 correct?</p> <p>19 A. Right. This one has Tom</p> <p>20 McDonald as the regulatory person on the</p> <p>21 next page.</p> <p>22 Q. And now the attachment has</p> <p>23 got three CVS pharmacies, true?</p> <p>24 A. Yes.</p>	<p>1 80 percent, right?</p> <p>2 A. Yes. Again, there are on an</p> <p>3 80 percent and above report.</p> <p>4 Q. And I can look down here and</p> <p>5 I can -- I can pick the fourth one down.</p> <p>6 CVS 884647.</p> <p>7 Sir, tell me, what was their</p> <p>8 new business that --</p> <p>9 A. Which fourth one down are</p> <p>10 you at?</p> <p>11 Q. Go with -- just you pick</p> <p>12 one. Go ahead, pick one of the CVS</p> <p>13 numbers.</p> <p>14 A. Well, the fourth one down is</p> <p>15 7293.</p> <p>16 Q. Tell me, any new business</p> <p>17 documenting a threshold change request</p> <p>18 and increase to them, sir?</p> <p>19 A. I cannot tell from this</p> <p>20 report because I didn't make this</p> <p>21 adjustment.</p> <p>22 Q. Every single one on this</p> <p>23 form, like every single one attached, was</p> <p>24 a CVS store that was over 80 percent of</p>

Page 486	Page 488
<p>1 their threshold for the month. True?</p> <p>2 A. Yes. They were over</p> <p>3 80 percent.</p> <p>4 Q. And the same reason is</p> <p>5 stated for every single one of them.</p> <p>6 "For now, consider these reasonable."</p> <p>7 Correct?</p> <p>8 A. That was the reason given on</p> <p>9 the document. Yes.</p> <p>10 Q. Sir, what you had going on</p> <p>11 here was a system whereby you preapproved</p> <p>12 every single CVS pharmacy that got to</p> <p>13 within 80 percent of their threshold</p> <p>14 automatically without them even asking,</p> <p>15 that's what the agreement with CVS was,</p> <p>16 true?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: I'm not aware</p> <p>20 of that agreement, that if they</p> <p>21 reached 80 percent they would be</p> <p>22 increased. I'm not aware of</p> <p>23 that -- that...</p> <p>24 BY MR. KENNEDY:</p>	<p>1 Q. Wouldn't that be contrary to</p> <p>2 everything you folks agreed to, a</p> <p>3 pre-agreement with CVS?</p> <p>4 MS. HENN: Objection to</p> <p>5 form.</p> <p>6 THE WITNESS: The business</p> <p>7 reason for these increases is what</p> <p>8 would need to be known. Whether</p> <p>9 or not the store had an increase</p> <p>10 in business overall and,</p> <p>11 therefore, they needed certain</p> <p>12 base codes increased.</p> <p>13 BY MR. KENNEDY:</p> <p>14 Q. What is the business reason?</p> <p>15 A. There's no reason --</p> <p>16 MS. HENN: Counsel.</p> <p>17 THE WITNESS: There is no</p> <p>18 reason here.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. There is no reason, is</p> <p>21 there?</p> <p>22 A. There's no business reason</p> <p>23 explained in this document, so.</p> <p>24 Q. And every one of those</p>
<p>1 Q. So we just went through</p> <p>2 probably 60 CVSs.</p> <p>3 A. Mm-hmm.</p> <p>4 Q. All of them appear in the</p> <p>5 80 percent list.</p> <p>6 A. Mm-hmm.</p> <p>7 Q. All of them are getting a</p> <p>8 15 percent increase for the same reason,</p> <p>9 "For now, consider these reasonable."</p> <p>10 And you're telling me there</p> <p>11 was no special agreement with CVS to</p> <p>12 automatically increase any single one of</p> <p>13 their stores that hit the 80 percent</p> <p>14 list?</p> <p>15 A. I'm not aware of any</p> <p>16 agreement, no.</p> <p>17 Q. That would be inappropriate.</p> <p>18 That would be contrary to everything you</p> <p>19 agreed to do with respect to monitoring</p> <p>20 the flow of opioids in our community,</p> <p>21 would it not?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 BY MR. KENNEDY:</p>	<p>1 increases happened the same day the</p> <p>2 request was made, true, every one we</p> <p>3 looked at?</p> <p>4 A. Our program --</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Every one we looked at?</p> <p>9 A. Our program, when a request</p> <p>10 would come in, we would look at the</p> <p>11 customers, go in through the McKesson</p> <p>12 system, and review their purchases. It</p> <p>13 doesn't take long to review the</p> <p>14 customers' purchases. Their history of</p> <p>15 what it is they are buying, looking at</p> <p>16 any omissions. And so to make a threshold</p> <p>17 change within the same day is not out of</p> <p>18 the ordinary during our review.</p> <p>19 MR. KENNEDY: What -- give</p> <p>20 me 5037, please.</p> <p>21 MS. ROZMAN: MCK Oriente</p> <p>22 564.</p> <p>23 (Document marked for</p> <p>24 identification as Exhibit</p>
Page 487	Page 489

Page 490	Page 492
<p>1 MCK-Oriente-564.)</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. Sir, this exhibit is -- this</p> <p>4 is an e-mail from Tom McDonald dated May</p> <p>5 31, 2011. Do you see that?</p> <p>6 A. Yes.</p> <p>7 Q. And it's to a whole group of</p> <p>8 McKesson people. Do you recognize any of</p> <p>9 those people?</p> <p>10 A. Let me -- just give me a</p> <p>11 minute to read this. I recognize some as</p> <p>12 DC, distribution center managers or</p> <p>13 directors --</p> <p>14 Q. Does it state there --</p> <p>15 A. -- of operations.</p> <p>16 Q. I'm sorry. The subject is</p> <p>17 state high percentage threshold</p> <p>18 customers?</p> <p>19 A. Yeah, high percentage to</p> <p>20 threshold customers. So at the end of</p> <p>21 the month, these -- these people are</p> <p>22 approaching their threshold.</p> <p>23 Q. And does he --</p> <p>24 A. Can I have a minute to read</p>	<p>1 This 10 percent buffer allowed for</p> <p>2 unusual (sic) fluctuations from month to</p> <p>3 month. That being said, we will need to</p> <p>4 make periodic adjustments to accounts as</p> <p>5 they grow their business. Customers at</p> <p>6 or near 100 percent on the last day of</p> <p>7 that month should be reviewed and a</p> <p>8 determination should be made to adjust up</p> <p>9 10 percent if required."</p> <p>10 Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Now, you're supposed to</p> <p>13 be --</p> <p>14 MS. HENN: Counsel, there is</p> <p>15 one correction. I think there was</p> <p>16 a -- you said "unusual" when the</p> <p>17 word was "usual."</p> <p>18 MR. KENNEDY: All right.</p> <p>19 MS. HENN: It says,</p> <p>20 "10 percent buffer used for usual</p> <p>21 corrections from month to month."</p> <p>22 Slight correction.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Is he talking about making</p>
<p>1 this?</p> <p>2 MS. HENN: Yes, you may.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Well, I'm going to read it</p> <p>5 through with you. We're going to read</p> <p>6 every single word. We can do that</p> <p>7 together or you can read it and then</p> <p>8 we'll read it together. But I'm going to</p> <p>9 read every word of it. All right.</p> <p>10 A. Sure, go ahead.</p> <p>11 Q. Does it state West -- so</p> <p>12 he's probably talking to his whole</p> <p>13 region. "I generally do not run the</p> <p>14 threshold warning report on the last day</p> <p>15 of the month. However, I believe there</p> <p>16 is a use for this practice. Attached is</p> <p>17 the report at 90 percent and greater ran</p> <p>18 this morning. I suggest you review this</p> <p>19 document. We originally set up</p> <p>20 thresholds in 2008 based upon an existing</p> <p>21 customer's 12-month usage number on a</p> <p>22 particular base code. We then took the</p> <p>23 highest month of that year and added</p> <p>24 10 percent to establish a threshold base.</p>	<p>1 10 percent adjustment up on any customer</p> <p>2 that gets to 90 percent of their</p> <p>3 threshold, sir?</p> <p>4 A. Okay. You're asking me</p> <p>5 to --</p> <p>6 Q. Let's read that last</p> <p>7 statement. "Customers at" --</p> <p>8 A. -- determine what -- you</p> <p>9 asked me a question, sir.</p> <p>10 Q. Let me read it back to you</p> <p>11 and then I'll ask you again, sir.</p> <p>12 "Customers at or near</p> <p>13 100 percent of the last day of the month</p> <p>14 should be reviewed and a determination</p> <p>15 should be made to adjust up by 10 percent</p> <p>16 if required?"</p> <p>17 My question to you is, sir:</p> <p>18 Does this sound like an approach, does</p> <p>19 this sound like an atmosphere or a</p> <p>20 culture where you folks at regulatory are</p> <p>21 monitoring a program to limit the amount</p> <p>22 of opioids going into our communities or</p> <p>23 you are trying to sell more opioids.</p> <p>24 What does that sound like to you?</p>

Page 494	Page 496
<p>1 MS. HENN: Objection to 2 form.</p> <p>3 THE WITNESS: What you're 4 asking me to -- my opinion here on 5 Tom's comments is review these 6 customers, determine if their 7 business is growing. If so, 8 submit those for regulatory 9 review. It doesn't mean they are 10 going to get it.</p> <p>11 It's not -- it's not a 12 rubber stamp that they would be 13 approved. It's, they can review 14 these customers and determine, 15 because thresholds are stagnant, 16 or they were stagnant. They were 17 locked in. And if a business is 18 increasing, they are going to hit 19 that threshold or be, as Tom puts 20 here, near 100 percent. And so 21 being proactive to do a review is 22 what Tom is saying.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. He's talking about making</p>	<p>1 that probability really small. You keep 2 increasing those thresholds. Then 3 pharmacies don't exceed their thresholds. 4 And then pharmacies don't have a Level 1 5 review and investigation triggered, 6 correct?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. Because they only trigger an 11 investigation if they exceed their 12 thresholds, true?</p> <p>13 MS. HENN: Objection to 14 form.</p> <p>15 BY MR. KENNEDY:</p> <p>16 Q. Is that true, sir?</p> <p>17 A. In -- back in that time 18 frame, they would need to have an omit in 19 order to go to a Level 1 review.</p> <p>20 Q. Which probably explains why 21 everything we talked about this morning, 22 you folks not reporting suspicious 23 orders. Because if you keep raising 24 thresholds, then people don't exceed</p>
<p>1 threshold requests without the customers 2 even asking. He's saying look at -- look 3 at the reports. If they are within 4 90 percent, maybe we don't even call 5 them.</p> <p>6 A. No, you're assuming that.</p> <p>7 Q. Let's -- I want to put this 8 in context, why we keep talking about 9 these thresholds.</p> <p>10 If you keep raising 11 thresholds you're going to sell more 12 opioids, right? That's -- that's real 13 clear. You keep raising thresholds, 14 you're selling more opioids, true?</p> <p>15 A. A higher threshold would 16 permit more opioids to be sold, yes.</p> <p>17 Q. And if you keep raising 18 thresholds, pharmacies aren't going to 19 exceed their thresholds, correct?</p> <p>20 A. Not necessarily. They could 21 still try to exceed them if they are 22 growing at a faster pace than what our 23 increase was.</p> <p>24 Q. But you're going to make</p>	<p>1 their thresholds. And if they don't 2 exceed their thresholds, they don't get 3 investigated. If they don't get 4 investigated, there is no suspicious 5 orders, and if there's no suspicious 6 orders, then you're not reporting 7 anything to the FDA, sir. And then 8 opioids are pouring into our community, 9 sir. That's right, isn't it? What I 10 just said is right?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: No. You said 14 FDA, sir.</p> <p>15 BY MR. KENNEDY:</p> <p>16 Q. Excuse me.</p> <p>17 A. DEA.</p> <p>18 Q. Other than FDA or DEA, what 19 I just said is right.</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: The process 23 that you explained, if -- if it 24 took place in that manner would be</p>

Page 498	Page 500
<p>1 correct.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. And, sir --</p> <p>4 A. As all the documents that</p> <p>5 you've shown me here, and that process, I</p> <p>6 would just like to say that those were</p> <p>7 not in the responsibility of the area</p> <p>8 that I worked. These are in the West,</p> <p>9 and in the North Central. So, you know,</p> <p>10 you're -- you're asking me just on</p> <p>11 processes that I did not do in my region.</p> <p>12 Q. With these threshold</p> <p>13 requests, sir, McKesson did everything</p> <p>14 they could possibly do with sales right</p> <p>15 in the middle of it to increase the</p> <p>16 thresholds so there would be no</p> <p>17 investigations, so there would be no</p> <p>18 suspicious orders, so there's nothing</p> <p>19 getting reported to the DEA and opioids,</p> <p>20 narcotics are pouring into our community,</p> <p>21 sir, correct?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 THE WITNESS: No, I would</p>	<p>1 A. Oh yes. Yes.</p> <p>2 Q. Have you ever seen this</p> <p>3 before?</p> <p>4 A. I don't recall seeing this</p> <p>5 exact document. I do know that the</p> <p>6 Aurora DC I believe had to show cause.</p> <p>7 Q. All right. Go to page 12,</p> <p>8 if you would. Do you see that top</p> <p>9 paragraph. You see the top paragraph on</p> <p>10 Page 12?</p> <p>11 A. Yes, sir.</p> <p>12 Q. This is the Department of</p> <p>13 Justice, writing, writing to McKesson's</p> <p>14 lawyers, all right?</p> <p>15 A. Yes, sir.</p> <p>16 Q. They say, "Second, McKesson</p> <p>17 Aurora routinely manipulated thresholds.</p> <p>18 It would often preemptively increase</p> <p>19 thresholds of its customers on particular</p> <p>20 drugs before the customers even submitted</p> <p>21 a threshold change request seeking a</p> <p>22 threshold increase." Do you see that?</p> <p>23 A. I see that written here,</p> <p>24 yes.</p>
<p>1 find that not to be correct, sir.</p> <p>2 MR. KENNEDY: Give me 5043</p> <p>3 please.</p> <p>4 MS. ROZMAN: Which is MCK</p> <p>5 Oriente 570.</p> <p>6 (Document marked for</p> <p>7 identification as Exhibit</p> <p>8 MCK-Oriente-570.)</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. Sir, this is a -- this is a</p> <p>11 letter from the United States Department</p> <p>12 of -- Department of Justice dated</p> <p>13 August 13, 2014. Correct?</p> <p>14 A. Yes.</p> <p>15 Q. And it is sent to attorneys</p> <p>16 representing McKesson. Is that what it</p> <p>17 indicates? Covington & Burling LLP in</p> <p>18 Washington D.C. Do you see that?</p> <p>19 A. Yes.</p> <p>20 Q. And this relation -- in all</p> <p>21 fairness, it relates to the Aurora</p> <p>22 distribution center. Do you see that?</p> <p>23 A. Where does it say Aurora?</p> <p>24 Q. First paragraph.</p>	<p>1 Q. That's what we've been</p> <p>2 talking about, right? In all parts of</p> <p>3 the country, that's what we've just been</p> <p>4 talking about for the last two hours,</p> <p>5 right?</p> <p>6 A. When -- when you said all</p> <p>7 different parts of the country, sir. Not</p> <p>8 in my part of the country.</p> <p>9 Q. Let's go down, sir. "Time</p> <p>10 and time again, McKesson Aurora increased</p> <p>11 a customer's threshold in a particular</p> <p>12 month so that customer did not exceed</p> <p>13 that threshold and thus trigger McKesson</p> <p>14 Aurora's obligation to conduct a Level 2</p> <p>15 or 3 review." Do you see that?</p> <p>16 A. I do see that written here,</p> <p>17 yes.</p> <p>18 Q. And that's exactly what</p> <p>19 we've been talking about the last couple</p> <p>20 hours, right?</p> <p>21 MS. HENN: Objection to</p> <p>22 form.</p> <p>23 THE WITNESS: That is what</p> <p>24 you've pointed out. Yes.</p>

Page 502	Page 504
<p>1 BY MR. KENNEDY:</p> <p>2 Q. And the third it says,</p> <p>3 "McKesson Aurora was often willing to</p> <p>4 increase a pharmacy's threshold for the</p> <p>5 flimsiest of reasons and without adequate</p> <p>6 investigation." Do you see that, sir?</p> <p>7 A. Yes.</p> <p>8 Q. Things like Thanksgiving,</p> <p>9 right, things like end-of-the-year</p> <p>10 increase, right, sir, things like because</p> <p>11 we consider this reasonable or things</p> <p>12 like Mr. Catton from sales says this is</p> <p>13 reasonable. Flimsy, flimsy reasons.</p> <p>14 MS. HENN: Objection to</p> <p>15 form. And I'd just like to note</p> <p>16 to the people on the phone,</p> <p>17 there's somebody without their</p> <p>18 mute button on, and if everyone</p> <p>19 could just make sure you are on</p> <p>20 mute, we would appreciate it.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. You see, sir, that's what</p> <p>23 we've been talking about, right? That's</p> <p>24 what we've been talking about.</p>	<p>1 suspicious order. The Level 1 review.</p> <p>2 True?</p> <p>3 A. The Level 1 was initiated</p> <p>4 when a customer would have an omit. It</p> <p>5 doesn't mean it's necessarily suspicious.</p> <p>6 Q. Now we're going to -- we're</p> <p>7 going to -- I'm -- I'm -- we're going to</p> <p>8 go back because we need to -- we need to</p> <p>9 kind of follow the protocol rules.</p> <p>10 A. Mm-hmm.</p> <p>11 Q. You listen very careful to</p> <p>12 my question. My question is real simple.</p> <p>13 Level 1 reviews. That was</p> <p>14 the first step in the investigation as to</p> <p>15 whether or not an order was suspicious.</p> <p>16 Correct?</p> <p>17 MS. HENN: Objection to</p> <p>18 form. You can answer.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. That's the first step. It</p> <p>21 gets triggered --</p> <p>22 A. Yes, when an omit occurs --</p> <p>23 yes.</p> <p>24 Q. -- when a customer orders</p>
<p>1 A. Yes. Some -- some of the</p> <p>2 reasons that you pointed out were not as</p> <p>3 strong as they could have been.</p> <p>4 Q. Well, their reasoning -- I'm</p> <p>5 sorry --</p> <p>6 MS. HENN: Counsel. I just</p> <p>7 want to make sure he has a chance</p> <p>8 to finish.</p> <p>9 MR. KENNEDY: Go ahead. I'm</p> <p>10 so sorry.</p> <p>11 BY MR. KENNEDY:</p> <p>12 Q. Go ahead, sir.</p> <p>13 A. That the reasons were not as</p> <p>14 strong as they could have been. Again,</p> <p>15 the request could come from sales who has</p> <p>16 spoken with the customer and they are</p> <p>17 conveying the message. It didn't come</p> <p>18 from the customer to regulatory. It went</p> <p>19 through sales. That was the -- that was</p> <p>20 the program.</p> <p>21 Q. So let me ask you. Let's</p> <p>22 talk about these Level 1 reviews real</p> <p>23 quick. Level 1 reviews. That is the</p> <p>24 first step in identifying, recognizing a</p>	<p>1 over the threshold, right?</p> <p>2 A. Yes.</p> <p>3 Q. But if you keep raising</p> <p>4 thresholds, nobody ever orders over the</p> <p>5 threshold. We've been through that,</p> <p>6 correct?</p> <p>7 A. Correct.</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 BY MR. KENNEDY:</p> <p>11 Q. But Level 1 is the first</p> <p>12 level investigation to determine whether</p> <p>13 or not the order is suspicious, true?</p> <p>14 A. Yes.</p> <p>15 MR. KENNEDY: Now, give me</p> <p>16 5036.</p> <p>17 BY MR. KENNEDY:</p> <p>18 Q. I'm going to look at what</p> <p>19 McKesson agreed to in the DEA 2008</p> <p>20 settlement agreement with respect to</p> <p>21 reviewing customers that ordered over</p> <p>22 their threshold. All right?</p> <p>23 MS. ROZMAN: That's MCK</p> <p>24 Oriente 563.</p>

Page 506	Page 508
<p>1 (Document marked for 2 identification as Exhibit 3 MCK-Oriente-563.)</p> <p>4 MS. HENN: And we will need 5 a break relatively soon if there 6 is a good spot to stop.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Do you see that, Page 1?</p> <p>9 A. Mm-hmm.</p> <p>10 Q. This is the settlement 11 agreement between the Department of 12 Justice and the DEA and McKesson. True?</p> <p>13 A. Yes. Yes.</p> <p>14 Q. All right. And this says, 15 "This agreement is applicable to all of 16 McKesson's distribution centers," right, 17 when it says, "DEA registered 18 facilities." True?</p> <p>19 A. Yes.</p> <p>20 Q. If you go to Page .3. See 21 where it says terms and conditions?</p> <p>22 A. Yes, sir.</p> <p>23 Q. And it says obligations of 24 McKesson?</p>	<p>1 DEA, or II, based upon a detailed review, 2 the order is for a legitimate purpose and 3 the controlled substances are not likely 4 to be diverted into other than legitimate 5 medical, scientific or industrial 6 channels."</p> <p>7 Do you see that?</p> <p>8 A. Yes.</p> <p>9 Q. So you're agreeing that if a 10 customer orders over their threshold that 11 we've been talking about, McKesson is 12 going to have somebody in place, it was 13 your Level 1, that's the start, you're 14 going to have somebody in place that's 15 been trained, that has been trained to 16 detect suspicious orders for the purposes 17 of determining whether such orders are 18 legitimate, whether they are being 19 diverted into -- or not being diverted 20 and only being used for legitimate 21 scientific, medical, and industrial 22 channels. That's what you agreed to.</p> <p>23 MS. HENN: Objection to 24 form.</p>
Page 507	Page 509
<p>1 A. Yes.</p> <p>2 Q. And this is what McKesson 3 agreed to with the United States 4 government, right?</p> <p>5 A. Yes.</p> <p>6 Q. And this is after the 7 payment of a \$13 million fine, true?</p> <p>8 A. Yes.</p> <p>9 Q. And it states under McKesson 10 obligations, "A, McKesson agrees to 11 maintain a compliance program designed to 12 detect and prevent diversion of 13 controlled substances as required under 14 the CSA and applicable DEA regulations. 15 "This program shall include 16 procedures to review orders for 17 controlled substances."</p> <p>18 This is the important part: 19 "Orders that exceed established 20 thresholds and criteria will be reviewed 21 by a McKesson employee trained to detect 22 suspicious orders for the purposes of 23 determining whether, I, such orders 24 should not be filled and reported to the</p>	<p>1 BY MR. KENNEDY:</p> <p>2 Q. Correct?</p> <p>3 A. That -- that is what 4 McKesson agreed to, yes.</p> <p>5 Q. Now, sir, McKesson, the 6 program that you set up, would I be 7 correct that you got a customer, let's 8 say OxyContin, let's say OxyContin, 9 they've reached their threshold. And 10 that's a dangerous drug, right?</p> <p>11 OxyContin is a dangerous drug. It's in 12 the middle of this crisis, correct?</p> <p>13 A. If it's not used in it -- as 14 prescribed, yes, it's a dangerous drug.</p> <p>15 Q. So I've got a customer and 16 they order over their threshold for 17 OxyContin. That triggers a Level 1 18 review.</p> <p>19 McKesson had salespeople. 20 You had salespeople doing your Level 1 21 reviews. Salespeople, sir.</p> <p>22 A. I'm not aware of salespeople 23 doing Level 1 reviews.</p> <p>24 MS. HENN: Objection to</p>

Page 510	Page 512
<p>1 form.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. Sir --</p> <p>4 A. Customer service -- again,</p> <p>5 sir, I can only speak for my region and I</p> <p>6 know in my distribution centers --</p> <p>7 MR. KENNEDY: 5030 please.</p> <p>8 MS. HENN: Are you done with</p> <p>9 your answer?</p> <p>10 THE WITNESS: No.</p> <p>11 In my region, sir, customer</p> <p>12 service people at the distribution</p> <p>13 center would make calls to the</p> <p>14 customer and go through that list,</p> <p>15 one, Level 1 excuse me, Level 1</p> <p>16 review.</p> <p>17 MS. ROZMAN: This is MCK</p> <p>18 Oriente 559.</p> <p>19 (Document marked for</p> <p>20 identification as Exhibit</p> <p>21 MCK-Oriente-559.)</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Sir, what we're showing you</p> <p>24 here is Exhibit 559, that's a Level 1</p>	<p>1 yes.</p> <p>2 Q. Sales. Let's look at the</p> <p>3 second page.</p> <p>4 A. I can only comment on what I</p> <p>5 know and in my area that I know. Sales</p> <p>6 do not do Level 1s.</p> <p>7 Q. Let's look at the second</p> <p>8 page. We'll go quick. Second page.</p> <p>9 8/20/08. Got another sales manager doing</p> <p>10 a Level 1 investigation, correct, another</p> <p>11 sales manager doing another</p> <p>12 investigation. Correct?</p> <p>13 A. Yes. This was at the Denver</p> <p>14 DC. Again, it looks like they were using</p> <p>15 account managers to assist with Level 1s.</p> <p>16 Q. Let's go to the next page.</p> <p>17 11/25/09. Kealey Pharmacy. Matt Lange,</p> <p>18 regional sales manager. He is doing the</p> <p>19 investigation, right?</p> <p>20 A. Yeah, 8144. I'm not sure of</p> <p>21 which distribution center that is, but</p> <p>22 it's not one of mine again, sir.</p> <p>23 Q. Next page.</p> <p>24 A. Next one. Retail sales</p>
<p>1 documentation form. Is it not?</p> <p>2 A. Observation Level 1</p> <p>3 documentation form. Yes. Out of the</p> <p>4 Denver distribution center. Again, not</p> <p>5 in my area for me to know about.</p> <p>6 Q. This form is used across the</p> <p>7 country -- this form is used across the</p> <p>8 country, is it not? This is a standard</p> <p>9 form used across the country?</p> <p>10 A. Yes, sir.</p> <p>11 Q. We see here on a Level 1</p> <p>12 investigation dated 5/25/08. Do you see</p> <p>13 that?</p> <p>14 A. Mm-hmm, yes, sir.</p> <p>15 Q. For Carl's Pharmacy, which</p> <p>16 means they breached their threshold</p> <p>17 because we are at a Level 1. And Dave</p> <p>18 Grushey, an account manager, did the</p> <p>19 investigation?</p> <p>20 A. In this case, yes, he did do</p> <p>21 it. Again, sir, this is not in my area.</p> <p>22 Q. He is a part of sales,</p> <p>23 right?</p> <p>24 A. He's an account manager,</p>	<p>1 manager Washington Courthouse. That</p> <p>2 would be a Dave Gustin.</p> <p>3 Q. And that's February 24th,</p> <p>4 right? That's in the Midwest, right?</p> <p>5 A. North Central, sir.</p> <p>6 Q. North Central.</p> <p>7 Next page. .5. 2/19/10.</p> <p>8 We've got another regional sales manager</p> <p>9 doing a Level 1 investigation to look for</p> <p>10 suspicious order, right? Is that right?</p> <p>11 A. Doing the -- doing the</p> <p>12 Level 1 to find out from the customer why</p> <p>13 they omitted.</p> <p>14 Q. All right. Now we've got</p> <p>15 a --</p> <p>16 A. And that was, again, Dave</p> <p>17 Gustin's North Central Chicago DC.</p> <p>18 Q. Go to the next page, .6.</p> <p>19 We've got another sales manager on 12/29,</p> <p>20 correct?</p> <p>21 A. Yes. Again, the North</p> <p>22 Central DC.</p> <p>23 Q. Now we go to the next page.</p> <p>24 We've got another sales manager, right,</p>

Page 514	Page 516
<p>1 on 6/30/09, right?</p> <p>2 A. Yes. On this one the DC is</p> <p>3 listed as 1844, but I believe they mean</p> <p>4 8144.</p> <p>5 Q. Where is that?</p> <p>6 A. 8144 is North Central. Dave</p> <p>7 Gustin's area again.</p> <p>8 Q. Next one we got 1/14/10.</p> <p>9 Another regional sales manager doing a</p> <p>10 Level 1 investigation. Is that right,</p> <p>11 sir?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: It is correct.</p> <p>15 Again, not in my area of</p> <p>16 responsibility of the Northeast,</p> <p>17 sir.</p> <p>18 BY MR. KENNEDY:</p> <p>19 Q. Sir, sir, can we agree here</p> <p>20 and have an understanding that sales</p> <p>21 folks, sales folks at McKesson, they have</p> <p>22 a financial interest in the outcome of a</p> <p>23 Level 1 investigation, true?</p> <p>24 A. They are obtaining the</p>	<p>1 THE WITNESS: I'm not -- I'm</p> <p>2 not familiar with the sales</p> <p>3 retention policies. I'm not in</p> <p>4 sales, sir. I don't get involved</p> <p>5 with that.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. Sales is all through your</p> <p>8 program. Sales is at every single aspect</p> <p>9 of this controlled substances monitoring</p> <p>10 program. They are calling the customers</p> <p>11 to ask them if they want to increase</p> <p>12 their thresholds. They are doing Level 1</p> <p>13 reviews, sir. They are providing the</p> <p>14 information for the onboarding, the</p> <p>15 beginning of the process, as to whether</p> <p>16 or not you are going to sell these folks</p> <p>17 opioids, and you don't know their</p> <p>18 compensation package?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: No, sir, I</p> <p>22 don't know their compensation</p> <p>23 package.</p> <p>24 BY MR. KENNEDY:</p>
<p>1 information here on a Level 1. It would</p> <p>2 go to a Level 2 and 3 that the regulatory</p> <p>3 director would be responsible for.</p> <p>4 Q. Can you answer my question?</p> <p>5 A. Yeah.</p> <p>6 Q. My question is real simple.</p> <p>7 A. Okay.</p> <p>8 Q. A salesperson at McKesson</p> <p>9 has a financial interest in the outcome</p> <p>10 of a Level 1 investigation of one of your</p> <p>11 customers. Is that true, sir?</p> <p>12 A. They could because of the</p> <p>13 compensation package which again I'm not</p> <p>14 totally familiar with because I'm not in</p> <p>15 sales.</p> <p>16 Q. Well, let me -- just -- it's</p> <p>17 more than that. Number one, your</p> <p>18 salespeople got a bonus for retention of</p> <p>19 customers, correct? If they could retain</p> <p>20 all the customers in their region for a</p> <p>21 one-year period, they got a</p> <p>22 thousand-dollar bonus, did they not, sir?</p> <p>23 MS. HENN: Objection to</p> <p>24 form.</p>	<p>1 Q. Are you disagreeing with me</p> <p>2 when I tell you that they got paid a</p> <p>3 bonus if they could retain all of the</p> <p>4 customers each year?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 THE WITNESS: I'm not</p> <p>8 disagreeing with you. I'm saying</p> <p>9 I am not aware of it. It has</p> <p>10 no --</p> <p>11 MR. KENNEDY: 5035, please.</p> <p>12 THE WITNESS: It has no</p> <p>13 determination on my decision when</p> <p>14 I made them working on my</p> <p>15 customers in the Northeast in</p> <p>16 regulatory.</p> <p>17 MS. HENN: Counsel, is this</p> <p>18 a good time for a break? We've</p> <p>19 been going about an hour and</p> <p>20 20 minutes.</p> <p>21 I'm going to just ask for a</p> <p>22 break. Thank you.</p> <p>23 MR. KENNEDY: Yeah, that's</p> <p>24 fine.</p>
Page 515	Page 517

Page 518	Page 520
<p>1 THE VIDEOGRAPHER: Stand by 2 please. Remove your microphones. 3 The time is 5:40 p.m. Off the 4 record.</p> <p>5 (Short break.)</p> <p>6 THE VIDEOGRAPHER: We are 7 back on the record. The time is 8 4:56 p.m.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. All right, Mr. Oriente. We 11 just asked to take a look at 5035 if we 12 could.</p> <p>13 MS. ROZMAN: Which is MCK 14 Oriente 562.</p> <p>15 (Document marked for 16 identification as Exhibit 17 MCK-Oriente-562.)</p> <p>18 MS. HENN: 562 you said?</p> <p>19 MS. ROZMAN: Yeah. Here --</p> <p>20 MS. HENN: Oh, this is new?</p> <p>21 MS. ROZMAN: Yeah.</p> <p>22 THE WITNESS: Thank you.</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. And you had indicated that</p>	<p>1 A. Yes.</p> <p>2 Q. "The more customers you have 3 enrolled in the programs and maintained 4 participation within your territory, the 5 more commission dollars you earn." Do 6 you see that?</p> <p>7 A. Yes.</p> <p>8 Q. Finally it says, "We ask the 9 retail compensation council to guide the 10 development of a compensation plan that 11 rewards you for sales results, and I'm 12 pleased to announce that we've increased 13 the total annualized target payout." Do 14 you see that?</p> <p>15 A. Yes.</p> <p>16 Q. And can we agree, sir, that 17 if you tell a customer that one of their 18 orders is suspicious and you refused to 19 ship them controlled substances, and you 20 report them to the DEA, that you're not 21 going to maintain a good sales 22 relationship with that customer?</p> <p>23 MS. HENN: Objection to 24 form.</p>
Page 519	Page 521
<p>1 you didn't really know and understand how 2 the salespeople were compensated at 3 McKesson, is that right?</p> <p>4 A. That is correct. I didn't 5 get involved with compensation plans for 6 sales.</p> <p>7 Q. Here is a memo to U.S. 8 pharmaceutical retail sales team. Do you 9 see that?</p> <p>10 A. Yes.</p> <p>11 Q. Dated April 1, 2010?</p> <p>12 A. Yes.</p> <p>13 Q. Talking about the 14 compensation plan. Do you see that?</p> <p>15 A. Yes.</p> <p>16 Q. And does it state, it's 17 highlighted, "Win new business. We 18 continue to emphasize on new accounts and 19 have raised the commission factor to 20 enrich the payouts."</p> <p>21 A. Yes, on new accounts.</p> <p>22 Q. Next bullet. "Prove our 23 value everyday and maintain 100 percent 24 customer retention." Do you see that?</p>	<p>1 BY MR. KENNEDY:</p> <p>2 Q. Would that be true?</p> <p>3 A. That is correct. And I 4 truly did not, in my region, have a good 5 relationship with our salespeople because 6 we had basically conflicting goals. They 7 were interested in sales and I was 8 interested in regulatory. So, you know, 9 there were salespeople that didn't like 10 my decisions, but they had to live with 11 them because I had the final say.</p> <p>12 MR. KENNEDY: Can you read 13 back the question.</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. I want you to listen to the 16 question and I want you to try to answer 17 my question as opposed to giving speeches 18 about what you want to talk about. Is 19 that agreeable?</p> <p>20 MS. HENN: Counsel.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. So I'm going to read back 23 the question and you try to answer it 24 again.</p>

Page 522	Page 524
<p>1 MR. KENNEDY: Go ahead, 2 please. 3 (Whereupon, the court 4 reporter read back the requested 5 portion of testimony.) 6 BY MR. KENNEDY: 7 Q. Do you agree with that 8 statement, sir? 9 A. Yes. 10 Q. Go back for a second. I 11 want to still talk about these Level 1 12 reviews if we could. 13 MR. KENNEDY: Go back to 14 5036. I want to -- 15 MS. HENN: 5036? 16 MR. KENNEDY: Yes, 5036 17 which is Exhibit 563. 18 BY MR. KENNEDY: 19 Q. This is the agreement that 20 you made with the FDA. Again, I think 21 it's Page 12. 22 MS. HENN: DEA, counsel. 23 BY MR. KENNEDY: 24 Q. Yeah. This is the agreement</p>	<p>1 The red line, orders that 2 exceed thresholds, it says, "Establish 3 thresholds and criteria, will be reviewed 4 by a McKesson trained to detect 5 suspicious orders for the purposes of 6 determining whether, I, such orders 7 should be not filled and reported to the 8 DEA, or II, based upon a detailed review 9 the order is for a legitimate purpose and 10 the controlled substances are not likely 11 to be diverted into other than legitimate 12 scientific or industrial channels." 13 Now, from what you've told 14 me, and from what the CEO from your 15 company told Congress, you took this 16 seriously, right, this is important. 17 You're reviewing folks that have gotten 18 above their threshold or ordered above 19 their threshold, correct? 20 A. They ordered above, but did 21 not receive above their threshold, yes. 22 Q. And Level 1 reviews, 23 according to your protocol, sir, they 24 were being done by warehouse managers,</p>
<p>1 with the DEA in 2008. And we're back to 2 the obligations. 3 It's right up on the board 4 if... 5 MS. HENN: Do you have the 6 document? 7 THE WITNESS: Yeah, but 8 it's page -- 563 -- 9 MR. KENNEDY: I'm sorry, 10 Page 3. 11 THE WITNESS: -- only has 11 12 pages, so it can't be on Page 12. 13 MS. HENN: Page 3. 14 THE WITNESS: Okay. Thank 15 you. 16 BY MR. KENNEDY: 17 Q. Page 3. 18 A. Okay. 19 Q. This is the agreement again. 20 This is your -- McKesson's agreement with 21 the DEA in 2008 after paying the 22 \$13 million fine. This is what they 23 agreed with respect to reviewing folks 24 that went over the thresholds.</p>	<p>1 were they not? 2 MS. HENN: Objection to 3 form. 4 BY MR. KENNEDY: 5 Q. Inventory managers, were 6 they not? 7 A. Not in my region. They were 8 done by customer service people in the 9 office. 10 MR. KENNEDY: Need 5044 11 please. 12 BY MR. KENNEDY: 13 Q. Customer service folks? 14 A. Yeah. 15 Q. Those are salespeople you 16 told us? 17 A. Not necessarily. In the 18 distribution center they have nothing to 19 do with sales. They are customer 20 service. They handle delivery issues. 21 They handle customer concerns. But they 22 are not in the sales department. 23 Q. Let's look at Exhibit 571. 24 MS. ROZMAN: It's identified</p>

Page 526	Page 528
<p>1 as MCK Oriente 571. 2 (Document marked for 3 identification as Exhibit 4 MCK-Oriente-571.) 5 BY MR. KENNEDY: 6 Q. So I want to ask you, we 7 want to look at how serious you were 8 taking these Level 1 reviews. The first 9 step in identifying suspicious orders. 10 Do you see this, this is Exhibit 571. 11 CSMP, controlled substances monitoring 12 program observation Level 1 documentation 13 form. Do you see that? 14 A. Yes, sir. 15 Q. And this Level 1 review on 16 3/20/09 was done by the inventory 17 manager, is that right? 18 A. Yes, this one was done by a 19 DC inventory manager out of the West 20 region. 21 Q. And it was for oxycodone. 22 That drug is in the middle of this 23 crisis, is it not, sir? 24 A. Oxycodone is one of the</p>	<p>1 seriously. 2 MS. HENN: Objection to 3 form. 4 THE WITNESS: I would 5 disagree with that. Because in 6 the area that I was responsible 7 for, in the Northeast region, sir, 8 these actions did not take place 9 by warehouse managers. 10 So again, this is all in the 11 West that I had no responsibility 12 for, sir. 13 BY MR. KENNEDY: 14 Q. We're not going to go 15 through them all, sir. But time and time 16 again, we've got warehouse managers doing 17 Level 1 investigations of your customers, 18 sir. 19 And who did you say was 20 doing it in your place? 21 A. Customer service reps. 22 Q. Customer service reps. So 23 we got inventory managers doing Level 1 24 investigations, warehouse managers, and</p>
<p style="text-align: center;">Page 527</p> <p>1 drugs in this crisis, yes. 2 Q. Not just one of them, sir. 3 It's in the middle of the crisis. Right? 4 A. Well, I mean it -- I can't 5 say that oxycodone was any worse than 6 hydrocodone. They were -- You know, it 7 depends on the area of the country. 8 Q. Let's look at .2. Second 9 page. 10 We got another Level 1 11 investigation of a customer that has 12 exceeded their threshold on 3/31/10. Now 13 you've got a warehouse manager doing the 14 investigation for oxycodone. Is that 15 true, sir? 16 A. According to this document 17 it is, sir. 18 Q. Let's -- 19 A. Again, you are asking me 20 about a document I've never seen and 21 about a region I'm not responsible for. 22 Q. It was the culture at this 23 company, sir, it was the culture at this 24 company that you did not take monitoring</p>	<p style="text-align: center;">Page 529</p> <p>1 in your area you've got customer service 2 folks, is that right? 3 A. Yes, sir. Now. 4 Q. And -- 5 A. Go ahead. 6 Q. That's who is doing it where 7 you are? 8 A. Yes, but what I wanted to 9 say was warehouse managers and DC 10 inventory managers are not in sales, sir. 11 Q. Oh, I know, sir. That I 12 know. So we've got salespeople doing it, 13 inventory guys doing it, warehouse folks 14 doing it, and your folks were called 15 what? 16 A. Customer service. 17 Q. Customer service. Are those 18 folks even full-time employees? 19 A. Yes, sir. 20 Q. Let's change -- let me -- 21 let me ask you how serious these 22 investigations were at McKesson. 23 MR. KENNEDY: Give me 5039. 24 MS. ROZMAN: Identified as</p>

<p style="text-align: right;">Page 530</p> <p>1 MCK Oriente 566. 2 (Document marked for 3 identification as Exhibit 4 MCK-Oriente-566.) 5 BY MR. KENNEDY: 6 Q. This is an e-mail from Jake 7 Kramer. Who is Jake Kramer? 8 A. Jake Kramer was the 9 distribution manager in Denver 10 distribution center. 11 Q. He's sending an e-mail on 12 February 28, 2012 to Robert Perrich, 13 true? 14 A. Yes. I don't know what 15 position Robert Perrich held or holds. 16 Q. And its subject is, it says 17 omit report. That would mean this -- 18 this customer ordered over their 19 threshold, right? 20 A. The CSMP omit V report, yes, 21 would be for customers that ordered above 22 their threshold. 23 Q. Now, we are over the 24 threshold with a customer. We've</p>	<p style="text-align: right;">Page 532</p> <p>1 you? 2 MS. HENN: Objection to 3 form. 4 THE WITNESS: No, it doesn't 5 because you're not following 6 through on the rest of the review. 7 So a Level 1 is to gather the 8 reason why the customer omitted. 9 And in this case they are asking 10 him if he needs an adjustment. 11 The customer may say he needs an 12 adjustment. Regulatory would then 13 review that and not necessarily 14 make the increase based off of the 15 review. 16 MR. KENNEDY: Let's go to 17 5042. 18 MS. ROZMAN: MCK Oriente 19 569. 20 (Document marked for 21 identification as Exhibit 22 MCK-Oriente-569.) 23 BY MR. KENNEDY: 24 Q. Sir, this is an e-mail from</p>
<p style="text-align: right;">Page 531</p> <p>1 triggered a Level 1 review, correct? 2 A. It should have, yes. 3 Q. And what does he say here? 4 So now you've got somebody over their 5 threshold. We need to investigate. This 6 could be a suspicious order. And he says 7 here, "Can you call prescription shop and 8 see if they need an adjustment?" 9 That's an increase in the 10 threshold, right? Is that what that is? 11 A. He's calling them to see if 12 they need an adjustment and what is -- 13 what is the reason, if it's a Level 1, 14 what is the reason for the omit. 15 Q. And when he says, he says, 16 he's not talking about investigation. 17 His response to an order over the 18 threshold is to have somebody else call 19 the pharmacy and say hey, do you need us 20 to raise your threshold. It sounds like 21 a sales call, not a program that's been 22 put into place to monitor and control the 23 opioids going into our communities, 24 right? Isn't that what it sounds like to</p>	<p style="text-align: right;">Page 533</p> <p>1 Jake Kramer. And Jake Kramer again is 2 who? 3 A. Jake Kramer was the 4 distribution center manager in the Denver 5 distribution center. 6 Q. This is August 19, 2010. Do 7 you see that? 8 A. Yes. 9 Q. To John Schultz, right? Do 10 you know who John Schultz is? 11 A. I don't. 12 Q. What about cc'd to 13 Saltzgaber? 14 A. I don't know Kirk either. 15 Q. And it says subject sales 16 ride-along Southern Colorado. Right? 17 A. Yes. 18 Q. And he says, "John, below is 19 a list of must-see accounts." So those 20 would probably be pharmacies, correct? 21 A. Yes. 22 Q. "Their monthly thresholds 23 are at a level. I would like to visit 24 them again and see the business for</p>

Page 534	Page 536
<p>1 myself. They have, quote, 'absolutely 2 nothing to worry about.' But part of the 3 CSMP, our monitoring program, requires 4 that I visit accounts over a certain 5 threshold."</p> <p>6 So these folks are at a 7 Level 1 and he's assuring everybody, he's 8 going to visit them, but they've got 9 absolutely nothing to worry about. I 10 just need to do it because that's what 11 our monitoring program says. Is that 12 what's going on here?</p> <p>13 A. It doesn't --</p> <p>14 MS. HENN: Objection to form.</p> <p>15 THE WITNESS: It doesn't say 16 Level 1. It says their monthly 17 thresholds are at a level, I would 18 like to visit them. There is no 19 mention here of Level 1.</p> <p>20 BY MR. KENNEDY:</p> <p>21 Q. Do you think this is an 22 appropriate response and message and 23 culture, sir, that they've got absolutely</p>	<p>1 MS. ROZMAN: Identified as 2 MCK Oriente 567. 3 (Document marked for 4 identification as Exhibit 5 MCK-Oriente-567.)</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. This e-mail string --</p> <p>8 MS. HENN: Hang on. Sorry, 9 I haven't gotten it to him yet, 10 Counsel.</p> <p>11 THE WITNESS: Thank you.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Do you see the e-mail, it 14 starts at the bottom. The first e-mail 15 is from Tom McDonald to Jake Kramer. Who 16 is Tom McDonald?</p> <p>17 A. Tom McDonald is the director 18 of regulatory affairs, was the director 19 of regulatory affairs in the West region. 20 He now has responsibility for the SoCal 21 distribution center and Sacramento 22 distribution center. Two DCs only in the 23 West now.</p> <p>24 Q. Tom McDonald writes to Jake</p>
<p>1 nothing to worry about, that's what 2 you're telling your folks. Because I 3 just do it because --</p> <p>4 A. I can't speak for what --</p> <p>5 Q. -- that's what our program 6 says.</p> <p>7 MS. HENN: Objection to form.</p> <p>8 THE WITNESS: Yeah, I can't 9 speak for what Jake was saying 10 here.</p> <p>11 You know, he may have just 12 seen that they were approaching 13 their threshold and wanted to 14 visit them, because I know we made 15 a requirement that customers at a 16 certain level be visited and 17 that's what he's referring to.</p> <p>18 His wording that they have 19 absolutely nothing to worry about, 20 I don't know what he's basing that 21 off of.</p> <p>22 MR. KENNEDY: Give me 5040 23 please.</p>	<p>1 Page 535</p> <p>1 Kramer on September 26, 2012. He says, 2 "This is another one with a high 3 oxycodone ratio." What does that mean? 4 What does that high oxycodone ratio 5 means?</p> <p>6 A. That means that his 7 oxycodone purchases to his overall RX 8 purchases are at an elevated percentage.</p> <p>9 Q. And Jake Kramer, he 10 responds, "Everybody is high. Everybody 11 is high, Tom. Are we supposed to cut 12 everybody off?"</p> <p>13 A. My answer to that would be 14 yes.</p> <p>15 Q. That ain't what they did, is 16 it?</p> <p>17 A. I don't know what they did.</p> <p>18 MS. HENN: Objection to form.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. Are you even suggesting to 21 me that they cut anybody off?</p> <p>22 MS. HENN: Objection to form.</p>

Page 538	Page 540
<p>1 THE WITNESS: This was in 2 2012. I know that in 2013 myself 3 and my counterparts turned off 4 several customers that had a high 5 percentage of oxycodone.</p> <p>6 BY MR. KENNEDY:</p> <p>7 Q. So yeah, let's go back, now 8 that you bring up this 2013.</p> <p>9 2008, McKesson gets fined 10 \$13 million for not reporting suspicious 11 orders, correct?</p> <p>12 A. Yes.</p> <p>13 Q. Now, they say we're going to 14 change things around here. We're 15 changing it, we're putting in a new 16 program.</p> <p>17 And five years later, in 18 2013, now you're shutting programs down, 19 correct, now you're shutting folks down 20 and you're getting shut down in 2013.</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 THE WITNESS: I'm not aware 24 where we were shut down as far --</p>	<p>1 doing it right. And then in 2017, 2 \$150 million fine because you're still 3 not doing it right. And now we are in 4 2018. Is that the sequence of your 5 interactions with the DEA with respect to 6 their actions and their sanctions and 7 your fines, sir?</p> <p>8 MS. HENN: Objection to 9 form.</p> <p>10 THE WITNESS: I believe 11 there were two fines paid by 12 McKesson. So what you're 13 referring to I believe was in '08, 14 and then the second one was paid 15 in 2017 that -- that I'm 16 referencing. I don't know of 17 three. You mentioned '8, '13 and 18 '17.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. I want to talk a little bit 21 about these regional national accounts. 22 Those are the big customers, right?</p> <p>23 A. Yes. Yes.</p> <p>24 Q. Those are the ones where</p>
Page 539	Page 541
<p>1 I mean in my distribution centers 2 in the Northeast I believe we had 3 certain DCs that could not ship 4 controls, yes.</p> <p>5 BY MR. KENNEDY:</p> <p>6 Q. And were you sanctioned 7 again in 2013?</p> <p>8 A. Yes.</p> <p>9 Q. So 2008, we're going to turn 10 over a new leaf and put in a new program. 11 And so you were sanctioned, you got a 12 problem again in 2013. And then in 2017, 13 sir, you pay a \$150 million fine for once 14 again not reporting suspicious orders. 15 Is that true?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: I don't know 19 the exact year that it was paid. 20 But yes, I know we paid a fine of 21 about \$150 million.</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. So '08 we're going to do it 24 right. Then in 2013 you are still not</p>	<p>1 McKesson makes its most money?</p> <p>2 A. Again, sir, I'm not in sales 3 so I don't know where we're making more 4 profit, whether it's an independent or 5 retail national accounts. I don't look 6 at the dollars and cents.</p> <p>7 Q. The majority of your 8 customers, if we look at individual 9 pharmacies, are the majority of them part 10 and parcel of regional national accounts, 11 the big chains?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. Would that -- would that be 16 true?</p> <p>17 A. Could you repeat the 18 question?</p> <p>19 Q. Are the majority of your 20 pharmacies part of regional national 21 accounts, the big chain pharmacies?</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: I don't know</p>

Page 542	Page 544
<p>1 the amount of the small 2 independent customers. I know in 3 the retail national accounts we 4 have close to 20,000 registrants.</p> <p>5 BY MR. KENNEDY:</p> <p>6 Q. 20,000. When you entered 7 into this settlement in 2008 with the DEA 8 and the Department of Justice, and you 9 instituted this new program, in addition 10 to identifying suspicious orders, you 11 told the DEA that you would institute a 12 program of knowing your customer. True?</p> <p>13 A. Yes.</p> <p>14 Q. In fact, if we look at the 15 program that was put together, you 16 emphasize, we're going to -- we're 17 looking at suspicious orders with 18 thresholds. But in order to prevent 19 diversion, to control the flow of opioids 20 into the country, we're going to know our 21 customer, right?</p> <p>22 A. That was part of it, yes, 23 sir.</p> <p>24 MR. KENNEDY: We want to</p>	<p>1 we'll get it.</p> <p>2 THE WITNESS: Yeah, 62.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Okay. This is your 5 monitoring the manual in 2008, correct?</p> <p>6 A. Yes. This is our operating 7 manual.</p> <p>8 Q. This is what you put in 9 place with respect to your agreement with 10 the DEA after paying 13 million, correct?</p> <p>11 A. Yes.</p> <p>12 Q. I want to go to page --</p> <p>13 MR. KENNEDY: Do you want to 14 give me a little bit more of that 15 page, please.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Do you see where it states 18 "DEA expects," the third highlight down, 19 "DEA expects McKesson to know their 20 customer"?</p> <p>21 A. Yes.</p> <p>22 Q. "This means understanding 23 the customer's business, why they 24 purchase, as well as how much they</p>
<p>1 look at 512. Is that one of --</p> <p>2 MS. ROZMAN: Well, it's 3 Exhibit 62 now.</p> <p>4 MR. KENNEDY: 62. Look at 5 62, and it's 345.</p> <p>6 MS. HENN: I'm sorry, which?</p> <p>7 THE WITNESS: 62, this one.</p> <p>8 MS. ROZMAN: It's 9 Exhibit 62.</p> <p>10 MS. HENN: 562?</p> <p>11 MR. KENNEDY: Yeah, and it's 12 our P-345. This is the first --</p> <p>13 THE WITNESS: Is this the 14 one?</p> <p>15 MS. ROZMAN: No, no. It's 16 Exhibit 62.</p> <p>17 MR. KENNEDY: You can just 18 look up if you want.</p> <p>19 THE WITNESS: Oh, oh. It's 20 that one.</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. We're just going to read the 23 first page. It's up on the screen.</p> <p>24 MS. HENN: Just a second,</p>	<p>1 purchase." Do you see that?</p> <p>2 A. Yes, sir.</p> <p>3 Q. If you go to Page 22 of 4 this, of this document.</p> <p>5 THE VIDEOGRAPHER: Watch 6 your microphone.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Do you see under due 9 diligence there on 22, if you look at the 10 screen it might be easier.</p> <p>11 A. I got it.</p> <p>12 Q. Does it state, 22, due 13 diligence. So this is the investigations 14 y'all have to do. "McKesson's 15 responsibility is to know its customer." 16 Do you see that?</p> <p>17 A. Yes.</p> <p>18 Q. And when it said that, when 19 you made that agreement, it didn't mean 20 some of your customers, did it?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 THE WITNESS: No. It said 24 know our customer.</p>

Page 546	Page 548
<p>1 BY MR. KENNEDY:</p> <p>2 Q. That means all your</p> <p>3 customers?</p> <p>4 A. I would say that's what it</p> <p>5 meant.</p> <p>6 Q. And you folks would divide</p> <p>7 your customers into two groups, the big</p> <p>8 chains are one group, and then the</p> <p>9 independent/small/medium size, that was a</p> <p>10 different group, correct?</p> <p>11 A. We divided them into two</p> <p>12 segments because their businesses are</p> <p>13 different, sir.</p> <p>14 Q. All right. But you've got</p> <p>15 to know all your customers.</p> <p>16 A. Yes.</p> <p>17 Q. The big chains and the</p> <p>18 independents and the small ones, right?</p> <p>19 A. Yes.</p> <p>20 Q. When somebody that's an</p> <p>21 independent or a small/medium, when they</p> <p>22 would breach your threshold, that Level 1</p> <p>23 investigation would involve placing a</p> <p>24 call to the particular pharmacy that</p>	<p>1 form.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. -- to find out what's going</p> <p>4 on in Idaho, correct?</p> <p>5 MS. HENN: Objection to</p> <p>6 form.</p> <p>7 THE WITNESS: Right.</p> <p>8 Because they had -- they perform</p> <p>9 their own due diligence internal</p> <p>10 regulatory review.</p> <p>11 BY MR. KENNEDY:</p> <p>12 Q. Okay. I'm going to write</p> <p>13 that down. I got a paper.</p> <p>14 MS. ROZMAN: We're going to</p> <p>15 mark as MCK Oriente 574.</p> <p>16 MR. KENNEDY: I'm going to</p> <p>17 put that up please.</p> <p>18 (Document marked for</p> <p>19 identification as Exhibit</p> <p>20 MCK-Oriente-574.)</p> <p>21 BY MR. KENNEDY:</p> <p>22 Q. So these national chains,</p> <p>23 the big customers, the CVS, they do their</p> <p>24 own due diligence, they've got their own</p>
<p>1 placed the order above their threshold,</p> <p>2 true?</p> <p>3 A. Yes.</p> <p>4 Q. And so if pharmacy X,</p> <p>5 Miller's Pharmacy on Main Street in</p> <p>6 Cleveland, Ohio, breached their</p> <p>7 threshold, you're getting ahold of</p> <p>8 Miller's Pharmacy on Main Street in</p> <p>9 Cleveland, Ohio, that ordered over their</p> <p>10 threshold. Right?</p> <p>11 A. Yes.</p> <p>12 Q. But if a big chain like CVS</p> <p>13 breaches their threshold, the call went</p> <p>14 to their corporate headquarters, their</p> <p>15 regulatory department, their oversight</p> <p>16 department. Correct?</p> <p>17 A. Yes, I believe that's how it</p> <p>18 worked.</p> <p>19 Q. So if a CVS store in Idaho</p> <p>20 places an order above their threshold,</p> <p>21 you are calling Providence, Rhode Island.</p> <p>22 You are calling the corporate office with</p> <p>23 respect to that Level 1 --</p> <p>24 MS. HENN: Objection to</p>	<p>1 regulatory department, correct?</p> <p>2 A. Yes.</p> <p>3 Q. And CVS, now that's a</p> <p>4 customer that you're doing over</p> <p>5 \$10 billion worth of business with,</p> <p>6 right?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: Again, sir, I</p> <p>10 don't know the exact dollar amount</p> <p>11 that McKesson does with each</p> <p>12 chain.</p> <p>13 BY MR. KENNEDY:</p> <p>14 Q. Let me ask you, sir, real</p> <p>15 simple question.</p> <p>16 If you're going to rely upon</p> <p>17 somebody like CVS to do the due</p> <p>18 diligence, you want to make sure they are</p> <p>19 doing a good job, don't you?</p> <p>20 A. We want to make sure they</p> <p>21 are following the requirements</p> <p>22 established for them, yes.</p> <p>23 Q. I mean that's -- you've got</p> <p>24 to make sure.</p>

	Page 550	Page 552
	<p>1 A. Yeah, we -- yes.</p> <p>2 Q. Sir, in 2010, do you</p> <p>3 understand CVS paid a \$77 million penalty</p> <p>4 in California, do you know that?</p> <p>5 A. In California, I was not</p> <p>6 aware. I knew they did in Florida have</p> <p>7 some stores. But I wasn't aware of</p> <p>8 California.</p> <p>9 MR. KENNEDY: 505, please.</p> <p>10 5005.</p> <p>11 MS. ROZMAN: Identified as</p> <p>12 MCK --</p> <p>13 MR. KENNEDY: 5 -- yeah,</p> <p>14 5005.</p> <p>15 MS. ROZMAN: MCK Oriente</p> <p>16 535.</p> <p>17 (Document marked for</p> <p>18 identification as Exhibit</p> <p>19 MCK-Oriente-535.)</p> <p>20 BY MR. KENNEDY:</p> <p>21 Q. Here's -- this is from the</p> <p>22 New York Times. "CVS to pay penalty in</p> <p>23 methamphetamine case," 2010, New York</p> <p>24 Times.</p>	<p>1 A. Yeah, that's highlighted</p> <p>2 here in Paragraph 2.</p> <p>3 Q. Let me ask you this. In</p> <p>4 2010, in 2010, you're saying, you know,</p> <p>5 if a CVS pharmacy goes above their</p> <p>6 threshold, we're going to call corporate</p> <p>7 and let them do the due diligence at CVS.</p> <p>8 Did you ever sit down and</p> <p>9 say, you know what, maybe they are not</p> <p>10 doing such a good job with their due</p> <p>11 diligence. Maybe we ought to do it</p> <p>12 ourselves. Did you say that in 2010 when</p> <p>13 you saw this?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 THE WITNESS: Sir, I did not</p> <p>17 see this in 2010. And when I</p> <p>18 would call or have contact with a</p> <p>19 chain corporate office, we did not</p> <p>20 rely solely on their information</p> <p>21 to make the determination. We</p> <p>22 gathered the information from</p> <p>23 them. We did not call the</p> <p>24 individual store.</p>
	<p>1 Folks at McKesson get the</p> <p>2 New York Times, right?</p> <p>3 A. Sir, I don't know what</p> <p>4 newspapers they do get. I know I have</p> <p>5 not seen this before.</p> <p>6 Q. Well, "CVS Caremark has</p> <p>7 agreed to pay \$77.6 million to settle an</p> <p>8 investigation that its drug stores</p> <p>9 allowed widespread sales of cough</p> <p>10 medicines used to manufacture the</p> <p>11 stimulant methamphetamine." That's a</p> <p>12 street drug, right, highly addictive,</p> <p>13 kills people. Is that right? You know</p> <p>14 what methamphetamine is.</p> <p>15 A. Yes.</p> <p>16 MS. HENN: Objection to</p> <p>17 form.</p> <p>18 THE WITNESS: Yes, it's made</p> <p>19 from cough medicines.</p> <p>20 BY MR. KENNEDY:</p> <p>21 Q. So CVS Pharmacy, a</p> <p>22 subsidiary, acknowledged that it had sold</p> <p>23 pseudoephedrine to criminals who used it</p> <p>24 to make meth. Do you see that?</p>	<p>1 BY MR. KENNEDY:</p> <p>2 Q. Exactly. You didn't call</p> <p>3 the individual store. You told us</p> <p>4 before, they do their due diligence</p> <p>5 and --</p> <p>6 A. We gather the information</p> <p>7 from their corporate office.</p> <p>8 Q. Exactly.</p> <p>9 A. And then we do our review.</p> <p>10 Q. The same people that were</p> <p>11 overseeing CVS for the conduct that cost</p> <p>12 them 77.6 million bucks, that's who you</p> <p>13 are relying on, right?</p> <p>14 MS. HENN: Objection to</p> <p>15 form.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Correct, sir?</p> <p>18 MS. HENN: Objection to</p> <p>19 form.</p> <p>20 THE WITNESS: I'm not sure</p> <p>21 who would have overseen this for</p> <p>22 them. Again, I was not aware, as</p> <p>23 I stated, that in California they</p> <p>24 paid this fine. I knew of the two</p>

Page 554	Page 556
<p>1 instances in Florida.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. But look at -- you have the</p> <p>4 duty to know your customer. And if your</p> <p>5 customer pays a \$77.6 million fine,</p> <p>6 McKesson ought to know about that, they</p> <p>7 have the duty to know their customer.</p> <p>8 And this is their biggest customer,</p> <p>9 right?</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Yes?</p> <p>14 A. This may -- this may have</p> <p>15 been known by McKesson, sir. It was not</p> <p>16 known by me, being responsible for the</p> <p>17 Northeast region that in California they</p> <p>18 paid this fine.</p> <p>19 MR. KENNEDY: Give me 5004,</p> <p>20 please.</p> <p>21 MS. ROZMAN: Identified as</p> <p>22 MCK Oriente 534.</p> <p>23 (Document marked for</p> <p>24 identification as Exhibit</p>	<p>1 A. Yes, they are.</p> <p>2 Q. Thank you. Now, does it</p> <p>3 state here, "Story highlights. The DEA</p> <p>4 says two pharmacies ordered more than</p> <p>5 3 million oxycodone units in a year. A</p> <p>6 typical pharmacy orders 69,000 units a</p> <p>7 year." And they ordered 3 million. Do</p> <p>8 you see that? Did I read that right?</p> <p>9 A. Yes.</p> <p>10 Q. And then it states, "Agents</p> <p>11 from the Drug Enforcement Administration</p> <p>12 raided two CVS pharmacies in Central</p> <p>13 Florida over the weekend, removing</p> <p>14 controlled substances and suspending the</p> <p>15 stores' ability to handle or distribute</p> <p>16 drugs such as painkillers, oxycodone and</p> <p>17 hydrocodone."</p> <p>18 Did I read that right?</p> <p>19 A. Yes.</p> <p>20 Q. And sir, can we agree that</p> <p>21 if McKesson has the duty to know its</p> <p>22 customers, they certainly should have</p> <p>23 known about this, right?</p> <p>24 A. We did know about -- we</p>
Page 555	Page 557
<p>1 MCK-Oriente-534.)</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. All right. Sir, now it's</p> <p>4 2012. It's 2012. If somebody goes over</p> <p>5 their threshold in a CVS store in Idaho,</p> <p>6 you are calling their regulatory</p> <p>7 oversight department in Rhode Island.</p> <p>8 But at the same time you're following</p> <p>9 that kind of procedure, now in 2012, the</p> <p>10 DEA makes a move on two Florida</p> <p>11 pharmacies, distributor, over pill sales.</p> <p>12 And those two pharmacies are CVS stores.</p> <p>13 Is that right?</p> <p>14 A. They are CVS stores. I</p> <p>15 believe --</p> <p>16 Q. Sir, are they CVS stores?</p> <p>17 A. Excuse me?</p> <p>18 Q. Are they CVS stores?</p> <p>19 MS. HENN: Objection to</p> <p>20 form.</p> <p>21 THE WITNESS: The -- the two</p> <p>22 stores in this article?</p> <p>23 BY MR. KENNEDY:</p> <p>24 Q. Yes.</p>	<p>1 heard about this. Are these two</p> <p>2 customers with McKesson in Florida?</p> <p>3 Q. Did you know about this with</p> <p>4 respect to McKesson, sir? Did you know</p> <p>5 about this --</p> <p>6 A. I heard --</p> <p>7 Q. Did you hear about this?</p> <p>8 A. I heard about this, yes.</p> <p>9 Q. All right. And let me ask</p> <p>10 you this, sir.</p> <p>11 A. And again --</p> <p>12 MS. HENN: Counsel.</p> <p>13 Counsel --</p> <p>14 THE WITNESS: Can I finish,</p> <p>15 please?</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. I just asked you if you</p> <p>18 heard about it and the answer was yes.</p> <p>19 MS. HENN: Counsel, he had</p> <p>20 something else to say.</p> <p>21 MR. KENNEDY: But he can't</p> <p>22 give speeches. You have to answer</p> <p>23 my questions.</p> <p>24 MS. HENN: He's not giving</p>

Page 558	Page 560
<p>1 speeches. He's trying to answer.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. My -- my question is very</p> <p>4 simple. Did you hear about this?</p> <p>5 MS. HENN: Asked and</p> <p>6 answered.</p> <p>7 THE WITNESS: I heard about</p> <p>8 the two stores in Florida, yes.</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. And my question to you now</p> <p>11 is, at this point in time, in 2012, after</p> <p>12 finding out this, did you folks sit down</p> <p>13 and say maybe we shouldn't be letting CVS</p> <p>14 monitor themselves out of their corporate</p> <p>15 headquarters in Rhode Island, maybe we</p> <p>16 should monitor them when they exceed</p> <p>17 their threshold?</p> <p>18 MS. HENN: Objection.</p> <p>19 BY MR. KENNEDY:</p> <p>20 Q. Did anybody sit down and</p> <p>21 have that kind of meeting in 2012?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 BY MR. KENNEDY:</p>	<p>1 THE WITNESS: I do not know</p> <p>2 who our largest customer is, sir.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. By 2012, you're doing</p> <p>5 \$19 billion worth of business with CVS.</p> <p>6 You didn't know that?</p> <p>7 MS. HENN: Objection to</p> <p>8 form.</p> <p>9 THE WITNESS: No, sir. I</p> <p>10 don't look at dollars with</p> <p>11 customers. I am not in sales.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Let's go to -- let's go to</p> <p>14 2013.</p> <p>15 MR. KENNEDY: If you can</p> <p>16 give me 305, please.</p> <p>17 MS. ROZMAN: Identified MCK</p> <p>18 Oriente 511.</p> <p>19 (Document marked for</p> <p>20 identification as Exhibit</p> <p>21 MCK-Oriente-511.)</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Now, this is -- this is a</p> <p>24 publication by the United States</p>
Page 559	Page 561
<p>1 Q. Did you go to such a</p> <p>2 meeting?</p> <p>3 A. That -- I did not go to such</p> <p>4 a meeting. That type of meeting would</p> <p>5 have been handled by our senior vice</p> <p>6 president Don Walker.</p> <p>7 Q. Did anybody come to you and</p> <p>8 say this meeting occurred, even if you</p> <p>9 didn't go to it?</p> <p>10 A. I don't recall if one did</p> <p>11 occur.</p> <p>12 Q. And if you can give me --</p> <p>13 this resulted in a \$22 million fine. Do</p> <p>14 you understand that, to CVS, a</p> <p>15 \$22 million fine?</p> <p>16 A. Yes, I am aware.</p> <p>17 Q. So at this point CVS has</p> <p>18 paid \$150 million in 2010, and now</p> <p>19 another \$22 million in 2012. Right? And</p> <p>20 they are your biggest customer, they are</p> <p>21 the biggest customer of McKesson, are</p> <p>22 they not?</p> <p>23 MS. HENN: Objection to</p> <p>24 form.</p>	<p>1 Attorney's Office. Do you see that?</p> <p>2 A. Yes.</p> <p>3 Q. And the date is April 3,</p> <p>4 2013. Correct?</p> <p>5 A. Yes.</p> <p>6 Q. You see -- the headline is</p> <p>7 "CVS to pay 11 million to settle civil</p> <p>8 penalty claims involving violations of</p> <p>9 the Controlled Substances Act."</p> <p>10 And then it states, "The</p> <p>11 United States has alleged that from</p> <p>12 October 6, 2005, to October 5th of 2011,</p> <p>13 CVS pharmacy stores in Oklahoma and</p> <p>14 elsewhere violated the Controlled</p> <p>15 Substances Act and the recordkeeping</p> <p>16 regulations by creating, entering, and</p> <p>17 maintaining invalid dummy DEA</p> <p>18 registration numbers or numbers other</p> <p>19 than the valid DEA registration number of</p> <p>20 the prescribing practitioner on</p> <p>21 dispensing records, which were at times</p> <p>22 provided to state prescription drug</p> <p>23 monitoring programs."</p> <p>24 Did I read that right?</p>

Page 562	Page 564
<p>1 A. That is what is written 2 here.</p> <p>3 Q. And these CVS stores in 4 several states, Oklahoma and elsewhere 5 were filling prescriptions for certain 6 prescribers whose DEA registration 7 numbers were not current or valid. Did 8 you see that?</p> <p>9 A. Yes.</p> <p>10 Q. And in knowing your customer 11 as was your obligation, McKesson should 12 have known about this \$11 million fine, 13 right?</p> <p>14 MS. HENN: Objection to 15 form.</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Is that right? They should 18 have known about it. They had the duty 19 to know their customers. And this is an 20 \$11 million fine. They should have known 21 about this. True?</p> <p>22 MS. HENN: Objection to 23 form.</p> <p>24 THE WITNESS: They --</p>	<p>1 MS. HENN: Objection to 2 form.</p> <p>3 THE WITNESS: I -- I can't 4 say that McKesson didn't know 5 about this. At a -- at a higher 6 level than me they may have been 7 aware of this.</p> <p>8 BY MR. KENNEDY:</p> <p>9 Q. And they should have been, 10 correct?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: They --</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. They should have been.</p> <p>16 A. They should have and could 17 have. I do not know if, you know, the -- 18 the vice president that I reported into 19 knew about this. I'm sure that he may 20 have. But for me to be in the Northeast 21 region and to know about Oklahoma, I'm 22 not -- I'm not going to be aware of that.</p> <p>23 Q. I'm going to ask you. It's 24 2013. Now, did -- did anybody above you</p>
<p>1 McKesson may have known about 2 this. I can't say.</p> <p>3 BY MR. KENNEDY:</p> <p>4 Q. Well, I'm not talking about 5 whether they did or they didn't.</p> <p>6 MS. HENN: Counsel, please.</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. My question is real simple: 9 Should they?</p> <p>10 MS. HENN: Let him finish 11 his sentences.</p> <p>12 MR. KENNEDY: But I want him 13 to answer my question.</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. Go ahead.</p> <p>16 MS. HENN: I know it's late 17 in the day, but it's basic --</p> <p>18 BY MR. KENNEDY:</p> <p>19 Q. Here's my question. I'm -- 20 we'll start all over.</p> <p>21 Would you agree that 22 pursuant to McKesson's obligation to know 23 their customer, they should have known 24 about this \$11 million fine in Oklahoma?</p>	<p>1 say look it, you are a director of 2 regulatory affairs for one of our 3 regions. How many folks had your job, 4 your similar job in the country?</p> <p>5 A. Four.</p> <p>6 Q. Did the folks above you call 7 you four in and say you know what, 8 they've been find 150 million, then 77, 9 and now another 11. Maybe we shouldn't 10 let these folks monitor themselves. 11 Maybe we should monitor them instead of 12 calling corporate headquarters. Because 13 corporate headquarters was the one 14 monitoring them when they got fined all 15 these monies.</p> <p>16 A. We don't let them monitor 17 themselves. We do monitor them. We go 18 to corporate headquarters for information 19 on the pharmacy.</p> <p>20 Q. And the same folks you're 21 getting information from were the same 22 people watching these stores when they 23 got all these fines, right? Right? Same 24 folks?</p>

Page 566	Page 568
<p>1 A. Yes.</p> <p>2 MR. KENNEDY: Give me 301,</p> <p>3 please. Now it's 2015.</p> <p>4 MS. ROZMAN: MCK Oriente</p> <p>5 507.</p> <p>6 (Document marked for</p> <p>7 identification as Exhibit</p> <p>8 MCK-Oriente-507.)</p> <p>9 BY MR. KENNEDY:</p> <p>10 Q. Now, it's 2015, sir. 2015.</p> <p>11 Now we've got a -- we've got a</p> <p>12 publication here again by the United</p> <p>13 States Attorney's Office, do we not?</p> <p>14 A. Yes.</p> <p>15 Q. And this, this headline, and</p> <p>16 this is from August 10, 2015, correct?</p> <p>17 A. Yes.</p> <p>18 Q. And the quote is, or excuse</p> <p>19 me, the headline is "Drug diversion</p> <p>20 claims against CVS Health Corp. resolved</p> <p>21 with \$450,000 civil settlement." Do you</p> <p>22 see that?</p> <p>23 A. Yes.</p> <p>24 Q. And then it says, the first</p>	<p>1 please.</p> <p>2 MS. ROZMAN: Identified as</p> <p>3 MCK Oriente 504.</p> <p>4 (Document marked for</p> <p>5 identification as Exhibit</p> <p>6 MCK-Oriente-504.)</p> <p>7 BY MR. KENNEDY:</p> <p>8 Q. Another publication by the</p> <p>9 United States Attorney's Office. Do you</p> <p>10 see here McKesson, excuse me, CVS is</p> <p>11 paying an \$8 million fine to settle</p> <p>12 allegations for unlawful distribution of</p> <p>13 controlled substances. Do you see that?</p> <p>14 A. Yes.</p> <p>15 MR. KENNEDY: Give me 300,</p> <p>16 please.</p> <p>17 MS. ROZMAN: MCK Oriente</p> <p>18 506.</p> <p>19 (Document marked for</p> <p>20 identification as Exhibit</p> <p>21 MCK-Oriente-506.)</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Now, it's 2016. Publication</p> <p>24 by the United States Attorney's Office,</p>
Page 567	Page 569
<p>1 paragraph, "Pharmacy chain CVS Health</p> <p>2 Corp. has agreed to pay \$450,000 to</p> <p>3 resolve the United States' allegations</p> <p>4 that several of its Rhode Island stores</p> <p>5 violated the federal Controlled</p> <p>6 Substances Act by filling invalid</p> <p>7 prescriptions and maintaining deficient</p> <p>8 records." Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. Let me ask you, who in the</p> <p>11 regulatory department was in charge of</p> <p>12 CVS?</p> <p>13 A. In August of 2015 I believe</p> <p>14 it may have been Tom McDonald.</p> <p>15 Q. And who was in charge in</p> <p>16 2012?</p> <p>17 A. I'm not certain if it was me</p> <p>18 or Tom.</p> <p>19 Q. And who was in charge in</p> <p>20 2010?</p> <p>21 A. I'm not certain if it was me</p> <p>22 or Tom. We switched accounts sometime</p> <p>23 during that time frame.</p> <p>24 MR. KENNEDY: Give me 297</p>	<p>1 District of Massachusetts. Headline,</p> <p>2 "CVS to pay \$3.5 million to resolve</p> <p>3 allegations that pharmacists filled fake</p> <p>4 prescriptions." Do you see that, sir?</p> <p>5 A. Yes.</p> <p>6 Q. And you're in charge of CVS</p> <p>7 by this time, aren't you?</p> <p>8 A. 2016, yes.</p> <p>9 Q. So you knew about this,</p> <p>10 right, because you've got a duty to know</p> <p>11 your customer. You knew about this,</p> <p>12 right?</p> <p>13 A. I don't recall if I saw this</p> <p>14 precise document.</p> <p>15 MR. KENNEDY: Give me 296,</p> <p>16 please.</p> <p>17 MS. ROZMAN: McKesson -- MCK</p> <p>18 Oriente 503.</p> <p>19 (Document marked for</p> <p>20 identification as Exhibit</p> <p>21 MCK-Oriente-503.)</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. Now, it's 2017. We have</p> <p>24 another publication by the United States</p>

Page 570	Page 572
<p>1 Attorney's Office, Eastern District of 2 California. Correct? Do you see that? 3 A. Yes. 4 Q. And the headline reads, "CVS 5 Pharmacy pays \$5 million to settle 6 alleged allegations of the Controlled 7 Substances Act." Do you see that, sir? 8 A. Yes. 9 MR. KENNEDY: Give me 5007 10 please. 11 MS. ROZMAN: MCK Oriente 12 537. 13 (Document marked for 14 identification as Exhibit 15 MCK-Oriente-537.) 16 MS. HENN: And Counsel, just 17 to note, I believe we have about 18 five minutes left.</p> <p>19 BY MR. KENNEDY: 20 Q. Mr. Oriente, this is a chart 21 that we created of CVS, DEA, Department 22 of Justice settlements between 2010 and 23 2016 that we've been talking about. 24 In a six-year period, CVS</p>	<p>1 pharmacy. 2 BY MR. KENNEDY: 3 Q. Exactly, sir. So you've got 4 a CVS pharmacy in Idaho, or Cleveland, or 5 Alabama or Colorado, and if they exceed 6 the threshold, you don't call the 7 pharmacy, you call CVS corporate, the 8 same folks that are monitoring CVS to the 9 tune of \$130 million worth of fine. That 10 was your program, sir, right?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 BY MR. KENNEDY: 14 Q. That was the program. Call 15 corporate. Correct?</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 THE WITNESS: We --</p> <p>19 BY MR. KENNEDY: 20 Q. Is that correct, sir?</p> <p>21 MS. HENN: Objection to 22 form.</p> <p>23 BY MR. KENNEDY: 24 Q. That's who you called?</p>
<p>1 paid \$130.6 million worth of fines for 2 violating the Controlled Substances Act 3 at the pharmacy level. Do you see this, 4 sir? 5 A. Yes, I see that. 6 Q. And let me ask you, at any 7 single point in time, did anybody, did 8 anybody above you, around you, say we 9 need to have a meeting because maybe, 10 maybe we shouldn't be letting CVS 11 corporate monitor themselves?</p> <p>12 MS. HENN: Objection to 13 form.</p> <p>14 BY MR. KENNEDY: 15 Q. Did anybody ever hold that 16 meeting, sir? 17 MS. HENN: Objection to 18 form. 19 THE WITNESS: We -- we don't 20 allow CVS corporate to monitor 21 themselves, we monitor them. We 22 use their corporate as a 23 communication line to get 24 information on the individual</p>	<p>1 A. We would call corporate to 2 get information on their stores. 3 Q. Exactly. 4 A. As opposed to dealing with 5 the individual pharmacies. 6 Q. You called corporate because 7 you don't want to make CVS corporate mad 8 because you were doing, by this point, 9 \$16 billion worth of business every year, 10 your biggest customer?</p> <p>11 MS. HENN: Objection.</p> <p>12 BY MR. KENNEDY: 13 Q. That's why you called 14 corporate and you didn't investigate a 15 single one of their pharmacies.</p> <p>16 MS. HENN: Objection to 17 form.</p> <p>18 BY MR. KENNEDY: 19 Q. Correct, sir?</p> <p>20 MS. HENN: Objection to 21 form.</p> <p>22 THE WITNESS: No, that's not 23 correct, because we didn't -- it 24 wasn't to get them mad. We called</p>

Page 574	Page 576
<p>1 them because they would have the 2 most information on that 3 particular pharmacy.</p> <p>4 BY MR. KENNEDY:</p> <p>5 Q. But everybody else, you 6 called the pharmacy, is that right?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 THE WITNESS: No, that is 10 not right. On chains we called 11 the corporate office.</p> <p>12 BY MR. KENNEDY:</p> <p>13 Q. Exactly.</p> <p>14 A. On chains we called the 15 corporate office.</p> <p>16 Q. But on everybody but --</p> <p>17 A. On the individual stores, 18 which is an individual pharmacy, there is 19 no corporate office to call so you call 20 that individual pharmacy.</p> <p>21 Q. For the independents you 22 investigated, but for the big customers 23 you called corporate?</p> <p>24 A. We investigated also, in a</p>	<p>1 A. Yes.</p> <p>2 Q. When you joined McKesson you 3 were the director of operations for the 4 Delran, New Jersey, distribution center, 5 is that correct?</p> <p>6 A. That is correct.</p> <p>7 Q. And in 2007 you became 8 director of regulatory affairs overseeing 9 a number of distribution centers?</p> <p>10 A. Yes. The Northeast region.</p> <p>11 Q. Why did you move into 12 regulatory affairs?</p> <p>13 A. Part of the responsibility 14 of the director of operations is to be 15 required to monitor and oversee the 16 maintaining of records in the controlled 17 substance. So besides having total 18 responsibility for the distribution 19 center, the DEA requirements are also 20 part of that.</p> <p>21 We were given the lifestyle 22 drug monitoring program to oversee as 23 part of our overall responsibilities. 24 And I found it very interesting to</p>
<p>1 different route.</p> <p>2 MR. KENNEDY: Thank you. I 3 got nothing further.</p> <p>4 MS. HENN: I'm going to have 5 some questions so I suggest we go 6 off the record.</p> <p>7 THE VIDEOGRAPHER: Stand by 8 please. The time is 5:42 p.m.</p> <p>9 Going off the record.</p> <p>10 (Short break.)</p> <p>11 THE VIDEOGRAPHER: We are 12 back on the record. The time is 13 5:54 p.m.</p> <p>14 - - -</p> <p>15 EXAMINATION</p> <p>16 - - -</p> <p>17 BY MS. HENN:</p> <p>18 Q. Mr. Oriente, you testified 19 earlier today that you joined McKesson in 20 2004, is that correct?</p> <p>21 A. Yes. 2004.</p> <p>22 Q. And before joining McKesson 23 you worked as the director of operations 24 and distribution at Eckerd?</p>	<p>1 monitor and look at what customers were 2 purchasing and the analytics that went 3 into it.</p> <p>4 So when the newly created 5 positions were rolled out, I was 6 interested in moving into the regulatory 7 department. It was a little more 8 analytical than -- than running the 9 distribution center.</p> <p>10 Q. And you said you found it 11 interesting to see how pharmacies were 12 purchasing. Why did you find that 13 interesting?</p> <p>14 A. I found that interesting to 15 do the research and to look at how they 16 were ordering controls versus 17 non-controls, the type of business that 18 they had. More interactions with 19 customers. And also just -- it was such 20 an important topic at that time, I felt 21 it was definitely something I wanted to 22 get involved with.</p> <p>23 Q. You testified earlier about 24 the evolution of McKesson's controlled</p>

<p style="text-align: right;">Page 578</p> <p>1 substances monitoring program. How would 2 you describe that evolution? 3 A. The program today is much 4 more system generated. It would be like 5 comparing a -- when we first started it 6 was a manual process. We always had 7 controlled -- we always looked at 8 controlled sales. It was a manual 9 process. There were paper reports. 10 People would sit there, look at the 11 report, look at the type of pattern that 12 the customer was ordering. It was very 13 manual, kind of like an old biplane. 14 Today we have a streamlined jet. 15 Reports are generated for 16 us. A lot of the analytics are generated 17 by our system. We're able to look at 18 customer purchases at a much higher rate 19 of speed to make determinations. We have 20 a lot more warning reports. And it's 21 been evolving continuously.</p> <p>22 And so what we have today is 23 much more robust than what we were doing. 24 We were still doing it. So it was</p>	<p style="text-align: right;">Page 580</p> <p>1 DEA agents when we were either calling to 2 report a customer or sending them a 3 letter notifying them that we cut 4 customers off. 5 Q. And what happened when you 6 communicated to DEA in those instances 7 about a pharmacy? 8 A. DEA would basically say 9 thank you for the information. And then 10 that was really the end of it. It was 11 not a two-way communication. We would 12 give them the information of a 13 particular -- either a pharmacy or maybe 14 a doctor that we saw a lot of activity 15 on. 16 They would again thank us 17 for the information. That was pretty 18 much the end of what we heard unless we 19 heard about it in the news later on if 20 there was additional action taken. But 21 we were never, you know, communicated 22 back on, on anything that we submitted. 23 Q. Tell me your mission and 24 responsibilities in McKesson's regulatory</p>
<p style="text-align: right;">Page 579</p> <p>1 still -- met the requirement, but it took 2 a lot more manual process to get to the 3 same determination. 4 Q. Could you describe the 5 relationship you've had with the DEA over 6 the course of your career in McKesson 7 regulatory affairs? 8 A. Yes. I felt that my 9 relationship with DEA was very good. 10 When I started in '07 in regulatory, our 11 Delran distribution center was always one 12 where the DEA paid compliments to when 13 they came in to do their cyclical audits. 14 Our recordkeeping was always good. Our 15 inventory was good. So the local DEA 16 office over my distribution center was 17 always satisfied with what we were doing. 18 When I went into regulatory 19 I dealt with the Washington D.C. office 20 that oversaw Landover. I dealt with the 21 New York office, as well as the New 22 Jersey office and the Pittsburgh office 23 of DEA, and the Rocky Hill office. And 24 would have conversations with different</p>	<p style="text-align: right;">Page 581</p> <p>1 affairs group. How do they compare with 2 the mission and responsibilities of 3 McKesson's sales group? 4 A. My responsibilities are to 5 monitor what a customer is purchasing and 6 to look at their percentage of controls, 7 their total controls that they are 8 buying, making sure that the mix of 9 products is typical of what a pharmacy 10 would be purchasing. 11 I don't look at dollars of a 12 customer. It's just either going to be 13 independent or retail national account. 14 And even with a retail national account 15 I'll look at volume, total doses, but I 16 don't look at dollars. So I'm never 17 making a determination based off of a 18 dollar value. 19 Sales, of course, would 20 be -- I can just surmise they are looking 21 to increase sales for their customer. 22 But what I liked is that we had final 23 say. So if I didn't feel that a customer 24 warranted an increase, I would not make</p>

Page 582	Page 584
<p>1 that increase.</p> <p>2 Q. How would you describe</p> <p>3 McKesson's culture in the area of</p> <p>4 compliance and regulatory affairs?</p> <p>5 A. I would say that McKesson</p> <p>6 has a corporate culture, they call it</p> <p>7 ICARE, I-C-A-R-E. It's integrity,</p> <p>8 customer focused, and then</p> <p>9 accountability, respect and excellence.</p> <p>10 I find that McKesson is a very -- they</p> <p>11 look at accountability and respect and</p> <p>12 excellence of the job that we do.</p> <p>13 As I mentioned earlier, I</p> <p>14 take -- took my job, take my job very</p> <p>15 seriously. I know that I play an</p> <p>16 important role in the monitoring of sales</p> <p>17 of controlled substances. I take that</p> <p>18 responsibility very personally.</p> <p>19 I think that McKesson has a</p> <p>20 very high ethics group when it comes to</p> <p>21 integrity in what we do.</p> <p>22 MS. HENN: I have no further</p> <p>23 questions.</p> <p>24 MR. PAPANTONIO: Sir, I've</p>	<p>1 identification as Exhibit</p> <p>2 MCK-Oriente-060.)</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Now, sir, I'm wondering, you</p> <p>5 have surely seen the -- what I call the</p> <p>6 death map. Have you seen the death map?</p> <p>7 A. Not that exact document, no.</p> <p>8 Q. You've not seen -- you've</p> <p>9 not seen this?</p> <p>10 A. Not the death map, no.</p> <p>11 Q. Is that right? Why don't</p> <p>12 you take a look at what I call the death</p> <p>13 map. Okay.</p> <p>14 MS. HENN: Counsel, do you</p> <p>15 have copies?</p> <p>16 MR. PAPANTONIO: Give --</p> <p>17 give a copy to the lawyers,</p> <p>18 please.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Now, let's look at this</p> <p>21 death map. Take a look at it. And tell</p> <p>22 me, is this the first time you've seen</p> <p>23 this.</p> <p>24 MS. MOORE: That's McKesson</p>
<p>1 got a few questions.</p> <p>2 Would you please put up</p> <p>3 Document Number 324.</p> <p>4 - - -</p> <p>5 EXAMINATION</p> <p>6 - - -</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. I want to ask you about,</p> <p>9 sir, while you were evolving to where you</p> <p>10 say you've been evolving. Is that what</p> <p>11 you said?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 THE WITNESS: I -- I believe</p> <p>15 I said that our program is</p> <p>16 continuously improving.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Okay. Let's look at --</p> <p>19 let's look at how many people have been</p> <p>20 dying across the United States while</p> <p>21 you've been evolving. Let's take a look</p> <p>22 at that.</p> <p>23 MR. PAPANTONIO: 324 please.</p> <p>24 (Document marked for</p>	<p>1 Oriente 60.</p> <p>2 THE WITNESS: No, I have</p> <p>3 not --</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Have you ever seen the death</p> <p>6 map?</p> <p>7 A. No, I've not seen the death</p> <p>8 map.</p> <p>9 Q. Before you came in here to</p> <p>10 testify, nobody showed you the death map,</p> <p>11 did they?</p> <p>12 A. No.</p> <p>13 Q. Well, let's do this realtime</p> <p>14 on the death map. Do you see, do you see</p> <p>15 down on the death map, if you'll take a</p> <p>16 look at the first -- the first very part</p> <p>17 of the death map, do you see where it</p> <p>18 has, do you see this area, this grey all</p> <p>19 the way to, it looks like a light brown.</p> <p>20 Do you see that right there?</p> <p>21 A. What -- what number are you</p> <p>22 referring to, 10?</p> <p>23 Q. I'm referring to 1999. Do</p> <p>24 you see up in the corner, sir? You may</p>

Page 586	Page 588
<p>1 want to look up here --</p> <p>2 A. You said grey, but I --</p> <p>3 there's a couple of shades here and I</p> <p>4 want to make sure I'm looking at the same</p> <p>5 one you are.</p> <p>6 Q. Okay.</p> <p>7 A. So there's a number to the</p> <p>8 right of it. Is that the 10?</p> <p>9 Q. Yeah.</p> <p>10 A. Okay.</p> <p>11 Q. Yeah, that's it.</p> <p>12 A. Thank you.</p> <p>13 Q. So, so this is the number of</p> <p>14 deaths that started as you were evolving</p> <p>15 as a company and trying to figure out how</p> <p>16 to evolve. Let's talk about the</p> <p>17 evolution of death.</p> <p>18 1999. Turn to the next</p> <p>19 page. Do you see that area around West</p> <p>20 Virginia? Can -- do you know where West</p> <p>21 Virginia is on a map?</p> <p>22 A. Yes, sir, right in this</p> <p>23 area.</p> <p>24 Q. Do you know where Ohio is on</p>	<p>1 form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Take a look at it. If it</p> <p>4 doesn't, tell me it doesn't. We'll let</p> <p>5 the jury decide.</p> <p>6 Does it get bigger in 2000,</p> <p>7 the death map?</p> <p>8 MS. HENN: Objection to</p> <p>9 form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Does it get bigger, sir?</p> <p>12 A. It looks to stay almost the</p> <p>13 same.</p> <p>14 Q. Okay. Well, let's move on.</p> <p>15 Let's look at -- okay. Let's focus just</p> <p>16 on tan. How about we do that.</p> <p>17 Now, how about let's go to</p> <p>18 2001. Does 2001 on the death map, is</p> <p>19 that area bigger or smaller than 19 --</p> <p>20 the 1999, on the death map?</p> <p>21 A. It's increased somewhat.</p> <p>22 Q. Increased. Okay. Let's</p> <p>23 look at 2002. This is the area that you</p> <p>24 were in charge of, correct?</p>
<p>1 a map?</p> <p>2 A. Up here.</p> <p>3 Q. And what -- tell me what</p> <p>4 color that is.</p> <p>5 A. Color for which state?</p> <p>6 Q. Either one. West Virginia</p> <p>7 or --</p> <p>8 A. Ohio is in the blue shades.</p> <p>9 West Virginia is in the tan shades.</p> <p>10 Q. Okay. Let's talk about the</p> <p>11 tan shades then, since we've got a lot to</p> <p>12 talk about on the evolution of the death</p> <p>13 map.</p> <p>14 This is 1999 is where the</p> <p>15 death map starts, correct?</p> <p>16 A. Yes.</p> <p>17 Q. And then the death map goes</p> <p>18 to 200, goes to 2000, correct?</p> <p>19 A. Yes.</p> <p>20 Q. Does that -- does that tan</p> <p>21 shade get better, that area you're</p> <p>22 supposed to be in charge of, does that</p> <p>23 get bigger?</p> <p>24 MS. HENN: Objection to</p>	<p>1 MS. HENN: Objection to</p> <p>2 form.</p> <p>3 THE WITNESS: Not the full</p> <p>4 area of West Virginia, no.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Well, do you see the West</p> <p>7 Virginia area, 2002, take a look at it.</p> <p>8 A. I see the West Virginia area</p> <p>9 in 2002. I did not have the entire state</p> <p>10 of West Virginia.</p> <p>11 Q. Well, we can look at that</p> <p>12 and tell West Virginia has now moved from</p> <p>13 just tan, they've gone all the way down</p> <p>14 to, they've got all the way to brown.</p> <p>15 Tell me what the deaths are for brown,</p> <p>16 what does that represent, 30 deaths?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. 30 deaths per 100,000</p> <p>21 people?</p> <p>22 A. To this rig chart. 30 plus.</p> <p>23 Q. Yeah, so 30 plus people in</p> <p>24 2001 in that, in West Virginia. Correct?</p>

<p style="text-align: right;">Page 590</p> <p>1 Let's go to 2002 --</p> <p>2 A. Per 100, per 100,000.</p> <p>3 Q. Per 100,000 people.</p> <p>4 Now let's go to 2003 on the</p> <p>5 death map. Do you see that big brown</p> <p>6 spot, that big blotch there? That's West</p> <p>7 Virginia, isn't it?</p> <p>8 Can you see it better now if</p> <p>9 you look up on the screen?</p> <p>10 A. No, I can see it from here.</p> <p>11 Q. All right. Now, what do we</p> <p>12 see there, we see brown, we see red, we</p> <p>13 see orange?</p> <p>14 A. Mm-hmm.</p> <p>15 Q. So colors are changing as</p> <p>16 you're trying to evolve and try to figure</p> <p>17 out how to do better after being fined</p> <p>18 \$13 million. How to do better after</p> <p>19 you've been fined \$150 million. How to</p> <p>20 do better after you have been -- after</p> <p>21 the DOJ and the DEA has investigated you.</p> <p>22 Right? As you are evolving, that's part</p> <p>23 of the evolution, correct?</p> <p>24 MS. HENN: Objection to</p>	<p style="text-align: right;">Page 592</p> <p>1 about putting them side by side.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Look up here on the screen,</p> <p>4 sir.</p> <p>5 A. I am.</p> <p>6 MR. PAPANTONIO: Would you</p> <p>7 put the next one up on the screen</p> <p>8 for me, please.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Wow. A lot of brown there,</p> <p>11 huh? What does the -- what does the dark</p> <p>12 brown mean? It means more than 30 deaths</p> <p>13 per 100,000, correct?</p> <p>14 A. Yes.</p> <p>15 Q. And the tan, what does that</p> <p>16 mean?</p> <p>17 A. 16 to 17. Or 14 or 15.</p> <p>18 Q. So do you realize what we're</p> <p>19 doing here, we're comparing what started</p> <p>20 in 1999 when you were selling pills to</p> <p>21 pharmacies, when McKesson was selling</p> <p>22 narcotics to pharmacies, the first map we</p> <p>23 see as far as people dying is the one on</p> <p>24 the left. Do you understand that?</p>
<p style="text-align: right;">Page 591</p> <p>1 form.</p> <p>2 THE WITNESS: Part of our</p> <p>3 evolution was to have enhanced</p> <p>4 reports that are system generated</p> <p>5 and have systems assist us in the</p> <p>6 reviews instead of a manual</p> <p>7 process. That's part of the</p> <p>8 evolution.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Let's see how that works.</p> <p>11 MS. HENN: And, Counsel,</p> <p>12 just -- just to let you know, you</p> <p>13 have two more minutes.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Okay. Then let's do this.</p> <p>16 Let's go -- since I've been told I have</p> <p>17 two minutes, let's go to Number 18. Just</p> <p>18 pull over to Page 18. We'll just</p> <p>19 compare.</p> <p>20 MR. PAPANTONIO: Would you</p> <p>21 please put up -- would you put up</p> <p>22 1999 compared to 2013 since I've</p> <p>23 been told I only have how many</p> <p>24 more minutes? Two minutes. How</p>	<p style="text-align: right;">Page 593</p> <p>1 A. Yes.</p> <p>2 Q. And the one on the right is</p> <p>3 what happened as late as, what's the year</p> <p>4 on that, 2013?</p> <p>5 MS. MOORE: 2016.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. 2016.</p> <p>8 That map is bright red with</p> <p>9 dead people, isn't it, sir?</p> <p>10 MS. HENN: Objection to</p> <p>11 form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. It is bright red with dead</p> <p>14 people?</p> <p>15 MS. HENN: Objection to</p> <p>16 form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Wouldn't you agree with</p> <p>19 that?</p> <p>20 Sir, do you understand that</p> <p>21 is children, mothers, fathers, uncles,</p> <p>22 sisters and brothers. That's a</p> <p>23 statistic. But what that statistic</p> <p>24 means, and those are family members dying</p>

Page 594	Page 596
<p>1 because your company participated with 2 CVS and Purdue and Teva and all these -- 3 Cardinal, and participated in expanding 4 the death map from what we see on the 5 left to what we see on the right. Are 6 you proud of that, sir?</p> <p>7 MS. HENN: Objection to 8 form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Are you proud of that?</p> <p>11 MS. HENN: Objection to 12 form.</p> <p>13 THE WITNESS: The epidemic 14 is not something that I am proud 15 occurred. I do my job to try to 16 limit that.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Yeah. Well, didn't you tell 19 me McKesson has an ICARE culture. Isn't 20 that what you said? It's ICARE culture. 21 And I think you said it's integrity, 22 accountability, excellence --</p> <p>23 MS. HENN: Counsel, we've 24 reached the end so I'd just ask</p>	<p>1 MR. PAPANTONIO: I'm going 2 to ask this question. You can 3 bring it up to the judge. I want 4 to ask this question since you 5 have this man here.</p> <p>6 MS. HENN: Counsel.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. You said you had an ICARE 9 program. Yes or no?</p> <p>10 MS. HENN: And I'm going to 11 tell you that this needs to be the 12 last question.</p> <p>13 MR. PAPANTONIO: Do you want 14 to instruct him -- okay --</p> <p>15 MS. HENN: I'm not 16 instructing him not to answer.</p> <p>17 MR. PAPANTONIO: Okay. This 18 is my last question.</p> <p>19 MS. HENN: Thank you, sir.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. You said you had an ICARE 22 program, right, that involved integrity, 23 it involved accountability, it involved 24 high ethics, it involved excellence.</p>
Page 595	Page 597
<p>1 you to ask your last question.</p> <p>2 MR. PAPANTONIO: I'm going 3 to ask the last question.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Isn't that what you told me, 6 on direct, isn't that what you said, the 7 ICARE program?</p> <p>8 A. That is what I said.</p> <p>9 Q. If we make a -- if we 10 look at --</p> <p>11 MS. HENN: All right.</p> <p>12 Counsel, we're done.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. -- if you look at that map, 15 the ICARE policy is a disaster, isn't it?</p> <p>16 MS. HENN: I'd like to go 17 off the record now, sir.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. If we look at that map, the 20 ICARE policy is a disaster. Yes or no?</p> <p>21 MS. HENN: Counsel, before 22 we went on the record again, you 23 agreed as the court ordered that 24 we would abide by the protocol --</p>	<p>1 Look at these two maps and 2 you tell me whether all that ICARE 3 program was working between 1999 and 4 2016?</p> <p>5 A. The ICARE principle that we 6 follow at McKesson, it covers all of 7 McKesson. The fact that West Virginia 8 deaths increased over these years, we did 9 our monitoring, and it isn't just in West 10 Virginia, the epidemic was widespread.</p> <p>11 Q. Okay.</p> <p>12 A. And we did what we could to 13 monitor and deter that from occurring.</p> <p>14 Q. Because like your --</p> <p>15 MS. HENN: Counsel.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Because like your CEO said, 18 you took it seriously.</p> <p>19 MS. HENN: Counsel.</p> <p>20 MR. PAPANTONIO: I don't 21 have any further questions.</p> <p>22 MS. HENN: Thank you, sir.</p> <p>23 THE VIDEOGRAPHER: Stand by 24 please. The time is 6:10 p.m.</p>

Page 598	Page 600
<p>1 This marks the end of today's 2 deposition. Off the record. 3 MR. O'CROININ: I do 4 actually have a couple questions 5 though. 6 (Brief pause.) 7 THE VIDEOGRAPHER: It's not 8 the end of today's deposition, but 9 we are going off the record. The 10 time is 6:10 p.m. 11 (Brief pause.) 12 THE VIDEOGRAPHER: The time 13 is 6:11 p.m. Back on the record. 14 - - - 15 EXAMINATION 16 - - - 17 BY MR. O'CROININ: 18 Q. I'm Conor O'Croinin, I 19 represent the CVS entities in this case. 20 A. Okay. 21 Q. And we have never met, have 22 we? 23 A. No, we have not. 24 Q. I know it's been a long day.</p>	<p>1 why they were increasing. Why they 2 needed an increase. 3 I don't know, you know, the 4 specific examples of specific reasons 5 that they submitted. 6 Q. So if you don't know the 7 specific reasons why they were submitted 8 or why they were approved, you couldn't 9 say one way or the other whether they 10 should have been approved? 11 MR. PAPANTONIO: Objection, 12 leading the witness. Ask a 13 question that's not leading. 14 Counsel, you have him on direct 15 right now. 16 MS. HENN: Counsel, there 17 are no speaking objections. 18 MR. PAPANTONIO: Objection 19 to form. Okay. We'll do it -- 20 we'll -- your question needs 21 improving. 22 BY MR. O'CROININ: 23 Q. What is that -- can you say 24 one way or the other whether they --</p>
<p>1 I'll try to be very quick. Mr. Kennedy 2 asked you some questions, if you recall, 3 about what you referred to as an 4 agreement between CVS and McKesson? 5 A. Yes, sir. 6 Q. Concerning threshold 7 increase requests? 8 A. Yes, sir. 9 Q. Just to be clear, do you 10 have any firsthand knowledge of such an 11 agreement? 12 A. I do not. 13 Q. Mr. Kennedy also asked you 14 some questions about the approval of 15 certain threshold increase requests made 16 by CVS. Do you recall that line of 17 questioning? 18 A. I do. 19 Q. All right. And do you know 20 the reasons for those approvals of those 21 requests? 22 A. They would vary. I mean 23 each threshold change request typically 24 would, you know, vary by the stores to</p>	<p>1 those requests ought to have been 2 approved? 3 A. Not seeing the reasons 4 listed for them, no. 5 Q. You were also asked 6 questions about McKesson's policy of 7 reaching out to CVS's corporate offices 8 as opposed to going to an individual 9 pharmacy. Do you remember those 10 questions? 11 A. Yes. 12 Q. Is that -- is that a policy 13 that McKesson has that is specific to 14 CVS, is it a special CVS policy? 15 A. No, it is not a CVS policy. 16 All the retail national accounts are 17 handled on a corporate level. 18 Q. Are you aware of how many 19 stores CVS has in the U.S.? 20 A. I would be guessing. I know 21 it's in the thousands. I'm also not sure 22 exactly how many McKesson has versus some 23 of the other wholesalers. 24 Q. Does 10,000 sound right to</p>

Page 602	Page 604
<p>1 you?</p> <p>2 A. I'm not -- not sure if it's</p> <p>3 that many. Yeah.</p> <p>4 Q. But you think it's in the</p> <p>5 thousands?</p> <p>6 A. Oh yes.</p> <p>7 Q. And Mr. Kennedy went through</p> <p>8 a number of press releases and articles</p> <p>9 concerning fines that CVS paid in</p> <p>10 connection with specific CVS stores. Do</p> <p>11 you remember that line of questioning?</p> <p>12 A. Yes.</p> <p>13 Q. Do you know whether the vast</p> <p>14 majority of CVS's stores have never been</p> <p>15 implicated in any kind of investigation</p> <p>16 or paid a fine?</p> <p>17 MR. PAPANTONIO: Objection.</p> <p>18 Form.</p> <p>19 THE WITNESS: I would say</p> <p>20 that with the number of total</p> <p>21 stores that CVS has, the number</p> <p>22 that was listed is a very small</p> <p>23 percentage.</p> <p>24 MR. O'CROININ: All right.</p>	<p>1 small amount, small percentage.</p> <p>2 Q. Okay. So you didn't mean to</p> <p>3 say that getting fined \$77 million in</p> <p>4 2010, and then 11 in '13, another</p> <p>5 \$350,000 in '13, and a \$1.9 million fine</p> <p>6 in '14, and \$22 million in '15, and</p> <p>7 \$450,000 in '15, and 8 million and 3.5</p> <p>8 million, another 5.</p> <p>9 You're not saying a total of</p> <p>10 \$130.6 million worth of fines over six</p> <p>11 years is a good job, are you?</p> <p>12 MS. HENN: Objection to</p> <p>13 form.</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. You don't mean to tell us</p> <p>16 that, do you?</p> <p>17 MS. HENN: Objection to</p> <p>18 form.</p> <p>19 THE WITNESS: I don't</p> <p>20 believe that's what I said. I</p> <p>21 said the number of stores --</p> <p>22 BY MR. KENNEDY:</p> <p>23 Q. My question is simple.</p> <p>24 MS. HENN: Counsel, please</p>
<p>1 That's all I have.</p> <p>2 MR. KENNEDY: Yeah, let</p> <p>3 me -- I'm going to ask you -- let</p> <p>4 me ask you a few questions in</p> <p>5 follow-up to the CVS questioning.</p> <p>6 If you can pull up 5007</p> <p>7 please.</p> <p>8 MS. HENN: Do you by chance</p> <p>9 have a copy for me?</p> <p>10 MR. KENNEDY: Of?</p> <p>11 MS. HENN: The exhibit.</p> <p>12 I'll just look here.</p> <p>13 - - -</p> <p>14 EXAMINATION</p> <p>15 - - -</p> <p>16 BY MR. KENNEDY:</p> <p>17 Q. Mr. Oriente, did you just</p> <p>18 tell us that you thought CVS was doing a</p> <p>19 very good job?</p> <p>20 A. No, I did not say that,</p> <p>21 that -- that I recollect.</p> <p>22 I said that the amount of</p> <p>23 stores that were fined here in comparison</p> <p>24 to the total number of stores would be a</p>	<p>1 let him finish his answer.</p> <p>2 BY MR. KENNEDY:</p> <p>3 Q. You don't mean to say that,</p> <p>4 do you? That they're doing a good job</p> <p>5 here with \$130 million worth of fines?</p> <p>6 MS. HENN: Objection to</p> <p>7 form.</p> <p>8 THE WITNESS: I don't</p> <p>9 believe I commented on whether</p> <p>10 they were doing a good job. I</p> <p>11 believe my comment was a small</p> <p>12 percentage of the stores had</p> <p>13 problems.</p> <p>14 BY MR. KENNEDY:</p> <p>15 Q. Let me ask you right now.</p> <p>16 Do you think CVS was doing a good job</p> <p>17 with \$130 million worth of fines over six</p> <p>18 years? Do you think that's a good job in</p> <p>19 monitoring the flow of narcotics into our</p> <p>20 communities. Do you think that is a good</p> <p>21 job?</p> <p>22 MS. HENN: Objection to</p> <p>23 form.</p> <p>24 THE WITNESS: I think based</p>
	Page 605

<p>1 off of the fines they could have 2 done a better job, yes. 3 MR. KENNEDY: I've got 4 nothing further. 5 MS. HENN: Thank you. But I 6 want to reserve signature. I 7 think I mentioned earlier the 8 whole transcript should be marked 9 highly confidential pending 10 review. 11 THE VIDEOGRAPHER: This 12 marks the end of today's 13 deposition. The time is 6:18 p.m. 14 (Excused.) 15 (Deposition concluded at 16 approximately 6:18 p.m.) 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 606</p> <p>1 INSTRUCTIONS TO WITNESS 2 3 Please read your deposition 4 over carefully and make any necessary 5 corrections. You should state the reason 6 in the appropriate space on the errata 7 sheet for any corrections that are made. 8 After doing so, please sign 9 the errata sheet and date it. 10 You are signing same subject 11 to the changes you have noted on the 12 errata sheet, which will be attached to 13 your deposition. 14 It is imperative that you 15 return the original errata sheet to the 16 depoing attorney within thirty (30) days 17 of receipt of the deposition transcript 18 by you. If you fail to do so, the 19 deposition transcript may be deemed to be 20 accurate and may be used in court. 21 22 23 24</p>
<p>1 2 CERTIFICATE 3 4 5 I HEREBY CERTIFY that the 6 witness was duly sworn by me and that the 7 deposition is a true record of the 8 testimony given by the witness. 9 10 It was requested before 11 completion of the deposition that the 12 witness, MICHAEL ORIENTE, have the 13 opportunity to read and sign the 14 deposition transcript. 15 16 17 18 MICHELLE L. GRAY, 19 A Registered Professional 20 Reporter, Certified Shorthand 21 Reporter, Certified Realtime 22 Reporter and Notary Public 23 Dated: July 24, 2018 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 559 560 561 562 563 564 565 566 567 568 569 569 570 571 572 573 574 575 576 577 578 579 579 580 581 582 583 584 585 586 587 588 589 589 590 591 592 593 594 595 596 597 598 599 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 619 620 621 622 623 624 625 626 627 628 629 629 630 631 632 633 634 635 636 637 638 639 639 640 641 642 643 644 645 646 647 648 649 649 650 651 652 653 654 655 656 657 658 659 659 660 661 662 663 664 665 666 667 668 669 669 670 671 672 673 674 675 676 677 678 679 679 680 681 682 683 684 685 686 687 688 689 689 690 691 692 693 694 695 696 697 698 699 699 700 701 702 703 704 705 706 707 708 709 709 710 711 712 713 714 715 716 717 718 719 719 720 721 722 723 724 725 726 727 728 729 729 730 731 732 733 734 735 736 737 738 739 739 740 741 742 743 744 745 746 747 748 749 749 750 751 752 753 754 755 756 757 758 759 759 760 761 762 763 764 765 766 767 768 769 769 770 771 772 773 774 775 776 777 778 779 779 780 781 782 783 784 785 786 787 788 789 789 790 791 792 793 794 795 796 797 798 799 799 800 801 802 803 804 805 806 807 808 809 809 810 811 812 813 814 815 816 817 818 819 819 820 821 822 823 824 825 826 827 828 829 829 830 831 832 833 834 835 836 837 838 839 839 840 841 842 843 844 845 846 847 848 849 849 850 851 852 853 854 855 856 857 858 859 859 860 861 862 863 864 865 866 867 868 869 869 870 871 872 873 874 875 876 877 878 879 879 880 881 882 883 884 885 886 887 888 889 889 890 891 892 893 894 895 896 897 898 899 899 900 901 902 903 904 905 906 907 908 909 909 910 911 912 913 914 915 916 917 918 919 919 920 921 922 923 924 925 926 927 928 929 929 930 931 932 933 934 935 936 937 938 939 939 940 941 942 943 944 945 946 947 948 949 949 950 951 952 953 954 955 956 957 958 959 959 960 961 962 963 964 965 966 967 968 969 969 970 971 972 973 974 975 976 977 978 979 979 980 981 982 983 984 985 986 987 988 989 989 990 991 992 993 994 995 996 997 998 999 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1009 10010 10011 10012 10013 10014 10015 10016 10017 10018 10019 10020 10021 10022 10023 10024 10025 10026 10027 10028 10029 10029 10030 10031 10032 10033 10034 10035 10036 10037 10038 10039 10039 10040 10041 10042 10043 10044 10045 10046 10047 10048 10049 10049 10050 10051 10052 10053 10054 10055 10056 10057 10058 10059 10059 10060 10061 10062 10063 10064 10065 10066 10067 10068 10069 10069 10070 10071 10072 10073 10074 10075 10076 10077 10078 10079 10079 10080 10081 10082 10083 10084 10085 10086 10087 10088 10089 10089 10090 10091 10092 10093 10094 10095 10096 10097 10098 10098 10099 100100 100101 100102 100103 100104 100105 100106 100107 100108 100109 100110 100111 100112 100113 100114 100115 100116 100117 100118 100119 100120 100121 100122 100123 100124 100125 100126 100127 100128 100129 100129 100130 100131 100132 100133 100134 100135 100136 100137 100138 100139 100139 100140 100141 100142 100143 100144 100145 100146 100147 100148 100149 100149 100150 100151 100152 100153 100154 100155 100156 100157 100158 100159 100159 100160 100161 100162 100163 100164 100165 100166 100167 100168 100169 100169 100170 100171 100172 100173 100174 100175 100176 100177 100178 100179 100179 100180 100181 100182 100183 100184 100185 100186 100187 100188 100189 100189 100190 100191 100192 100193 100194 100195 100196 100197 100198 100199 100199 100200 100201 100202 100203 100204 100205 100206 100207 100208 100209 100210 100211 100212 100213 100214 100215 100216 100217 100218 100219 100219 100220 100221 100222 100223 100224 100225 100226 100227 100228 100229 100229 100230 100231 100232 100233 100234 100235 100236 100237 100238 100239 100239 100240 100241 100242 100243 100244 100245 100246 100247 100248 100249 100249 100250 100251 100252 100253 100254 100255 100256 100257 100258 100259 100259 100260 100261 100262 100263 100264 100265 100266 100267 100268 100269 100269 100270 100271 100272 100273 100274 100275 100276 100277 100278 100279 100279 100280 100281 100282 100283 100284 100285 100286 100287 100288 100289 100289 100290 100291 100292 100293 100294 100295 100296 100297 100298 100299 100299 100300 100301 100302 100303 100304 100305 100306 100307 100308 100309 100310 100311 100312 100313 100314 100315 100316 100317 100318 100319 100319 100320 100321 100322 100323 100324 100325 100326 100327 100328 100329 100329 100330 100331 100332 100333 100334 100335 100336 100337 100338 100339 100339 100340 100341 100342 100343 100344 100345 100346 100347 100348 100349 100349 100350 100351 100352 100353 100354 100355 100356 100357 100358 100359 100359 100360 100361 100362 100363 100364 100365 100366 100367 100368 100369 100369 100370 100371 100372 100373 100374 100375 100376 100377 100378 100379 100379 100380 100381 100382 100383 100384 100385 100386 100387 100388 100389 100389 100390 100391 100392 100393 100394 100395 100396 100397 100398 100399 100399 100400 100401 100402 100403 100404 100405 100406 100407 100408 100409 100410 100411 100412 100413 100414 100415 100416 100417 100418 100419 100419 100420 100421 100422 100423 100424 100425 100426 100427 100428 100429 100429 100430 100431 100432 100433 100434 100435 100436 100437 100438 100439 100439 100440 100441 100442 100443 100444 100445 100446 100447 100448 100449 100449 100450 100451 100452 100453 100454 100455 100456 100457 100458 100459 100459 100460 100461 100462 100463 100464 100465 100466 100467 100468 100469 100469 100470 100471 100472 100473 100474 100475 100476 100477 100478 100479 100479 100480 100481 100482 100483 100484 100485 100486 100487 100488 100489 100489 100490 100491 100492 100493 100494 100495 100496 100497 100498 100499 100499 100500 100501 100502 100503 100504 100505 100506 100507 100508 100509 100510 100511 100512 100513 100514 100515 100516 100517 100518 100519 100519 100520 100521 100522 100523 100524 100525 100526 100527 100528 100529 100529 100530 100531 100532 100533 100534 100535 100536 100537 100538 100539 100539 100540 100541 100542 100543 100544 100545 100546 100547 100548 100549 100549 100550 100551 100552 100553 100554 100555 100556 100557 100558 100559 100559 100560 100561 100562 100563 100564 100565 100566 100567 100568 100569 100569 100570 100571 100572 100573 100574 100575 100576 100577 10057</p>	

Page 610

1

2 ACKNOWLEDGMENT OF DEONENT

3

4 I, _____, do
5 hereby certify that I have read the
6 foregoing pages, 1 - 611, and that the
7 same is a correct transcription of the
8 answers given by me to the questions
9 therein propounded, except for the
10 corrections or changes in form or
11 substance, if any, noted in the attached
12 Errata Sheet.

13

14

15

16 MICHAEL ORIENTE DATE

17

18

19 Subscribed and sworn
to before me this

20 _____ day of _____, 20 _____.
21 My commission expires: _____

22

23 Notary Public

24

Page 611

1 LAWYER'S NOTES

2 PAGE LINE

3 _____

4 _____

5 _____

6 _____

7 _____

8 _____

9 _____

10 _____

11 _____

12 _____

13 _____

14 _____

15 _____

16 _____

17 _____

18 _____

19 _____

20 _____

21 _____

22 _____

23 _____

24 _____